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Abstract 
Background: Malnutrition is a major challenge for patients diagnosed with 
ovarian cancer and affects between 28% and 67% of women at some point in 
their cancer trajectory. It is strongly associated with poor health outcomes and 
decreased survival. Few studies have evaluated nutritional status in this 
population. The impact of nutritional intervention on outcomes such as body 
composition and survival is also not well understood. Characterising changes in 
nutritional status and understanding how women perceive a cancer diagnosis to 
affect their diet and nutritional needs is required.  
Aim: This study characterises nutritional status of women diagnosed with ovarian 
cancer during the period of acute first-line treatment. It also explores the 
perceptions of women regarding their nutrition and dietary needs and their 
preferences for supportive intervention.  
Methods: A mixed-method (quantitative/qualitative) study was conducted to 
prospectively assess nutritional status. 58 newly diagnosed women and 27 
controls were recruited and anthropometric/body composition measures (weight, 
body fat, dry lean mass, lean mass total body water and extracellular water) and 
biochemical markers (prealbumin, albumin, C-reactive protein, CA125) assessed 
at baseline, during treatment and at the end of treatment. Women also completed 
a study specific questionnaire on their health and dietary intake as well as quality 
of life questionnaires. Data was analysed using SPSS. Two focus groups with 8 
eight women were conducted and discussions centred on the importance of 
nutrition. The group sessions were recorded, transcribed verbatim and analysed 
using thematic analysis.   
Results: The findings are that some women (43%) are malnourished by the time 
they attend a cancer centre for investigation or treatment of ovarian their cancer. 
They have lost weight, have decreased lean mass and a low prealbumin. Their 
quality of life is also affected. Women in the study consider their diet and nutrition 
to be important and do not feel adequately supported by their clinical team. 
Nutritional support based on current practice does not seem to improve nutrition 
outcomes.  
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Conclusion: Well-designed, targeted, randomised controlled trials with specific 
interventions aimed at early treatment and prevention of further nutritional 
complications in ovarian cancer patients are urgently required.  
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List of definitions 
Baseline assessment: Assessment of patients before they received any 
treatment. 
During treatment assessment: Assessment of cancer patients on their first visit 
to the hospital following surgery, usually at 2-3 weeks. 
It also refers to the assessment carried out following 
1 cycle of chemotherapy for women treated with neo-
adjuvant chemotherapy. 
End of treatment assessment: Assessment of patients following completion or 
stoppage of acute first-line treatment. It is also the 
assessment following surgery (the last treatment) for 
controls and women diagnosed with borderline 
malignancy and stage 1 & 2 ovarian cancer) and 
treated with surgery alone.  
Cachexia  A multifactorial syndrome defined by an on-going loss 
of skeletal muscle mass (with or without loss of fat 
mass) that cannot be fully reversed by conventional 
nutritional support and leads to progressive functional 
impairment. Cachexia includes sarcopenia as a part 
of it pathology. 
Dietary intake                                            An individual’s food and nutrient intake. 
Lifestyle An individual’s attitudes, values and way of life. It is 
used in this thesis to refer to an individual’s particular 
way of living in aspects concerning their health such 
as diet, exercise and self-management of symptoms 
and treatment effects. 
Malignant ascites    A build-up of fluid within the peritoneal cavity that 
contains cancer cells. 
Borderline malignancy Ovarian tumours of low malignant potential. They are 
different to ovarian cancer because they grow slowly 
and do not grow into the stroma.  
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Disease related malnutrition The point at which the severity or persistence of 
inflammation results in a decrease in lean body mass 
associated with functional impairment. In this thesis it 
refers to malnutrition arising from disease related 
factors such as malabsorption, inflammation, insulin 
resistance, and anorexia.   
Nutritional intervention A specific aspect of nutritional support which involves 
manipulating dietary intake through counselling or 
additional nutrients. 
Nutritional status The condition of the body in those respects influenced 
by diet or the levels of nutrients in the body and their 
ability to maintain normal metabolic integrity. 
Nutritional support The management of patients’ nutritional needs which 
includes counselling and provision of nutritional 
supplements. 
Quality of life  The general well-being of an individual. 
Respondent Each woman who participated in the focus group 
discussions. 
Sarcopenia  The reduction in muscle tissue of more than 2 
standard deviations below that typical of healthy 
adults. The reduction results in functional impairment 
and decreased survival.  
Sarcopenic-obesity A condition where an obese individual (increased fat 
mass) has decreased muscle mass and function. 
Self-efficacy An individual’s belief in their capacity to execute 
behaviours necessary to produce desired goals.  
Self-management A treatment that aims to maximise functioning of self-
regulatory processes and often combines biological, 
psychological and social intervention techniques. The 
individuals manage their day-to-day tasks to minimise 
the impact of disease on health status. 
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Teachable moment The window of opportunity when learning a particular 
topic becomes possible or easiest. A diagnosis of 
cancer is said to be such a moment for adoption of a 
healthier lifestyle. 
Total Parenteral Nutrition (TPN) The delivery of nutrition intravenously. 
Volunteer Each woman who participated in the observational 
study. 
Well-being  The general state of wellness. 
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List of abbreviations 
APPR  Acute phase protein response 
BCM  Body cell mass 
BIA Bioelectrical impedance analysis 
BME   Black and ethnic minority 
BMI  Body mass index 
BW  Body weight 
CNS  Clinical nurse specialist 
CRF  Cancer related fatigue 
CRP  C-reactive protein 
CRUK  Cancer research UK 
CT  Computerised tomography 
DoH  Department of Health 
DXA   Dual energy x-ray absorptiometry 
EOC  Epithelial ovarian cancer 
EORTC   European organisation for research and treatment of                         
cancer 
ERP                                                                                   Enhanced recovery programme  
FIGO International Federation of Gynaecology and   
Obstetrics 
GOG  Gynaecologic oncology group 
GP  General Practitioner 
HAPA Health action process approach  
LOA Loss of appetite 
MUST  Malnutrition universal screening tool 
NCSI National cancer survivorship initiative 
NHS  National Health Service 
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NICE National Institute for Health and Care Excellence 
NSCLC Non-small cell lung cancer 
OS Overall survival 
Qlq  Quality of life questionnaire 
QoL/qol                                                                  Quality of life 
UK  United Kingdom 
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1 Introduction 
1.1 Overview 
The incidence of malnutrition in women diagnosed with ovarian cancer varies 
between 28% and 67% (1, 2) and can be higher in women who also have bowel 
obstruction (3). The clinical endpoints of cachexia which are weight loss, anorexia, 
decreased quality of life, reduced physical activity and reduced overall survival, 
(4) are devastating for the patient. Up to 20% of patients with cancer die of the 
effects of malnutrition rather than of the malignancy (5). Only a few studies have 
evaluated nutritional status or how it changes over time in women with ovarian 
cancer (5). Clinically, investigations into malnutrition and its effects are often left 
too late when clinical signs become evident. The patient is unlikely to respond to 
interventions at this stage thus perpetrating the misconception that nothing but 
palliation of the worst effects of cachexia is all that can be achieved for 
malnourished/cachectic cancer patients (6). Furthermore, there is evidence that 
mechanisms that ultimately lead to the severe wasting of cachexia are operating 
early in the natural history of the disease (6) when the patient may be able to 
respond better to nutrition intervention. Although nutrition started to feature more 
in patient care in more recent years with consensus groups and health 
departments in Europe becoming more involved in making broad statements 
about nutrition, cancer patients’ nutritional needs remain largely unmet (7). 
Therefore objectively identifying malnutrition, characterising nutritional status, 
and understanding the impact of an ovarian cancer diagnosis on women’s diet 
and nutritional needs as well as their perceptions of the adequacy of nutritional 
support in practice is important. It provides an opportunity to increase knowledge 
about this complex syndrome as well as help to design patient informed 
interventions.   
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1.2 Main aim  
The main aim of this thesis was to identify and characterise changes in the 
nutritional status of women with ovarian cancer from diagnosis to the end of 
primary treatment.  
 
1.2.1 Study specific objectives 
The observational study (Study A) aimed to utilise multiple nutritional assessment 
tools at baseline, during treatment and at the end of treatment to address the 
following: 
 To compare the nutritional status of ovarian cancer cases with that of 
benign controls (at baseline and at the end of treatment)  
 To compare changes in the nutritional status of women over time: at 
baseline, during treatment and at the end of treatment and at baseline and 
at the end of treatment for controls 
 To assess how disease and well-being markers such as CA125, CRP and 
albumin are affected by ovarian cancer and to investigate the relationship 
between these markers and nutritional status  
 To investigate the relationship between lifestyle factors such as smoking, 
alcohol intake and menopause and nutritional status in cases and controls 
 To investigate the impact of some ovarian cancer symptoms such as pain, 
nausea, abdominal distension etc. on nutritional status, dietary intake and 
overall health status of cases 
 To determine which nutritional assessment best evaluates nutritional 
status in ovarian cancer patients  
 
The qualitative enquiry (Study B) complimented study A and aimed to;   
 Explore patients’ understanding of their nutritional status, and their 
information and support needs to meet nutritional challenges  
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 Explore the impact of the physiological (nutritional) changes on patients’ 
eating habits and daily activities and discover some of their coping 
strategies and recommendations for a desired intervention.   
 Explore how a health behaviour model, Health Action Process approach 
(HAPA), could be used to improve a potential future intervention package 
 Consolidate evidence from study A with patients’ perspectives of 
nutritional needs to make recommendations for future interventions 
 
1.3 Research design 
Assessing nutritional status is complex; no one method is universally approved 
or accepted for this purpose. Some of the major limitations in countering disease 
related malnutrition have been as a result of the lack of accepted, standardized 
criteria for defining and assessing malnutrition indices (8). The evolving challenge 
of malnutrition is also related to the increasing obesity epidemic, which can mask 
underlying lethal muscle wasting resulting in a combination of excess weight and 
reduced muscle mass and/or strength. Traditional methods of nutritional 
assessment based on weight assessment may no longer be relevant in many 
cases and may result in malnutrition being frequently undiagnosed. In addition, 
in its early stages cancer causes a series of metabolic and functional changes 
and malnutrition may only be later demonstrable by anthropometric changes 
(body shape, size and composition) (8). This means that body composition 
assessments may not always be sensitive enough to identify some of these early 
changes. Furthermore, the lethal nature of ovarian cancer and the quick relapse 
(median interval of 18-24 months) in 70% of patients with advanced stage 
disease (9) warrants intervention that targets a woman’s entire life rather than 
just the acute phase. This requires patient involvement; their perceptions of their 
challenges are therefore invaluable. 
  
To counter some of these challenges in assessing nutritional status and to also 
gain insight from patients, a multi-dimensional approach of using mixed methods 
and multiple tools for assessment was used.  
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1.4 Mixed-method approach 
The research was divided into two separate but related studies. Study A involved 
the quantitative assessments of nutritional status and dietary analysis while Study 
B involved qualitative analysis of women’s perceptions of their dietary and 
nutritional status to illuminate the quantitative assessments and preliminary 
findings. Study B also provided insight into women’s nutritional concerns, their 
nutritional support needs and important clues for development of future 
interventions.  
 
1.5 Thesis layout 
This thesis is presented in 11 chapters. Chapter 1 is the introduction and outlines 
the overall purpose of the study, the research design and thesis structure. 
Chapter 2 is the literature review. This chapter examines existing literature on 
disease related malnutrition/cachexia, its pathophysiology, effects and current 
management. It also focuses on the nutritional issues specific to ovarian cancer 
patients, how these are different from other cancers and how they are currently 
managed. It highlights the knowledge gaps and uses the literature to formulate 
the research questions. Chapter 3, the first of 3 methods chapters, provides 
overall justification for the research and a rationale for its design. The research 
sites, patient pathways, and ethical and regulatory procedures are described. It 
also introduces the two studies, Study A, the observational study and study B, 
the patients’ perspective study. Chapter 4, the second methods chapter, outlines 
the conduct of study A. It also describes the tools for assessment and the analytic 
methods used. It is followed by chapter 5, which outlines the findings from study 
A. Results are presented here in four sections. Section A presents findings on 
patient demographics, disease, treatment and symptoms for cases and controls 
where applicable. Sections B and C present findings on nutritional/body 
composition and biochemical statuses respectively for cases and controls at 
baseline, during treatment and at the end of treatment as appropriate. The last 
section of this chapter, section D, presents findings on diet and eating habit 
changes starting 3 months prior to baseline assessment to the end of treatment. 
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It also outlines associations between diet changes with nutritional status and 
overall health status as well as evaluate the impact of current nutritional 
interventions on nutritional status. Chapter 6, the second to present results from 
study A, outlines findings on the impact of ovarian cancer on quality of life, 
measured using the Euroqol EQ-5D questionnaire. Results are presented on the 
two aspects of the questionnaire. The first consists of 5 quality of life domains of 
mobility, self-care, usual activity, pain/discomfort and anxiety/depression. The 
second is the visual analogue scale representing the overall health status, a proxy 
for quality of life. The association between affected domains and overall health 
status with nutritional status is outlined. Chapter 7, the final of the methods 
chapters describes the conduct of the focus group discussions and how the data 
were analysed. The findings from analysis of patients’ perspective on diet and 
nutrition are narrated in chapter 8. The final chapter, 9, provides an overall 
discussion of the results, highlights the strengths and weaknesses of the research 
and sets out suggestions for future work.  
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2 Literature Review 
2.1 Summary of chapter 
This chapter is dedicated to a review of the literature. The review focuses on the 
definition, classification, prevalence and pathophysiology of 
malnutrition/cachexia. The manifestations and impact of malnutrition are also 
reviewed. Particular attention is paid to current practice in nutritional support for 
cancer patients, strategies that have worked and those that have not. Finally, 
attention is paid to the nutritional challenges faced by women diagnosed with 
ovarian cancer, what has been achieved and what could be achieved in 
managing the challenges. Knowledge gaps are identified and the opportunities 
for research that lead to the overall research question are explored. 
   
This thesis adopts use of both terms malnutrition and cachexia to refer to disease 
related malnutrition in cancer patients. The terms are frequently used non-
exclusively in literature. Researchers tend to use the term ‘cachexia’, while 
clinicians most often refer to ‘malnutrition’. Nutrition care literature usually refers 
to malnutrition indices rather than cachexia indices. For this reason the terms are 
used interchangeably in this thesis unless otherwise specified.  
  
2.2 Cancer and malnutrition  
The prevalence of malnutrition in cancer patients could be as high as 80% 
depending on cancer location and stage, treatment history, clinical setting and 
assessment criteria (10, 11). The problem is that a variety of definitions for 
malnutrition syndromes are found in the literature resulting in confusion (12) and 
there is a lack of a validated, universal classification system (13). The public 
health definitions generally describe a state of nutrition in which a deficiency or 
excess (or imbalance) of energy, protein, and other nutrients causes measurable 
adverse effects on tissue/body form (body shape, size and composition) and 
function, and clinical outcome (6). These definitions imply that if the imbalance is 
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corrected, then the problem of malnutrition will resolve. This is true in the absence 
of disease where malnutrition is caused by an inadequate or excessive 
consumption of nutrients. Although nutritional intake has been shown to be 
substantially reduced in most patients with cancer experiencing weight loss (14), 
it is not always diminished during the course of cancer (15). Recent evidence, 
suggests that this may be due to varying degrees of acute or chronic inflammation, 
which are contributing factors in the pathophysiology of malnutrition (12). There 
is also evidence to suggest that in some instances of cancer and HIV, nutrition 
supplementation fails to reverse malnutrition. This emphases the role of 
underlying abnormalities of host metabolism; with host tumour competition and 
tumour products interacting to affect both energy balance and metabolism of 
macronutrients (15).  
 
A consensus definition of disease related malnutrition has been given as “The 
point at which the severity or persistence of inflammation results in a decrease in 
lean body mass associated with functional impairment”, (Jenson et al., 2010; p. 
157) (12). This form of malnutrition is partially attributable to a decrease in nutrient 
intake, but is also tightly linked to the effect of the inflammation. This definition is 
applicable in cancer patients where there is a complex interplay between 
underlying disease, disease-related metabolic alterations and, in some cases, the 
reduced availability of nutrients (because of reduced intake, impaired absorption 
and/or increased losses, or a combination of these) (6). ‘Cachexia’ is a 
preferential term to describe this form of malnutrition in cancer patients, although 
conceptually the states are along a continuum so that “not all malnourished 
patients are cachectic, but all cachectic patients are invariably malnourished” (16, 
17).  
 
2.3 Cachexia 
Cachexia is a major problem associated with reduced physical functioning, 
tolerance to chemotherapy and survival (18). The word cachexia is derived from 
Greek words Kakos (bad) (12) and héxis (condition) (19). Its complexity has made 
it difficult for experts to agree a definition and the lack of a universal definition, 
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diagnostic criteria, and classification have impeded knowledge advancement for 
clinical trials and practice (20, 21). The consequences of this include delays in its 
identification, inadequate prevention and ineffective treatments (6) in clinical 
practice.  
 
There has been progress in the understanding of cachexia over the past decade 
(22). In recent years, international groups have worked together to provide 
universally acceptable, clinically relevant definitions of key terms and consensus 
statements (6, 12). The Special Interest Group on cachexia-anorexia in chronic 
wasting diseases (6) adopted the definition of cachexia as “a complex metabolic 
syndrome associated with underlying illness and characterized by loss of muscle 
with or without loss of fat mass” (Evans 2008) (23). Loss of muscle mass is 
important as it leads to frailty and loss of function. The important aspect of this 
definition is that it also recognised that weight change should be corrected for 
fluid retention. Fluid retention (24) is a common clinical symptom of some cancers. 
More is now understood and known about the cachexia/malnutrition processes 
since that definition was published leading to further adaptation of the definition 
to;  
 
“A multifactorial syndrome defined by an on-going loss of skeletal muscle mass 
(with or without loss of fat mass) that cannot be fully reversed by conventional 
nutritional support and leads to progressive functional impairment. Its 
pathophysiology is characterised by a negative protein and energy balance 
driven by a variable combination of reduced food intake and abnormal 
metabolism (22)”. 
 
This later definition acknowledges that cachexia can occur before or without loss 
of fat mass, meaning that overweight and obese individuals can be cachectic. 
Therefore although weight loss is considered a signal event of the cachectic 
process depletion of other reserves such as muscle mass is important and should 
be considered. This later definition is more comprehensive and takes into account 
functional, metabolic and body composition disturbances (25) which are all 
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common in cancer patients undergoing treatment (15, 26). The consensus view 
is that cancer cachexia should be viewed as a continuum with three stages of 
clinical relevance: precachexia, cachexia, and refractory cachexia (27). Clinical 
and metabolic signs such as anorexia and glucose intolerance are ongoing and 
can precede involuntary weight loss in the precachexia phase. The risk of 
progression to the next phase, cachexia, varies and depends on such factors as 
cancer type, stage, lack of response to anticancer therapy. Patients in the 
cachexia phase have weight loss of more than 5% over the last 6 months, or a 
BMI less than 20 and on-going weight loss of more than 2% or sarcopenia and 
on-going weight loss of more than 2%.  
 
The next phase is refractory cachexia where the cancer is very advanced or is 
progressive and unresponsive to treatment. This stage is characterised by 
catabolism, unmanageable weight loss, low performance status and a low life 
expectancy of less than 3 months. Therapeutic interventions at this stage tend to 
focus on symptom relief of for example pain and nausea and not to provide cure. 
This diagnostic framework although helpful needs sufficient validation (28). Blum 
et al., 2014 (17) attempted to validate the criteria and reported that the diagnostic 
criteria based on weight loss and BMI distinguish between cachectic and non-
cachectic patients (concerning food intake, catabolism and function) and is 
associated with survival. Unfortunately others (18) have found the clinical 
relevance of pre-cachexia in patients with cancer to be limited as the present 
framework identifies very few patients. They suggest further refinement of the 
criteria to be able to identify more patients in the pre-cachexia phase, who have 
a greater chance of responding to nutrition interventions. This highlights that the 
current definition has its limitations and will possibly require revising in future.  
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Figure 1: below summarises what is currently understood about the relationship 
between cancer and cachexia.  
Figure 1: A conceptual representation of the cachexia definition 
 
Reproduced with permission. Source: Evans (23)  
 
Cachexia affects inflammatory, metabolic and other regulatory systems leading 
to fat or muscle loss or both. Whereas fat loss results in weight loss, muscle loss 
has more impact on function resulting in fatigue and ultimately decreased survival. 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
Anorexia Insulin 
Resistance 
Hypogonadism 
Anaemia 
FAT LOSS MUSCLE WASTING 
Weight Loss Weakness and Fatigue 
Cachexia Diagnosis 
Weight loss >5% over past 6 months OR 
BMI <20 and any degree of weight loss >2% OR 
Appendicular skeletal muscle index consistent with sarcopenia (males <7·26 kg/m2; 
females <5·45 kg/m2) and any degree of weight loss >2% 
 
Inflammation 
CANCER 
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2.4 Overview of the pathophysiology of cachexia 
Cachexia is characterized by a negative protein and energy balance driven by 
reduced food intake, low physical activity, systemic inflammation and abnormal 
metabolism mediated by cytokines, neuroendocrine hormones and tumour-
specific factors (22). The dynamic changes in body composition and function 
observed in cachexia result from an imbalance between metabolisable energy 
content and the body’s energy demands (29). Advanced stage of disease is the 
common cause for patients’ nutritional deterioration (30). Inflammation plays a 
major role in the degree of weight loss and the severity of the underlying 
metabolic changes. Muller et al., (31) suggest that there are more complex 
pathways of ‘fat–muscle crosstalk’ (via myokines or cytokines) regulating 
development of cachexia and that the regulation of body weight is through the 
integrated control of individual body components such fat free mass and fat mass 
(29). They suggest that these components are interrelated and their proportions 
are stable despite weight changes.  Their view is that changes in body weight are 
dependent on relationships between tissues and organs rather than on individual 
components or masses themselves. A detailed discussion of this concept is 
beyond the scope of this thesis.  
 
2.4.1 Host-tumour interaction and inflammation 
2.4.1.1 Tumour factors 
Agents produced by the tumour directly, or produced systemically in response to 
the tumour, such as pro-inflammatory cytokines (IL-1, IL-6, TNF-α and IFN-γ) and 
hormones (insulin, cortisol and glucagon) are implicated in the pathogenesis of 
cachexia (15). Tumour cells are said to produce both pro-inflammatory and pro-
cachectic factors, which then stimulate a host inflammatory response (32). These 
include the proteolysis-inducing (33) and lipid-mobilising factors (34) which are in 
turn involved in pathways that induce proteolysis in muscles and in hepatocytes, 
resulting in production of IL-6, IL-8 and C-reactive protein (CRP) (35).  
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2.4.1.2 Inflammation  
It is thought that the cachexia process is driven by inflammatory cytokine 
production in response to tumour cells. Increased systemic inflammatory cytokine 
production, which correlates with the amount of weight loss have been shown in 
mice tumour models (36, 37). The TNF-alpha and the tumour factor proteolysis-
inducing factor are thought to play an important role in skeletal muscle atrophy in 
cachectic patients. They increase protein degradation through the ubiquitin-
proteasome pathway and depress protein synthesis through phosphorylation of 
eukaryotic initiation factor 2 alpha (38). High levels of IL-6 have been shown to 
correlate with high CRP values and concomitant body weight loss (6). 
 
2.4.1.3 C-reactive protein (CRP) and Acute Phase Protein Response 
(APPR) 
Acute phase response proteins are produced as a response to inflammation (39). 
It has been shown that up to 50% of patients with solid epithelial cancers may 
have an elevated acute phase protein response (APPR) (40). APPR is thought to 
be associated with increased metabolism. Some longitudinal studies have found 
a poorer prognosis in patients displaying this response, independent of weight 
loss (41). In clinical care, CRP is commonly used to assess inflammatory 
response. An elevated CRP concentration has been associated with a poor 
prognosis in colorectal, breast and ovarian cancer. Hypoalbuminaemia (which is 
often associated with elevated CRP levels) has been reported to be a good 
predictor of poor prognosis in many types of cancer (42). Despite the 
understanding of the role of individual factors the exact mechanisms linking 
cachexia, APPR, and poor outcomes is still not clearly understood.  
 
2.4.1.4 Prealbumin (transthyretin) 
Prealbumin is also called transthyretin and is produced by the liver. Serum 
prealbumin has been reported to reflect changes in the clinical status of certain 
cancer patients (43). It also remains a relevant nutritional marker because it is a 
good marker of visceral protein status and is affected earlier by acute variations 
in protein balance (44). 
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2.4.1.5 Albumin  
Albumin is the most common protein found in the blood. Its main function is to 
regulate the osmotic pressure of blood. Normal albumin levels in adults range 
between 3.5 to 5 g/dL. Its levels are affected by impaired liver function, ascites 
and inflammation. Recently, serum albumin has been used to determine the 
severity of cancer, disease progression and prognosis (45, 46). The use of 
albumin as a nutritional marker is limited because non-nutritional factors, such as 
hydration and disease process can obscure the effects of actual nutrient 
deprivation (47). On the other hand it has a strong correlation with morbidity and 
mortality and is therefore often referred to as a marker of illness rather than of 
nutrition. The association between hypoalbuminemia and poor prognosis in 
patients with cancer is well documented (46).  
 
2.4.1.6 Cancer/Carcinoma Antigen 125 (CA125)  
CA125 belongs to the mucin glycoprotein family.  It is a repeating peptide of the 
mucin MUC16. It was shown to be excreted by ovarian tumours more than 30 
years ago (48). It promotes proliferation of cancer cells while inhibiting anti-cancer 
immune responses (49). The significance of CA125 in ovarian cancer 
management is three-fold; 1) As a biomarker where increase beyond 35U/l is 
generally associated with ovarian cancer (50). When used with imagining it helps 
to distinguish between benign and malignant disease in women who present with 
pelvic masses. Recently, this approach has helped to streamline diagnosis such 
that only women who need treatment in a specialised cancer centre do so, and 
not women with benign disease. 2) It is used to monitor response to therapy in 
women with ovarian cancer (51). Often in responders (women who respond to 
treatment) the CA125 level decreases or returns to baseline. In contrast an 
increase from a post-treatment level or baseline may indicate disease 
progression or recurrence. 3) It is a potential a screening test for the early 
detection of ovarian cancer. The probability of ovarian cancer is thought to be 
better predicted on longitudinal monitoring of CA125 through a method called 
Risk of Ovarian Cancer Algorithm (ROCA) (52).  
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2.4.1.7 Neuroendocrine factors 
In recent years there has been an increase in the understanding of the role of 
hormones involved in the metabolism of nutrients and maintenance of 
homeostatic functions (53-61). They include insulin, leptin, ghrelin, neuropeptides 
and cortisol. Cancer appears to affect the regulation of most neuroendocrine 
factors resulting in insulin resistance, reduced anabolic activity, and elevated 
cortisol (62). Although insulin secretion is relatively normal in cancer, there tends 
to be reduced insulin sensitivity (peripheral insulin resistance). Insulin resistance 
results in a reduced action on tissue glucose uptake and suppression of hepatic 
glucose production resulting in inefficient metabolism and availability of 
carbohydrates to the body and also affects muscle protein anabolism (63). It has 
been suggested that the systemic inflammatory response associated with cancer 
plays a role in insulin resistance (64). 
 
Other hormones and neuropeptides implicated in energy control, feeding 
behaviour and accretion of fat include ‘ghrelin’, (a 28 amino acid neuropeptide) 
released by endocrine cells of the stomach fundus in response to fasting and 
stimulating food intake. Its levels increase with weight and it is said that it can 
stimulate energy intake by 30% in patients with cancer anorexia without any side 
effects (55, 65). There is insufficient data at the moment to prove whether infusion 
of ghrelin changes body weight.  
 
Other mechanisms thought to be active in cancer malnutrition/cachexia include 
increased circulating lactate secondary to anaerobic metabolism of cancer cells 
and exacerbated by hepatic impairment (66); testosterone or its derivatives as 
well as insulin-like growth factor 1. The contribution of these mechanisms is not 
fully understood and discussion of these factors in detail is beyond the scope of 
this thesis. However understanding the roles of the different factors presents 
research opportunities where manipulation of mechanisms to stimulate food 
intake, or prevent breakdown of body reserves hold potential for improved patient 
outcomes. 
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2.4.2 Metabolic dysregulation  
Tumours escape all the normal mechanisms of metabolic control and causing 
increased levels of metabolic activity at the expense of the host (67). Terms such 
as ‘host-tumour response’, ‘parasitic metabolism of the tumour at the expense of 
the host’ and ‘the impact of the tumour on the metabolism of the host’ have all 
been used to describe this intriguing metabolic relationship between the tumour 
and host. Cancer cells interact with host cells to produce cytokines which lead to 
an acute phase response, neuro-endocrine activation and a chronic state in which 
catabolism dominates anabolism (28). Metabolic alterations have been studied 
extensively in animal models, and in various clinical settings. Interestingly in 
animal models, cachexia occurs only when tumour burden represents 10% to 40% 
of the animal’s weight, when in clinical practice cachexia develops in patients 
whose tumours rarely exceed 1kg in weight and represent about 1% of body 
weight (15). This suggests that the type of tumour is more relevant in the 
development of cachexia than the size of the tumour. This could be important for 
identifying patients who may benefit from nutrition intervention. Malignant cells 
have been shown to have a high degree of anaerobic glycolysis and produce 
large amounts of lactate, and a net uptake of amino acids by human tumour tissue, 
suggesting an increase in metabolic demands by the tumour (68).  
 
2.4.2.1 Carbohydrate metabolism 
Nitenberg and Raynard (15, 69) suggest that tumours are ‘glucose-traps’ that 
produce lactates by anaerobic glycolysis, the lactate are then oxidised or recycled 
into glucose in the liver, resulting in an energy-wasting (‘futile’) metabolic pathway. 
In time neoglucogenesis seems to increase the use of the energy substrates in 
the cancer patient during the course of cancer and does not correspond to any 
usual mechanism of homeostatic regulation (70).  Carbohydrate metabolism in 
cancer patients is also characterized by glucose intolerance, with a reduction in 
the sensitivity of peripheral tissues to insulin (54). The result is that even where 
there is sufficient consumption of carbohydrate the body may not be able to utilise 
it efficiently to provide energy. This has implications for intervention programmes 
where the underlying tumour is active. 
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2.4.2.2 Lipid metabolism 
Increased mobilization of peripheral fat and excessive oxidation of fatty acids are 
consistent metabolic abnormalities in cancer patients (71) the result of which is 
eventual depletion of lipid stores. Cachectic patients have an increase in plasma 
concentrations of glycerol and free fatty acids as well as an increase in lipoprotein 
lipase activity (enzyme required for clearance of triglycerides) (15). This seems 
to be peculiar to cachectic patients as some studies have found no differences in 
the level of glycerol and free fatty acid metabolism between weight stable cancer 
patients and healthy volunteers compared to cachectic cancer patients who 
release glycerol and free fatty acids from the adiposities in the circulation more 
quickly than healthy subjects (72).  
 
2.4.2.3 Protein metabolism 
The debate on whether a reduction in protein synthesis, an increase in 
degradation or a combination of both is more relevant to the development of 
cachexia continues (73). In cancer there seems to be lack of the adaptive 
mechanism present in other conditions (such as fasting), that allows for slow 
protein catabolism and preservation of functional lean body mass (74). There is 
often an increase in protein turnover, a reduction in muscle protein synthesis, an 
increase in inflammatory (‘acute phase’) hepatic protein synthesis, a constantly 
negative nitrogen balance and various changes in the plasma amino acid profile 
(75). There are also suggestions that total protein turnover is accelerated as a 
result of increased hepatic protein synthesis coupled with an increase in muscle 
protein breakdown (76, 77). Regional changes in protein metabolism in cachectic 
states lead to marked hypoalbuminaemia. It is thought that this is due to a 
redistribution of peripheral proteins towards the visceral protein synthesis (acute 
phase protein synthesis) of the host and/or the tumour (78).   
 
2.4.2.4 Energy Expenditure 
There is controversy over whether cancer patients have elevated energy 
expenditure, relative to malnourished non-cancer patients. Some studies report 
that it was elevated and contributed to significant weight loss (79). These studies 
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were challenged for using non-specific methodologies and heterogeneous 
groups (80). Indirect calorimetric studies show no change, a minimal increase, or 
even lower EE in cancer patients than in weight-losing non-cancer patients or 
weight-stable cancer patients (81-83). The more accepted view is that energy 
expenditure should be interpreted as a function of the type and spread of the 
tumour, the patients nutritional status and the type of treatment where appropriate 
(15). That energy expenditure normalises after tumour resection, favours the 
hypothesis that any increases in energy expenditure are tumour driven (81). 
Intervention strategies at the time of aggressive tumour activity and heavy 
treatment therefore need to be carefully considered.  
 
Figure 2 illustrates the multiple factors contributing to cachexia. These factors 
span across different categories of disrupted metabolism and nutritional intake. 
Causation of cancer cachexia is therefore multi-factorial. Different factors come 
into effect at various time points along the disease pathway. 
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Figure 2: Factors that cause and influence cachexia 
 
Reproduced with permission. source: Balogun et al., (5) 
 
2.5 Clinical manifestations of cancer cachexia 
The clinical manifestations of cachexia include weight loss, anorexia, reduced 
overall survival, decreased quality of life and reduced physical activity (4). 
Involuntary weight loss in cachexia, signals alteration of the normally precise 
controls that serve to maintain body weight and body composition throughout 
adulthood (29). Body composition changes at the chemical level result from 
imbalances between the macronutrients absorbed from the diet and the 
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metabolic fuels oxidized to meet energy requirements (29). Nutrition assessment 
tools measure directly or indirectly the adequacy of macronutrients in the body 
evidenced by anthropometric changes in body shape, size and composition. 
 
2.5.1 Weight loss 
Mechanisms other than reduced dietary intake and mechanical obstruction by the 
tumour are involved in the weight loss, including both tumour and host factors 
(32).  Progressive weight loss in cancer cachexia is in excess of that explained 
by reduced food intake and therefore is unlikely to be effectively treated by 
satisfying any deficit in intake alone (84). Besides, evidence suggests that earlier 
in the cancer trajectory, patients are characterised by periods of loss, gain and 
stable behaviour of fat and muscle until very close to death when weight loss 
becomes predominant (85). Müller et al., suggest that cachexia is not an 
unmitigated trajectory of weight loss, but is instead characterised by opposing 
forces of catabolism driven by the cancer and treatment anabolism when 
treatment is effective. These opposing forces may result in periods of stability and 
regain, as well as loss (29). This is particularly significant when considering 
nutritional intervention and windows of opportunity for maximum benefit of 
patients.  
 
Loss of body weight is a main identifying feature of cachexia and can be a major 
source of distress for cancer patients and their carers because it makes the 
disease visible and is usually taken as signifying the proximity of death (86). A 
recent systematic review showed a negative relationship between health-related 
quality of life and loss of weight, with weight loss at presentation being an 
independent prognostic variable (87). However ascites and oedema can lead to 
paradoxical weight gain (88). In advanced cachexia, water retention may occur 
as a consequence of severe hypo-albuminaemia and often accounts for an 
increase in body weight in spite of severe body wasting (6). These are common 
prior to treatment and can also be signs that the patient is progressing towards 
refractory cachexia. Single measures may therefore mask weight loss. However 
over time, changes in body weight can still be an informative indicator of 
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nutritional decline, where rapid weight loss may be indicative of more severe 
malnutrition (15, 89).  
 
2.5.2 Fat loss/gain 
Adipose tissue acts as an insulator and lipid reservoir, storing energy in the form 
of triglycerides during periods of excess energy intake, and releasing it in the form 
of non-esterified fatty acids (88) for other organs during fasting periods. Its role 
(in particular white adipose tissue) extends to neuroendocrine control of energy 
homeostasis, appetite and immune/inflammatory responses (90). Loss of fat has 
been shown to occur alongside increased circulating free fatty acids and 
decreased triglycerides in plasma of cachectic mice (90). Morphological changes 
observed in adipocytes appear to be more severe in cachectic compared to pair-
fed (fed the same amount of food) animals, indicating that reduced food intake 
alone was not sufficient to account for the extent of fat depletion in cancer 
cachexia. Moreover there is evidence that even though patients may regain 
weight when using appetite stimulants this weight is from an increase in adipose 
tissue and not muscle mass (91). The same has also been observed in patients 
receiving parenteral nutritional supplementation (92) and those using insulin for 
treatment of cancer cachexia (93). This change in body composition may not be 
identified if inappropriate assessment tools are used. This loss of muscle mass 
or sarcopenia is a condition characterised by loss of muscle mass and strength 
which although primarily associated with aging, is also associated with 
malnutrition and cachexia (6). It is relevant in cancer cachexia in that even though 
the loss of adipose tissue accounts for the majority of the weight loss, the loss of 
muscle impacts most upon morbidity and mortality (22, 94). Patients with limited 
accretion of lean body mass show no significant improvement in quality of life 
(32).  
 
2.5.3 Muscle mass loss   
Muscle accounts for 60% of the body protein stores and its decrease is 
associated with functional impairment (6). In healthy adults, muscle mass 
remains fairly constant in the absence of stimuli such as exercise and thus protein 
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synthesis and degradation generally remain in balance. There is loss of muscle 
mass that conventionally occurs with aging (16). This loss of lean muscle mass 
occurs at the rate of approximately 1% per year after 30 years of age (95). In 
cachexia there is more protein breakdown and loss of skeletal muscle (96). This 
imbalance between anabolic and catabolic rates within muscle is responsible for 
accelerated muscle loss (6). Cancer cachexia produces a marked depletion of 
skeletal muscle with an estimated 75% fall in protein mass at 30% weight loss 
(97). Skeletal muscle loss is associated with significant increases in health risks 
and an impaired health state resulting in increased morbidity, mortality and 
hospital stay (98). Muscaritoli et al., 2010 suggested that the loss of skeletal 
muscle should be considered the most clinically relevant phenotype feature of 
cachexia. 
 
Loss of muscle mass is not restricted to patients who appear thin nor is it limited 
to loss of skeletal muscle (6). It also incorporates depletion of visceral protein 
which can be estimated by serial measures of indicators of visceral protein status 
such as transthyretin (23), retinol-binding protein (RBP) and albumin (99). Both 
correlate with decreased survival. Frailty or illnesses often lead to sedentary 
behaviour which may worsen lean body mass loss by disuse-induced 
deconditioning and deterioration in skeletal muscle mass (100).  
 
2.5.4 Inadequate food intake 
Various events occur in cancer cachexia that result in reduced food intake (below 
80% of the usual food intake (101). Reduced food intake is both a consequence 
of tumour effects and treatment-related side effects as well as a contributor to 
cachexia progression. The mechanisms by which tumour effects alter food intake 
include anorexia, nausea/vomiting, pain, taste/smell changes, fatigue, alterations 
in the central nervous system (CNS) which controls food intake, early satiety, 
decreased response to insulin, increased circulating lactate and the production 
of some cytokines (102-104). In addition the side effects of cancer treatment that 
can cause nausea and vomiting, abdominal cramps and bloating, mucositis, 
paralytic ileus and malabsorption (15, 105) may also result in decreased food 
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intake. Meanwhile local tumour effects such as pain (general or on swallowing), 
gastrointestinal obstruction, and malabsorption (103) also affect food intake. This 
is particularly common in tumours impinging on the gastrointestinal tract such as 
ovarian cancer. Oral feeding with regular food, which is preferred to enteral feeds 
or Total Parenteral Nutrition (TPN) (106), becomes complicated in cancer 
patients where ascites and/or mass compression of the gastrointestinal tract  are 
common.  
 
2.5.5 Socio-economic influence  
Healthy behaviours following a cancer diagnosis are thought to contribute to 
increased survival rates (107). Culture and socioeconomic status can strongly 
influence these behaviours. Social and economic factors have been associated 
with cancer mortality and survival (69). Financial concerns constitute an obvious 
significant barrier to changes in health behaviours. A study of some ethnic 
minority in breast cancer survivors in America showed that women understood 
that they could have been making different choices about their diet, but could not 
afford to (108).   
 
Social, cultural and symbolic understandings of the nature of food, mediate the 
effect of the changing physiology of illness, and are significant for patients, 
families and health professionals (109). The emotional meaning attributed to food 
may change with different life stages, however individuals are embedded in social 
and cultural organisations that affect decisions about what should be eaten and 
why at each stage (109). Furthermore diet and eating habits are a complex 
behavioural phenomenon that results from an interaction between where we live, 
what is available, what we can afford, how much time we have to dedicate to the 
process of procuring and preparing food, and even what we are allowed in terms 
of family traditions, societal, religious, and gender norms (110). Therefore 
research strategies focussing on both the preventative and the therapeutic impact 
of diet would benefit from sensitively factoring in cultural diversity groups (111). 
Interventions that ignore a patient’s social situation are unlikely to succeed in the 
long term (111).   
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2.5.6 Ethnicity 
Cancer research UK suggests that in the UK, there is evidence of lower cancer 
symptom awareness amongst those experiencing deprivation and those from 
Black and Minority Ethnic communities (BME) (112). They also state that there is 
evidence of inequalities based on ethnicity at each stage of the cancer patient 
pathway, starting from information provision through to palliative care. There is 
lack of evidence of documentation of ethnic variations in the nutritional status of 
cancer patients. A review of 82 physical activity trials by Speck et al., (2010) (113) 
concluded that 76% of reviewed studies did not properly describe the sample 
characteristics and race was the factor most commonly overlooked.  However, it 
has been shown that African American women although at lower risk of being 
diagnosed with ovarian cancer, they tend to present with more aggressive 
disease and experience worse survival (114). Postmenopausal African American 
women with a BMI > 40, 1 year before diagnosis and those with weight gain since 
the age of 18 were reported to have a higher risk of ovarian cancer (115). There 
is also evidence that in breast cancer patients, being overweight or obese is 
associated with a higher risk of secondary tumours, recurrence, and mortality 
(116). Black breast cancer survivors have been shown to be 70% more likely to 
be obese than their white counterparts (117). The limited data so far suggests 
that black patients are more likely to gain weight after diagnosis (118) and are 
less likely to meet physical activity or nutrition recommendations (119) Others 
have suggested, based on findings from multi-centre trial of breast cancer 
survivors (N = 692; blacks = 71) that a behavioural intervention may support 
clinically meaningful weight loss (120). 
 
2.5.7 Psycho-emotional impact 
Psychological factors that occur frequently in cancer patients such as fear, 
depression and anxiety independently affect quality of life and performance 
status. They also negatively impact on appetite and food intake (89, 121, 122). 
The distress suffered is due to disease effect, the aggressive standard medical 
treatments (surgery, chemotherapy, and radiation therapy) and related side 
effects (123-125), and fears about disease recurrence and death (126). 
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Gynaecological cancers, including ovarian cancer entail additional consequences 
because the body parts involved are emotionally charged, being associated with 
femininity, sexuality, and childbearing (127). The damage to them threatens 
female identity often causing further psychological morbidity (128). A relatively 
high prevalence of anxiety and depression has been reported with up to 21% of 
all gynaecological cancer patients found to be clinically depressed while 29% 
were above the 75th percentile for anxiety (129). A separate study showed that 3 
months following chemotherapy, 38% of ovarian cancer patients had clinical 
anxiety and another 33% were depressed (130).  
 
Traditionally women have been predominantly responsible for the procurement, 
preparation and serving of food, and through the provision of healthy and tasty 
meals, maintain harmonious family relations that symbolize love and nurturing for 
family members (131). A cancer that often results in personal struggles not only 
with food but survival itself causes a direct conflict with what could be termed 
‘natural state of being’. Studies have shown in some cancer survivors that family 
can be both a motivator and a barrier to health behaviour changes (132). Family 
members tend to continue to view women as a wife and/or a mother and expect 
them to fulfil their household and child-rearing tasks (108). The expectations are 
unlikely to be different in ovarian cancer survivors, despite that most women 
would be beyond their childbearing years. The prevalence of the psycho-social 
impact compared to other populations is discussed further with the quality of life 
findings in section 9.3 page 253.   
 
This section was used to demonstrate that factors that affect food intake are 
varied and are both internal (disease related or psychological) and external 
(socio-economic). They extend beyond the disease and its effects, to include 
family, financial and societal issues as illustrated in Figure 2. Decreased food 
intake contributes to the cancer cachexia/malnutrition conundrum and it is often 
a symptom of the underlying disease while on the flipside it will itself contribute 
to cachexia. Thus, the paradigm of mal/nutrition along the cancer trajectory is not 
static. Management of nutritional needs should therefore shift with the changing 
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needs. Life stage and its associated priorities will affect the emphasis that might 
be placed on each outcome of wellness and well-being (133). Moreover, the 
processes are intertwined such that clear lines cannot be drawn between reduced 
food intake, anorexia and cachexia. For example, tumour volume might cause 
early satiety resulting in reduced food intake, which may also be interpreted as 
anorexia (loss of appetite), which contributes to cachexia, which in turn will 
exacerbate the anorexia.   
 
2.5.8 Anorexia 
Anorexia is one of the most significant contributors to reduced food intake, 
promoting skeletal muscle wasting and therefore cancer cachexia (15). Anorexia 
and reduced food intake are physiological responses prompted by the growing 
tumour (134) and are prevalent up to 40% at diagnosis and 70% in advanced 
disease (135). It is commonly the symptom which prompts individuals to consult 
their physicians in the first place, and its alleviation can be perceived as a sign of 
effective management of the disease (136). There are still difficulties in clearly 
defining and diagnosing anorexia because of the multifactorial pathogenesis 
related to disturbances of the central physiological mechanisms controlling food 
intake and its precise neurochemical mechanisms (136). It has been suggested 
that anorexia is the most frequent and most important contributory factor in 
nutritional deterioration among cancer patients (137). The onset of anorexia 
significantly affects the clinical course of the disease (134). Food aversions 
especially related to chemotherapy treatment can exacerbate the problem of 
anorexia. Around 33% of cancer patients experience changes in the recognition 
of some tastes resulting in aversion to some foods (138). 
 
Various definitions of cachexia have been offered and include: a loss of appetite 
associated with the systemic effects of cancer (139); or a  syndrome of patients 
with malignant diseases consisting of loss of appetite, aversion of food, 
disturbances of taste and smell and a decrease of nourishment below 80 % of 
the usual food intake (101). The expert group (6) added that its pathogenesis in 
the context of cancer “is complex and multifactorial and is believed to result from 
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inflammation-driven resistance of the hypothalamus to appropriately respond to 
orexigenic (i.e. appetite stimulating) and anorexigenic (i.e. satiety stimulating) 
signals”. The question remains whether treating anorexia and improving energy 
intake will result in a long-term benefit for cancer patients with active disease 
(136). Despite this uncertainty improving anorexia and energy intake could have 
a positive impact on quality of life (140).   
 
Anorexia exacerbates the detrimental effects of tumour-related alterations of 
metabolism and is an independent prognostic factor in terminally ill cancer 
patients (141). Despite its significance, anorexia is often neglected in the clinical 
management of cancer patients.  
 
2.5.9 Weakness and fatigue  
2.5.9.1 Weakness  
The concept of cachexia and its impact has evolved to encompass functional 
components such as decreased exercise capacity and muscle strength which can 
result in adverse effects on quality of life, self-care and independence) (142). 
Impaired protein metabolism significantly impairs structure, function and 
wellbeing (143), manifesting in a number of clinical consequences, including 
reduced QoL, fitness, and the ability to sustain physiological function (143).  
 
2.5.9.2 Fatigue  
Cancer-related fatigue (CRF) is characterized by feelings of tiredness, weakness, 
and lack of energy. It may be an early symptom of malignant disease, reported 
by as many as 40% of patients at diagnosis increasing to 80% and 90% in those 
treated with chemotherapy and radiotherapy respectively (144). The exact reason 
for cancer fatigue is unknown, but it is thought to be related to both the disease 
process and treatments, including surgery, chemotherapy, and radiation therapy 
and high amounts of cytokines. Fatigue is also related to anaemia, which can be 
as a result of treatment. Other suggested mechanisms of action range from 
tumour-induced "hyper metabolic" state where tumour cells compete for nutrients 
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at the expense of the normal cell's growth and metabolism to medications used 
to treat side-effects such as nausea, pain, depression (145). A study of women 
with ovarian cancer found a positive correlation between fatigue and CA125, 
suggesting that fatigue was related to tumour burden (146). They did not find a 
significant relationship between fatigue and age, stage of disease, course of 
treatment, or depression. In a systematic review by Servaesa et al., (2002) (147), 
6 of 7 studies that investigated anaemia and fatigue found no significant 
relationship between them. However they found several studies showed that the 
intensity of fatigue strongly correlated with indicators of psychological distress 
such as depression, somatisation and anxiety. Fatigue is a significant problem 
that can persist for months and even years following completion of cancer 
treatment.  
 
2.6 The impact of malnutrition 
2.6.1 Morbidity and mortality 
Approximately half of cancer patients will have lost at least 5% of their pre-illness 
weight at presentation (148). The prevalence of cancer-related malnutrition 
ranges from 30% to 64% in inpatients and is related to an increased risk for 
adverse clinical outcome (149, 150). It is estimated that between 20% and 40% 
of patients with cancer die of the effects of malnutrition rather than of the 
malignancy itself (151),(152). For this reason there have been suggestions that 
malnutrition should be treated as a problem equal to the primary diagnosis (153). 
The risk of complications and death during the course of treatment is high for 
such patients (89). Some studies have shown mortality to depend both on the 
extent of weight loss and on baseline BMI. In a series of more than 1000 medical 
oncology patients, mortality among those with >20% loss of weight and a baseline 
BMI of <21 kg/m2 was four times that of patients with <6% weight loss and a BMI 
above 27 (154). In a study of pancreatic cancer patients, cachexia was shown to 
be significantly associated with poorer survival despite the fact that cachectic and 
non-cachectic patients did not differ in tumour size or lymph node status (155). 
Malnourished patients are at risk of increased length of intensive care and 
hospital stay, total parenteral nutritional utilisation and a delay to resumption of 
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an oral diet and for those patients who are discharged there are more 
readmissions, general practitioner (GP) visits and consultations resulting in 
increased resource utilisation and cost compared to their well-nourished 
counterparts (156). Falls and fractures are common in patients with muscle 
weakness. 
 
Each phase of the cancer survivorship continuum, that is, treatment and recovery; 
long-term disease-free living or living with stable disease or living with advanced 
cancer, is associated with different nutritional needs and challenges (157). 
However the evidence of the success of nutritional interventions to counteract the 
deleterious consequences of cancer cachexia in any of the phases is limited. 
Lack of scientific evidence to inform practice means that in general daily oncology 
practice nutrition is not often prioritised (158). Health care providers tend to 
prioritise the strength of evidence and are less likely to discuss diet with their 
patients if they perceive the evidence base as weak (159). There is a gap 
between practice and suggestions that to improve prognosis, nutrition 
intervention should be delivered as soon as the diagnosis is made and 
concomitantly with oncology treatment. This curative approach could potentially 
improve performance status (160), improve patients' tolerance to treatment (161), 
reduce postoperative complications (162), enhance immuno-metabolic host 
response (163), shorten length of hospital stay and control cancer-related 
symptoms (e.g. anorexia, nausea, among others) (103) and  improve QoL (164). 
 
2.6.2 Infections and wound healing  
Malnutrition is associated with alterations in cellular physiology and organic 
function with implications for surgical outcome and postoperative morbidity and 
mortality respectively (165-167). Malnourished patients undergoing surgery are 
more likely to have complications such as increased blood loss, fatigue, poor 
wound healing, impaired immune competence, impaired inflammatory response 
in particular impaired T cell activity and admissions to intensive care units, (103, 
168, 169). These undesirable outcomes decrease the quality of life for the patient, 
and are also costly to the health care provider. Serum albumin levels less than 
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35g/l significantly increase the risk of post-operative complications  in patients 
with no co-morbidities or dehydration (165). Co-morbidities such as chest 
infections due to decreased immunity and electrolyte imbalance with implications 
for lung function and cardiac complications are also common.  
 
2.6.3 Complications during cancer treatment  
The feasibility of complete cytoreduction is related to tumour volume and location, 
as well as a patients' ability to withstand a long operation (age, performance 
status, nutritional status) (170). Survival in patients requiring chemotherapy 
directly correlates with dose and the timely completion of the prescribed 
chemotherapeutic regimen (171). Poorly nourished patients tend to have a 
suboptimum response to therapy and have an increased risk of treatment-related 
side effects and death during the course of treatment (89). It has been shown in 
patients with advanced breast cancer that response rates are lower among those 
who had lost weight before chemotherapy (28). In a prospective study of 100 
Non-Small Cell Lung Cancer (NSCLC) patients undergoing chemotherapy, those 
who were malnourished and hypoalbuminaemic experienced major toxicities 
significantly more frequently than those who were not (172). A retrospective 
review of data gathered in 1555 consecutive chemotherapy patients with 
gastrointestinal cancer showed that patients who had self-reported weight loss 
before treatment experienced more frequent and severe toxicities (stomatitis, and 
plantar-palmar toxicity) despite being treated for a shorter period (shorter due to 
breaks in treatment being more often) (173). Failure to complete intended 
chemotherapy regime is also common and leads to increased mortality.  
 
2.6.4 Decreased physical activity 
Decreased physical activity can be due to fatigue caused by muscle wasting or 
other complications common in cancer such as anaemia. It can also be because 
of the cancer treatment. Cancer survivors particularly the elderly have been 
shown to experience a fundamental deterioration in physical functions because 
of the effect of surgical treatment, chemotherapy, and radiotherapy, and this is 
more prevalent in women than men (174). The relationship between fatigue and 
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physical activity has been demonstrated in a systematic review which concluded 
that this was associated with less daytime activity (147).  Fatigue described 
earlier can affect all areas of life by making the patient too tired to take part in 
daily activities, relationships, social events, and community activities, with a 
profound effect on their quality of life. 
 
2.6.5 Decreased quality of life (QoL) 
The World Health Organisation (1995) (140) described QoL as reflecting  a 
patient’s subjective evaluation of all dimensions of their health experience, 
including physical health, psychological state, level of independence, social 
relationships, personal beliefs, and their relationship to salient features of the 
environment. It is a multidimensional concept that includes the impact of the 
disease together with therapeutic interventions, expectations and personal 
satisfaction (30). Various aspects of a cancer diagnosis and treatment including 
anorexia and reduced energy intake often impinge on QoL as does cancer related 
fatigue which affects physical functioning and the ability to perform activities of 
daily living. Quality of life has in recent years become a critical endpoint in the 
management of cancer patients as well as the design of clinical trials (123, 136, 
175). Appropriate care of patients now requires an evolving response and 
measures to preserve and/or enhance the quality and quantity of life (123). This 
emphasis helps to shift mind-sets from goals of therapy that are focused only on 
tumour response and survival (126), to include lifestyle issues that may previously 
not have been considered as important.   
 
It is difficult to quantify the interrelationship between QoL and nutrition. This is 
partly due to the fact that it is conceptually challenging to clearly define and clarify 
the definitions and indexes of quality of life in nutrition terms (176, 177). In a 
systematic review of studies that relate QoL with nutritional status in cancer 
patients (178),  there was evidence of a correlation between nutritional status and 
quality of life. The lack of specific measures of the impact of nutritional status on 
QoL means that most studies used generic questionnaires such as the EORTC-
QLQ-30. Using non-specific tools makes interpreting data difficult because the 
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influence of underlying disease on nutritional status cannot be isolated. 
Regardless, a study of gastric, pancreatic and colorectal cancer patients with 
weight loss at presentation showed them to have significantly lower mean quality 
of life scores than patients with no weight loss (173). The poorer QoL scores in 
patients with weight loss was thought to occur because they received significantly 
less chemotherapy and developed more toxicity rather than it being due to 
reduced tumour responsiveness to treatment. A recent systematic review of the 
effectiveness of interventions in malnutrition and cachexia found that there were 
significantly greater benefits to quality of life in cancer patients who received 
nutritional oral nutritional supplements compared with routine care  (164). 
 
The detrimental effects of malnutrition in cancer patients are unquestionable. 
Recent progress towards understanding its causation and progression and efforts 
to find consensus definitions of terms are to be applauded. This is crucial for 
future efforts to manage malnutrition. Also crucial to its management is 
comprehensive assessment of the patient’s nutritional status and identification of 
clinically relevant limits. Malnutrition evolves during the course of the cancer and 
is a continuum, which will require periodic reassessment (15) to identify patients 
at risk of malnutrition and to see if they can benefit from nutritional intervention. 
At the other end of the spectrum those who are unlikely to benefit from 
interventions would be appropriately managed with symptom control. The next 
section introduces and reviews literature specific to ovarian cancer. The statistics, 
management and nutritional challenges faced by women diagnosed with the 
disease are considered.  
 
2.7 Ovarian cancer 
2.7.1 Statistics 
Ovarian cancer has the highest mortality of all gynaecologic malignancies (179). 
It is the 5th commonest women’s cancer in the UK, after breast, bowel and lung 
and endometrial or womb cancer. There were 7116 new cases of ovarian cancer 
diagnosed in the UK in 2011, and 4271 deaths from it in 2012 (180). It is mainly 
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a disease of the older post-menopausal woman, with almost 85% of cases being 
diagnosed in women over 50 years. A very small proportion of the cancers are 
detected at a localized stage when the disease can be cured successfully. About 
two-thirds of patients are diagnosed with advanced stage disease with regional 
or distant disease (181, 182). Despite aggressive surgery and chemotherapy, the 
prognosis for these women is poor, with an overall 5-year survival rate of around 
30%. Survival of ovarian cancer patients has remained relatively unchanged for 
almost three decades (183). Table 1: shows the detailed 5-year survival rates of 
2008 according to Cancer Research UK (CRUK). These figures suggest that 
around 46% of women diagnosed with ovarian cancer now survive beyond 5 
years, in contrast to the previous 30%. It is however evident that that higher 
survival is due to women diagnosed with early stage disease (stage 1 & 2). The 
general poor outcome in late stage disease is due in part to the lack of effective 
prevention and early detection strategies. Significant research is underway to 
develop highly sensitive and specific early detection tests that are minimally 
invasive (184).  
 
It is estimated that at diagnosis only 15% of ovarian cancer is localized to the 
ovary, 17% is regional, and the majority, 62% occurs as distant disease (185). 
Although ovarian cancer has historically been called the “silent killer” meaning 
that it does not normally manifest symptoms, in retrospect, many patients will 
note a several-month history of vague abdominal discomfort that is generally 
nonspecific (186). Recent evidence shows ovarian cancer does manifest with 
early symptoms of bloating, abdominal pain, feeling full after eating, frequent 
urination, and irregular menstrual bleeding but that these are variable between 
patients and often misdiagnosed as benign gastrointestinal and gynaecological 
issues and are consequently not believed to represent serious underlying 
pathology (187). As such, 75% of ovarian cancer is diagnosed late after the 
cancer has reached stage III or IV (188). Malignant ascites, a build-up of fluid in 
the peritoneal cavity secondary to cancer is common in women with advanced 
disease. It often makes women unwell and has been described as the worst 
experience of the cancer journey (189). Around 77% of all newly diagnosed 
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patients with ovarian cancer have ascites and another 31% develop ascites at 
first relapse (190).  
 
Table 1: The Five-Year Stage-Specific relative survival rates of adults aged 
between 15 and 99 years in England and Wales for 2004-2008 
*percentages may not add due to rounding  
Source: Adapted from CRUK http://www.cancerresearchuk.org/cancer-info/cancerstats 
(Accessed April 2014) 
 
Although the 5-year survival rates of ovarian cancer are predicted to increase to 
about 46%, they continue to fall beyond the 5 years to 35 % at 10 years as shown 
in Table 2.  
 
Table 2: The One, five and ten-year net survival (%) predicted for patients 
diagnosed in 2010-2011 in England and Wales 
Adapted from CRUK (180), (accessed Aug 2015) 
 
2.7.2 Causation 
The cause of ovarian cancer continues to baffle scientists. Advances in research 
now point to ovarian cancer being a general term for a series of molecularly and 
etiologically distinct diseases that simply share an anatomical location (183). 
Stage at 
diagnosis 
Number of cases 
in each stage 
% of all cases 
5-year relative 
survival (%) 
Stage I 424 29 92.0 
Stage II 62 4 55.1 
Stage III 652 45 21.9 
Stage IV 216 15 5.6 
Unstaged 89 6 27.6 
All stages 1 443 100* 43.5 
 1yr survival (%) 5-yr survival (%) 10-yr survival % 
Net survival 72.4 46.2 34.5 
95% Lower Confidence 
Limit 
72.4 45.9 33.8 
95% Upper Confidence 
Limit 
72.5 46.4 35.3 
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Pathological and genomic findings indicate that many ovarian cancers are 
derived from non-ovarian tissues and that the different histological types share 
few molecular similarities (191). Although now generally accepted that the distal 
fallopian tube is the likely source of high-grade serous ovarian cancers, evidence 
persists that some high grade serous tumours originate from the epithelial surface 
of the ovary (186). There is a strong epidemiological link between clear cell and 
endometrioid cancers with endometriosis (192). The known types of histological 
subtypes of ovarian cancer are shown in Table 3. 
 
Table 3: The known histological subtypes of epithelial ovarian cancer (EOC) 
Adapted from Engelberth et al., 2014 (186) 
 
Advances in molecular biology and the emergence of new technologies means 
new strategies for prevention, early detection and treatment of the disease may 
be identified. These may involve the development of “personalized medicine,” 
where prevention, detection and treatment are aimed at the specific molecular 
mechanisms of an individual tumour and its microenvironment, as well as at the 
specific genetic and biologic profile of the host (183). Some lifestyle factors 
including physical activity and obesity are thought to play a role in ovarian cancer 
risk and mortality (193).  
 
Histological subtype Percentage of EOC 
cases (%) 
Tissue of origin 
Serous, high grade (type II) 70 Fallopian tube fimbria 
Serous, low grade (type I) <5 Fallopian tube fimbria 
Clear cell (type I) 10 Endometrial/endometriosis 
Endometrioid (low grade, 
type I; high grade, type II) 
10 Endometrial/endometriosis 
Mucinous (type I) <5 - 
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2.7.3 Treatment  
Treatment of ovarian cancer predominantly focuses on the primary diagnosis and 
has been said to neglect the concomitant malnutrition which portends an 
unfavourable postoperative risk of complications and poor recovery (194). 
Standard treatment includes cytoreductive (debulking) surgery, chemotherapy 
and/or radiotherapy. The specific combination depends on prognostic factors 
such as stage, tumour grade and histology (195). Studies dating back more than 
30 years have consistently demonstrated an inverse correlation between the 
volume of tumour remaining at the completion of initial surgery and overall 
survival (OS) for patients with ovarian cancer (196). Therefore the goals of initial 
surgery in ovarian cancer are to diagnose and stage disease and to provide 
therapeutic benefit with cytoreduction. The terms “optimal” and “suboptimal” refer 
to the size of the largest residual tumour nodule that remains after debulking 
surgery: 1 cm or less is considered optimal, and greater than 1 cm suboptimal 
debulking (196). Patients with a high risk of major morbidity or mortality from 
primary debulking receive neo-adjuvant chemotherapy (197). This treatment 
pathway shows a decreased survival when compared to optimal or complete 
debulking (198, 199). The decision of which patients are best suited to undergo 
neo-adjuvant chemotherapy is not readily agreed upon.  Despite progress in the 
use of imaging in recent years, there are still no objective criteria that enable 
gynaecological oncologists to determine this. Precise histologic diagnosis and 
accurate staging are required before chemotherapy treatment since 
chemotherapy regimens and prognosis are determined by the type and stage of 
the disease (198). Ovarian malignancies are surgically staged according to 
International Federation of Gynaecology and Obstetrics (FIGO) staging system 
(24) outlined in Table 4. Stage II disease is the least commonly diagnosed stage 
of ovarian cancer. This is likely because there is no anatomic boundary between 
the pelvis and upper abdomen. If disease has spread outside the ovary to pelvic 
structures, it is also likely to spread to the upper abdomen. Due to the observed 
higher recurrence rate seen for stage II disease, the Gynaecologic Oncology 
Group (GOG) is now including stage II in the category of advanced disease for 
trial purposes (200).  
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Table 4: FIGO staging and prognosis of ovarian cancer 
Reproduced with permission. Source: Jelovac et al., (188) 
 
2.7.4 Prognosis 
Biochemical and histological prognostic factors in ovarian cancer are known to 
include stage, tumour histology, grade, and cytology (201-203). Performance 
status, residual tumour volume and presence or absence of ascites have been 
FIGO 
Stage Characteristics 
Stage 
distribution 
10-year 
survival rate 
I Disease confined to the ovaries 
20% 73% 
IA One ovary, capsule intact, no ascites 
IB Both ovaries, capsule intact, no ascites 
IC Stage IA or IB plus ascites or washings, 
capsule ruptures, tumour on ovarian 
surface 
II Disease spread confined to the pelvis 5% 45% 
III Disease confined to the abdominal cavity, 
including surface of the liver; pelvic, 
inguinal, or para-aortic lymph nodes; 
omentum or bowel 
58% 21% 
IIIA Negative lymph nodes, plus microscopic 
seeding of peritoneal surface 
IIIB Negative lymph nodes, peritoneal 
implants <2 cm 
IIIC Positive lymph nodes and/or abdominal 
implants >2 cm 
IV Spread to liver parenchyma, lung, pleura, 
or other extra-abdominal sites 
17% <5% 
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shown to be independent predictors of survival in patients with epithelial ovarian 
cancer (202, 204, 205). Change in body weight during primary chemotherapy 
(206) and malnutrition (207) have both been reported as potential prognostic 
factors. Patients diagnosed with ovarian cancer are 19 times more likely to 
present with a poor nutritional status before treatment compared to patients with 
benign conditions or endometrial cancer (208). Malnutrition has been reported to 
some extent in 67% in this patient group in retrospective studies (209). This is a 
problem that requires proactive management. Challenges to managing the 
disease remain and much is still unknown; for example why patients with the 
same ovarian tumour characteristics (histological type, stage, and grade), will 
experience variations in survival. This has previously driven extensive research 
efforts on molecular prognostic factors to enable more efficient and targeted 
therapeutic regimens (210). Lifestyle factors such as nutrition and physical 
activity are thought to contribute to prognosis, disease free survival and the 
response to complications from treatment (210).  
 
2.7.5 Nutritional challenges 
Cancer is a challenging disease. However gynaecological cancers, and ovarian 
cancer in particular entail additional consequences beyond those common to 
other cancer patients (211). The location of the ovarian tumour deep in the 
abdomen limits the possibility of a precise early diagnosis. Late diagnosis is 
associated with advanced disease, which in turn is associated with worsening 
nutritional and performance outcomes. Patients tend to have 1) a reduced ability 
to eat (feeling too full too quickly, nausea and vomiting), 2) bowel obstruction and 
sometimes 3) diarrhoea, the consequences of which may cause patients to stop 
eating. In addition to the systemic and metabolic disturbances and treatment 
effects discussed in earlier sections, the psychological impact of a disease arising 
in a reproductive organ consequently reduces appetite and nutritional intake 
(128).  
 
A study by Fuchs-Tarlovsky et al., (2013) comparing nutritional status of 120 
women (57 with ovarian cancer and 63 with benign tumours), showed 
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measurements of skin-fold thickness at four different sites and arm circumference 
to be statically lower in the cancer group (p < .05). Body fat and protein reserves 
appeared to be significantly lower when measured by the Siri equation but not 
when measured by Dual Energy X-Ray Absorptiometry (DXA) scan or Bio-
Electrical Impedance (BIA). Biochemical parameters like albumin, transferrin, 
haemoglobin, lymphocytes levels were significantly lower in the cancer group p 
< .05) (212). This is one of a few studies where comprehensive nutritional 
assessment was performed in a homogenous ovarian cancer population. The 
findings support the school of thought that nutritional management should be 
implemented as soon as possible in patients diagnosed with ovarian cancer. 
Evidence suggests that nutritional deterioration in ovarian cancer patients 
continues as they enter into treatment. Six months post diagnosis ovarian cancer 
patients (including women who start off being overweight or obese), show weight 
loss and a significant decrease in their BMI and serum albumin levels (208). 
Another study by Gil et al., also prospectively assessed nutritional status in 
patients with ovarian cancer (213), using weight and body composition. They 
found that women lost weight following surgery but regained it slowly over the 
following year and did not lose muscle mass. As such they did not find any 
changes in Body Cell Mass (BCM) over the 12-month period following treatment. 
It must be noted that BCM is a nonspecific measure of body composition which 
includes all the metabolically active tissues such as muscle, organs, intracellular 
and extracellular water, and bone tissue. An increase in intra/extracellular water 
(hydration/ascites) for instance may mask a decrease in muscle mass. 
 
Literature and advice on nutritional management of patients undergoing 
treatment for ovarian cancer is not clear and recommendations made by advisory 
bodies in Europe, America and Australia for cancer patients lack evidence and 
are largely based on expert opinion (214). For example it is still not clear which 
patients should be treated aggressively and what mode of therapy should be 
pursued in women with bowel obstruction (215). Lack of accurate information can 
disempower women and lead to erroneous beliefs or fears that may constitute 
barriers to effective management of disease and treatment related symptoms 
(216). Provision of factual information can counter misconceptions and help 
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patients to develop accurate expectations (216) and enhance feelings of control 
(217). An effective patient-clinician partnership will empower a woman to face the 
fight of her life (183). 
 
Understanding the roles and goals of both the physician and patient, clear and 
honest communication and a balance of power are necessary tools for involving 
patients in the management of their nutritional care. 
 
2.8 Nutrition care 
Nutrition care refers to the management of patients’ nutritional needs and 
includes nutrition screening, nutrition assessment and nutrition 
support/intervention. It encompasses formulation of a nutrition care plan, 
implementation of the plan, patient monitoring, evaluation of the plan, evaluation 
of the care setting, and reformulation of the plan or termination of therapy (218). 
These stages are discussed further in the following sections. Implementing 
nutrition care plans in cancer patients has proved very challenging for reasons 
discussed below. 
 
2.8.1 The challenges  
One of the challenges faced by oncology clinicians and researchers in the 
nutrition field has been that there are no universal accepted standardized criteria 
for assessing malnutrition indices (8). Historic definitions for malnutrition 
syndromes had many limitations including, poor specificity, sensitivity, and inter-
observer reliability and lack of validated diagnostic criteria (219). Misdiagnosis of 
malnutrition is said to be frequent alongside confusion caused by the not so clear 
and overlapping definitions. Disease causes a series of metabolic and functional 
changes in earlier stages, and these changes are only later demonstrable by 
anthropometric changes (body shape, size and composition) (8). For this reason 
nutritional assessments should consider the physiological requirements and 
nutritional intake, functional status and body composition (148) and not just one 
of these.  
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 Lack of validated, scientifically sound, standardised tools with sufficient 
sensitivity and specificity to identify various levels of malnutrition means that the 
impact of underlying disease, hydration state, inflammation etc. cannot always be 
separated from nutritional status. Unclear diagnostic criteria has compounded the 
problem and led to grouping together of different stages of malnutrition, instead 
of individualised assessments that take into consideration function and possible 
treatment options. Progress had previously been hampered by overlooking the 
nutritional state of patients in pre-surgical assessments (54) and the lack of 
training of healthcare practitioners in assessment and diagnosis of malnutrition.   
 
The evolving challenge of malnutrition now also relates to the increasing obesity 
epidemic, which can mask the underlying lethal muscle wasting (16), resulting in 
a combination of excess weight and reduced muscle mass and/or strength 
(sarcopenic obesity). The picture of a cachectic patient is no longer just the 
classical underweight patient. This also challenges the traditional methods of 
assessment that largely rely on weight assessment.  
 
This clinical picture was well painted by Baracos (220) who said,  
“We were surprised to record an average of fat mass in excess of 20kg, in a 
cohort of metastatic colorectal cancer patients at one month from death, in spite 
of preceding weight loss and large burden of metastatic disease”. 
 
The complexity of the malnutrition/cachexia syndrome continues to draw 
attention from specialists. Expert groups have met to define terms and also set 
guidelines, criteria and frameworks for assessment. These definitions are based 
on the current scientific understanding of the effect of the disease on nutrient 
intake and body composition. Universally accepted definitions and parameters 
can potentially propel clinical practice forward and also provide a unified platform 
on which to carry out research. Unfortunately as knowledge increases these 
guidelines are bound to change.  
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2.8.2 Nutritional screening 
Nutrition screening refers to a process to identify an individual who is 
malnourished or who is at risk for malnutrition to determine if a detailed nutrition 
assessment is indicated (218). An ideal screening tool should be easy to use, 
standardized, rapid, non-invasive, and cost-effective to identify cancer patients at 
nutritional risk in daily clinical practice (221). The Nutrition Screening Survey in 
the UK and Republic of Ireland (2011), reported that the ‘Malnutrition Universal 
Screening Tool’ (‘MUST’) was the most commonly used nutritional screening tool 
in all care settings (i.e. 85% hospitals and 92% care homes) (222). The survey 
also found that in a few centres no screening tools were being used and/or no 
training on nutritional screening provided.  
 
Despite there being a variety of validated screening tools for nutritional screening 
in cancer patients (223-225), the guidelines issued by the National Institute for 
Health and Clinical Excellence (NICE) regarding nutritional screening, dietary 
requirements and care of people identified as at risk are often not followed (226). 
Some of the factors contributing to this include poor training, lack of time, 
competing tasks, and a perception that this basic care is less important than other 
duties or is the responsibility of others. Although the proportion of hospitals 
screening 76-100% patients on admission has increased significantly over the 
last few years (222), there is still limited information about the nutritional status in 
particular of cancer outpatients because the practice of nutritional screening is 
rarely performed in this setting (227). Where some screening has been carried 
out it is mainly to inform treatment plans such as chemotherapy dose calculation, 
rather than for the management of nutritional needs. Nutritional screening is 
particularly relevant in cancer patients as it could lead to timely management of 
weight loss, which if left untreated has undesirable consequences.  
 
2.8.3 The importance of screening 
Nutritional screening if appropriately used would 1) be carried out on all cancer 
patients in any setting (hospitals, outpatients, care homes, home) where patients 
are being cared for). 2) Identify patients including those who are well nourished, 
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malnourished, or at risk of malnutrition. 3) Be followed up with an appropriate 
referral to a specialist or for a complete nutritional assessment where appropriate. 
Nutritional screening might include: BMI, unintended weight loss, impaired food 
intake, treatment plan and disease severity (148). It can therefore be viewed as 
an instrument to determine whether additional information (via formal 
assessment) is required to warrant an intervention (218). The lack of routine 
screening procedures was shown to leave more than 50% of nutritionally at risk 
patients unidentified (228, 229). Identifying these patients provides an opportunity 
for early intervention associated benefits including improved response to 
treatments and quality of life (7). 
 
Nutrition screening is a gateway for individualised patient management. A 
nutrition care algorithm is indicated in Figure 3. This algorithm shows how 
screening links with other aspects of the care of patients. Nutritional screening 
and assessment should continue beyond the instigation of nutritional support.  
 
Figure 3: Nutritional care algorithm 
Reproduced with permission. Source: Ukleja et al., (230) 
 
Van Cutsem et al., suggested that nutritional management should be prophylactic 
rather than reactive and nutritional interventions should be an integral part of 
cancer therapy in order to improve clinical outcomes (103). In the UK, the 
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Department of Health (231) acknowledges that it is essential for management 
and regulatory structures of health and care providers to accept a wider 
responsibility which ensures that all professional staff, at all levels of the services, 
see issues around nutrition and help with eating and drinking as a core part of 
their responsibilities, for which they will be held to account (231). This raises the 
issue of expertise, training and experience amongst staff, which has long blighted 
this field. These challenges start high in the clinical hierarchy with physician 
practices, which often fall short, of addressing the nutrition aspects of cancer 
patients (232). This was demonstrated in a survey of all trainee oncologists 
(specialist registrars) in the UK. It showed 80% (n= 267) of trainee participants 
said a patient was malnourished compared to 14% of nutrition experts while only 
59 % said the patient was at risk of malnutrition compared to 86% of the experts. 
The lack of standardised guidelines and necessary training among professionals 
is clearly an issue that cascades down to affect the management of patients.  
 
2.8.3.1 Malnutrition Universal Screening Tool (MUST) 
MUST is a five-step screening tool to identify adults who are malnourished, at risk 
of malnutrition (undernutrition), or obese. It is a tool that was developed by the 
Malnutrition Advisory Group, a standing committee of BAPEN (British Association 
for Parenteral and Enteral Nutrition) in 2003. It uses a BMI score, weight loss 
score as well as an acute disease score to calculate the malnutrition risk. 
Management guidelines are provided to manage patients who are identified as 
being at risk of malnutrition. Although widely used in the NHS to screen patients, 
it is not an appropriate instrument for use in this research as it does not assess 
or characterize malnutrition. It is only able to identify at risk patients.  
 
2.8.4 Nutritional assessment 
Patients identified as nutritionally at risk through screening should have a nutrition 
assessment. American Society for Parenteral and Enteral Nutrition (ASPEN) 
defined nutrition assessment as “a comprehensive approach to diagnosing 
nutrition problems that uses a combination of the following: medical, nutrition, and 
medication histories; physical examination; anthropometric measurements; and 
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laboratory data” (218). Dietary considerations should also be included and 
increasingly functional assessments are also being considered, as muscle 
wasting becomes better understood. Nutritional assessment is more rigorous and 
complex than screening since it is carried out to confirm the presence, extent, 
degree of severity, and type of malnutrition (148). This is done by documenting 
baseline nutrition parameters, identifying nutritional risk factors and specific 
nutrition deficits, establishing individual nutrition needs, and identifying medical, 
psychosocial, and socioeconomic factors that may influence the prescription and 
administration of nutrition support therapy (230). In summary the objectives of 
nutritional assessment should include 1) identifying patients who might benefit 
from dietary nutritional intervention, 2) determining the severity and cause(s) of 
malnutrition, 3) assessing risk of morbidity and mortality related to malnutrition 4) 
assessing the efficacy of an intervention (15). 
 
Nutritional assessment is a measure of body composition. A change in body 
composition in turn reflects a change in the physiological reserves of energy and 
protein in the body (220). Methods that have been used to assess nutritional 
status include anthropometric and laboratory measurements (e.g. weight change, 
mid-arm muscle circumference, triceps skinfold thickness, serum albumin, 
transferrin assays and nitrogen balance studies, hydro densitometry and air 
displacements) (65, 148, 233-236). In more recent years, the use of other 
methods such as DXA, BIA, Computed Tomography (CT) and Magnetic 
Resonance Imaging (MRI) has increased, while the use of albumin has been 
questioned. Although some require specialised and highly skilled personnel to 
operate, and have high operational costs, they can differentiate a unit of body 
weight into specific amounts of lean or fat. 
 
In efforts to achieve universal definitions and diagnostic criteria, the previously 
mentioned consensus group (22) suggested that cancer cachexia be viewed as 
continuum (with three stages of clinical relevance: precachexia, cachexia, and 
refractory cachexia) and that not all patients traverse the entire spectrum as 
outlined in Figure 4. Once patients enter the refractory cachexia phase, the 
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burden and risks of artificial nutritional support are likely to outweigh any potential 
benefit. Therefore potential intervention is most likely to benefit patients if 
administered in the first two stages of this classification.  
 
Figure 4: The stages of cachexia 
 
Reproduced with permission. Source: Fearon et al., (22) 
 
A model of screening, assessment and management of cachexia based on the 
consensus definition and classification of cachexia is shown below in Figure 5. 
This model is similar in principle to the model of screening and assessment in 
Figure 3 except in this model, patients could be screened for cachexia, using the 
consensus suggested cut off points. A detailed multimodal management plan 
would then be implemented for those patients identified as being cachectic. The 
management plan would include for example monitoring, nutrition, exercise and 
anti-inflammatory strategies depending on the phase of cachexia the patients are 
at, but always alongside the routine optimum oncological and general medical 
management. Once patients have been assessed, their specific management 
identified then they would fit into the previous nutrition algorithm (230) with 
periodic reassessments and evaluation, but using the specific cachexia cut-off 
points.  
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Figure 5: Management algorithm for cancer cachexia 
 
Reproduced with permission. Source: Fearon et al., (22) 
 
If validated this classification and management model would help to address 
some of the previous challenges of identifying patients who might gain 
demonstrable clinical benefit from nutritional support. It would provide a rationale 
for intervention which has often relied more on inherent plausibility of the adverse 
effects of malnutrition and on individual opinion rather than scientific evidence 
(28). However as discussed earlier, this model already has limitations and some 
authors, Blauwhoff-Buskermolen et al., (2014) suggest that the diagnostic criteria 
should be revised to increase sensitivity. This proves how difficult it is to achieve 
universal acceptable criteria for such a complex syndrome.  
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2.8.5 Nutritional intervention 
Nutrition intervention in this thesis refers to nutritional support (additional or 
alternative provision of nutrients (237) and or advice or counselling provided by 
a professional to patients identified as requiring it, based on screening or 
assessment. This excludes the use of nutrition formulas given routinely as in the 
‘Enhanced Recovery after Surgery’ programmes (238), which became part of 
routine surgical management in the NHS (239). The aim of intervention is 
primarily to improve or maintain nutrient intake with the ultimate outcomes being 
to improve cure rates (including by enhancing adherence to treatment), lengthen 
survival time and to improve QoL in line with the three major goals in cancer 
treatment (123). The main interest of this thesis however is to assess 
interventions based on regular diet. These have the advantage of being able to 
be tailored to individual needs (164). 
 
The negligible response of cachexia to available pharmacological and nutritional 
interventions has for a long time led to the misconception that the complex 
syndrome of cachexia is uniquely amenable to palliative care (6). However, 
recent clinical and experimental evidence indicates that those mechanisms 
ultimately leading to the severe wasting of cachexia are operating early during 
the natural history of disease, suggesting that appropriate interventions, if 
administered early, might be effective in preventing or delaying the onset of this 
syndrome (6). As such, some authors advocate for interventions be delivered as 
soon as possible after diagnosis and concomitantly with oncology treatment (103). 
The latest consensus definition and framework for classifying cachexia also 
support this approach. Prior to reaching its refractory phase, cachexia is not 
completely irreversible, treating symptoms that affect and reduce food intake and 
stimulating appetite can help. Treating some metabolic abnormalities such as 
insulin resistance could also help to offset or delay as long as possible, the 
stepwise decline that occurs in patients with progressive disease.  
 
Nutritional intervention has in the past mainly focused on additional nutrients 
being provided and usually in the perioperative phase or towards the end of life 
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for palliation. Some of the arguments for supplementation/support in this phase 
include that optimal nutritional support provides the substrate to meet the 
increase in metabolic demand. This then limits catabolism, promotes wound 
healing, and musters a defence against infection (15). Adequate nutrition can limit 
nutritional deterioration of cancer patients and improve some metabolic and 
nutritional indices (89). Although the reasoning is sound, such short-term 
interventions have yielded short-term results associated with quick recovery from 
surgery and less infections but no long-term benefit. Moreover the selection 
criteria of patients requiring intervention have been controversial. Some 
researchers advocated for nutritional supplementation even in patients unlikely 
to show improvement (240) offering that simple dietary recommendations could 
significantly increase oral protein-energy intake in the course of treatment or in 
palliative care, regardless of whether there appears to be a beneficial effect. 
Others argued that not all patients are suitable for nutrition supplementation, and 
that it is indicated only when spontaneous oral protein-calorie intake is insufficient 
despite observance of dietary advice (15). Yet some other authors felt that in the 
case where the tumour was in situ, nutritional response is limited and is always 
lower than that observed in malnourished non cancer patients receiving 
equivalent artificial nutrition (241). Sadly the overall findings of a meta- analysis 
by Baldwin et al., 2011 (242) suggest that oral nutritional supplements have no 
overall effect on survival and that the effect on body weight and energy is 
inconsistent. The only improvements noted were in some aspects of quality of life 
and greater patient satisfaction. The weaknesses in the individual studies such 
as irregularities of the cut off points for entry into the studies provide an 
opportunity on which to build future research.  
 
Nutritional intervention strategies such as counselling and guidance have been 
used and evaluated in systematic reviews in the last few years. Some studies 
have shown that intensive individualised nutritional counselling with regular foods, 
with or without supplements, can increase nutritional intake and prevent therapy-
associated weight loss and treatment interruptions in cancer patients (188, 189). 
A study of head and neck patients undergoing radiotherapy was one of the first 
to show that dietary counselling could be more effective than adding oral 
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nutritional supplements to the diet. Patients receiving dietary counselling 
significantly improved all QoL function scores in association with an adequate 
dietary intake and nutritional throughout the entire assessment period (243). 
There have been similar reports including a systematic review and meta-analysis 
by Halfdanarson et al., 2008 (244) of the effect of diet counselling on quality of 
life in cancer patients showing that dietary counselling may provide positive 
impact on QoL. Although an improvement in survival due to nutritional 
interventions has not yet been demonstrated convincingly, evidence points to 
improving nutritional indices and QoL by addressing clinical and psychological 
factors that are affected by diminished response to oncology treatment or weight 
loss (245). The European Society for Clinical Nutrition and Metabolism guidelines 
recommend individualised counselling and the use of high-protein dietary 
supplements for gastrointestinal and head-neck cancer patients undergoing 
radiotherapy with or without chemotherapy (246). Researchers are now shifting 
the focus from nutritional endpoints such as change in food intake and their 
impact on nutritional status to nutritional end points and their impact on clinical 
outcomes and functional endpoints (164). These include outcomes such as 
survival, toxicity and quality of life. This shift in focus is partly because the overall 
effectiveness of nutritional interventions on nutritional, clinical and patient centred 
outcomes remains doubtful.   
 
2.9 Nutritional Intervention in ovarian cancer 
There is limited evidence and historical controversy over earlier published work 
regarding nutrition supplementation in ovarian cancer and other gynaecological 
cancers owing to serious methodological flaws such as variations in nutritional 
status before surgery, small sample sizes, inadequate randomization, use of 
unmatched control groups, retrospective data, heterogeneous populations and a 
failure to assess patients’ nutritional status adequately (233, 247). As such it has 
been difficult to interpret studies that have looked at the effect of nutrition 
supplementation on patient outcome. Even the recent interest in ‘Immunonutrition’ 
(a nutritional therapy aiming to reinforce the immune system's defences) 
(234) failed to yield other benefits besides reducing infectious complications and 
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length of pre- and post-operative fasting (248, 249). Furthermore there are now 
suggestions that, as crucial as nutritional intervention may be, timing of the 
intervention is also crucial and that maybe the immediate pre-operative phase is 
not necessarily an appropriate window for urgent nutritional compensation (158). 
If patients can tolerate it, oral feeding with regular diet is a preferred to enteral 
feeding or Total Parenteral Nutrition (TPN) (106).  
 
As long as there are no indisputable results on which to base rational nutritional 
support in malnourished surgical patients (250), malnutrition will continue to be a 
considerable problem for surgeons and patients undergoing major surgery and/or 
without chemotherapy (251-254). The lack of a universal agreement on a nutrition 
supplement consensus despite attempts is due to the problems highlighted 
earlier in this section but is also due to the fact that in most trials carried out so 
far, 1) malnutrition had been defined by a multitude of different scores and 
threshold values for weight loss and serum protein, 2) study designs are rarely 
dedicated to malnourished patients, 3) the quantity of calories are not sufficiently 
explained (i.e. no clarity of what was actually consumed in case of oral 
supplements) and 4) there is no clear rationale for the type and quantity of 
nutrients provided (255). These considerations make comparison among trial 
results difficult and the conclusions difficult to apply in clinical practice (250). 
There are logistical and cost challenges if nutritional support requires 
preoperative hospitalization for at least 7 to 10 days. Finally there remains the 
challenge that severe malnutrition is often an indirect sign of advanced cancer 
(unresectable tumour, metastatic spread) which usually makes patients 
unsuitable for a surgical approach (250).  
 
In a previous publication (5) our research group found that there are no 
randomised control trials that evaluated the impact of additional oral nutrients or 
other interventions such as dietary counselling in the ovarian patient group. Gupta 
et al., (256) evaluated the impact of nutrition on survival in a cohort of women 
diagnosed with ovarian cancer.  
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The other seven studies evaluated the efficacy and safety of early postoperative 
feeding compared to delayed feeding.  Even so, only one (257) was a site specific 
study of ovarian and peritoneal cancer patients, the other 6included all 
gynaecological cancers with one, Schilder et al., 1997 (258)  including non-cancer 
patients. Health outcomes related to surgical protocols were the primary outcome 
for all the studies. They showed that early postoperative feeding was safe and 
well tolerated by patients and also that there was reduction in postoperative 
complications such as infection and length of stay. This evidence supports the 
post-operative Enhanced Recovery Programme (ERP) (oral intake as soon as 
possible after surgery) currently practiced in many surgical settings in the UK 
National Health Service (259-261). There was no strong evidence of an impact 
on long-term outcomes. Gupta et al., (256) found that patients who were well 
nourished at baseline or whose nutritional status improved at 3 months had 
significantly better survival than those whose nutritional status deteriorated. 
However their baseline assessment included patients who had as well as those 
who had not had any treatment, making it difficult to objectively determine the 
impact of the intervention from that of treatment. 
 
The majority of patients treated for ovarian cancer in the UK do not receive a 
nutritional management package at the onset. There are exceptions where 
nutritional problems interfere with planned treatment and patients are referred to 
a dietician for intervention. Patients’ weight and height are assessed at first 
contact and prior to treatment. Comprehensive nutritional screening is often only 
carried out at the time of admission to hospital. Even so, there are questions of 
how well applied the assessment outcomes are to daily patient care. Similar to 
nutritional supplementation trials, most included heterogeneous populations and 
the methods used to assess nutritional status varies by trial making comparisons 
between studies difficult. Nutritional support tends to be more robust where there 
are complications to treatment (based on observations made while recruiting 
patients), or in end stages where enteral and parental routes are preferred, and 
usually as part of palliation. There is no clear evidence of what type of nutrients 
could be used to slow down or reverse cachexia and what doses and conditions 
would enable this to happen. Researchers often focus on very specific and 
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usually short time periods (around treatment) for assessment and intervention, 
whereas the processes that lead to cachexia precede any signs or symptoms and 
continue where there is underlying disease.  
 
The lethal nature of ovarian cancer and the quick relapse warrants interventions 
that target a woman’s entire life rather than just the acute phase. Healthy weight 
management, diet, and a physically active lifestyle could prevent recurrence, 
second primary cancers, and other chronic diseases for cancer survivors (157). 
While intensive nutritional therapy may be suitable for patients who are severely 
nutritionally compromised, most patients could benefit from a more patient 
centred approach. Health behaviour modification approaches leading to the 
empowerment of women to self-manage their dietary and nutritional needs may 
benefit patients as they transition from the end of primary treatment to 
survivorship.  
 
2.10  A behaviour change and self-management 
approach? 
Cancer care occurs in a continuum that stretches from prevention to the end of 
life. The identified six major phases on the cancer-care continuum are: prevention, 
early detection, diagnosis, treatment, survivorship, and end-of-life care (262). 
This implies that care needs to be viewed as long term and extending beyond the 
acute phase, a concept that challenges the previous paternalistic paradigm 
where the expert prescribes care. Moreover nutritional experts suggest that 
healthy weight management, a healthful diet, and a physically active lifestyle 
aimed at preventing recurrence, second primary cancers, and other chronic 
diseases should be a priority (157) for cancer survivors. Therefore planning for 
long term care requires an on-going collaborative relationship between patients 
and providers instead of an acute, prescriptive relationship (262). As such, there 
is need for evidence to build a sound knowledge base to ensure best practice for 
all phases of the cancer continuum where patients can potentially actively 
participate in their own care. New patient care models must enable oncology 
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providers to form partnerships with patients and families, and other providers, 
such as primary care clinicians (262). Consensus groups and health departments 
in Europe have pressed for patient involved strategies of nutrition management 
in cancer patients. The European Partnership Action Against Cancer consensus 
group in their recent policy statement speculated that cancer care is undergoing 
a paradigm shift from disease-focused management to a patient-centred 
approach in which increasingly more attention is paid to psychosocial aspects, 
quality of life, patients' rights and empowerment and survivorship (263).  
 
Understanding factors that influence behaviour change may help to improve the 
services offered in the area of dietary and nutritional support. Approaches that 
aim at changing behaviour by promoting self-efficacy and self-management of 
nutritional needs could complement clinician input and improve outcomes. Self-
management strategies may benefit patients as they transition from the end of 
primary treatment to survivorship, a period in which cancer survivors express 
feelings of absolute abandonment (264). The demands of survivorship include 
regularly participating in routine but less frequent oncology visits, understanding 
the signs and symptoms of disease recurrence, adjusting to and managing the 
late-term effects of cancer and cancer-treatment, re-establishing normal routines 
and social roles, and dealing with residual psychological distress in order to 
minimize negative impact on QoL and relationships (262). Strategies that 
incorporate health behaviour change can encourage replacement of health-
compromising behaviours by health-enhancing behaviours. Health behavioural 
change theories are designed to describe, predict, and explain such processes, 
theories or models and examine a set of psychological constructs that explain 
what motivates people to change and how they take preventive action (265). 
 
These theories attempt to explain why behaviours change and cite environmental, 
personal, and behavioural characteristics as the major factors in determining 
behaviour. For instance 30-60% of cancer survivors report making healthy dietary 
changes, but these reports are not corroborated by evidence as many studies 
have shown that many survivors do not adhere to guidelines and their lifestyles 
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are not different from those of adults without cancer (266). Understanding why 
cancer survivors find it difficult to make changes that are sustainable over time is 
important. More so because survivors have been shown to be highly motivated 
to seek information about food choices, physical activity, and dietary supplements 
to improve their treatment outcomes, quality of life, and overall survival (157). 
Understanding behaviour change presents a window of opportunity to bridge the 
gap between patients seeking information and translating that desire into action. 
This opportunity, or ‘teachable moment” when individuals might be more 
motivated to make changes that may reduce health risks (19, 267) can be 
capitalised on for delivery of strategic interventions. A healthy life lifestyle 
following a cancer diagnosis may improve long-term outcomes (268) especially 
because evidence suggests that cancer survivors are also at a greater risk than 
the general population of other conditions such as cardio-vascular diseases and 
diabetes (269). 
 
Some health behaviour models identify threats or risks as important influences 
on behaviour while others are problem oriented. If an individual perceives the 
threat or problem to be real with a potential to impact on lifestyle or livelihood then 
they may be more willing to consider changing their behaviour. Interventions and 
new behaviours are likely to be effective/sustained if they target these ‘real 
threats’ – teachable moments. Schuz et al., 2009 (270) outlined that different 
behaviour change models emphasize different aspects of approaching the 
behaviour of individuals. A few stage theory models, shown in Table 5, 
emphasise the transitioning from preintentional, intentional and actional stages 
of change, which are most relevant for making individual diet related behaviour 
changes as well as incorporation into intervention studies. 
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     Table 5: A summary of stage theories of behaviour change 
Theory Main constructs Suggested use 
Transtheoretical 
Model (TTM) (271) 
(Prochaska 1979 in 
Prochaska et al., 
1992) (272) 
This model subdivides individuals into ‘levels of motivational readiness’ along a 
continuum of behaviour change.  
The different stages are pre-contemplation, contemplation, preparation, action 
and maintenance.  
It assumes that individuals at the same stage of change face similar problems 
and barriers and can be helped by the same intervention.  
Self-efficacy and decisional balance drive the transition between stages. 
For management of 
addictive behaviours 
such as smoking and 
often by practitioners 
more than researchers. 
 
Precaution Adoption 
Process Model 
(PAPM) Weinstein 
1998 (273) in 
Weinstein and 
Sandman 1992 (274), 
This model suggests that factors that influence behaviour will be different 
depending on the threat or problem.  
The different stages are defined according to mental state.  
It identifies 7 stages along the path of awareness which are; unaware, 
unengaged, undecided, decided not to act, decided to act, action and 
maintenance. 
It explains how a person comes to take action. 
 
It is useful for the 
development and 
evaluation of behaviour 
change interventions. 
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Theory Main constructs Suggested use 
Health Action Process 
Approach (HAPA) 
Schwarzer 1992 in 
(275) 
It is a framework of motivational and volitional constructs which distinguishes 
between pre-intentional motivation processes that lead to behavioural intention, 
post-intentional volition process and actual behaviour change.  
Perception of risk, consequences and competences (self-efficacy) are key to the 
pre-intention phase.   
Self-efficacy and planning are important for the post-intentional volition phase.  
Self-efficacy is important at all stages and includes pre-action, maintenance and 
recovery self-efficacies.  
It is useful for predicting 
and explaining individual 
health behaviour 
changes  
 
This model is described 
in more detail in chapter 
8  
Model of Action 
Phases (MAP) 
Heckhausen et al., 
1987 in (276) 
This model describes successful goal pursuit in four stages of pre-decision, pre-
action, action and post-action phases.  
It considers goal setting and self-regulation as necessary for successful 
behaviour change.  
It also extends to evaluation of thoughts once a successful behaviour has been 
adopted.  
The model deals explicitly with the sequence of intentions and the cognitive 
processes involved to transform intention into action. 
 
It can be used to explain 
how people transform 
what they want to do into 
what they actually do. Its 
use extends beyond 
health, to education, 
relocation and other 
settings. 
 
 
 
80 
 
 
 
Theory Main constructs Suggested use 
Integrated Change 
Model (I-Change 
model) de Vries et al., 
2004 (277) 
This model’s assumption is that the stages of awareness of a problem, motivation 
and action (determined by self-efficacy, planning and goal setting) phases can be 
identified. 
These are influenced by behavioural, psychological, biological and socio-
economic situations.  
Behaviour is the result of a person’s intentions and abilities. The model integrates 
aspects of other models such as the Transtheoretical Model  
It is useful in explaining 
types of health behaviour 
as it takes into account 
psychosocial and 
information effects. 
Similarities between 
the models 
The models assume that individual pass through an ordered set of qualitatively different stages on their way 
to adopting health behaviour. 
Stage transitions are shifts in perception and cognition, each requiring different information. 
There are different barriers to change at different stages. Different is information required for each stage. 
Self-efficacy is key for transitioning forward between stages. 
Individuals can relapse or progress and there is no prescribed minimum amount of time to be spent in a 
particular stage. 
Models can be used in experimental studies using matched or mismatched interventions.  Individuals in a 
given stage should respond better to an intervention that is correctly matched to their stage. 
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The basic principle of the stage models of behaviour change is that individuals 
pass through different mind-sets on their way to behaviour change (270). Thus, 
interventions may be most efficient when tailored to these particular mind-sets. 
For example, patients who have not decided on changing their behaviour (non-
intenders) may benefit from confrontation with outcome expectancies and some 
level of risk communication (278). This could best be achieved by learning that 
the new behaviour has positive outcomes as opposed to the negative outcomes 
that accompany the current behaviour. In contrast, intenders will not benefit from 
such a treatment because they have already moved beyond this mind-set. They 
should benefit from planning to translate their intentions into action and actors will 
need intervention that prepared for particular high-risk situations such as disease 
relapse. Thus incorporating an appropriate health behaviour model supports 
individualisation of care.  
 
Health behaviour change models assume qualitative differences between 
individuals who have not yet decided to change behaviour and those who are 
already decided. The if-then plans (implementation intentions) (279) are 
differentially effective depending on the presence of intentions being more 
effective in individuals who have already formed intentions to act than in those 
without such intentions (280). The differentiation between intention and action is 
characterized by overt changes in behaviour supported by cognitions such as 
self-efficacy. Self-efficacy is an individual's impression of their own ability to 
perform a demanding or challenging task based upon factors like the individual's 
prior success in the task or in related tasks, the individual's physiological state, 
and outside sources of persuasion, or the belief that one can achieve what one 
sets out to do (281).  It is thought to be predictive of the amount of effort an 
individual will expend in initiating and maintaining a behavioural change. Self-
efficacy is a powerful direct influence on individuals’ health behaviour and 
supports differences between individuals who only intend to change and those 
who already act (282). It is also important for stage transitions across all stages 
of change (283). Ultimately individuals with high self-efficacy expectancies are 
thought to be healthier, more effective, and generally more successful than those 
with low self-efficacy expectancies. 
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Understanding the challenges of cancer related malnutrition and how this affects 
short and long term outcomes and that cancer survivors can benefit from being 
involved in their own care could lead to more structured administration of self-
management strategies. Management of and by oneself and taking responsibility 
for one’s own behaviour, self-management (SM) could optimise patients’ care 
and experiences. Self-management in the context of cancer care was described 
by Foster et al., (284) as the  
 
“Approaches used by the individual affected by cancer and its effects to optimise 
living with the illness and its effect” or more recently the “awareness and active 
participation by the person in their recovery, recuperation, and rehabilitation, to 
minimise the consequences of treatment, promote survival, health and well-
being.” (285).  
  
Its aim is to keep wellness in one's psychological foreground (286). An important 
aspect in addition to the core tasks and skills of SM being that it is set within the 
context of the family (287). It is a lifelong dynamic process of self-monitoring and 
self-evaluation (288).  
 
A model of self-management for cancer survivors was identified by the Expert 
Patient Programme (Department of Health 2001) as an appropriate approach to 
providing care in cancer survivors. Self-management support for cancer survivors 
is one of the five key shifts highlighted in the National Cancer Survivorship 
Initiative (NCSI) Vision Document (285). Incorporating these principles in care 
can enable and empower patients and families to care for themselves, in 
partnership with their providers, across the cancer-care continuum in the way 
they mutually determine (262).  
 
In more lethal cancers like ovarian cancer, with a 40-50% rate of recurrence 
within 3 years in women who achieve a remission after first-line chemotherapy; 
an average duration of survival of 12 to 18 months after recurrence (289) and a 
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20% and 6% 5 year survival if diagnosed with stage III and IV respectively (290), 
it is important that oncology providers work in partnership with patients and their 
families a way they mutually determine (262). The patient-clinician contact is 
likely to be more frequent than in other chronic diseases, therefore a model of 
care that involves both clinicians and patients uniting to address the nutritional 
imperatives of care when appropriate seems most suited. 
 
2.11  Summary 
Surviving ovarian cancer mainly depends on patient characteristics, tumour 
biology (stage, grade etc.) and the quality of treatment (256, 291). Whereas the 
first two are non-modifiable, quality of treatment can be. Nutrition is or should be 
an important aspect of quality of treatment that could potentially impact on patient 
outcomes. Women with ovarian cancer may have co-existing excess weight or 
obesity. In addition many will also have ascites which adds additional weight. 
Appropriate screening and assessment methods that will be able to identify 
malnutrition in these circumstances are required so that treatment is provided 
(237). Gathering objective data on nutritional status and its evolution throughout 
the disease course is a necessary first step towards effectively managing 
nutritional deterioration (143). The current situation whereby nutritional support is 
not routinely provided can be summarised as being due to 1) lack of useful 
universally acceptable and practical criteria 2) the lack of reproducible nutritional 
data, 3) lack of publications in large cohorts and 4) complex guidelines (158). The 
focus of research should include all nutritional dimensions as well as patients’ 
expectations and the impact of the disease (143). Although nutrition 
supplementation has been shown to be desirable in the perioperative period (15), 
clear evidence for its effects on recurrence rates, prognosis or long term benefits 
in quality of life has not been demonstrated. Questions that arise from this are 
whether there maybe prognostic value in focusing intervention effort at other 
phases and not just the perioperative phase in surgical patients (158) or whether 
it is time to attempt regular diet based types of interventions that provide 
structured support for women. These interventions could become part of the post 
diagnosis lifestyle of women rather than an acute intervention phase. 
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Placing a nutrition intervention package within the current treatment pathways 
requires more research evidence. Issues such as 1) When is the optimum time 
for intervention? Is it early in the pathway even prior to treatment or later when 
patients have had surgery or started chemotherapy? 2) What are the logistical 
considerations for early intervention? Is there a confirmed diagnosis (some 
patients only get diagnosed at or post-surgery), does stage, type of tumour matter 
or should all patients be treated the same 3) What nutritional package to use and 
what is the selection criteria for patients? 4) Are patients willing to allocate some 
of their time for nutritional issues or is their treatment priority? 5) Who decides 
that the patient needs intervention if it is not so severe as to affect the treatment 
plan; patient or clinician?  6) Who is best suited to deliver the intervention? and 
7) What is the role of the patient in their management? These questions could be 
answered by well-designed randomised trials. An important preliminary step is to 
characterise the nutritional status of the relatively under researched population of 
ovarian cancer patients, to identify, quantify and understand the problem of 
malnutrition in this population.  
 
The next chapter outlines the aim and objectives of the research and discusses 
the rationale behind the chosen methods of assessment and also describes the 
instruments used to carry out assessments. 
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3 Methods (background) 
3.1 Introduction to chapter 
The methods for this thesis are presented in three chapters. This first chapter 
provides an overview of the rationale, justification and design of the research. It 
also outlines the aims and objectives of the study. The research sites, patient 
pathways, and ethical and regulatory procedures are described. This chapter also 
introduces the two studies (Study A and Study B) that were undertaken for this 
thesis. Study A examined the nutritional status of women referred to two inner 
city gynaecological cancer centres for investigation and/or treatment of ovarian 
cancer. The nutritional status of women diagnosed with the cancer (cases) was 
compared to that of women diagnosed with a benign gynaecological condition 
(controls). The impact of an ovarian cancer diagnosis on well-being and eating 
habits was also investigated in study A. Study B explored women’s perceptions 
of the importance of diet and nutrition and their satisfaction with current nutritional 
support following an ovarian cancer diagnosis. It also elicited women’s views of 
what would constitute a suitable nutritional intervention. The conduct of study A, 
the tools used for assessment and analytic methods used are outlined in the 
study specific methods chapter 4. The conduct and analysis of study B are 
outlined in Chapter 7.   
 
3.2 Justification and study design 
In Chapter 2 (literature review) it was revealed that few studies have evaluated 
nutritional status in women diagnosed with ovarian cancer (5) and fewer still have 
measured nutritional status at multiple time points (204) despite evidence that 
malnutrition is a continuum which requires regular reassessment. Currently, there 
are no published Randomised Control Trials (RCTs) specifically addressing the 
treatment of malnutrition in women with ovarian cancer or investigating the use 
of nutrition assessment linked to preoperative nutritional interventions in this 
patient group (237). This is worrying considering that the incidence of malnutrition 
in women with ovarian cancer varies between 28% and 67% (1, 2) and is up to 
 
 
86 
 
75% where there is associated bowel obstruction (3). Evidence suggests that the 
mechanisms which ultimately lead to the severe wasting of cachexia are 
operating early in the natural history of disease (6). Investigation of nutritional 
changes in women undergoing diagnosis and treatment for ovarian cancer is an 
important prerequisite for future intervention research. Identifying if and when 
nutritional changes occur could inform strategies for improved timing and context 
of nutritional support and perhaps change the current conception that “nothing 
can be done, and palliation of the worst effects of cachexia is all that can be 
achieved” (6). 
 
3.3 Aims & objectives 
3.3.1 Aim 
The main aim of this thesis was to identify and characterise changes in the 
nutritional status of women with ovarian cancer from diagnosis to the end of 
primary treatment and to make recommendations for a potential future 
intervention package.  
 
3.3.2 Specific objectives  
3.3.2.1 Study A specific objectives 
The observational study (Study A) aimed to utilise multiple nutritional assessment 
methods at baseline, during treatment and at the end of treatment to address the 
following: 
 To compare the nutritional status of ovarian cancer cases with that of 
benign controls (at baseline and at the end of treatment)  
 To compare changes in the nutritional status of women over time: at 
baseline, during treatment and at the end of treatment for cases and at 
baseline and at the end of treatment for controls 
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 To assess how disease and well-being markers such as CA125, CRP and 
albumin are affected by ovarian cancer and to investigate the relationship 
between these markers and nutritional status  
 To investigate the relationship between lifestyle factors such as smoking, 
alcohol intake and menopausal and nutritional status in cases and controls 
 To investigate the impact of some ovarian cancer symptoms such as pain, 
nausea, abdominal distension etc. on nutritional status, dietary intake and 
overall health status of cases 
 To determine which nutritional assessment best evaluates nutritional 
status in ovarian cancer patients  
 
3.3.2.2  Study B specific objectives 
The qualitative enquiry (Study B) complimented study A and aimed to;   
 Explore patients’ understanding of their nutritional status, and their 
information and support needs to meet nutritional challenges  
 Explore the impact of the physiological (nutritional) changes on patients’ 
eating habits and daily activities and discover some of their coping 
strategies and recommendations for a desired intervention.   
 Explore how a health behaviour model, Health Action Process approach 
(HAPA), could be used to improve a potential future intervention package 
 Consolidate evidence from study A with patients’ perspectives of 
nutritional needs to make recommendations for future interventions 
 
3.4 Research design 
3.4.1 Mixed-method approach 
Mixed methods research is a methodology for conducting research that involves 
collecting, analysing, and integrating (or mixing) quantitative and qualitative 
research (and data) in a single study or a longitudinal program of inquiry (292). It 
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was intended through this approach, to obtain and analyse objective nutritional 
data through study A. It was also the intention to partly interpret these findings 
analytically using statistical methods as well as interpret them through patients 
narratives’ using the qualitative inquiry, study B. In this regard, qualitative and 
quantitative methods were felt to be commensurate means of generating 
knowledge (293), deriving their value from the aims of understanding all aspects 
of nutritional challenges. The study set out to characterise the nutritional status 
of women diagnosed with ovarian cancer and undergoing first line treatment. 
Women undergoing major surgical treatment for benign pelvic masses or uterine 
conditions were recruited as controls. The retrospective element of the study 
(collecting diet and weight data up to 3 months prior to assessment) provided an 
opportunity investigate the early onset of cachexia. The prospective aspect of the 
study provided an opportunity to gain knowledge of women’s nutritional status 
and support needs from the point of diagnosis. Quantitative analysis was used to 
characterise within and between group changes in nutritional status. The 
qualitative enquiry of focus group discussions provided insight into women’s 
nutritional concerns, their nutritional support needs and important clues for 
development of future interventions. More data sources and analytic perspectives 
were perceived to provide a more comprehensive insight into the challenges 
faced by women. The additional dimensions of patients own interpretation of 
events, health behaviours, emotions and personal circumstances were felt to be 
important and requiring assessment in this research.  
 
The challenges of using mixed methods include that it is a relatively new 
phenomenon with many unknowns on how best to use the methodology. 
However the point of interface our two studies, i.e. presenting for focus group 
discussion, the preliminary findings from objectively collected was considered to 
be invaluable. It provided an opportunity to obtain a real expression (women’s 
perspectives) of the complex interaction between disease, and its physiological 
impact (nutritional status) on women diagnosed with ovarian cancer. Thus the 
study would not only detect nutritional deficits using quantitative analysis, and but 
also extend the contextual understanding of the nutritional problem and support 
needs using women’s views. This approach also means that deficiencies of any 
 
 
89 
 
one method could be overcome by the combined strengths of these two 
approaches (294). Ultimately this approach has potential to increase the 
relevance of our findings for translation into clinical care, and to be a sound a 
base for future research.  
 
3.5 Research outline 
Figure 6 illustrates the five major phases of the research. Phase I involved 
reviewing literature, refining the research question and formulating research aims 
and objectives. It also involved consulting with clinical teams, designing study 
documents, and applying for ethical regulatory approvals to conduct the study. 
The second phase involved identifying suitable places to approach, consent and 
assess patients as well as setting up at a secondary research site. A substantial 
amendment for the recruitment of women with benign disease from non-
gynaecological cancer clinics was submitted to the ethical review committee in 
this phase. Recruitment of patients to the focus groups also took place in this 
phase. Data analysis and write up of the thesis followed. The final step, extending 
beyond this thesis was to disseminate the results to surviving participants. The 
research processes in each phase of the study were constantly reviewed and 
adapted in response to emerging challenges and needs. These steps are 
described in detail in subsequent sections.     
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Figure 6: Research outline 
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3.6 Research sites and patient pathways  
3.6.1 Research sites  
The main study site was a London inner city NHS Foundation Trust and teaching 
hospital. The Trust has a designated cancer centre, providing specialist care for 
women suffering from gynaecological cancer within a network of 6 Hospitals. It 
hosts outpatient and day care cancer services. The second research site was a 
different inner city hospital, with a gynaecological referral centre for a separate 
network of hospitals within London. Set up at the second site was initiated 6 
months after commencement of enrolment to boost recruitment numbers. 
Additional controls were recruited from a women and babies specialist hospital 
associated with the primary study Trust. Participants for the focus group 
discussions were also recruited from the gynaecological oncology clinics at the 
primary study site. Additional participants were recruited via the Eve Appeal and 
Ovacome charities, utilising databases of patients. Patients approached via the 
ovarian cancer charities did not need to have been treated in either of the two 
trusts. 
  
3.6.2 Patient pathway management 
3.6.2.1 Cases /Women newly diagnosed with ovarian cancer 
The network referral systems were managed centrally in each cancer centre. The 
coordinator received referral requests from unit hospitals and allocated 
appointments to patients to the appropriate consultant clinic and a slot for 
discussion in the Multi-Disciplinary Meeting (MDM). All new patients referred to 
the gynaecological centre were reviewed by the MDM. MDMs were held weekly 
in both cancer centres. While the primary study site ran a combined surgical and 
oncology clinic each week; the secondary site held separate oncology and 
individual surgeon clinics. All clinics were generally run on the same day and time 
each week.  
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Decisions about care and times to treat were originally outlined in a government 
document, The Cancer Reform Strategy (2007) part of The NHS Cancer Plan 
2000. It was a long term national strategy to prevent, diagnose and treat cancer; 
and to reform the way cancer services are delivered aimed to improve patient 
experience and to invest in equipment and the cancer workforce (295). This 
document was superseded by A Strategy for Cancer (296)). The new document 
set out an ambitious vision for improving the delivery of information to cancer 
patients and their carers. Rather than setting targets the later focuses on 
improving certain cancer-related outcomes, such as one-year-survival rates. The 
Cancer-Networks continued to be the vehicle for delivery of the cancer strategy. 
Times to treat patients (Figure 7) also remained in place. Cancer centre treatment 
protocols were based on these strategic documents guidelines and were 
particularly relevant to study A as they dictated the short recruitment window prior 
to treatment.  
 
Figure 7: The national cancer waiting times  
 
 
 
 
 
 
 
 
Adapted from UCLH Gynaecological Cancer Centre Audit; Jan - Dec 2009 
 
3.7 Negotiating access to research sites 
Study A was embedded within the clinical setting to benefit from consultant and 
other clinical team support as well as MDM meetings. This was informed by 
previous research (297) that showed that recruiting newly diagnosed ovarian 
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cancer patients or women suspected of having this cancer is particularly 
challenging. The presence of the researcher in the clinics acted as a prompt for 
consultants to identify eligible patients and alert the researcher.  
 
In accordance with standard ethical practice, researcher access to clinics, 
identification of eligible patients relied on members of the clinical team. The 
researcher relied on clinicians to identify potential patients from clinic lists and 
alert her to when patients would attend the pre-assessment clinics. Missed 
opportunities to recruit patients occurred when some clinics at site 2 coincided 
with clinics at the primary site or when appointments were added to the list at the 
last minute.  
 
3.8 Regulatory and ethical considerations 
3.8.1 Ethical approval 
Ethical approval to carry out the research was granted by The National Research 
Ethics Service North London Committee 3 in March 2011(REC reference number 
is 1/LO/0001). A substantial amendment for the change of inclusion criteria for 
controls was approved by the same ethical committee on 12 October 2011. The 
amendment allowed for recruitment of patients from general gynaecological 
clinics if they were having surgery to remove their uterus and or ovaries. Later in 
February 2012, the committee approved a Site Specific Assessment (SSA) 
authorization to recruit patients from a second study site.   
 
The initial submission was rejected as a number of ethical issues were raised by 
the ethical committee. These related to recruiting patients who are newly 
diagnosed with cancer and could be potentially suffering from nutrition related 
issues. The specific issues included that; 
 Participants were recruited at a stressful time therefore had to demonstrate 
suitability/sensitivity of materials used in recruitment including wording and 
phrasing in documents 
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 The appropriateness of raising nutritional concerns in this group of patients 
if there was no dietary advice, support or feedback offered 
 Lack of clarity on confidentiality issues particularly to do with focus group 
discussions in study B, how data was to be recorded, stored and analysed  
 
The above issues were carefully considered and addressed as described below 
for the second submission. 
 
3.8.1.1 Recruiting patients at a stressful time 
The time of a cancer diagnosis can be stressful and emotional for patients, such 
that recruiting patients at this stage requires sensitivity and empathy from 
researchers. Patients were reassured that their routine care was available to 
them throughout the study. This included dietetic referral if appropriate. Concerns 
raised by patients during any part of the study were referred to the relevant clinical 
team member with the patients’ consent. The research team consisted of staff 
with experience recruiting ovarian cancer patients around the time of diagnosis. 
They would identify concerns and distress and act appropriately if it arose. The 
first supervisor and chief Investigator is an experienced cancer nurse and health 
care researcher well versed in the sensitive nature of observation and information 
collection at the time of a cancer diagnosis. Other supervisors were professors 
and consultants in gynaecology oncology and gastro-intestinal medicine and 
could provide guidance and support if issues arose.   
 
3.8.1.2 Raising awareness without dietary support 
The very sensitive nature of nutrition around the time of diagnosis in this 
population is one of the reasons this area is under researched. However to 
provide better care there is a need for scientific evidence acquired ethically and 
sensitively at this stage. We understood that the heightened awareness caused 
by the nutrition assessments could be a potential source of concern for some 
patients, especially those who associated weight change with disease 
progression. Measures were put in place to support patients appropriately with 
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an opportunity for referral to an appropriate member of their care team for 
management of their nutritional concerns if necessary.  
 
3.8.1.3 Confidentiality 
Patient confidentiality was a priority and was protected throughout the research. 
Patients in study A were assigned a study reference number at the time of 
consent and this was used to identify them subsequently. All their data was linked 
to the study reference number; only researchers could access patient identifiers. 
Information contributed by participants in study B was treated as confidential. All 
personal identifiers were removed from the data and participants were referred 
to as respondents one to eight. Data were stored in secure password protected 
computers or in files in a locked section of the research office. The research office 
is secure and can only be accessed through a code-only-entry door.  
 
3.9  Informed consent 
3.9.1 Study A 
Written informed consent was taken when women indicated to the researcher 
that they had read the information leaflet and had sufficient time to consider 
participating in the study. Some women preferred to give written consent on the 
same day. They could do so provided the researcher was satisfied that they had 
read and understood the information leaflet. Other women preferred to take the 
information sheet home, to read in their own time. In this case permission was 
sought for the researcher to telephone them between 24 to 48 hours to find out 
whether they wanted to participate. If they did, an arrangement was made to meet 
with them when they next attended hospital/outpatient clinic to answer any 
questions they might have and to take consent.   
 
Prior to signing the consent form, the researcher ensured that women understood 
what the study was about and their right to withdraw anytime. There was an 
option for a ‘Language Line’ telephone interpreter for patients whose first 
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language was not English. Patients could also use family and friends to 
translate/interpret if they chose to. Patients were asked to consent to current and 
future use of their data and samples; they could opt out of future studies if they 
chose to. Each patient was given a copy of their signed consent form and a copy 
placed in their medical notes. A third copy was filed with the research documents 
in the secure research office.  
 
3.9.2  Study B 
Women gave their written informed consent when they attended for the focus 
group the discussions. The study had already been explained to them when they 
attended clinic or were contacted via the cancer charities. The patient information 
leaflets had been given or sent in the post upon confirmation of interest to 
participate. Women were given further opportunity to ask questions about the 
study prior to signing their consent form and therefor participating in the group 
discussions. Women recruited via the ovarian cancer charities had to provide 
evidence in the form of a hospital letter confirming their diagnosis. 
 
3.10   Doctors letters 
Patients General Practitioners (GP) were sent a letter informing them that the 
patient was participating in the study and that there was no additional action 
required on their part. GP letters were not sent to women in the focus group 
discussions as it was a one off discussion and women did not have to reveal their 
GP details. 
 
3.11   Advisory group 
A dietician, a clinical psychologist and a clinical nurse specialist were involved in 
the development of the study protocol. They and a lay member from the 
administrative team of an ovarian cancer charity (Ovacome) were selected to 
form an advisory group for the study. It was intended that they would meet 3 times 
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during the recruitment period to provide guidance and to ensure maintenance of 
the multi-disciplinary and patient-focused approach. 
 
3.12   Disseminating results 
3.12.1 Publications 
The results from the research are a core component of this doctoral thesis. 
Findings from this thesis will subsequently be written and submitted for 
publication in peer-reviewed journals. 
 
3.12.2 Communicating findings to participants 
Upon completion of the thesis surviving participants will be provided with their 
individual nutritional status results and the main findings of the study. Clinic lists 
and electronic records will be checked to ensure that patients are still alive, before 
mailing the results. Surviving cancer patients will also be telephoned in the event 
they wish to discuss the findings. In the case of controls, each participant will be 
sent their nutritional footprint as well as the main findings of the study. 
Participants will be provided with a telephone number should they wish to contact 
the researchers to discuss the results. Similarly, surviving participants who 
participated in focus group discussions will be sent a summary of the main 
findings of the study. They will be offered an opportunity of a telephone call to 
discuss the finding if they wish. 
 
This chapter has identified the methodologies that guided the design and conduct 
of this research. The strengths of the complementary nature of quantitative and 
qualitative research approaches were reviewed. Issues relating to ethical 
considerations have been made explicit. The conducts of the two individual 
studies are outlined in chapters 4 and 7. 
  
 
 
98 
 
4 Methods (The Observational Study) 
4.1 Introduction to chapter 
This chapter provides a detailed description of the eligible participants, the 
outcomes of interest and the tools used for data collection. It also outlines how 
the study was conducted and the data analysed. The numbers of recruited 
patients, completed questionnaires and assessments are outlined in a flow 
diagram.  
 
4.2 Participants/subjects 
4.2.1 Cases  
Cases were women who had a new diagnosis of ovarian cancer, primary 
peritoneal cancer or a fallopian tube cancer. These cancers are staged and 
managed similarly. Women were approached to participate in the study while they 
were having further investigations and awaiting treatment. At this point women 
were aware of the potential/confirmed malignant diagnosis. A confirmed 
diagnosis at recruitment was not necessary as women with benign disease were 
eligible to be controls for the study. 
 
4.2.2 Women with borderline/low malignant potential tumours 
These were women suspected of having ovarian cancer but were later diagnosed 
with borderline malignancy following surgery. Women with a diagnosis of 
borderline ovarian malignancy were a separate group because their tumours 
behave differently from invasive ovarian cancer or benign tumours. The growth 
of their tumours is more controlled as they do not usually invade other tissues 
although they can sometimes become cancer. 
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4.2.3 Controls 
This group originally consisted of women suspected of having ovarian cancer but 
to be later diagnosed with benign ovarian disease. In a previous study that ended 
recruitment in 2009, 363 of 741 suspected ovarian cancer patients had in fact 
diagnosed with benign disease (297). However the number controls recruited this 
way was low. This was because improved diagnostic algorithms and more 
rigorous investigations since, (biomarkers, imaging, biopsy and cytology) led to 
more accurate identification of possible ovarian cancers prior to treatment. 
Therefore increase numbers, the inclusion criteria were amended to allow 
recruitment of women having major abdominal surgery to remove their ovaries 
and/or uterus for any benign gynaecological condition such as fibroids and 
endometriosis. The additional group of women were recruited from the primary 
study site general gynaecological preadmission assessment clinics.  
 
4.3 Inclusion and exclusion criteria  
4.3.1 Inclusion criteria 
 Women aged 18 years and above being treated for the first time for a 
suspected or confirmed ovarian malignancy (including fallopian tube and 
primary peritoneal cancers)  
 Women with a suspected benign adnexal mass  
 Women undergoing a hysterectomy or removal of ovaries for a known 
benign condition  
 
4.3.2 Exclusion criteria  
 Patients under the age of 18 years  
 Women with a history of treatment for ovarian malignancy  
 Women with a history of treatment for endometrial cancer 
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4.4 Outcomes 
The primary outcome for the study was the nutritional status of participants at 
different time points (baseline, during treatment and end of treatment). Nutritional 
status refers to the state of the body in those respects influenced by the diet, the 
levels of nutrients and the ability of those levels to support normal metabolic 
integrity. There is no single acceptable method of measuring this or a marker of 
nutritional status. A variety of nutritional status, body composition and well-being 
markers were selected for the study. Current clinical practice guidelines and/or 
consensus classifications were used to categorise participant’s nutritional status. 
Where these were not available, a rationale for chosen criteria is provided.  Each 
outcome and number of times it was measured throughout the study are outlined 
in Table 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
101 
 
Table 6: A description and frequency of assessment of the nutritional status, body 
composition, disease and wellbeing outcomes investigated by the study 
*During treatment is applicable for cases only 
Assessment  Definition/description 
Frequency of 
assessment 
Body weight A measure of a person’s mass or weight Baseline, during 
treatment*, and 
end of treatment 
Body Mass Index 
(BMI) 
A measure of relative weight based on an 
individual's mass and height 
Baseline, during 
treatment*, and 
end of treatment 
Body fat 
(percentage) 
Total mass of fat in the body. It includes 
essential and storage body fat 
Baseline, during 
treatment*, and 
end of treatment 
Lean body mass A component of body composition, 
calculated by subtracting body fat weight 
from total body weight. The lean body mass 
determines the pharmacokinetic variability 
of several anticancer agents 
Baseline, during 
treatment*, and 
end of treatment 
Dry lean mass A component of body composition 
calculated by deducting total body water 
from lean body mass less   
Baseline, during 
treatment*, and 
end of treatment 
Total body water This is the total amount of fluid in a person’s 
body. Water is important as the medium of 
the body's internal environment 
Baseline, during 
treatment*, and 
end of treatment 
Extracellular water 
 
The 1/3 of total body water that is contained 
in areas outside of cells.  Such as the 
interstitial ( surrounds the cells) and  
intravascular fluids 
Baseline, during 
treatment*, and 
end of treatment 
Pre-albumin 
/Transthyretin 
A hepatic protein that is decreased in 
malnutrition and in acute and chronic 
inflammation, and thus is also a 'negative 
acute phase protein’ 
Baseline and end 
of treatment 
Disease/wellbeing    
CA125 Also known as mucin 16, it is a glycoprotein 
found in greater concentration in tumour 
cells.  It is present in greater concentration 
in ovarian cancer cells hence considered a 
reliable tumour marker  
Baseline and end 
of treatment 
C-reactive protein 
(CRP)  
An acute phase reactant protein produced 
in the liver. The levels rise in response to 
inflammation   
Baseline and end 
of treatment 
Serum albumin The most abundant protein in human blood 
plasma. It is a negative acute-phase protein 
that is down-regulated in inflammatory 
states 
Baseline and end 
of treatment 
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4.5 Data collection and tools of assessment 
For this study, nutritional status was measured using weight and BMI and body 
composition measures of body fat, dry lean mass and lean mass. Body water was 
assessed to determine its link to the presence of ascites. Serum markers of 
nutritional status, well-being as well as disease burden prealbumin, albumin, CRP 
and CA125 and were also measured. A variety of other methods for assessing 
nutritional status that include anthropometry, volume displacement, and more 
recently, direct methods including magnetic resonance imaging (MRI), Computed 
Tomography (CT) and Dual Energy X ray Absorptiometry (DXA) amongst others 
are also used. Most are expensive to use and use radiation such that they are 
only suitable in patient populations that would otherwise require their use as part 
of their on-going treatment and monitoring. They also often require a specific skill 
set and expertise to perform and to interpret the results. In the following sections 
I outline the rationale for choosing our outcomes as well describe the methods 
used to assess them. 
 
4.5.1 Body weight (BW) 
Body weight represents the sum of protein, fat, water and bone mineral mass. 
Changes in weight often reflect a change in body composition. A change in weight 
must be measured against a usual/baseline to be meaningful. Weight and weight 
change were used to assess malnutrition relative to known cut off points for 
cachexia. BW was measured using Seca scales, which are validated for use in 
clinical settings. Participants were asked to remove heavy outer clothing and 
footwear and weight was measured to the nearest 0.1kg. It was also used with 
height to calculate Body Mass Index (BMI) and for determining body composition 
using Bioelectrical Electrical Impedance (BIA) through use of a Quadscan.  
 
4.5.1.1 Weight change prior to baseline assessment 
Weight change was assessed through self-reporting for the 3-month period 
preceding baseline assessment, and through periodic measurements thereafter. 
The three month period falls in the suggested 3 to 6 month time-frame for relevant 
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weight loss in cancer patients prior to diagnosis (23). Weight change was 
recorded in the questionnaire as a loss or gain. Participants were also asked to 
provide a value/estimate of the weight change. Although self-reporting can be 
affected by recall bias, there is evidence to support the reliability of self-reported 
weight and weight history (298, 299). The consensus classification of cachexia 
(27) was used to categorise participants by weight loss into no cachexia (weight 
stable), pre-cachexia and cachexia. The refractory cachexia stage did not apply 
for weight change prior to treatment since women had not received treatment at 
that point.  
 
An additional category of ‘weight gain’ was identified as relevant for the 
identification of malnutrition in our study. Some women presented with a history 
of abdominal distension and weight gain. Since there are no guidelines/criteria 
for patients who gain weight in the classification of cachexia, a > 2% cut-off was 
chosen to represent significant weight gain. It corresponds with the 2% lower cut-
off for pre-cachexia. 
 
4.5.2 Height 
Standing height was measured using a stadiometer. Patients were measured 
without footwear and stood facing forward. Measurements were recorded to the 
nearest 0.1cm. Height on its own is not a measure of nutritional wellbeing. It was 
used with weight to calculate BMI and inputted into the BIA to determine body 
composition. Height is a constant variable and was assessed once during the 
study. 
 
4.5.3 Body Mass Index (BMI) 
Body weight and height are used to calculate Body Mass Index (BMI or Quetelet’s 
index).  It is calculated by dividing weight (kg) by the square of the height (m) (h2). 
The desirable range associated with optimum life expectancy is between 20 and 
25 (300). Values less than 18.5 are associated with under nutrition and values 
above 27 are associated with increased risk of disease. BMI provides a useful 
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way of assessing weight in relation to height, but it can be less meaningful in 
cancer patients with ascites that masks actual weight change. Used with other 
measures/markers it can help to build a comprehensive picture of nutritional 
status. 
 
Participants were classified using BMI categories adapted from WHO, 2004, and 
modified to fit with the cachexia classification by using the lower cut-off point of 
20 instead of 18.5. 
 
4.5.4 Body composition using bio electrical impedance analysis 
(BIA)  
Body composition is a measure of the relative proportions of protein, fat, water, 
and mineral components in the body. The components of body composition 
selected for this study are;  
 Body fat  
 Dry lean mass 
 Lean mass   
 Total body water   
 Extracellular water  
 
The water components were of interest because of the presence of ascites in 
many ovarian cancer patients. The components are described earlier in this 
chapter see Table 6. Lean mass and dry lean do not currently have clinically 
relevant cut off limits and are used in this study to show trends.  
 
A Bodystat Quadscan (4000), a multi-frequency Bioelectrical Impedance 
Analyser (BIA) was used to determine body composition. This method has been 
validated for use in cancer patients.  Bioelectrical Impedance analysis is a quick, 
easy, economical, portable and non-invasive method of fluid assessment and 
body composition analysis (301). It was a method of choice for this study because 
of its ease of use and its ability to discriminate between malnourished and well-
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nourished patients. It is based on the principle that in certain proportions an 
individual is considered to be within a normal range for their age, sex and height, 
and below the expected proportion maybe considered to be malnourished. It 
estimates alterations in fat-free mass (FFM) and Body Cell Mass (BCM- fat-free 
mass minus the bone mineral mass and extracellular water) as well as taking into 
account disease related fluid changes in the body (271). The latter is an important 
aspect in ovarian cancer where ascites is common.  
 
Figure 8: Quadscan and position of electrodes on patient 
 
 
 
Reproduced with permission. Http://www.bodystat.com/products/quadscan-4000/ 
 
Measurement is done by attaching small stickers (electrodes) to a patient’s wrists 
and ankles as shown in Figure 8. The patients is then connected via leads to the 
Quadscan. The machine passes a small non harmful electrical current through 
the body. The flow of this current (impedance) is dependent on the frequency 
applied. The current passes freely through the fluids contained in muscle tissue, 
but encounters relative resistance when it passes through fat tissue. At low 
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frequencies (5 kHz), the current cannot bridge the cellular membrane and will 
pass predominantly through the extra cellular space. At higher frequencies (200 
kHz) it penetrates cell membranes and the current is conducted by both the extra-
cellular water (ECW) and Intra-cellular water (ICW). By applying predictive 
equations, estimation of ECW and Total Body water and by deduction ICW can 
be made. Weight, height age and gender are required for the predictive equations 
(301). The resistance of the fat tissue to the electrical current is the 'bioelectrical 
impedance' measurement. The machine calculates and provides a summary of a 
variety of body composition measures.  
 
Use of BIA has a potential to allow for identification of early lean mass depletion 
and therefore provide an opportunity to initiate intervention (302). BIA could also 
help to characterize the type of weight changes such as increase in fat mass 
instead of FFM. A draw-back of BIA analysis is that it is reliant on ideal testing 
conditions and can be easily affected by hydration, temperature and food intake. 
This was not always possible in this study due to the opportunistic approach to 
recruitment and timing of assessments to coincide with existing clinic visits.  
 
4.5.5 Protein/Biochemical markers 
Laboratory tests are often used to detect subclinical deficiency and also to 
confirm a clinical diagnosis. Measurement of serum and plasma proteins 
including pre-albumin and albumin can provide indirect information about the 
levels of visceral protein (303). The relevance of each marker including CRP and 
CA125 for this study are described below. It was designed that biochemical 
markers be analysed at baseline and at the end of treatment so that they were 
not influenced by surgery or chemotherapy. 
 
4.5.6 Prealbumin (transthyretin) 
Prealbumin has a half-life of 2–3 days. It is a good marker of visceral protein 
status and is affected by acute variations in protein balance (303). It is therefore 
thought to be a sensitive marker of nutritional status. Its superiority over other 
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proteins such as albumin and transferrin in assessing nutritional status has been 
demonstrated in cancer patients undergoing radiotherapy (303).  
 
4.5.7 Albumin  
Serum albumin has a longer half-life of 21 days which makes it only minimally 
valuable as a nutritional marker because new steady levels can only be reached 
after 100 days (47). In conditions where malnutrition develops relatively quickly, 
its levels will not immediately reflect the effect, and recent protein intake has little 
effect on the albumin pool. Its levels are affected by impaired liver function, 
ascites and inflammation. Albumin has a strong correlation with morbidity and 
mortality (304) and is therefore often referred to as a marker of illness rather than 
of nutrition. It is used in this study as a prognostic marker of health and wellbeing. 
Albumin is routinely and regularly assessed in women diagnosed with ovarian 
cancer but not in general gynaecological patients undergoing surgery. Since the 
albumin values were extracted from patient records, controls therefore do not 
have this assessment. The study was not adequately funded to include additional 
analysis of albumin for controls. 
 
4.5.8 C-reactive protein (CRP)  
CRP is an acute phase protein synthesised by the liver to initiate or sustain the 
systemic inflammatory response. Its levels therefore rise in response to 
inflammation. It is commonly used in clinical settings to assess the extent of the 
systemic inflammatory response. Its rise can be caused by a number of 
conditions including infection and cancer (305). C-reactive protein is measured in 
mg/L. Normal levels are below 10 mg/dl or 3mg/dl in patients at high risk of 
cardiovascular disease. It was considered as a marker of inflammation in this 
study and its inclusion helped to further characterise the effect of the disease on 
women. Its association with nutritional status was also evaluated. The values of 
CRP were also extracted from patient records and matched for the dates of 
assessment. 
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4.5.9 CA125 
CA 125 is a tumour marker recommended for clinical use in the diagnosis and 
management of ovarian cancer. The normal range for CA125 is 0-35 kU/L. CA125 
is also often used to monitor the treatment of ovarian cancer or check for signs 
of recurrence. It is used in this study as a marker of ovarian cancer and a monitor 
of the effectiveness of treatment. Responders to treatment are women whose 
CA125 normalised following treatment while non-responders are those women 
whose CA125 remained above 35kU/L. CA125 levels were extracted from patient 
records.  
 
4.5.10 Clinical assessment 
Clinical assessment consists of a physical examination by treating clinician to 
detect signs which and a symptom report by patient, which were noted in medical 
records. It is most useful during the advanced stage of nutritional depletion when 
overt symptoms are present (306). For this study, the presence of obvious clinical 
symptoms such as wasting, subcutaneous fluid accumulation such as oedema 
and ascites were recorded by the researcher at each assessment. Medical 
records (electronic and case notes) and Multi-Disciplinary Team (MDT) reports 
were searched for clinical signs and symptoms that are relevant to nutrition and 
diet at each assessment time point. Medical records were also reviewed to 
confirm diagnosis, treatments, comorbidities and other relevant information 
including date of diagnosis, type of treatment(s), disease stage and grade, 
morphology, ascites drained, complications during treatment, residual tumour, 
nutritional intervention, referral to a dietician etc. This information helped to 
further characterize patients and identify other factors that could contribute to 
nutritional status.  
 
4.6 Life style and quality of life  
Life style and quality of life were assessed using questionnaires administered at 
baseline during treatment and at the end of treatment. A study specific 
questionnaire, and internationally validated EORTC QLQ-C30, FAACT A/CS-12 
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and EuroQol‐5D (EQ-5D were used to collect diet, lifestyle, health and quality of 
life information. They are described below. 
 
4.6.1 The study specific questionnaire 
4.6.1.1 Design 
The researcher designed the study specific questionnaire based on literature 
review and the objectives of the study. It aimed to collect demographic, symptom 
(including, the relevant symptoms of increased abdominal size and persistent 
bloating, persistent pelvic and abdominal pain, unexplained change in bowel 
habits, and difficulty eating and feeling full quickly, or feeling nauseous) life style, 
health and dietary information at each time point. Samples of the questionnaire 
are provided in appendix 3. The questionnaire was administered at three different 
time points (baseline, during treatment and at the end of treatment). The 
questionnaire maintained the same structure and numbering but asked questions 
that were relevant to the assessment time point. Different or additional questions 
at each time point had different numbers. For example question 1.9 in 
questionnaire 1 (baseline) asked for women’s ethnicity. As people’s ethnicities do 
not change, this question was not asked again in subsequent assessments. As 
such the question number 1.9, remained specific to that question and was not 
used again. On the other hand question 2.2 asking about change in eating habits 
is present was asked at subsequent assessments. The difference is the period of 
reference. In questionnaire 1, the change refers to three months prior to taking 
part in the study. In questionnaire 2, it refers to the period since diagnosis and in 
questionnaire 3 to the period since surgery or first cycle of chemotherapy. 
Maintaining the numbering in the questionnaire enabled easy data capture into 
the Access Database. The same template was used to capture data from all 
assessment time points. Each questionnaire being identified by the assessment 
period. Questionnaire 1 was completed at baseline, questionnaire 2 ‘during 
treatment’ and questionnaire 3 at the end of treatment. Free text boxes were 
provided at the end of the questionnaire for women to provide additional 
information if they so wished. Relevant additional free text information was 
analysed and incorporated into the qualitative inquiry. 
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4.7 Validation 
The questionnaire was validated for relevance and comprehension as follows. 
Ten clinical and research colleagues were asked to complete the baseline 
questionnaire and subsequently asked about the relevance of questions and if 
there were relevant questions that were missing.  We also wanted to know if the 
questions were clear. We asked participants to identify questions that were 
difficult to answer, confusing, contained words difficult to understand, or wording 
that was potentially upsetting. We asked for suggestions for rewording questions. 
This feedback was incorporated into the next version of the questionnaire. The 
edited version was piloted in the first 10 women to participate in the study. Their 
feedback on the questionnaire was minimal and had to do with numbering and 
typing errors. This feedback was incorporated into the final version of the 
questionnaire which then was rolled out to all women.  
 
4.7.1 EORTC QLQ-C30 
The European Organization for Research and Treatment of Cancer Quality of Life 
Core Questionnaire (EORTC QLQ-C30) (307) has been used internationally as 
generic a questionnaire to assess quality of life.  Version 3.0 of this questionnaire 
(QLQ-C30) was used in this study. The strength of QoL life assessment is that it 
rightly assumes patients to be the best source for identifying what is important to 
their well-being (207). This kind of patient involvement justifies its use against the 
negatives of the assessments being subjective and non-static. The QLQ-C30 is 
composed of both multi-item scales and single-item measures. These include five 
functional scales, three symptom scales, a global health status / QoL scale, and 
six single items. Each of the multi-item scales includes a different set of items - 
no item occurs in more than one scale. All of the scales and single-item measures 
range in score from 0 to 100. A high scale score represents a higher response 
level. Thus a high score for a functional scale represents a high/healthy level of 
functioning, a high score for the global health status/QoL represents a high QoL, 
but a high score for a symptom scale/item represents a high level of 
symptomatology/problems (307). Even if low points are obtained in the functional 
and symptom sections and quality of life points are high, the quality of life is 
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indicated as low (308). This tool has been used as a malnutrition predictor in other 
cancers (238). Because this questionnaire is not validated in non-cancer patients, 
it was not analysed for this study.  
 
4.7.2 Functional Assessment of Anorexia/Cachexia Therapy 
(FAACT A/CS-12) 
The Functional Assessment of Anorexia/Cachexia Therapy (FAACT) is a 
validated and reliable QoL questionnaire for cancer and HIV-infected patients 
with anorexia/cachexia [18]. FAACT A/CS-12 measures specific 
anorexia/cachexia-related concerns. Anorexia or loss of appetite is a common 
symptom of malignancy and causes decreased nutrient intake. It has been said 
to be one of the common symptoms prompting women diagnosed with ovarian 
cancer to see their general practitioner. The extent and prevalence of anorexia 
can be determined using the FAACT A/CS-12 questionnaire. The A/CS-12 
provides unique information relating only to anorexia and not captured by generic 
chronic illness questionnaires (135). Direct questioning using of the A/CS-12 
helps to reveal the extent of anorexia in the population. Its main disadvantage is 
that it is only validated for use in patients with cancer and suffering from anorexia, 
and has not been validated for use in our control group. Data on the presence of 
anorexia was used in the symptom and nutritional status analysis. 
 
4.7.3 EuroQol (EQ-5D) 
This was the questionnaire of choice for measuring quality of life in the study as 
it is validated for use in cancer and non-cancer patients. EuroQol (EQ-5D) 
measure of health outcome is a widely used simple, generic instrument to 
measure health in a standardized way (309). It is a generic measure of health for 
clinical and economic appraisal. It is applicable to a wide range of health 
conditions and treatments and provides a simple descriptive profile and a single 
index value for health status from which Quality Adjusted Life Years (QALY) can 
be calculated (310). The data from the dimensions can also be used to describe 
patients’ problems.   
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It is a two part generic measure of quality of life. The first part has five domains 
or dimensions which are mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression. Each of the 5 dimensions of the scale records three levels of 
severity, which are indicated by numbers. No problems are coded 1, some or 
moderate problems are coded 2 and extreme problems coded 3. These 
dimensions are interpreted in line with the goals of each research project. An 
overall health state can also be described by with a five-digit number, for instance 
12113 where each number represents no problems or some or severe problems 
on that dimension. The permutation above can be interpreted as no problems on 
the dimension of mobility, some problems on the dimension of self-care, no 
problems with respect to usual activities and pain/discomfort and severe 
problems on the dimension of anxiety/depression.  
 
The second part of the questionnaire is the visual analogue scale (VAS) which 
measures overall self-rated health status. The status is measured on a vertical, 
visual analogue scale where the endpoints are labelled ‘Best imaginable health 
state’ and ‘worst imaginable health state’. The VAS scale is from 0 to 100. The 
best health state score is 100 and the worst 0. This information can be used 
independently of the first part, as a quantitative measure of health outcome as 
judged by the individual respondents (310). This quantitative measure was useful 
in this study to provide an overall perception of health status and as a proxy for 
quality of life for cases and controls. EuroQol VAS has been used to assess 
health-related quality of life in other studies (311-313). The advantages of using 
this instrument are that it is cognitively undemanding (314), generic, can be used 
in the clinical and economic evaluation of health care as well as in population 
health. It is specifically designed for self-completion by respondents and is ideally 
suited for use in clinics, and in face-to-face interviews and is validated for non-
cancer patients too.  
 
4.8 Sample size  
The plan was to recruit 100 women, 50 women with a cancer diagnosis and 50 
with a benign diagnosis. It was calculated that this number would be statistically 
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sufficient to reveal differences in nutritional markers between cases and controls; 
assuming that up to 50 % of cases would suffer from some degree of malnutrition. 
The 50% was determined by averaging the lowest and highest estimates of 
malnutrition given in literature, i.e. between 28% (1) and 67% (2).  
 
4.9 Identification and recruitment of patients 
The researcher was responsible for the recruitment of patients at both research 
sites. Patients were identified from MDM lists, clinic lists, preadmission 
assessment lists, consultant clinics and theatre lists by a suitable member of the 
clinical team.  Patients were identified to the researcher who approached them in 
the clinic/ward and introduced the study to them. Interested patients were given 
time to read the information leaflet and decide if they wanted to participate. 
Women who were admitted for treatment, or were transferred as inpatients from 
other hospitals, were approached to participate on the ward. Some women were 
approached in the preadmission/assessment clinics. In all cases the researcher 
ensured that patients were aware of their potential cancer diagnosis before 
approaching them. Those willing gave their written consent as described in 
chapter 3 section 10. NHS Protocols for admission of patients for surgery 
changed during the course of the research. More patients were admitted on the 
morning of their surgery instead of the traditional day or more before surgery. 
This reduced the potential for contact with patients prior to treatment. 
 
Recruitment commenced in April 2011 and that of cases ended in June 2012 (1 
year and 3 months after commencement) when the recruitment target of 50 
women with a newly diagnosed cancer was reached. Women were followed up 
until the end of December 2012. Two patients were followed up in January and 
February 2013. Recruitment of controls continued until Dec 2013 due to slow 
uptake of the study. Follow-up was concluded in April 2014. 
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4.10  Assessments and data collection  
Women who consented underwent relevant assessments, gave blood samples 
as well as completed the questionnaires. Where possible data collection and 
assessments were scheduled to coincide with the clinic appointments and 
hospital visits to avoid additional attendances for patients. Assessments were 
carried out in a lockable consultation room in the outpatient clinic or on patients’ 
beds on the ward. Each assessment lasted approximately 15 minutes and 
included measurements of weight, height, and body composition using BIA as 
well as completing a questionnaire. At baseline and end of treatment patients 
donated samples of blood (2X10ml) for the assessment of pre-albumin and 
storage of whole blood for future research. In limited instances where there were 
no other scheduled clinic visits, assessments were carried out in patients’ own 
homes (with patients’ permission). Assessments were carried out at three specific 
time points as shown in Table 7.  
 
Table 7: The assessment time points for cases and controls  
 
4.10.1 Cases 
Taking part in the study involved 2 or 3 assessments depending on a patient’s 
diagnosis and treatment plan. Women who were treated with surgery alone only 
had two assessments, at baseline and at the end of treatment. They were 
considered as cured and needed no further treatment. Women who were treated 
with surgery with/or chemotherapy underwent three assessments; at baseline, 
Baseline During treatment End of treatment 
After written informed 
consent but before the 
start of any treatment 
2-4 weeks post-surgery or 
3 weeks post 1st cycle of 
chemotherapy.  
 
(only applies to women 
treated with surgery 
and/or chemotherapy) 
At completion of acute first 
line treatment of surgery + 
chemotherapy or 
chemotherapy alone 
Or 
The last assessment for 
women treated with 
surgery alone and controls 
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during treatment and at the end of treatment. Baseline assessment was the same 
for all women. It was done any time prior to commencement of treatment. The 
‘during treatment’ assessment was done when patients attended clinic following 
surgery or when patients attended for their 2nd cycle of chemotherapy. No blood 
samples were required at either of these assessments. The ‘end of treatment’ 
assessment was the last, after completion/ or termination of neo/adjuvant 
chemotherapy treatment as shown in Table 8. The end of treatment assessment 
often occurred between 3 and 6 months after completion of the chemotherapy. 
This was the identified time for the study as it was the first visit to clinic for the 
woman for follow-up (that is assuming there were no complications). If there were 
complications or the woman required further treatment, this assessment was 
done any time prior to commencing that treatment. If not possible to carry out the 
assessment for whatever reason, the next opportunity was at 6 months women 
attended for their next follow-up. In general women with successful treatment are 
followed up every three months for the first 2 years and every 6months for the 
next 3 years.  
 
4.10.2 Women with borderline malignancy 
Tumours of borderline malignancy also called tumours of low-malignant potential 
are epithelial ovarian neoplasms that are intermediate between benign and 
malignant. They are characterised by epithelial proliferation without stromal 
invasion (315). Women diagnosed with tumours of borderline malignancy were 
assessed at baseline and at the end of treatment similar to controls. Although 
surgery for borderline tumours is considered curative, at the time of this study 
follow-up regimens were similar to those for continue to be followed up similar to 
women diagnosed with ovarian cancer. 
 
4.10.3 Controls  
Controls were assessed at baseline and at the end of treatment. These women 
required no further treatment. Controls are often discharged from care following 
surgery. Their follow-up was often scheduled between 6-8 weeks following 
surgery allowing them time to recuperate.  
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        Table 8: Schedule of assessments for cases and controls 
 
 
 Treatment 
Cases Controls Borderline 
malignancy 
 
Assessment 
Early stage 
(Stage 1 & II) 
Late stage 
Stage (III & IV) 
  
Surgery Surgery 
Surgery + 
chemotherapy 
Chemotherapy 
+ surgery Surgery Surgery 
Baseline       
During treatment  
   Post-surgery -   - - - 
   Post cycle 1 of 
chemotherapy 
- - -  - - 
End of treatment  -     
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4.11  Blood sample collection and processing 
Participants donated a total of 40ml of blood, 20ml at baseline and another 20ml 
at the end of treatment. The blood was collected in 10ml standardised vacutainer 
tubes. One tube was for biochemical analysis of serum prealbumin and the other 
for whole blood sample collection and storage. The latter were processed and 
stored for use in future studies (with patient consent). Collection and processing 
procedures of blood samples were standardised to previous protocols within the 
research group. Upon collection, each tube was inverted 5 times to ensure blood 
mixed with the medium in the tube. The whole blood sample was placed in an 
upright position for one hour at room temperature. The serum sample was 
immediately placed on ice. Both samples could be processed after a minimum 
time of 1 hour or else the whole blood sample had to also be placed on ice. Both 
samples were to be processed within 3 hours of collection. Processing was done 
by spinning each sample in a centrifuge at 3000rpm. The supernatant from each 
sample was aliquoted into a secondary tube which was labelled with unique 
patient and sample ID numbers and frozen immediately at – 80 degrees. A cell 
pellet remaining after the extraction of plasma was also stored for potential future 
research.  
 
In total, two hundred and sixty eight individual samples were taken, processed 
and frozen. Twenty were from women who became ineligible to participate post 
diagnosis. At the end of the study, 126 samples serum samples were thawed and 
2ml of each sample pipetted into a separate tube. These were labelled and sent 
for analysis of prealbumin at Sheffield United Hospitals. The remainder of the 
serum was refrozen at -80 degrees Celsius. Prealbumin was analysed using 
nephelometry on a Siemens anti transthyretin reference number OUIF09 and 
Siemens Calibrator OQIM13 traceable to IRP DA470. UCLH did not offer an 
analysis service (for prealbumin) for research and the time. CA125, CRP and 
albumin values were extracted from patient records and matched for the date of 
assessment. 
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Venepuncture was performed by the researcher or phlebotomist if the patient was 
also having a routine blood test. The researcher also processed the samples 
except occasionally where the researcher was attending to patients. In this case 
an experienced laboratory technician assisted with sample processing in order to 
comply with the 3 hour window for processing.  
  
4.12  Food intake and dietary habits 
Data on eating habits was captured in Section 2 of the study specific 
questionnaires as well as the anorexia questionnaire. This data was used to show 
how an ovarian cancer diagnosis affects women’s diet and eating habits. Factors 
that influenced their decisions on food choices were analysed. The study 
explored whether there were differences in nutritional outcomes between women 
who reported changing their diet and those who did not. Women’s views on the 
nutritional intervention/support they received during treatment are explored and 
the relationship between such intervention and nutritional status examined. At the 
point of completing the questionnaire women had a suspected or recent diagnosis 
of ovarian cancer but had not commenced treatment. Since women were 
recruited early in their cancer journey, most had not received specific nutritional 
advice/counselling at the time, thus the study captured virgin information. The 
results of this analysis are presented in section D of chapter 5. 
 
4.13 Data capture 
Data from all original source documents collected were captured into the 
Microsoft Access Database. The researcher created in this database, templates 
of every form and questionnaire used to collect data. Data was manually captured 
from each document into the database. The database is safe and under the 
custodianship of UCL/UCLH data protection policies. For this reason, all data 
including patient identifiers were captured. The assigned unique volunteer ID was 
used to label every form, questionnaire or sample for each woman. Retrieving 
data from the database for analysis was done by running data queries. These 
allow the researcher to select required data, for the required time point for each 
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specific woman or groups of women. This data was then transferred into a spread 
sheet, Microsoft excel or IBM SPSS for analysis.   
 
4.14 Analysis  
Nutritional status was categorised using clinical and international consensus 
criteria for the classification of malnutrition and/or cachexia where applicable. 
Except in the case of unverifiable errors, all data were included in the analysis 
including some outliers (high and low weight and BMI). It was important that all 
data were represented in the study. Missing data were excluded from analysis. 
Data were missing due to patients being lost to follow-up, withdrawal of consent 
to continue in the study, declining specific assessments such as giving a blood 
sample if already given blood for routine tests, patients being too ill on the day of 
assessment and patients not returning questionnaires. Women who did not return 
outstanding questionnaires were telephoned and/or written to, to remind them to 
do so. 
 
4.14.1 Statistical analysis 
IBM SPSS Statistics 22 was used to analyse the data. Descriptive analysis was 
performed to characterise the study population. Within group differences between 
time-points were analysed using non parametric tests, the related sample 
Wilcoxon signed rank test. Differences between cases and controls were 
explored using the Mann-Whitney U test while the Kruskal-Wallis test was used 
to show associations between nutritional status and presence or absence of 
symptoms. The relationships between different variables and outcomes were 
explored using, Spearman’s correlation and calculation of the Odds ratio. 
A p <0.05 was considered to be statistically significant.  
 
4.14.2 Quality of life 
The Euroqol EQ-5D questionnaire was analysed using SPSS to determine the 
proportions of women reporting problems with each dimension. The EQ-5D 
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scores were presented as a health profile, using frequencies of reported problems 
for each level of each dimension. Problems with relevant dimensions were 
correlated with nutritional outcomes. The VAS scale was analysed using the non-
parametric related sample Wilcoxon signed rank test to compare heath statuses 
across time points and the Mann Whitney U test to compare cases and controls. 
The Kruskal Wallis test was used to determine association between health status 
with symptoms and type of treatment while Spearman’s correlation was used to 
determine the relationship between quality of life and nutritional status. These 
findings are presented in Chapter 6. 
 
4.15 Recruitment flow diagram  
Participants were sub-grouped by diagnosis into cases, borderline malignancy, 
and controls. Those who, following surgery did not meet the inclusion criteria 
were excluded from analysis. Participants were lost to follow-up if they died (2 
cases), relocated (2 cases) or withdrew consent (1 case). Some declined to be 
assessed or were no longer interested in further assessments (5 controls and 
one woman with a borderline malignancy). Some women did not respond to 
telephone contact or return the questionnaire. These all resulted in some missing 
data. Only four women were diagnosed with borderline ovarian malignancy and 
were therefore excluded from analysis due to the small sample size. A flow 
diagram showing the numbers of patients approached, recruited and the 
assessments undertaken are shown in the flow diagram in Figure 9.  Further 
findings from this study are presented in the next chapter. 
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Figure 9: The recruitment flow diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Borderline 
malignancy 
(n=4) 
Approached (n=193) Declined to participate  
Too unwell (n=11) 
Prioritising treatment 
(n=21) 
Not interested (n=28) 
Time constraints (n=30) 
 
 
 
 
 
Recruited (n=103) 
Cases 
(n=58) 
Excluded: not 
meeting inclusion 
criteria 
(n=13) 
Baseline assessment  
(n=102)  
1 death  
Treatment and Diagnosis 
Controls  
(n= 27) 
Analysed 
  
Baseline  
Weight (n = 57) 
BIA (n = 40)  
Prealbumin (n = 46) 
Albumin (n1 = 56)  
CRP (n = 51) 
CA125 (n = 55) 
Questionnaires (n = 47) 
 
During treatment 
Weight (n = 48) 
Questionnaires (n = 42) 
BIA (n = 34) 
 
End of treatment 
Weight (n = 48) 
BIA (n = 45) 
Prealbumin (n = 42) 
Albumin (n = 46) 
CRP (n = 46) 
CA125 (n = 45) 
Questionnaires (n = 38) 
 
 
Excluded from analysis: 
(sample size too small) 
Analysed  
 
Baseline  
Weight (n =27) 
BIA (n = 24) 
Prealbumin (n= 24) 
Questionnaire (n=20) 
Albumin (N/A) 
CRP N/A 
CA125 (N/A) 
 
During treatment 
N/A 
 
 
 
End of treatment 
Weight (n =19) 
BIA (n = 16) 
Prealbumin (n = 14) 
Questionnaires (n = 15) 
Albumin (N/A) 
CRP N/A 
CA125 (N/A) 
n=89 
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5 The observational study results Part 1: 
(patient characteristics, lifestyle, nutritional 
and biochemical statuses) 
5.1 Introduction to chapter 
This is the first of two chapters that present findings from the observational study 
A. It is divided into 4 sections. Section A provides a description of the women who 
participated in the study based on age, ethnicity, menopausal status, diagnosis, 
stage of the disease, treatment and symptoms. Section B presents results on 
lifestyle, which includes smoking and alcohol intake. Nutritional and body 
composition outcomes of weight, BMI, body fat, dry lean mass, lean mass and 
total and extracellular body water are also presented. Findings on biochemical 
markers including prealbumin, albumin, C - reactive protein (CRP) and CA125 
findings are presented in section C. Findings are presented for cases and controls 
at ‘baseline’, ‘during treatment’ and for the ‘end of treatment’ as applicable. A 
comparison is made between cases and controls where appropriate. Dietary 
changes captured using the study specific questionnaire are detailed in Section 
D. These changes relate to the period starting 3 months prior to baseline 
assessment, to assess the impact of the disease on diet and eating habits to the 
end of treatment assessment to assess the impact of treatment. Findings are 
presented on the specific diet changes, the reasons and rationale for the change 
in diet, the current practice on nutritional/dietary support as well as women’s 
suggestions for an ideal future intervention. Findings from study A show 
outcomes that were affected, how they were affected and importantly, what that 
means for the woman involved. Quality of life results are presented in chapter 6.  
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5.2 Section A: General description, disease and 
treatment 
5.2.1 Age and ethnicity 
The median ages of cases, controls and women diagnosed with a borderline 
malignancy were 60, 49 and 35 respectively. The independent samples test 
showed that cases were significantly older that controls (p < .01). The majority of 
participants were Caucasian (white British, and white other) 52/58 (91%) and 
20/27 (74%) of cases and controls respectively. There were 3/58 (5%) and 4/27 
(14%) black African/Caribbean and 2/58 (3%) and 3/27 (11%) Asian/mixed Asian 
cases and controls respectively. 
 
5.2.2 Menopausal status 
Figure 10: Percentage of menopausal and non-menopausal cases and controls 
 
 
Figure 10 shows that the majority of cases were menopausal, 38/58 (66%). Only 
7/58 (12%) were non-menopausal while 13/58 22% either did not know or did not 
provide their menopausal status information. Twenty six percent (7/27) of controls 
were menopausal while 10/27 (37%) were not. A further 37% did not provide 
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information on their menopausal status. It is expected that more controls in the 
missing group were non-menopausal due to the young median age. Increasing 
age in menopausal women is associated with a decline in metabolic rate and an 
increase in body fat. The median age of menopause in this study was 50. The 
average age of menopause in the United Kingdom is 51. 
 
5.2.3 Diagnosis  
The histological diagnoses of ovarian cancer and benign conditions of women in 
the study are shown in Table 9.  
  
Table 9: The list of the histological diagnoses of cancer and benign conditions of 
cases and controls in the study 
 
 
Cases Controls 
Histology Total Histology Total 
Tubal Cancer 1 Endometriosis 5 
Adenosquamous carcinoma 1 Serous cystadenoma 2 
Transitional cell carcinoma  1 Ovarian fibrothecoma 2 
Serous with clear cell elements 1 Benign ovary 3 
Serous with mucinous 
adenocarcinoma 
1 Mucinous cystadenoma 4 
Clear cell and endometrioid 
carcinoma 
1 Benign leiomyoma 7 
Endometrioid adenocarcinoma 2 mature cystic teratoma 2 
Mucinous adenocarcinoma 3 Brenner tumour 1 
Primary peritoneal 
adenocarcinoma 
4 Simple endometrial 
hyperplasia 
1 
Clear cell carcinoma 5   
Serous adenocarcinoma 38   
Total 58  27 
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5.2.4 Stage of disease and treatment 
The classification of cases by stage of disease, treatment type, relevant 
symptoms and weight change at baseline are outlined in Table 10. Nineteen 
percent (11/58) cases were diagnosed with early stage disease (stage I and II) 
while 46/58 (79%) were diagnosed with advanced disease (stage III and IV). One 
woman could be not be staged due to complications during her surgery.  
 
Women diagnosed with stage I & II disease were treated with surgery alone 5/11 
(45%) or surgery with chemotherapy 6/11 (55%) if cancer was also found on the 
surface of the ovary or the cytology tested positive for cancer cells. Of the 26 
women diagnosed with stage III disease, one woman was treated with surgery 
alone because she had a low-grade tumour that had been completely excised 
while 12/26 (46%) were treated with primary cytoreductive surgery followed by a 
course of chemotherapy. A further 9/26 (35%) were treated with interval 
debulking surgery, i.e. 3 cycles of chemotherapy followed by surgery and the 
remaining 3 cycles of chemotherapy given after surgery. The rest 4/26 (15%) 
were treated with chemotherapy alone. Twenty women were diagnosed with 
stage 4 disease. Only 2 women in this group were treated with primary 
cytoreductive surgery first. The majority, 15/20 (75%), were treated with interval 
debulking surgery. This is the recommended treatment for stage 4 patients with 
high metastatic tumour burden or for patients whose general condition is poor. 
Two women in this group were treated with chemotherapy alone while one 
woman died before receiving any treatment. Women treated with chemotherapy 
alone had either not shown satisfactory response to the chemotherapy, or their 
disease had progressed through treatment, which precluded successful 
debulking surgery. 
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              Table 10 : The classification of cases by stage of disease, type of first treatment, relevant symptoms at baseline and death  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
** Significant difference (Kruskal Wallis test) between early stage (I&II) and late stage (III&IV) (p < .05) 
Cases only 
FIGO stage  
1 2 3 4 Not staged Total (N) 
Participants N (%)  10 (17%) 1 (1.7%) 26 (45%) 20 (34%) 1 (1.7%) 58 
Median age (range) 56 (45-73) 46 62 (36-82) 68 (38-88) 56 - 
Treatment type 
Surgery only 5 (50%) 0 (0%) 1 (4%) 
0 (0%) 0 (0%) 5 
Surgery then chemotherapy 5 (50%) 1 (1.7%) 12 (46%) 2 (10%) 1 (100%) 21 
Chemotherapy then surgery 
0 (0%) 0 (0%) 9 (35%) 15 (75%) 0 (0%) 24 
Chemotherapy only 
0 (0%) 0 (0%) 4 (15%) 2 (10%) 0 (0%) 6 
No treatment 
0 (0%) 0 (0%) 0 (0%) 1 (5%) 0 (0%) 1 
Relevant symptoms  
Distension/Swelling 4 (40%) 0 (0%) 13 (50%) 13 (65%) 1(100%) 31 
Pain/Discomfort 5 (50%) 1 (100%) 15 (75%) 10 (50%) 1(100%) 32 
Ascites** 3 (30%) 1 (100%) 21 (81%) 16 (80%) 0 (0%) 41 
Nausea/vomiting/loss of 
appetite/bloating 
4 (40%) 0 (0%) 10 (38%) 8 (40%) 0 (0%) 22 
Fatigue 0 (0%) 1 (100%) 5 (19%) 4 (20%) 
0 (0%) 10 
Deaths** @ 31/2 years post 
recruitment 
1 (10%) 0 13 (50%) 10 (50%) 0 (0%) 24 
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5.2.5 Symptoms 
Relevant symptoms in cases included ascites, abdominal pain/discomfort, 
abdominal distension/swelling, nausea, vomiting, and loss of appetite (LOA), 
bloating and fatigue. The Kruskal Wallis test showed a statistical association 
between the prevalence of ascites and the stage of disease p < .01. There was 
also a significant association between abdominal distension and presence of 
ascites, p = .05 as expected. Pain and/discomfort were more prevalent in women 
with stage III than in those with stage IV disease (75% vs. 50%). The lower level 
of pain and discomfort may partly explain why women with stage IV disease had 
not presented earlier to their GP/hospital (pain and discomfort are analysed 
further in the quality of life, (chapter 6). Nausea, vomiting, loss of appetite and 
bloating were reported less frequently (there was a combined report of 22 for 
these symptoms). Fatigue was the least frequently reported symptom; only 10 
women reported experiencing it 
 
5.2.6 Deaths 
Twenty-four women (41%) with cancer had died by 31 October 2014 three and a 
half years after commencement of recruitment. Of the 24 women who had died, 
23 had been diagnosed with stage III or IV and one with stage I disease. Although 
a heart attack was the primary cause of the death of the woman with stage I 
disease, her post mortem report indicated her cancer had recurred with 
widespread deposits within the abdomen. One woman died in the control group 
within the same period. Her cause of death was complications arising from 
diabetes.  
 
5.3 Section B: Life style, nutritional status and body 
composition 
5.3.1 Lifestyle 
Findings presented here on smoking and alcohol are from data collected using 
the study specific questionnaire.  
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5.3.1.1 Smoking 
Figure 11: The percentages of cases and controls who ever smoked 
 
 
Only 10/58 (17%) of the cases ever/smoked, see Figure 11. Of these 5 gave up 
5 or more years prior to participating in the study. Four gave up between 18 
months and 4 years prior to their participation. Only one woman stated that she 
still smoked up to 15 cigarettes per day. Eight of twenty seven controls (30%) 
stated that they were or previously had been smokers. Of these, half had since 
stopped. The average number for those who still smoked was 11 cigarettes. 
These results align with Public Health England’s (2016) figures and their report 
which concluded that smoking is least common amongst women aged 55 and 
over. Smoking may influence eating habits e.g. by decreasing snack frequency 
and energy intake. Although smoking has been linked to mucinous ovarian 
cancer (316), the small sample size and even smaller number of cases and 
controls who ever/smoked limits further analysis of the potential impact of 
smoking on diet and nutritional status.  
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5.3.1.2 Alcohol intake 
  Figure 12: The percentages of cases and controls who ever drank alcohol 
 
 
At baseline, 23/58 (40%) of cases had ever consumed alcohol as shown in   
Figure 12. Only 2 cases stated that they drank more than the recommended 14 
units per week. The median number of drinks per woman per week was 3.2. 
Controls were found to drink a median of 4 units per/week. The relevance of 
alcohol to nutritional status is that, calories from its consumption tend to replace 
other desired nutrients. The recommendation in the UK is that men and women 
who drink regularly are safest not to drink more than 14 units/week. A potential 
or actual diagnosis of cancer does not seem to have influenced women’s drinking 
habits as those women who drank, stated that they consumed similar amounts 3 
months prior to their baseline assessment. The low average drinking within the 
groups limits scope for further analysis of a potential impact of drinking on 
nutritional status.  
 
5.3.2 Nutritional status 
Nutritional status and body composition were assessed using weight, BMI, 
percentage body fat, dry lean mass, lean mass. Total body water and 
extracellular water were also analysed to show if there was an association with 
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the presence of ascites. The median age of menopause for this study is 50. This 
age is used as a cut-off point for classifying pre-menopausal (50years ≤) and 
menopausal (> 50years). Findings for each outcome are presented below.  
 
5.3.2.1 Weight  
Weight change prior to recruitment 
All but one of the 58 cases were weighed at baseline. Forty seven women 
completed the baseline questionnaire, and the numbers of those who 
retrospectively reported weight change prior to recruitment are stated in     Table 
11. Twenty-three women reported losing weight in the three months preceding 
diagnosis. Weight loss ranged between 3.4% and 15.8 % of the baseline weight. 
Baseline body weight was used since prior weight could not be ascertained. Eight 
women reported that they gained weight in the same period. Self-reported weight 
change negatively correlated with abdominal swelling. This suggests that despite 
women presenting with abdominal distension, they reported overall weight loss. 
One woman with an overall weight loss reported that she had started to gain 
weight in more recent weeks. Similarly a woman with overall weight gain reported 
an initial weight loss followed by weight gain. Weight was therefore found to 
involuntarily fluctuate between gain and loss.
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    Table 11: The relationship between prior self-reported weight change and signs and symptoms at baseline for cases  
     Superscript refers to the number of missing values in that group 
     *Significant difference (Kruskal Wallis test) observed in the different categories of weight change (loss, gain) (p < .05) 
Patients  Stable weight 
(change < 2%)  
N (%) 
Wt. change 
unknown   
N (%) 
Weight loss 2-
4.9% (pre-
cachexia)  
N (%) 
Weight loss > 
5% (cachexia)  
N (%)  
Weight gain > 
2% 
N (%) 
Total (N) 
Number of patients 19 15 5 10 8 47 
Median age (range) 61 (43-82) 56 (42-75) 66 (53-71) 59 (37-76) 65 (40-88) - 
BMI < 20 0 (0%) 1 (6%) 1 (20%) 1 (10%) 0 (%) 3 
Signs 
Prealbumin < 
16mg/dl* 
5 (26%)3 6 (40%)3 1 (20%) 4 (40%)2 3 (38%)3 19 
Albumin < 36g/l 2 (11%) 3 (20%)1 1 (20%) 1 (10%)1 3 (38%) 10 
Stage 
1 5 (26%) 3 (20%) 1 (20%) 0 (0%) 1 (12.5%) 10 
2 0 (0%) 0 (0%) 0 (0%) 1 (10%) 0 (0%) 1 
3 9 (47%) 6 (40%) 3 (60%) 5 (50%) 3 (38%) 26 
4 4 (21%) 6 (40%) 1 (20%) 4 (40%) 5 (63%) 20 
Unstaged 1 (5%) - - - - 1 
Symptoms 
Ascites 11 (58%) 11 (73%) 3 (60%) 9 (90%) 6 (75%) 40 
Distension 7 (37%) 11 (73%) 3 (60%) 6 (60%) 3 (38%) 30 
Pain/Discomfort 12 (63%) 8 (53%) 5 (100%) 8 (80%) 7 (88%) 40 
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Table 11 also shows that 5 of 19 women who reported a stable weight prior to 
recruitment had low prealbumin with 2 of those 5 also having a low albumin. This 
suggests that in some women the inflammatory processes that can contribute to 
cachexia were on-going without a manifest change in weight. The ten women 
who reported a weight loss > 5% of their baseline body weight warrant formal 
classification as cachectic. Four women in this group had correspondingly low 
prealbumin, one of whom also had low albumin. Weight change prior to treatment 
was negatively correlated with baseline prealbumin (r = -.340; p = .07). The 
correlations table is shown in appendix 6 because of its size. 
 
Of the 8 women who gained at least 2% of their baseline body weight, 3 had low 
prealbumin and albumin and also had ascites and pain/discomfort at baseline. 
Five of the 8 women were diagnosed with stage IV disease. The combination of 
late stage disease, decreased prealbumin and or albumin suggests that weight 
gain in these women was likely to be related to their distension and ascites.  
 
Weight change during the study 
It was not possible to assess weight in 10 cases during and at the end of 
treatment due to poor health or death. An illustration of the difference in weight 
for each woman between baseline, during treatment and at the end of treatment 
is shown in Figure 13. This multiple line graph depicts the actual gain or loss in 
kg for each of the 43 cases whose weight was assessed at all three time points. 
The graphs show a general decrease in weight between baseline and during 
treatment, and an increase between the ‘during treatment’ and end of treatment 
for cases time points for cases. 
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Figure 13: Multiple line graph showing cases’ weight change from baseline to 
during treatment to the end of treatment. 
 
 
A descriptive summary of weight showing the median, standard deviations and 
Inter Quartile Ranges (IQR) is shown in Table 12. Further analysis of women’s 
overall weight using box plots is shown in Figure 14.  
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Table 12: The descriptive analysis of weight at baseline, during treatment and   
at the end of treatment for cases and controls 
 Baseline 
During 
treatment 
End of 
treatment 
Cases 
N Valid 57 48 48 
Missing 1 10 10 
Mean 73.8 69.5 71.8 
Median 69.2 66.2 66.2 
Std. Deviation 18.84 17.74 17.69 
Minimum 46.0 44.7 48.8 
Maximum 143.2 132.3 131.1 
Percentiles 25 59.8 56.4 60.7 
50 69.2 66.2 66.2 
75 84.9 76.5 78.1 
Controls 
N Valid 27  19 
Missing 0  8 
Mean 74.6  72.1 
Median 73.0  71.0 
Std. Deviation 12.68 n/a 11.95 
Minimum 51.0  50.0 
Maximum 106.6  93.9 
Percentiles 25 63.8  63.5 
50 73.0  71.0 
75 82.0  83.2 
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Figure 14: The box plots showing weight at baseline, during treatment and at end 
of treatment for cases and controls  
 
O, *: The floating numbers represent outliers 
 
The box plots show a generally wide dispersion of weight in both cases and 
controls across all time points (long whiskers). Outliers are identified by ‘O’ and 
‘*’. Outliers are all in the top end of the graph so they lie outside the expected 
upper ranges of weight. The cases were 50 and 55 years old. One had stage 3 
and the other stage 4 disease. Both were treated with chemotherapy first, 
suggesting that they had other comorbidities. Both had normal levels of CA125 
at the end of treatment implying that they had responded to treatment.   
 
The Wilcoxon Signed Ranks Test showed a significant weight difference in cases 
between baseline and during treatment (p < .01). The median weight decreased 
from 69 (IQR: 58.1 - 83.5) to 65.6 (IQR: 56.4 - 76.8) during this period. There was 
also a significant increase (p < .01) in weight (kg) from during treatment to the 
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end of treatment 66.7 (IQR: 60.6-77.9). There was an overall borderline 
significant decrease between baseline and end of treatment weight, p = .06. The 
average weight loss between baseline and end of treatment was 2.3 kg. There 
was no significant difference in weight at baseline and at the end of treatment for 
controls, p > .05. The Independent Samples Median test showed no significant 
weight differences between cases and controls at baseline and end of treatment 
weights, p >.05 in both instances.  
 
Cases’ weight was further analysed by subgrouping women into those with 
ascites and those without, at baseline. The median weight for women without 
ascites was (69.4) and that of women with ascites was (68.8). The Independent 
Samples test showed no significant difference between them, p > .05. Five 
women who lost more than 5% body weight prior to baseline assessment 
continued to lose weight to the end of treatment. One woman lost more than 40% 
of her original weight by the end of treatment. Her weight decreased from 82.4 
kg at baseline to 61kg at the end of treatment. She reported that she had already 
lost 13kg (15%) of her original body weight at baseline assessment. Others lost 
between 10 and 13%. None of these women had a BMI less than 20 despite the 
weight loss. Three of the 5 women had elevated CA125 at the end of treatment 
meaning that they had residual or progressive disease.   
 
Overall findings from the analysis of weight are; 1) That prior to treatment, weight 
change (fluctuations between gain and loss) is a continuum affected by dietary 
change, malnutrition/cachexia and the presence of ascites and large tumours; 2) 
Weight tends to decrease during the early stages of treatment but increase 
thereafter such that it is only marginally lower at the end of treatment than at 
baseline; 3) Women with advanced disease ultimately lose more weight than that 
added by ascites; and 4) Weight does not separately account for ascites which is 
highly prevalent in this patient group. This is a limitation for its use as a measure 
of nutritional status in this patient group. 
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5.3.2.2 Body Mass Index (BMI) 
Weight and BMI are closely related. The latter is a measure of one’s weight for 
their height. For this reason BMI is presented here to show findings not already 
revealed by analysing weight. Participants were classified using categories 
adapted WHO 2004 and modified to fit cachexia classification by using the lower 
cut-off point of 20 instead of 18.5 as shown in  Table 13. Only four cases were 
found to have a BMI less than 20 and would have been considered at risk of 
cachexia at baseline. A third (29.3%) of cases were of normal weight while 17% 
were varying degrees of obese (BMI > 30). There were no underweight controls. 
Forty four percent of controls were overweight while 30% were obese.   
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    Table 13: The classification of cases and controls’ BMI at baseline using cachexia classification cut-off points  
 
 
 
 
 
 
 
Participants Un-
classified 
 
Underweight 
<20 
Normal 
weight 
(20-24.9) 
Overweight 
(25-29.9) 
Class I 
obesity 
(30-34.9) 
Class II 
obesity 
(35.0-39.9) 
Class III 
obesity> 
40 
Total (N) 
Cases N (%) 1 (1.7%) 4 (6.9%) 19 (32.8%) 17 (29.3%) 9 (15.5%) 6 (10.3%) 2 (3.4%) 58 
Controls N (%) 0 (0%) 0 (0%) 7 (25.9%) 12 (44.4%) 5 (18.5%) 3 (11.1%) 0 (0%) 27 
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A descriptive summary of BMI at the three assessment time points is shown in 
Table 14. Further analysis using box plots and subdividing women by age of 
menopause is shown in Figure 15. 
 
 
Table 14: The descriptive analysis of BMI at baseline, during treatment and at 
the end of treatment for cases and controls. 
  Baseline BMI During 
treatment 
BMI 
End of 
treatment 
BMI 
Cases 
N Valid 40 36 46 
 Missing 18 22 12 
Median  27.5 24.1 25.8 
Minimum  18.8 17.5 18.1 
Maximum  51.3 47.1 47.8 
Percentiles 25 23.1 22.3 23.2 
 50 27.5 24.2 25.8 
 75 33.2 28.5 31.8 
Controls 
 N Valid 24 
n/a 
16 
 Missing 3 11 
Median  26.5 26.3 
Minimum  21.8 21.4 
Maximum  37.9 32.8 
Percentiles 25 
50 
24.1 
26.5 
23.3 
26.3 
 75 29.9  28.0 
 
The median BMI for all assessed cases was 27.5, 24.1 and 25.8 at baseline, 
during treatment and at the end of treatment respectively. Median BMI for 
controls was 26.5 and 26.3 at baseline and at the end of treatment 
respectively. The Related Samples Wilcoxon Signed Rank Test showed a 
significant difference between baseline and during treatment BMI for cases, p 
< .01, between during treatment and end of treatment, p < .01 and a borderline 
significance between baseline and end of treatment, p = .06. No significant 
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difference between baseline and end of treatment was observed in controls 
p > .05.   
 
Cases and controls were sub-divided by the median age of menopause to 
identify differences that are due to age. The box plots showing this analysis 
are shown in Figure 15.  
 
Figure 15: The box plots showing BMI at baseline, during treatment and end of 
treatment by age of menopause for cases and controls 
 
O, *: The floating numbers represent outliers 
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The relatively short box plots and whiskers for premenopausal cases and 
controls compared to menopausal cases and controls suggests that BMI is 
less dispersed in younger women than it is in older women. Premenopausal 
cases have the lowest BMI of any other group across all time points. The BMI 
of premenopausal cases fell by 2 units during treatment, but these units were 
regained by the end of treatment. On the contrary menopausal cases lost 4 
units of BMI from baseline to during treatment, and regained only 2 of those 
by the end of treatment, thus not reaching their baseline BMI. Controls BMI 
was stable between baseline and end of treatment remaining at 26 for 
premenopausal women and 27 for menopausal women.  
 
The Mann-Whitney U test showed a significant difference between the BMI of 
menopausal versus that of non-menopausal cases during treatment p <.05. 
The small sample sizes for premenopausal cases (8, 7 and 10 at baseline, 
during treatment and end of treatment respectively) and menopausal controls 
(8 at baseline and 7at the end of treatment) may not have allowed for subtle 
changes to be identified at other time points. Overall, controls and menopausal 
cases have a high BMI. Even with a loss of 2 units during treatment, 
menopausal cases’ median BMI, at 24 is on the upper end of normal/healthy.  
 
The main findings from the analysis of BMI are; 1) Loss of significant weight 
(>2% of body weight) does not result in a corresponding critical level fall in BMI; 
2) Older cases who are also more likely to be diagnosed with advanced 
disease tend to have a higher BMI than younger cases; and 3) Weight lost by 
menopausal women is not fully gained back by the end of treatment indicating 
that this group may benefit from targeted nutritional intervention.  
 
5.3.3 Body composition  
Body composition was assessed using BIA. Findings on five components of 
body composition, body fat, lean mass, dry lean mass, extracellular water and 
total body water (TBW) are presented here. Clinical criteria for dry lean mass 
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and lean mass are either not available or have not been empirically validated. 
Data is presented here to show trends, rather than clinically relevant cut-off 
limits. Although there are no cancer cachexia consensus references or 
clinically relevant or agreed cut off points for body fat, the general classification 
by Heymsfield, Heo et al., (317) as shown in Figure 16,  is used to characterise 
women. The descriptive analysis of body fat, dry lean mass and lean mass is 
outline in Table 15. 
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Table 15: The descriptive analysis of body fat, dry lean mass and lean mass at baseline, during treatment and at the end of treatment for    
cases and controls’ 
 Body fat (%) Dry lean mass (kg) Lean mass (%) 
   
Baseline 
During 
treatment 
End of 
treatment Baseline 
During  
treatment 
End of 
treatment 
Baseline 
During  
treatment 
End of 
treatment 
Cases 
N Valid 40 36 46 40 37 45 40 35 44 
Missing 18 22 12 18 21 13 19 24 15 
Mean 40.7 37.8 39.1 9.4 8.8 9.1 59.3 62.5 60.9 
Median 41.0 38.6 38.9 9.9 9.6 9.7 59.0 62.1 61.1 
Std. Deviation 8.47 7.99 7.96 2.70 2.91 2.95 8.47 7.84 8.11 
Minimum 21 21 23 4.1 2.6 2.6 38.5 46.2 43.5 
Maximum 62 54 57 14.9 14.5 14.5 79.3 79.2 77.0 
Percentiles 25 34.2 31.1 32.6 7.3 7.0 6.8 54.5 56.6 55.4 
50 41.0 38.6 38.9 9.9 9.6 9.7 59.0 62.1 61.1 
75 45.5 44.1 44.2 11.4 10.8 11.2 65.8 69.2 67.6 
Controls 
N Valid 24  16 24  16 24  16 
Missing 3  11 3  11 3  11 
Mean 37.8  37.1    62.2  62.9 
Median 39.3  36.7 11.4  10.5 60.8  63.4 
Std. Deviation 5.99 n/a 6.29  n/a  5.99 n/a 6.3 
Minimum 27  23 3.5  3.7 50  55 
Maximum 50  45 16.4  15.5 73  77 
Percentiles 25 32.5  33.5 8.8  7.3 58.3  57.2 
50 39.3  36.7 11.4  10.5 60.8  63.4 
75 41.7  42.8 14.0  13.3 67.5  66.5 
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5.3.3.1 Body fat 
Cases and controls were classified by body fat categories as shown in Figure 
16. 
Figure 16: The categories of body fat at baseline, during treatment and at the 
end of treatment for cases and controls 
 
 
 
Only one case had less body fat than the recommended minimum of 24% at 
baseline and during treatment. A different woman was in this category at the 
end of treatment. More women may have been classified in this category at 
the end of treatment since some of those not assessed at this point were too 
poorly (n = 10) and may have lost weight and body fat.  
 
The changes in body fat from baseline to during treatment and end of treatment 
are illustrated by the line in Figure 17. There was an increase in the percentage 
of cases within the healthy range from 17% at baseline to 24% during 
treatment and 26% at the end of treatment. The proportion of obese women 
increased to 33% at the end of treatment. None in the control group were below 
recommended body fat at baseline and only one was at the end of treatment. 
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There were proportionately less obese controls than cases at baseline and end 
of treatment. 
 
Figure 17: Multiple line graph showing changes in body fat (%) between 
baseline, during treatment and the end of treatment for cases 
 
 
Box plots showing overall distribution of body fat for cases and controls across 
all assessment time points are shown in Figure 18 A. The Wilcoxon Signed 
Rank Test showed a significant difference between baseline and during 
treatment body fat, p < .05. There was a borderline significance p = .083 
between baseline and end of treatment body fat an overall decline of 3.8%. No 
significant differences were observed between treatment and end of treatment, 
p =.91. Controls’ body fat also declined by 2.6% from 39.3% at baseline to 
36.7% by the end of treatment. This change was not statistically significant, p 
> .05. The Independent samples median test showed no significant difference, 
p > .05 between cases and controls at baseline and at the end of treatment.  
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Figure 18: The box plots showing body fat at baseline, during treatment and at 
the end of treatment for cases and controls 
A 
 
B 
 
O, *: The floating numbers represent outliers 
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Further analysis by subdividing cases by the study median age of menopause 
showed that premenopausal cases have the lowest while menopausal controls 
have the highest percentage body fat. Premenopausal cases lost body fat 
during treatment and had not regained it to baseline levels at the end of 
treatment. Menopausal cases however, gained body fat to a higher percentage 
that they were at baseline. The Kruskal Wallis test showed significant 
differences between premenopausal and menopausal cases’ body fat during 
treatment (p < .01) and end of treatment (p < .05). There was a borderline 
difference, p = .06 at baseline. There were significant differences between 
premenopausal and menopausal controls’ body fat at baseline p < .05 and at 
the end of treatment p < .05. As in the general population, older women in this 
study have more body fat than younger women.  
 
These findings show that; 1) Premenopausal cases lose more body fat; 2) 
Older women do not regain body fat to baseline levels; 2) The majority of cases 
are overweight or obese at all three time points indicating that malnutrition in 
the early part of the ovarian cancer trajectory is not represented by the 
standard thin and macro-nutrient deficient patient; 3) In menopausal cases, 
weight gained during the course of treatment is likely to be in the form of body 
fat. 
 
5.3.3.2 Dry lean mass  
The changes in dry lean mass across the three assessment time points are 
illustrated by line graphs in Figure 19. The graph shows a general trend of a 
fall in dry lean mass during treatment and a subsequent increase at the end of 
treatment.  
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Figure 19: Multiple line graph showing changes in dry lean mass between 
baseline, during treatment and the end of treatment for cases 
 
 
Box plots showing the distribution of dry lean mass are shown in Figure 20. 
The lower median dry lean mass for premenopausal cases compared to same 
age controls suggests that premenopausal cases may already have lost dry 
lean mass at baseline and continued to do so during treatment to the end of 
treatment. This loss between baseline and during treatment may partly be 
explained by the younger women’s treatment plan. They are more likely to 
have had surgery, involving removal of their female reproductive organs and 
tumours leading to consequent loss of dry lean mass. There is an 
unexplainable gain in dry lean mass in menopausal cases from 9.1 to 9.7.  
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Figure 20: The box plots showing dry lean mass (kg) at baseline, during 
treatment and at the end of treatment for cases and controls 
A 
 
B 
 
O, *: The floating numbers represent outliers 
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The Wilcoxon Signed Ranks Test showed an overall significant decrease (p < 
.05) in dry lean mass between baseline and during treatment for cases and 
baseline and end of treatment for controls. Sub group analysis by age of 
menopause revealed that for cases, this difference was due to premenopausal 
cases losing dry lean mass during treatment. Age was significantly and 
negatively correlated with dry lean mass, p < .05. These findings are expected 
as dry lean mass is a sum of total protein and bone mineral mass. Both are 
expected to be lower in older women due to sarcopenia, a natural aging 
process.  
 
The main findings here are that 1) Being older and having persistent disease 
at the end of treatment are associated with a lower dry lean mass and 2) 
Premenopausal cases may have lost dry lean mass at the baseline 
assessment and do not seem to regain it.  
 
5.3.3.3 Lean mass 
Lean mass is the proportion of the body mass that is not fat and is highly 
related to whole body resting energy expenditure. Table 15 shows that the 
median lean mass percentage was 59 at baseline, decreasing to 62 during 
treatment and further to 61 by the end of treatment. These changes are 
illustrated by the multiple line graph in Figure 21. The graph shows gains and 
losses in lean mass at each time point. 
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Figure 21: Multiple line graph showing changes in lean mass between baseline, 
during treatment and the end of treatment for cases 
 
 
There was a significant difference between baseline and during treatment and 
baseline and end of treatment lean mass (p < .05) in cases. No significant 
differences were observed between baseline and end of treatment for controls 
and the Independent median test showed no significant differences between 
baseline and end of treatment lean mass between cases and controls (p > .05).  
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Figure 22: The box plots showing lean mass at baseline, during treatment and 
at the end of treatment for cases and controls 
A 
 
B 
 
O, *: The floating numbers represent outliers 
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Subgroup analysis by age of menopause showed premenopausal cases to 
have the highest percentage of lean mass of all groups followed by 
premenopausal controls, shown in Figure 22. Lean mass also seemed to 
increase in all cases during treatment cases. This is difficult to explain except 
perhaps that it is linked with increase in body fluid related to intravenous 
infusions during surgery and chemotherapy. The differences according to age 
are expected as fat free mass is known to vary with some biological factors 
such as age and adiposity. Lean mass increased from baseline to ‘during 
treatment’ in both premenopausal and menopausal cases and then marginally 
decreased by end of treatment. These changes are in contrast to what was 
observed with body fat, which decreased during treatment and then increased 
by the end of treatment. The main finding is that the overall decrease in weight 
observed in cases may be due to loss of body fat rather than lean or dry lean 
mass.  
 
5.3.3.4 Total body water (TBW %)  
Total body water and extracellular water were analysed for cases to identify if 
ascites had an identifiable impact on them. The normal range for total body 
water for women is between 45 and 60% of their weight. The descriptive 
analysis for total body water is shown in Table 16.  
 
Table 16: The descriptive analysis of % total body water at baseline, during 
treatment and at the end of treatment for cases 
 
Baseline During Treatment End of treatment 
N Valid 40 35 43 
Missing 18 23 15 
Mean 47.5 49.5 48.8 
Median 47.7 49.4 48.6 
Std. Deviation 4.92 4.39 5.08 
Minimum 35.4 40.40 37.60 
Maximum 58.8 59.8 58.4 
Percentiles 25 44.7 46.2 45.5 
50 47.7 49.4 48.6 
75 50.6 52.1 52.8 
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The Wilcoxon Signed rank test showed baseline total body water to be 
significantly lower than during treatment, p < .05. No significant differences 
were observed at other time points. This seems to confirm the increase in lean 
mass outlined in the previous section during this time. The Kruskal Wallis test 
showed no significant association between total body water and the presence 
of ascites at baseline, p > .05. The independent samples test showed no 
significant differences between baseline and end of treatment total body water 
between cases and controls p > .05 either. A borderline association, p = .06 
was shown between pain/discomfort and total body, in chapter 6, section 6.1.3.  
 
These findings show that despite documented clinical evidence of ascites, 
cases were generally at the lower end of expected total body water with a 
median of 47.7% (IQR: 44.7-50.6) at baseline. Although this improved 
significantly during treatment, p < .01, the measures remained on the low end 
of normal hydration at 49.4% during treatment and 48.6% at the end of 
treatment. The relationship between total body water and pain may be a factor 
in the link between ascites and pain/discomfort. When the build-up of ascites 
is severe it can cause abdominal distention which in turn causes discomfort or 
pain.  
 
5.3.3.5 Extracellular water (ECW %) 
Extracellular body water accounts for a third of total body water and is that fluid 
outside of the cells such as interstitial fluid. The descriptive analysis of 
extracellular water is shown in Table 17. 
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Table 17: The descriptive analysis of % extracellular water at baseline, during 
treatment and at the end of treatment for cases 
 Baseline During treatment End of treatment 
N Valid 40 35 43 
Missing 18 22 14 
Mean 22.7 23.7 23.9 
Median 22.7 23.6 23.0 
Std. Deviation 4.26 3.44 5.70 
Minimum 14.1 17.7 16.6 
Maximum 36.7 32.2 56.1 
Percentiles 25 20.3 21.4 21.1 
50 22.7 23.6 23.0 
75 24.9 25.3 25.4 
 
 
The Wilcoxon Signed rank test showed no significant differences between 
baseline and during treatment, during treatment and end of treatment and 
baseline and end of treatment, (p > .05) extracellular water. The Kruskal Wallis 
test showed no significant association between baseline extracellular water 
and the presence of ascites. The independent median test showed no 
significant differences, (p > .05) between cases and controls extracellular 
water at baseline and at the end of treatment. A significant association was 
found between pain/discomfort and extracellular water, p = .03 when using 
pain data from a quality of life questionnaire, section 6.1.3.  
 
The findings on body water are unexpected. An association between 
extracellular body water and ascites were expected particularly at baseline, 
when 71% of cases were documented to have ascites.  
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5.4 Section C: Biochemical/protein markers 
Results on the biochemical markers of nutrition (prealbumin), wellbeing 
(albumin), inflammation (CRP) and disease CA125 are presented here.  
 
5.4.1 Pre-albumin (normal range 0.16 - 0.4 g/L) 
The lower cut-off point of 16mg/dl in line with local clinical guidelines is adopted 
for this study. Descriptive analysis of prealbumin showing median, standard 
deviation and interquartile range is shown on Table 18. The classification of 
cases and controls by the level of prealbumin in shown in Table 19. 
 
Table 18: The descriptive analysis of prealbumin at baseline and at the end of 
treatment for cases and controls 
 Baseline End of treatment 
Cases 
N Valid 44 42 
Missing 14 16 
Mean 0.19 0.24 
Median 0.17 0.23 
Std. Deviation 0.07 0.07 
Minimum 0.08 0.09 
Maximum 0.37 0.41 
Percentiles 25 0.14 0.20 
50 0.17 0.23 
75 0.24 0.29 
Controls 
N Valid 24 13 
Missing 3 14 
Mean 0.23 0.27 
Median 0.23 0.27 
Std. Deviation 0.07 0.08 
Minimum 0.13 0.14 
Maximum 0.36 0.42 
Percentiles 25 0.18 0.23 
50 0.23 0.27 
75 0.28 0.30 
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Table 19: The classification of cases and controls by the level of prealbumin at 
baseline and end of treatment. 
 Baseline N (%)  End of treatment N (%) 
Prealbumin  (g/L) Cases Controls Cases Controls 
Missing 14 (24%) 4 (15%) 16 (28%) 14 (52%) 
Low (0.16 <) 18 (32%) 4 (15%) 5 (9%) 1 (4%) 
Low normal (0.17 - 0.20) 10 (17%) 5 (19%) 7 (12%) 0 (0%) 
Normal (> 0.20) 16 (28%) 14 (52%) 30 (52%) 12 (44%) 
Total (N) 58 27 58 27 
 
 
Thirty two percent of cases had clinically low prealbumin (<16/L) at baseline 
compared to 9% at the end of treatment, shown in Table 19. A further 17% had 
borderline prealbumin of below 0.20g/L. All cases with a clinically low 
prealbumin at baseline had advanced disease (stage III or IV). The Kruskal 
Wallis test showed a significant association between prealbumin and stage of 
disease at baseline (p < .01) and a borderline association at the end of 
treatment, p < .06. Some controls, 15%, had low prealbumin at baseline 
compared to only 4% at the end of treatment. Women in the control group had 
longstanding issues such as fibroids and endometriosis which may have had 
an impact on their prealbumin. A bar graph illustration of cases and controls 
prealbumin is shown on Figure 23.  
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Figure 23: The bar chart showing prealbumin levels (g/L) at baseline and at the 
end of treatment for cases and controls 
 
 
 
 
The median prealbumin for cases at baseline was 0.17 (IQR: 0.14-.-0.24), 
shown in Table 18. The related samples Wilcoxon Signed Rant Test showed 
a significant increase, (p < .01) between baseline and end of treatment to 0.23 
(IQR: 0.20-.029). The Independent samples test also showed a significant 
difference between baseline cases and controls’ prealbumin, p < .05. No 
significant differences were found between case and controls at the end of 
treatment, p > .05. The Kruskal Wallis test showed prealbumin to be 
associated with the stage of disease, presence of ascites and 
swelling/distension at baseline, p < .01 in all instances. A change in eating 
habits prior to treatment was associated with a low prealbumin Table 29. There 
was no correlation between prealbumin and eating habits at the end of 
treatment. 
  
These findings suggest a direct and linear relationship between diet and 
prealbumin at baseline when women reported that their eating habits had 
changed the most. That pre-albumin was already affected by the time women  
presented to the hospital and had returned to normal in most cases by the end 
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of treatment despite residual disease in some women suggests that 
prealbumin reflects short-term nutritional changes.  
 
5.4.2 Albumin 
Albumin was not routinely assessed in patients undergoing surgery where 
cancer was not suspected. Albumin values for this study were extracted from 
electronic patient records and are therefore not available for controls. A cut-off 
point of 36g/L in line with local clinical guidelines was adopted. The descriptive 
analysis for albumin is shown on Table 20 and the classification in Table 21. 
  
Table 20: The descriptive analysis of albumin at baseline and at the end of 
treatment for cases 
 Baseline End of treatment 
N Valid 56 46 
Missing 2 12 
Mean 40.7 44.2 
Median 42.0 45.0 
Std. Deviation 6.71 5.49 
Minimum 21.0 27.0 
Maximum 53.0 61.0 
Percentiles 25 36.0 41.0 
50 42.0 45.0 
75 46.8 48.0 
 
Table 21: The classification of cases by the level of albumin at baseline and end 
of treatment  
 Baseline  
N (%) 
End of treatment  
N (%) 
Missing 2 (3%) 12 (21%) 
Low (< 36g/L) 11 (19%) 2 (3%) 
Low Normal (36-39 g/L) 14 (24%) 5 (9%) 
Normal (> 40g/L) 31 (53%) 39 (67%) 
Total (N) 58  58 
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The median albumin at baseline was within the normal range, 42 (IQR: 36-47), 
shown in Table 20. However, nineteen percent of cases had a clinically low 
albumin while 14% had borderline normal albumin, as shown in Table 21. 
There was a strong association (Kruskal Wallis test) between presence of 
ascites and low albumin, p < .01, with all 19% of cases with low albumin having 
ascites. Only 3% of cases had a low albumin at the end of treatment despite 
residual disease in some women. The majority of cases 67% had a normal 
albumin at the end of treatment. The Wilcoxon Signed Rank Test showed a 
significant difference between baseline and end of treatment albumin, p < .01.   
 
A bar graph illustrating the level of albumin by type of first treatment for cases 
is shown in Figure 24. This graph shows that albumin was lower at baseline 
and at the end of treatment in cases treated with chemotherapy alone or 
followed by surgery compared to those who were treated with surgery alone 
or followed by chemotherapy.  
 
Figure 24: The bar chart showing albumin levels (g/L) for cases by type of first 
treatment at baseline and at the end of treatment  
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Ascites, swelling and changes in eating habits were associated with low 
albumin at baseline, as was shown in Table 10. A calculation of odds ratios 
showed that women who gained weight during treatment were 3.3 times more 
likely to have increased albumin compared to those who lost weight. 
Spearman’s correlations showed that albumin positively correlated with health 
status (r = 0.440; p < .01) shown in Table 35. 
 
The findings about albumin, ascites and swelling were expected since albumin 
is a measure of well-being. However additional findings that changes in eating 
habits are associated with a low albumin show that food intake correlates with 
biochemical changes in the body. Loss of weight shown by a decrease in BMI 
is associated with being unwell and low overall health status.   
 
5.4.3 C - reactive protein (CRP) with normal range <10mg/L 
Normal concentration levels of CRP in healthy human serum is between 5 and 
10 mg/L. The descriptive analysis of cases’ CRP at baseline and at the end of 
treatment is shown in Table 22 and the classification of cases by CRP level is 
shown in Table 23.  
 
Table 22: The descriptive analysis of C-reactive protein (CRP) at baseline and 
at the end of treatment for cases 
 Baseline End of treatment 
N Valid 51 46 
Missing 8 13 
Mean 57.9 35.8 
Median 47.5 12.6 
Std. Deviation 61.47 53.59 
Minimum 0.60 0.60 
Maximum 347.1 188.5 
Percentiles 25 10.2 1.38 
50 47.5 12.6 
75 86.5 49.8 
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Table 23: The classification of cases by the level of C-reactive protein (CRP) at 
baseline and at the end of treatment. 
  
Baseline 
(%) 
End of treatment 
(%) 
Missing 7 (12%) 12 (21%) 
Normal 12 (21%) 22 (38%) 
Elevated 39 (67%) 24 (41%) 
Total (N) 58 58 
 
 
Sixty seven percent of cases had elevated CRP at baseline compared to only 
21% who had a normal CRP as shown in Table 23. The percentage of women 
with normal CRP increased to 38 by the end of treatment. CRP decreased 
from a median of 47.5 (IQR: 10.2-86.5) at baseline decreased to 12.6 (IQR: 
1.38 - 49.8) at the end of treatment. The Wilcoxon Signed Rank test showed 
these differences to be statistically significant, p < .05.  
 
The bar graphs showing the levels of CRP in cases are shown in Figure 25. 
CRP was more elevated in cases with advanced disease (Stages 3 & 4) that 
in women with early stage disease (one woman with stage 2 disease was 
included with those with stage I disease). CRP was also elevated in cases that 
were treated with chemotherapy first.  
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Figure 25: The bar graph showing C-reactive protein (CRP) by stage of disease 
and type of first treatment at baseline and at the end of treatment for cases 
 
 
 
 
No significant associtaions were found between CRP and symptoms at 
baseline, or any correlation with other outcomes. This suggests that an 
elevated CRP,  an indicatior of inflammation reflects the presence of cancer 
and is not dependent of stage, or presence of other symptions.  
 
5.4.4 CA-125  
CA125 is a useful tool for detecting ovarian cancer following an onset of 
symptoms. But it is also important for monitoring the response to treatment 
and for predicting a patient’s prognosis after treatment. The clinical cut off 
points are 35u/L. It is used in this study to differentiate between women with 
no clinical evidence of disease and those with residual or progressing disease 
at the end of treatment.   
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Figure 26: The bar chart showing CA125 at baseline, during treatment    and at 
the end of treatment for cases 
 
 
The above graph shows that 53/58 (91%) of all cases had an elevated CA125 
at baseline. Seventeen women had elevated CA125 at the end of treatment. 
This implies that they had residual or recurrent disease. CA125 was shown to 
be associated the stage of disease, p < .05, the presence of ascites, p < .05 
shown as shown in Table 25. Baseline CA125 also significantly but negatively 
correlated with prealbumin, p < .01 and albumin, p < .05. There was a 
borderline positive correlation with extracellular body water, p = .07, confirming 
the link between ascites and CA125, shown in Table 26. Women with an 
elevated CA125 at the end of primary treatment should be targeted for 
nutritional intervention as they are likely to require further treatment in the near 
future. 
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          Table 24: Odds ratios (cases only)  
Variable/ 
Outcome 
Weight 
Gain/loss 
BMI 
Gain/Loss 
Body Fat 
Gain/Loss 
Prealbumin 
Gain/Loss 
Albumin 
Gain/Loss 
Dry lean mass 
Gain/Loss 
Weight OR= 0.505   
pv= 0.1   
CI=[ 0.221 - 1.132 ] 
OR= 0.423  
pv= 0.049   
CI=[ 0.176 - 0.985 ] 
OR= 1.091  
pv= 0.863   
CI=[ 0.404 - 2.95 ] 
OR= 0.846   
pv= 0.773   
CI=[ 0.269 - 2.659 ] 
OR= 0.711   
pv= 0.45   
CI=[ 0.291 - 1.721 ] 
OR= 0.283  
pv= 0.021   
CI=[ 0.093 - 0.802 ] 
BMI OR= 0.574   
pv= 0.181   
CI=[ 0.252 - 1.289 ] 
 
OR= 0.462   
pv= 0.134   
CI=[ 0.163 - 1.251 ] 
OR= 0.958   
pv= 0.941   
CI=[ 0.304 - 3.02 ] 
OR= 0.895 
 pv= 0.814   
CI=[ 0.353 - 2.257 ] 
OR= 0.251  
pv= 0.012   
CI=[ 0.082 - 0.716 ] 
Body fat OR= 0.545   
pv= 0.181   
CI=[ 0.221 - 1.317 ] 
OR= 0.429   
pv= 0.07   
CI=[ 0.168 - 1.06 ] 
 
OR= 1.768   
pv= 0.382   
CI=[ 0.501 - 6.745 ] 
OR= 1.236  
pv= 0.676   
CI=[ 0.458 - 3.38 ] 
OR= 0.446  
pv= 0.125   
CI=[ 0.155 - 1.236 ] 
Dry lean OR= 0.28   
pv= 0.008   
CI=[ 0.107 - 0.699 ] 
OR= 0.421  
pv= 0.067   
CI=[ 0.163 - 1.051 ] 
OR= 0.48   
pv= 0.156   
CI=[ 0.169 - 1.305 ] 
OR= 0.814   
pv= 0.749   
CI=[ 0.224 - 2.884 ] 
OR= 1.243  
pv= 0.673   
CI=[ 0.454 - 3.475 ] 
 
Prealbumin OR= 1.941  
 pv= 0.146   
CI=[ 0.799 - 4.821 ] 
OR= 2.186  
pv= 0.106   
CI=[ 0.854 - 5.741 ] 
OR= 1.54   
pv= 0.434   
CI=[ 0.522 - 4.622 ] 
 
OR= 0.915  
pv= 0.863   
CI=[ 0.332 - 2.553 ] 
OR= 1.189  
pv= 0.762   
CI=[ 0.385 - 3.679 ] 
Albumin OR= 3.294   
pv= 0.008   
CI=[ 1.387 - 8.128 ] 
OR= 2.987  
pv= 0.017   
CI=[ 1.232 - 7.506 ] 
OR= 0.983   
pv= 0.974   
CI=[ 0.346 - 2.753 ] 
OR= 1.4   
pv= 0.601   
CI=[ 0.403 - 5.254 ] 
 
OR= 1.417  
pv= 0.514   
CI=[ 0.498 - 4.091 ] 
Health 
status 
OR= 2.485   
pv= 0.069   
CI=[ 0.942 - 6.796 ] 
OR= 2.864  
pv= 0.046   
CI=[ 1.037 - 8.275 ] 
OR= 1.371   
pv= 0.613   
CI=[ 0.402 - 4.779 ] 
OR= 2.596   
pv= 0.179   
CI=[ 0.674 - 11.485 
] 
OR= 0.54   
pv= 0.272   
CI=[ 0.174 - 1.603 ] 
OR= 1.083  
pv= 0.894   
CI=[ 0.332 - 3.551 ] 
Variable /Outcome >median =1, median < =0 
Change: Gain = 1, Loss = 0 
Grey is significant, Blue is borderline significant 
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Table 25: The Kruskal Wallis test of association between nutritional, well-being and cancer outcomes with symptoms at baseline for cases 
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C
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Stage (grouped into early (1) and late (2) 
Chi-Square 2.055 1.239 .008 .008 3.864 .983 .350 10.013 2.885 1.327 5.771 
df 1 1 1 1 1 1 1 1 1 1 1 
Asymp. Sig. .152 .266 .931 .931 .049 .321 .554 .002 .089 .249 .016 
Pain/discomfort (grouped into no (0) and yes (1) 
Chi-Square .749 .590 1.616 1.616 .239 .508 1.345 .117 .010 .223 .222 
df 1 1 1 1 1 1 1 1 1 1 1 
Asymp. Sig. .387 .442 .204 .204 .625 .476 .246 .733 .921 .637 .637 
Swelling and distension (grouped into no (0) and yes (1) 
Chi-Square 1.068 .208 .005 .005 .101 .261 .069 15.567 5.866 1.468 .327 
df 1 1 1 1 1 1 1 1 1 1 1 
Asymp. Sig. .301 .649 .945 .945 .751 .609 .793 .000 .015 .226 .568 
Ascites (grouped into no (0) and yes (1) 
Chi-Square 1.151 .903 .016 .016 .158 .136 .010 15.724 21.309 1.422 4.520 
df 1 1 1 1 1 1 1 1 1 1 1 
Asymp. Sig. .283 .342 .898 .898 .691 .712 .921 .000 .000 .233 .033 
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Table 26: Spearman’s correlations between all baseline outcomes in cases. 
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Spearman'
s rho 
AGE Correlation 
Coefficient 
1.000 .143 .371* -.371* -.540** .297 -.100 -.162 -.172 -.007 -.054 .072 
Sig. (1-
tailed) 
. .243 .031 .031 .002 .070 .314 .214 .200 .487 .396 .364 
Baseline 
weight 
Correlation 
Coefficient 
.143 1.000 .814** -.814** .592** .925** -.834** -.883** -.273 .062 -.057 -.028 
Sig. (1-
tailed) 
.243 . .000 .000 .001 .000 .000 .000 .088 .382 .392 .447 
Baseline 
body fat 
Correlation 
Coefficient 
.371* .814** 1.000 -1.000** .146 .897** -.848** -.928** -.228 -.126 -.123 .175 
Sig. (1-
tailed) 
.031 .000 . . .239 .000 .000 .000 .132 .270 .274 .196 
Baseline 
lean 
mass  
Correlation 
Coefficient 
-.371* -.814** -1.000** 1.000 -.146 -.897** .848** .928** .228 .126 .123 -.175 
Sig. (1-
tailed) 
 
 
.031 .000 . . .239 .000 .000 .000 .132 .270 .274 .196 
 
 
168 
 
 
A
G
E
 
B
a
s
e
li
n
e
 
w
e
ig
h
t 
B
a
s
e
li
n
e
 
b
o
d
y
 f
a
t 
B
a
s
e
li
n
e
 
L
e
a
n
 m
a
s
s
 
B
a
s
e
li
n
e
 
d
ry
 l
e
a
n
 
m
a
s
s
 
B
a
s
e
li
n
e
 
B
M
I 
B
a
s
e
li
n
e
 
e
x
tr
a
c
e
ll
u
la
r 
w
a
te
r 
B
a
s
e
li
n
e
 
T
o
ta
l 
b
o
d
y
 
w
a
te
r 
B
a
s
e
li
n
e
 
C
A
1
2
5
 
B
a
s
e
li
n
e
 
p
re
a
lb
u
m
in
 
B
a
s
e
li
n
e
 
a
lb
u
m
in
 
B
a
s
e
li
n
e
 
C
R
P
 
Baseline 
dry lean 
mass  
Correlation 
Coefficient 
-.540** .592** .146 -.146 1.000 .305 -.442* -.402* -.084 .150 -.022 -.286 
Sig. (1-
tailed) 
.002 .001 .239 .239 . .065 .012 .021 .341 .233 .457 .079 
Baseline 
BMI 
Correlation 
Coefficient 
.297 .925** .897** -.897** .305 1.000 -.807** -.875** -.290 -.005 -.033 .070 
Sig. (1-
tailed) 
.070 .000 .000 .000 .065 . .000 .000 .075 .491 .436 .366 
Baseline 
extracellu
lar water  
Correlation 
Coefficient 
-.100 -.834** -.848** .848** -.442* -.807** 1.000 .959** .294 .028 .126 -.042 
Sig. (1-
tailed) 
.314 .000 .000 .000 .012 .000 . .000 .072 .446 .270 .419 
Baseline 
total body 
water 
Correlation 
Coefficient 
-.162 -.883** -.928** .928** -.402* -.875** .959** 1.000 .212 .060 .146 -.086 
Sig. (1-
tailed) 
.214 .000 .000 .000 .021 .000 .000 . .149 .385 .238 .339 
Baseline 
CA125 
Correlation 
Coefficient 
-.172 -.273 -.228 .228 -.084 -.290 .294 .212 1.000 -.446* -.338* -.021 
Sig. (1-
tailed) 
.200 .088 .132 .132 .341 .075 .072 .149 . .011 .046 .459 
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Baseline 
prealbum
in 
Correlation 
Coefficient 
-.007 .062 -.126 .126 .150 -.005 .028 .060 -.446* 1.000 .727** -.248 
Sig. (1-
tailed) 
.487 .382 .270 .270 .233 .491 .446 .385 .011 . .000 .111 
Baseline 
albumin  
Correlation 
Coefficient 
-.054 -.057 -.123 .123 -.022 -.033 .126 .146 -.338* .727** 1.000 -.182 
Sig. (1-
tailed) 
.396 .392 .274 .274 .457 .436 .270 .238 .046 .000 . .187 
Baseline 
CRP 
Correlation 
Coefficient 
.072 -.028 .175 -.175 -.286 .070 -.042 -.086 -.021 -.248 -.182 1.000 
Sig. (1-
tailed) 
 
.364 .447 .196 .196 .079 .366 .419 .339 .459 .111 .187 . 
*. Correlation is significant at the .05 level (1-tailed). 
**. Correlation is significant at the 0.01 level (1-tailed). 
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5.5 Section D: Dietary analysis 
This section presents findings on changes to diet and food intake habits of women 
diagnosed with ovarian cancer. These changes relate to the period starting 3 
months prior to baseline assessment to the end of treatment. The results are 
presented for two periods, baseline and from baseline to the end of treatment. 
Findings are presented on the specific diet changes, the reasons and rationale 
for the change, current practice on nutritional/dietary support as well as women’s 
suggestions for an ideal future intervention. Associations between changes in diet 
and nutritional status are also presented. The relationship between current 
intervention/support and nutritional status is outlined. Suggestions for a potential 
future intervention package are also presented.  
 
5.5.1 The specific changes made to diet  
The majority of women, 32/47 (68%), who completed the baseline study 
questionnaire indicated that they changed their diet prior to treatment and/or 
confirmed diagnosis. Eighteen of 38 (47%) women who completed the end of 
treatment questionnaire said they had never received any nutritional 
advice/intervention from the clinical team. Five of 38 women at the end of 
treatment did not answer the question on diet change. The specific diet changes 
and the number of women who made those changes are shown in Table 27.
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       Table 27: The specific dietary changes made prior to treatment and during the period of treatment 
The sums of the columns may not add up to the total number of women who made changes because some women did not provide information on the changes   
made while some made more than one change
Foods that were preferred  
Baseline 
N (%) 
End of 
treatment 
N (%) 
Foods that were avoided  
Baseline 
N (%) 
End of 
treatment 
N (%) 
Fruit and vegetables 8 1 Sweet foods 7 4 
Small amounts of everything  8 1 Red meat 7 4 
White meat/fish 4 2 Processed food 2 4 
Flax seed Diet/Budwig 2 0 Alcohol 1 0 
More of everything 1 2 Hard to swallow food 1 0 
Green tea 1 0 Peanuts 1 0 
Strong flavoured food 1 0 Acidy food 1 0 
Became vegetarian 1 2 Heavy foods e.g. pies and steak 1 0 
Soft food 1 1 Raw foods/nuts 0 1 
Sweet foods 0 2 Bland foods 0 1 
Full fat milk, cheese 0 3 Spicy food 1 0 
Dried fruit 0 1 Tea/coffee 0 3 
Fried food 0 1 Dairy 0 1 
Orange juice 0 1 Poultry 0 1 
Brown/whole meal bread 1 0 Salt 0 1 
Not stated 4 6 Packed juice 0 1 
   Not stated 3 6 
Women who made diet changes 32 19  32 19 
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Of those women who made changes between baseline and end of treatment, 
8/38 (21%) reported only being able to tolerate small amounts of food at a time. 
A similar number said they ate more fresh fruit and vegetables. Eating only white 
meat and fish and following the Budwig or Flax seed diet were also some of the 
changes made. The flaxseed oil and cottage cheese based diet is designed to 
correct the Deoxyribonucleic Acid (DNA) so that it starts to produce healthy cells 
(318). No obvious food preferences stood out during the treatment period. 
Women reported eating more of everything, full fat foods, vegetarian diets and 
sometimes more sweets. Sweet or sugary foods, red meat and processed foods 
were more likely to be avoided at both time points. The tendency to prefer eating 
healthy foods that women reported before treatment could be true of be affected 
by an “intention to please”, with participants reluctant to report consumption of 
foods known to be unhealthy (319). Self-reported dietary studies have been 
shown to under-report true habitual food intake with people changing their diet 
during the period of the survey (320). Women may have intended to ‘eat healthy’ 
in the face a cancer diagnosis but the intention to consume a healthy diet is not 
always a proxy for intake (321). It is not possible to verify or counter women’s 
statements from our data, however, the qualitative data from focus group 
discussions (chapter 8, Theme 2) revealed a similar trend. Women revealed that 
they had greater determination to ‘eat healthy’ earlier in their cancer journey. 
Their best intentions were often hampered by the difficulty in sustaining the 
motivation to continue with diets faced with negative effects of chemotherapy, the 
need to satisfy cravings and an increased appetite said to be due to the 
chemotherapy. The latter led them to consume sweet and rich foods even against 
their better judgement.  
 
5.5.2 The reasons and rationale given by women for changing 
their diet 
The reasons and rationale given by women for changing their diet are outlined in 
Table 28. The most common reason given for changing diet prior to treatment 
was loss of appetite 10/47 (21%). Anxiety about a possible/confirmed cancer 
diagnosis was the second most common reason 7/47 (15%) that affected eating 
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habits at baseline. Other reasons included swelling of the abdomen making 
eating uncomfortable, bloating or feeling full too quickly. Some of these reasons 
such as swelling of the abdomen explain why many women reported being able 
to eat only small amounts of food at a time. They also indicate why maintaining 
sufficient food intake is often a problem for some women.  
 
Table 28: The reasons given by women for changing their diet at baseline and 
during the treatment period  
The sum of the responses does not correspond to the number of women because some gave   
more than one reason and some no reason 
 
 
 No of patients 
  
Baseline 
N (%) 
End of treatment 
N (%) 
No of women who completed  
questionnaire out of the total of 58 
47 (81%) 38 (65%) 
No of women who changed their diet  32 (68%) 21 (55%) 
Reasons for change in diet   
Loss of appetite 10 (21%) 5 (13%) 
Anxiety about a cancer diagnosis  7 (15%) 1 (3%) 
Swelling of abdomen  6 (13%) 0 (0%) 
Bloating/feeling full quickly  5 (11%) 0 (0%) 
Too unwell  3 (6%) 1 (3%) 
Change in taste  2 (4%) 16 (42%) 
Pain  2 (4%) 0 (0%) 
Difficulty swallowing  1 (257) 0 (0%) 
Nausea/vomiting  1 (257) 0 (0%) 
To put on weight  1 (257) 1 (3%) 
Increased appetite  0 (0%) 2 (5%) 
Change in sense of smell  0 (0%) 2 (5%) 
To increase platelet count  0 (0%) 1 (3%) 
To boost immune system  0 (0%) 1 (3%) 
Want to eat healthy  0 (0%) 1 (3%) 
Women who gave more than one 
reason 
5 (11%) 7 (18%) 
Women who did not give a reason 2 (4%) 0 (0%) 
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The reasons given for changing diet during treatment appeared to be different 
from those given prior to treatment. The most common reason, given by 16/38 
(42%) of women who changed their diet during the treatment period was a 
change in the taste of food. Women attributed this change in test to the effect of 
chemotherapy treatment. Therapeutic reasons such as eating foods that could 
raise platelet count or build the immune system or to gain weight were also 
reported. The cancer trajectory seemed to influence the rationale for modifying 
diet. These results suggest that changes to diet were made in response to 
symptoms, treatment side effects and perceived physiological need.  
 
Although change in taste was reported by 17/47 (36%) at baseline, only 2 
attributed their diet choices to it as shown in Table 28. Similarly 8 and 11 women 
reported changes in smell prior to and during treatment respectively, yet only 2 
reported that it affected their diet choices. This implies that the impact of some 
symptoms may vary by time point, i.e. prior to treatment versus during the 
treatment. The reporting of the impact seems to depend on whether the symptom 
is caused by the disease or by treatment or whether there are other more 
distressing symptoms or side effects at the time. Symptoms such as abdominal 
swelling, anxiety about a cancer diagnosis and bloating were no longer reported 
by the end of treatment. During this time change in taste was reported as affecting 
diet choices the most.  
 
Although few women reported positive diet changes such as eating to put on 
weight and to be healthy etc., the reasons given for diet and eating habit change 
largely indicate that a diagnosis of ovarian cancer has a negative impact on food 
intake. Food intake was affected prior to presentation to the hospital and this 
continued throughout treatment for some women. The major drivers of diet 
change prior to treatment were symptoms such as loss of appetite, anxiety about 
a cancer diagnosis, discomfort due to abdominal distension or swelling and 
bloating or feeling full too quickly. Pain was rarely mentioned as a contributor. 
Women often made independent decisions on food choices particularly before 
treatment when most had not received any advice or treatment. Increased fruit 
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and vegetable intake and elimination of sweet and sugary foods were the most 
common choices. Changes in diet were not attributed to a change in sense of 
smell, even though the latter was common prior to and during treatment. The 
effect of positive eating is difficult to assess because of the small number of 
women who reported it.  
 
5.5.3 The relationship between dietary changes and nutritional 
and well-being outcomes 
5.5.3.1 Baseline 
Table 29 shows the characteristics of women who reported making changes to 
their diet versus those who did not in the phase prior to treatment. The Kruskal-
Wallis test was used to analyse differences between groups. No significant 
association was observed with the level of education between who reported 
making dietary changes and those who did not (p > .05). There was a significant 
difference (p < .01) by stage of disease, (early stage I & II versus late stage III & 
IV). Eighty five percent of women who made dietary changes had late stage 
disease. Significantly more women in the group that changed their diet 
experienced a change in taste (p < .05). No significant differences were observed 
in the change in smell, p > .05. Diet change was not attributed to either change 
in smell or taste prior to treatment. Significantly more women (p < .01) with ascites 
at baseline were in the group that changed their diet. Dietary changes were not 
associated with abdominal swelling, pain and nausea/vomiting were not different 
between the groups. There was significant association between changes in diet 
at baseline with treatment with neo-adjuvant chemotherapy, p < .05.  
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Table 29: The characteristics of women who made dietary changes prior to 
treatment versus those who did not 
**Significant difference observed between those who reported a change in eating habits and those 
who did not (Kruskal Wallis test) (p < .05)  
 
 
 
Characteristics Made changes to diet 
  
Yes  
N (%) 
No  
N (%) 
N (%) of a total of 58 cases 32 (55%) 15 (26%) 
Median age (range) 61 (36-88) 57 (40-82) 
Education 
Below O level 5 16%) 3 (20%) 
O level 4 (13%) 5 (33%) 
A level/professional 
qualification 
8 (25%) 3 (20%) 
University degree 9 (28%) 4 (27%) 
Education unknown  5 (16%) 0 (0%) 
Treatment** 
Surgery + chemotherapy 11 (34%) 12 (80%) 
Chemotherapy + surgery 20 (63) 3 (20%) 
Other (no treatment) 1 (3%) - 
Change in taste and smell 
Change in taste**  14 (44%) 3 (20%) 
Change in smell  7 (22%) 1 7%) 
Stage** 
1 
2 
3 
4 
Not staged 
2 (6%) 6 (40%) 
1 (3% 0 (0%) 
13 (41%) 6 (40%) 
14 (44%) 2 (13%) 
0 (0%) 1 (7%) 
Weight loss prior to baseline assessment 
Self-reported wt. loss  13 (41%) 4 (27%) 
Self-reported wt. gain  6 (19%) 1 (7%) 
Signs and symptoms at baseline 
Pain 17 (53%) 10 (67%) 
Swelling 18 (56%) 5 (33%) 
Ascites** 26 (81%) 6 (40%) 
Nausea 12 (38%) 5 (33%) 
Prealbumin (16mg/dl <)** 14 (44%) 1 (7%) 
Albumin (36g/l <) ** 7 (22%) 0 (%) 
Median health status (range)** 50 (10 - 82) 80 (40 - 100) 
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Table 29 above shows that low prealbumin and albumin were significantly 
associated with reporting making changes to diet at baseline (p < .01) and (p 
< .05) respectively. Women who reported not making changes to their diet had 
significantly higher health status scores at baseline, p < .01. This association is 
important as it shows that those who felt the need to change their diet also felt 
that they had a lower quality of life. Weight, BMI, body fat, dry lean mass and lean 
mass were not significantly different between the two groups. It is possible that 
the non-significant difference in weight is due to a cancelling effect as some 
women gained and others lost weight. The weight gained would not have been 
healthy weight but ascites. This is supported by that women who reported weight 
gain and those who reported weight loss at baseline both reported making 
changes to their diet.   
 
5.5.3.2 During treatment 
Twenty on of 38 women (55%) who completed the end of treatment questionnaire 
reported making changes to their diet during the treatment period. The 
comparison of nutritional and well-being outcomes between those who made 
changes and those who did not are shown in Table 30. The Kruskal Wallis test 
showed no significant differences between making changes and age, stage of 
disease, education and marital status. Changes in the taste and smell of food 
were both significantly different between the groups (p < .01 and p < .01) 
respectively. However only changes in taste were reported to affect diet/food 
intake (all sixteen women). Only 2 women reported that their diet was affected by 
changes in the smell of food. Four women expressed that they thought the 
changes in taste were due to chemotherapy.  
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Table 30: The characteristics of women who made dietary changes during the 
treatment period versus those who did not 
**Significant difference observed between those who reported a change in eating habits and those 
who did not (Kruskal Wallis test) (p < .05)  
 
 
 
Changing diet during the treatment period treatment was associated with a 
significant loss of weight (p < .01) and dry lean mass (p < .05). No significant 
associations were found with prealbumin, albumin and health status. However all 
women who had low prealbumin and or albumin at the end of treatment were in 
the group that changed their diet in the same phase. The decrease in dry lean 
mass and the fact that we found no correlation between dry lean and 
responders/non-responders to treatment (using CA125) supports its possible 
association with diet.  
 
Characteristics Reported of a change in eating habits 
 Yes  No  
N (%) of a total of 58 cases 21 (36%) 12 (21%) 
Median age (range) 62 (50 - 81) 56 (38 - 82) 
Education  
Below O Level 3 (14%) 1 (8%) 
O Level 2 (9%) 5 (42%) 
A level/professional qualification 5 (23%) 0 (0%) 
University degree 7 (32%) 4 (33%) 
Education not stated  5 (0%) 2 (17%) 
Symptoms 
Change in taste  16 (73%) 2 (17% ) 
Change in smell  11 (50%) 0 (0%) 
Weight ** 
Stable 2 (9%) 0 (0%) 
Loss  > 2% 12 (55%) 2 (17%) 
Gain > 2% 8 (36%) 10 (83%) 
Dry lean mass** 
Stable 3 (14%) 1 (8%) 
Gain < 2% 4 (18%) 5 (42%) 
Loss > 2% 10 (45%) 2 (17%) 
Missing values 5 (18%) 4 (33%) 
Signs 
Prealbumin <16mg/l 3 (14%) 0 (0%) 
Albumin < 36g/l 1 (5%) 0 (0%) 
Median health status (range) 65 (20-100) 80 (50-100) 
Death @ 31/2 years  8 (36%) 2 (17%) 
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5.5.4 Women’s experiences with nutritional support offered by 
the clinical team 
Table 31 shows the responses given by women when they were asked, in 
questions 2.17 to 2.26 of the study specific questionnaire, if they had received 
nutritional intervention (information/advice, referral to a dietician, supplements); 
the adequacy of this and what if support anything women would have liked 
support throughout treatment. Fifteen of 38 (39%) of those who completed the 
end of treatment questionnaire had received some form of nutritional intervention. 
Four women had been referred to a dietician, 2 were counselled/advised, 1 was 
prescribed oral nutritional supplements prior to treatment while another received 
intravenous (230) nutrition following surgery. The other 11 remaining women had 
been given nutritional information/advice. A nurse, dietician, pharmacist or doctor 
delivered the intervention. All but one woman who received intervention found it 
to be helpful or somewhat helpful. It served to support, reassure, encourage and 
create awareness of suitable foods to eat or avoid. Three women said that 
although the advice was helpful, it was not specific enough to meet all their needs. 
One woman felt that the intervention was not helpful as she was only given a 
generic Macmillan cancer support leaflet. Some women (7) went on to seek 
further information on their own initiative.  
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Table 31: A summary of the nutritional support provided by the clinical team 
throughout the course of the study 
 
Nearly half of women, 18/38 (47%) who completed the questionnaire reported 
that they did not receive any nutritional intervention from the clinical team. Eight 
of these women went on to seek information on their own initiative. A Kruskal-
Wallis test showed no significant difference (p > .05) in the ages of women who 
received or did not receive information and also those who sought or did not seek 
information on their own initiative. Those who sought further information, did so 
from the internet, Macmillan booklet, support group, family, a doctor and from 
other patients. 
 
Reasons for seeking diet and nutrition information included wanting to know more 
about their condition, pressure from family to eat well, wanting to be healthy, 
 Received nutrition information from clinical team 
Yes 
15 
No 
17  
Who was 
information 
provided by 
Ward sister, Macmillan nurse, pharmacist, doctor, dietician, 
chemotherapy nurse 
N/A 
Was the 
information 
helpful 
Yes 
14 
No 
1 
N/A 
How was 
information 
helpful/not 
helpful 
 Provided support with eating 
appropriately to build strength for 
surgery  
 Created awareness of what to eat to 
help cope with treatment  
 Reassured patients that they were 
eating appropriately 
 Managed expectations of side 
effects of treatment  
 Helped to eat appropriately to 
maintain weight and to continue 
with chemotherapy  
 Encouraged to eat small amounts 
when there was loss of appetite  
 Helped with what foods to avoid 
 Provided with prescription for 
shakes and Ensure© (nutritional 
supplements) 
 Anchoring during a period of 
changing food habits 
 
Given a 
Macmillan leaflet 
(leaflet not 
specified) 
 
N/A 
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wanting to know if some foods make the cancer and wanting to cope with 
chemotherapy effects. One woman wanted reassurance that her diet was not 
contraindicated for her diagnosis. Some women did not seek further information 
because they felt reasonably well, or were eating well and felt confident that their 
routine diet met their needs. However, some women were disinclined to seek 
information independently because they were confused about their situation, 
were worried about treatment or simply just too caught up with their illness. 
 
5.5.5 The impact of current practice on nutritional and well-
being outcomes 
The study explored whether women who received nutritional intervention or 
support had better nutrition outcomes. The Kruskal Wallis test showed no 
significant differences or associations in the baseline characteristics of women 
who received nutrition intervention and those who did not in terms of age, stage 
(early versus late), symptoms, albumin and prealbumin. Nor were any differences 
observed in weight, BMI, dry lean mass, lean mass, prealbumin, or health state 
at baseline and at the end of treatment. Table 32 below shows that a significant 
difference was observed only in the change in albumin, p < .05. Women who 
received intervention had a larger median increase (difference between baseline 
and end of treatment albumin level) compared to the group that did not.  
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Table 32: The relationship between current practice and nutritional status and 
well-being at the end of treatment  
**Significant difference observed between those who receiving intervention and those who did 
not (Kruskal Wallis test) (p < .05)  
 
 
The results show that women were not routinely offered support by their clinical 
team. If offered, support was on an ad hoc basis and delivered by different 
members of the team. It is unclear who initiated discussion about nutrition (patient 
or clinician) or if any criteria were used to determine which women were to receive 
this intervention or what the desired outcomes were. Moreover the samples 
involved here are mall and may not have allowed subtle changes to be observed. 
These also become some of the reasons why a well desired clinical trial is needed.   
 
5.5.6 Women’s perspectives of an ideal nutritional intervention 
Seventeen of 38 women (45%) who completed the end of treatment 
questionnaire gave their views of the type of support they would have like or if 
they received support whether this was adequate or not. Eight women were from 
Characteristics 
Reported that they received 
nutritional intervention 
  Yes No  
N  (%) of a total of 58 cases 15 (26%) 18 (31%) 
Median Age (range) 60 (46 - 75) 62 (38 - 82) 
Stage  
1 
2 
3 
4 
Not staged 
4 (27%) 1 (5%) 
1 (7%) 0 (0%) 
7 (47%) 7 (37%) 
3 (20%) 9 (47%) 
0 (0%) 1 (5%) 
Nutritional and health status at the end of treatment 
Weight   
Stable 1 (7%) 1 (6%) 
Weight loss > 2%  6 (40%) 8 (44%) 
Weight gain > 2%) 8 (53%) 10 (56%) 
Prealbumin 16mg/l< 2 (13%) 1 (6%) 
Albumin 36g/l <** 0 (0%) 1 (6%) 
Health status median (range) 70 (33-100) 78 (20-100) 
Death @ 31/2 years  5 (33%) 5 (28%) 
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the group that received some intervention/support and nine from the group that 
did not. Table 33 the views of women on the intervention they received or would 
have liked to receive. Suggestions that were made for improvement of nutritional 
support included routine use of hand-outs as a basis for discussion, opportunities 
to talk over issues and not be told to eat anything, advice on diet to address 
specific needs such as a low platelet count. There were also suggestions to 
model the support on what patients have found helpful in other NHS requests to 
be referred to a dietician. These suggestions point to that some women are aware 
of services that could be available to them.  
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Table 33: The views of women of the support they received or would have liked to have received during the course of investigations and 
treatment 
Women who did not receive information  Women who received information/support 
Advice to improve platelets instead of niece seeking information A simple pamphlet clearly marked out reasons why / why not certain foods 
are good / bad for people on chemotherapy. Clearly marked not vague 
Suggestions on foods that help to combat cancer The support provided was adequate (X3) 
Information on foods to assist in recovery from treatment and 
nutrients to get energy levels back  
Advice on which foods that are least likely to cause nausea during 
chemotherapy 
Leaflets of examples of what one should 'try' and eat daily Support provided was adequate, the main people supporting you always 
give time despite pressure of work 
Referral to a dietician to made easy I had a lot more information from the specialist nurse after a heart attack. 
They actually give patients a talk and leaflets, it’s a model you may want to 
follow. 
Talk over issues and not be constantly told eat 'anything' and all 
food is good at this time 
I would have liked more information on specific foods that are useful to those 
recovering from ovarian cancer. Possibly a personal diet plan to improve my 
recovery 
Recommend best diet, where to go for information and if there are 
any support groups within my area 
 
Give more information about diet, nutrition  
Give out information and discuss the issues and changes and 
advise what to eat. 
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This chapter showed that women make changes to their diet even before they 
come into hospital for investigation/treatment of their cancer. The changes are 
largely based on symptom burden. Women continue to make changes throughout 
the course of treatment based on disease symptoms, treatment side effects and 
a desire to eat healthily. Changes to diet are associated with poor nutritional 
status (low pre-albumin), poor well-being (low albumin) and an overall lower 
quality of life (low health status) at baseline. Nutritional support is not offered 
routinely despite that women wish for it to be. There was no observable 
association between nutritional intervention with nutritional and well-being 
outcomes except for albumin. It is possible that a low albumin was the reason 
women were provided with nutritional intervention in the first instance. The 
suggestions for a future intervention are considered together with suggestions 
that emerged from focus group discussions in the next study, B. They are 
assimilated to make recommendations for a potential future intervention trial.
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6 The observational study results Part 2 
(Quality of life and summary of findings)  
6.1 Introduction to chapter 
This is the second of the observational study results chapters. Section A presents 
findings on the analysis of the Euroqol EQ-5D quality of life instrument. Results 
are presented on the two components of the instrument. The first, the EQ-5D 
consists of 5 domains/dimensions which are mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression. The responses to the three levels of 
each dimension, (no problem, some/moderate problem and unable to/extreme 
problem) were reclassified into two categories of ‘no problems’ and ‘problems’, 
due to there being too few extreme problems. Cases are sub grouped by the 
median age of menopause for this study, 50. Comparisons of the prevalence of 
problems are made between cases and controls. The problems are analysed for 
association with nutritional status. The second component, the Visual Analogue 
Scale (EQ-VAS) provides a global assessment of each woman’s perception of 
her health on a scale of 0-100 (worst imaginable health to best imaginable health). 
This is independent measure is used as a proxy for the overall quality of life. 
Correlations and associations between overall health status (quality of life) and 
nutritional status are reported for each time-point for cases and controls. Section 
B provides an overall summary of the findings from the observational study.  
 
6.2  Section A: Quality of life findings 
6.2.1 The proportion of cases reporting problems 
The proportion of cases reporting problems for the EQ-5D dimensions at baseline, 
during treatment, and at the end of treatment are shown in  Sub-grouping women 
by the age of menopause enabled identification of intergroup differences since 
ovarian cancer is predominantly a disease of menopausal women. A summary of 
the frequencies for each dimension and level is included in appendix 7
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Figure 27: The bar chart showing the proportion of cases reporting problems for the EQ-5D dimensions at baseline, during       
treatment and at the end of treatment  
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The above graph shows that self-care was the least reported problem in cases 
across all three time points. Between 40/58 (70%) and 52/58 (90%) of all women 
reported that they had no problem with their self-care at any given time. Mobility 
was reported as a problem by 3/7 (43%) of non-menopausal women and 18/38 
(47%) of menopausal women at baseline. The frequency increased to 57% in 
menopausal cases during treatment, but decreased in both groups at end of 
treatment. Usual activity was a problem for older women particularly during 
treatment. They reported it at 57% at baseline, 80% during treatment and 47% at 
the end of treatment. Premenopausal women reported less of this problem rising 
only to rising 57% during treatment. The increase in mobility and self-care 
problems during treatment is likely to reflect the complex recovery process 
following major surgery and complications arising from the side-effects of 
chemotherapy treatment. Pain/discomfort and anxiety/depression were the most 
reported problems at baseline, and at the end of treatment. Premenopausal 
cases reported more problems with both dimensions than older women. They 
reported a pain/discomfort prevalence of between 60% and 89% across the three 
time points while older women reported between 50% and 71%. They also 
reported an anxiety/depression prevalence of 89%, 57% and 80% at baseline, 
during treatment and at the end of treatment respectively compared to 69%, 55% 
and 30% for menopausal women.  
 
These findings suggest that a diagnosis of ovarian cancer affects all but one 
dimension of quality of life when measured using the EQ-5D instrument. Overall, 
the problems of self-care, pain/discomfort and anxiety/depression persisted to the 
end of treatment. Pain/ discomfort and anxiety/depression are known to 
negatively impact food intake and therefore nutritional status.   
 
6.2.2 The proportion of controls reporting problems 
The proportion of controls reporting problems for EQ-5D dimensions at baseline 
and end of treatment are shown in Figure 28. The proportions of controls in each 
dimension are outlined in appendix 7. Controls were not sub grouped due to the 
small sample size and an even smaller a number of menopausal women.  
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Figure 28: The bar chart showing the proportion of controls reporting problem for 
the EQ-5D dimensions at baseline and at the end of treatment 
 
 
Self-care was again the least reported problem. It was not reported at baseline 
and was reported at 10% at the end of treatment. Mobility was a problem for 35% 
of women at baseline and 40% at the end of treatment. The most reported 
problems at baseline were usual activity at 53%, pain/discomfort at 71% and 
anxiety/depression at 71%. These problems persisted to the end of treatment, 
with usual activity reported at 60%, pain/discomfort at 50% and 
anxiety/depression at 50%. These findings suggest that women diagnosed with 
benign gynaecological diseases perceive the various domains of their quality of 
life to be affected similarly to women diagnosed with ovarian cancer. This would 
be expected pre-diagnosis.    
 
6.2.3 The relationship between EQ-5D dimensions and 
nutritional status  
The problematic dimensions of usual activity, pain/discomfort and 
anxiety/depression were analysed for association with nutritional and biochemical 
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outcomes at baseline using the Kruskal Wallis test. No association was found, 
p > .05 in all instances between all 5 dimensions with weight, BMI, body fat, lean 
mass, dry lean mass, albumin, CRP and CA125 for cases. There was a significant 
association between pain/discomfort and extracellular water, p < .05 and a 
borderline significance, p = .06 between pain/discomfort and total body water at 
baseline. Prealbumin was the only outcome to be significantly associated with 
difficulties with usual activity, p < .05 at baseline for cases. No significant 
associations were found with all dimensions and outcomes for controls. These 
findings suggest that women who had ascites were more likely to suffer from pain 
and discomfort. They also suggest that problems with various quality of life 
dimensions are independent of nutritional status with the exception of prealbumin 
which is associated with challenges in carrying out usual activities in cases.  
 
6.2.4 Visual Analogue Scale (VAS) 
A descriptive analysis of the perception of women’s own health status using the 
Visual Analogue Scale (EQ VAS) is provided in Table 34. A wide range of scores 
were observed ranging from 0 (worst possible health) to 100 (best possible health) 
for cases and 3 – 95 for controls.  
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Table 34: The descriptive analysis of EQ VAS at baseline, during treatment and 
at the end of treatment for cases and controls 
All Cases health status 
 Baseline During treatment End of treatment 
N Valid 46 37 25 
Missing 12 21 33 
Median 50 57 70 
Range 90 100 80 
Minimum 10 0 20 
Maximum 100 100 100 
Cases treated with surgery + chemotherapy 
N 20 20 10 
Median 72.5 65 85 
Range 70 100 55 
Minimum 30 0 45 
Maximum 100 100 100 
Cases treated with chemotherapy + surgery 
N 25 17 15 
Median 50 60 70 
Range 90 80 75 
Minimum 10 20 20 
Maximum 100 100 95 
Menopausal cases 
N 37 30 20 
Median 59 58 69 
Range 90 100 80 
Minimum 10 0 20 
Maximum 100 100 100 
Premenopausal cases 
N 9 7 5 
Median 57 69 69 
Range 85 45 20 
Minimum 10 50 60 
Maximum 95 95 80 
All controls 
N Valid 17 n/a 10 
 Missing 10 n/a 17 
Median 45 n/a 66 
Range 92 n/a 85 
Minimum 3 n/a 8 
Maximum 95 n/a 93 
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6.3 Cases 
The EQ-VAS frequencies at baseline, during treatment and end of treatment are 
also illustrated in graphs A, B and C of Figure 29. In graphs A and B, women are 
sub-grouped by the age of menopause. Only 5 non-menopausal women 
completed the end of treatment VAS. Sub-grouping could not be performed on 
this small sample size, hence only menopausal women are included in graph C. 
 
Figure 29: The bar charts showing EQ VAS at baseline, during treatment and at 
the end of treatment by age of menopause for cases 
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The median health status score improved progressively from 50 at baseline to 57 
during treatment and 70 at the end of treatment. The Related-Samples Wilcoxon 
Signed Rank test showed no significant difference between baseline and the 
during treatment scores, p > .05. There was a significant increase between 
treatment and end of treatment, p < .01. There was also a significant overall 
increase from baseline to end of treatment, p < .05. These findings suggest that 
women did not perceive their overall health to improve immediately following 
surgery or their first chemotherapy cycle. This is probably due to that both 
treatments can have significant side effects and/or a difficult recovery phase. 
Although the end of treatment score of 70 suggests overall improvement in health 
status from baseline, some women did not complete the final questionnaire due 
to poor health and death. Thus the healthy volunteer effect may apply here. 
 
The change in cases’ VAS scores overtime, by age of menopause and type of 
first treatment are illustrated in Figure 30. This graph shows that younger women 
recorded the highest health status during treatment. Women treated with 
chemotherapy first had a constant increase in their health status from baseline to 
the end of treatment. The Kruskal Wallis test was used to further examine the 
relationship between baseline health status and stage of disease, type of first 
treatment and the presence of ascites at baseline treatment. There was no 
significant association between health status and the stage of disease p > .05. 
There was significant association between health status and the presence of 
ascites at baseline, p < .05. There was also a significant association between 
health status and type of first treatment, p < .01. 
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Figure 30: Multiple line graphs showing changes in EQ VAS median scores 
between baseline, during treatment and the end of treatment by menopausal 
status and type of first treatment for cases 
 
 
Spearman’s correlational analysis showed a negative relationship between 
health status and age during treatment ((r = -316, p = .05), Table 35). This 
suggests that older women recorded lower health status scores during this time. 
There was also a significant negative relationship between health status and 
having chemotherapy as a first treatment at baseline. (r = -390, p < .01). This is 
unsurprising as women diagnosed with early stage disease (I & II) are generally 
younger (as was shown in Table 10) and treatment with surgery first followed by 
chemotherapy is the choice treatment for women with operable disease and less 
comorbidities.  
 
6.4 Controls  
The distribution and slope of the VAS scores in the controls are shown by graphs 
D and E in Figure 31. Subgroup analysis by age of menopause was not possible 
because of the small sample size. Only 10 women were assessed at the end of 
treatment so that frequencies from such a small sample would not provide 
meaningful results. As such the end of treatment distribution is not included in 
graph D.    
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Figure 31: The bar and line graphs showing the proportion of controls reporting 
problem for the EQ-5D dimensions at baseline and end of treatment 
 
 
Thirty one percent of controls recoded a health status below 20 at baseline, 
Figure 31. The related sample Wilcoxon Signed Rank Test showed a borderline 
significant difference between baseline and end of treatment health status (p 
= .06). A larger sample size particularly at the end of treatment may have yielded 
a significant result. Health status was not significantly different between baseline 
and end of treatment between cases and controls although controls had lower 
scores in both instances. These results suggest that women diagnosed with 
benign disease perceive their health status to be similar or worse than that of 
women diagnosed with ovarian cancer. 
 
The relationship between nutritional status and quality of life (using overall health 
status) is explored below. Correlations were computed among nutritional status 
and biochemical indicators for cases and the findings are shown in Table 35. 
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Table 35: The Spearman’s correlations between health status and nutritional, body composition and biochemical outcomes for cases 
 
AGE Weight BMI 
Body 
fat 
Lean 
mass 
Dry 
lean 
mass 
Extrac
ellular 
water 
Total 
body 
water 
Prealb
umin 
Album
in 
CRP CA125 
Spearman’s 
rho 
Baseline 
health 
status 
Correlation 
Coefficient 
.060 -.004 .083 .017 -.017 .252 -.047 -.079 .478** .440** -.178 -.264 
Sig. (2-tailed) .691 .978 .653 .928 .928 .164 .799 .666 .003 .002 .258 .079 
N 46 45 32 32 32 32 32 32 36 45 42 45 
 During 
treatment 
health 
status 
Correlation 
Coefficient 
-.316* -.010 -.089 -.277 .224 .288 .046 -.022 
n/a n/a n/a n/a 
Sig. (2-tailed) .057 .956 .665 .171 .283 .153 .825 .916 
N 37 34 26 26 25 26 26 26 
 End of 
treatment 
health 
status 
Correlation 
Coefficient 
-.039 -.010 -.094 -.192 .192 -.001 .021 -.006 .214 .135 -.328 -.106 
Sig. (2-tailed) .854 .961 .670 .381 .381 .995 .925 .977 .338 .530 .136 .629 
N 25 25 23 23 23 23 23 23 22 24 22 23 
 
**. Correlation is significant at the 0.01 level (2-tailed) 
*. Correlation is significant at the 0.05 level (2-tailed) 
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Three correlations were statistically significant. Albumin and prealbumin 
positively and significantly correlated with quality of life at baseline (r = .42, p 
< .05) and (r = .478, p < .01) two tailed, respectively. No significant correlations 
were shown at the end of treatment, largely because both markers had 
returned to normal levels despite that some women had residual disease. 
Quality of life did not significantly correlate with BMI, body fat, lean mass or 
dry lean mass at any time point. Prealbumin was the only outcome to have a 
borderline significant correlation with quality of life in controls, (r = .494, p = .07) 
at baseline.  
 
These results suggest that albumin, a well-known indicator of well-being, is 
confirmed to be such in this study of women newly diagnosed with ovarian 
cancer. Significantly, the results also show a strong relationship between 
nutritional status and quality of life, revealed by the correlation between 
prealbumin and overall health status in cases. Prealbumin is considered an 
objective marker of nutritional status. 
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6.5 Section B: Summary and discussion (observational study) 
6.5.1 Diagrammatic representation of main findings 
 Figure 32:  Summary of findings 
 
 
 
 
 
 
 
 
 
 
 
 
Weight, BMI, body fat and dry lean 
mass are affected in some women 
at baseline  
Prealbumin correlated with 
short and medium term 
changes in symptoms; eating 
habits and quality of life  
Women make dietary 
changes starting prior to 
treatment with or without 
professional support 
Premenopausal women had higher increases in BMI, and lean mass between baseline and end of treatment 
Women who died, transferred to a hospice or were too unwell to continue in the study are likely to have had worse nutritional status 
Eating habits returned to pre-disease patterns by the end of treatment 
Routine nutritional advice/support from healthcare professionals was not shown to have an impact on nutritional status 
Biochemical markers prealbumin and albumin positively correlated with overall health status at baseline  
 
 
Changes are 
reactive: driven 
by symptoms 
and perceived 
health or 
physiological 
need 
Weight and BMI helpful in 
indicating trends not individual 
nutritional status as they do 
not account for ascites 
No standard clinical cut-offs 
for dry lean mass 
BMI and body 
fat use is 
limited by 
increased 
adiposity in 
the general 
population 
 
Some nutritional status outcomes are already impaired by the time 
women are first seen in the hospital for investigations/treatment 
Prealbumin, albumin and 
CRP are affected in 
some women at baseline  
Albumin 
reflects 
general well-
being  
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6.5.2 Summary and discussion 
The results show that in some women nutritional status measures of weight, BMI, 
body fat and dry lean mass as well as biochemical markers; prealbumin, albumin 
and CRP were already impaired by the time women presented to the hospital for 
investigations and treatment of ovarian cancer. There was no association 
between total body water, extracellular water with the presence of ascites. In 
general women were on the lower spectrum of hydration, which may partly 
explain the lack of association. Both were however associated with pain and 
discomfort at baseline. We also found that an additional category of ‘weight gain’ 
was necessary for the classification of cachexia in our study population. This was 
because more than half of the women had ascites and distension when they 
presented to the hospital/clinic. Some women who reported gaining weight prior 
to treatment were shown to be clinically similar or worse off compared to women 
who lost weight. They had advanced disease, low prealbumin and albumin as 
well as ascites. A higher BMI correlated positively with increased albumin levels. 
A higher BMI and increased albumin were both associated with higher health 
status scores (quality of life). Younger women were more likely to have increased 
BMI by the end of treatment. Others have also found age and advanced disease 
to be associated with an increased risk of being malnourished (2) and impaired 
survival and greater risk of death among patients with ovarian cancer (322). A 
literature review by Cress et al., 2015 confirmed that age had a great effect on 
overall survival in epithelial ovarian cancer and that long-term survivors were 
more likely to be younger than 50 years of age. They suggest that a better 
performance status may mean that younger women tolerate more aggressive 
surgery and chemotherapy better. Ten women were lost to follow-up. Some had 
died, some relocated to hospices or moved to be close to family for end of life 
care while others were too ill to continue with the study. Most of these women are 
likely to have been classed as being in the refractory phase of cachexia. Nutrition 
intervention is unlikely to make any difference at this stage. 
 
A diagnosis of ovarian cancer has a negative impact on ‘food intake’, one of the 
key contributors to cachexia. Food intake is affected prior to presentation to the 
hospital and continues through treatment for some women. The major drivers of 
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diet change are symptoms, treatment effect and perceived physiological need. 
These often result in women making independent decisions on food intake. 
Choices included increased fruit and vegetable intake; the elimination of sweet 
and sugary foods as well as red meat; and eating small amounts at a time. 
Change in taste, a common side effect of chemotherapy affects food intake the 
most during treatment. There were no longer specific ‘healthy eating’ related 
dietary changes observed by the end of treatment, raising the suspicion that 
women had either not implemented the intended changes stated prior to 
diagnosis or they had abandoned them during the course of treatment. Women 
who made changes to their diet prior to baseline were shown to have significantly 
lower prealbumin and albumin as well as health status scores at baseline. 
Similarly women whose diet changed during treatment lost more weight and dry 
lean mass than women whose diet did not change. A decrease in dry lean mass 
in women whose diet changed during treatment highlights the potential link 
between nutritional status and diet. Prealbumin correlated with change in eating 
habits further suggesting that there may be a direct and linear relationship 
between dietary intake and prealbumin at baseline when women reported that 
their eating habits had changed the most.  
 
Significantly more women with ascites (p < .01) reported having changed their 
diet at baseline. That women who reported that their diet had changed at baseline 
were more likely to be treated with neo-adjuvant chemotherapy (p < .05), 
suggests that these women had more advanced disease and therefore 
complications associated. The relationship between the speed of onset of 
disease and the development of symptoms probably has a bearing on their 
impact on diet. Unfortunately little is known about the natural history of ovarian 
cancers before they become clinically apparent. Work by Brown and Palmer 
(2009) (185) investigating the preclinical natural history of serous ovarian cancer 
estimated that on average serous ovarian cancers have already progressed to a 
late stage nearly 1 year prior to their discovery. Serous ovarian cancers constitute 
70% of all cancers that present at stage III or IV (323) and account for  the majority 
of deaths.  
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There was an overall sense of lack of nutritional support of women by clinicians 
treating them. However there were no significant associations between receiving 
nutritional intervention and improvement in nutritional status. There was however 
and association with well-being (albumin). The significant differences in albumin 
are likely due to helpful nutritional support/advice that improved patients eating 
habits and therefore wellbeing. The advice may also have helped women to eat 
well and continue with treatment, which improved their underlying health status.  
 
Quality of life results showed that cases and controls experienced problems with 
mobility, usual activity, pain/discomfort and anxiety/depression across all time 
points. These findings are not surprising (at baseline), since the benign conditions 
were severe enough to warrant surgical intervention. Premenopausal cases and 
controls reported more problems at the end of treatment than menopausal 
women. That controls were still reporting problems 6-8 weeks post-surgery is 
perplexing. As such our findings on anxiety and depression contradict what Yang 
et al., (2013) (324) showed from a meta-analysis, that the overall prevalence of 
anxiety in individuals with a cancer diagnosis was higher than that in non-cancer 
controls. They however concur with others that among ovarian cancer patients, 
younger age groups are disproportionately affected (325). The 
anxiety/depression was found to persist, with almost half of individuals 
experiencing anxiety symptoms at three months post-treatment. Prealbumin was 
the only nutritional outcome to be associated with difficulties with usual activities 
at baseline in cases. In this case, prealbumin may have reflected general 
wellness. Our study also found albumin and prealbumin to correlate with quality 
of life (EQ-VAS), confirming albumin to be a measure of well-being. More 
importantly, they show nutritional status (prealbumin) to be correlated with quality 
of life. 
 
The next chapter describes the methods that were followed to elicit women’s 
perspectives on diet and nutrition issues through focus group discussions and 
free text data from the study specific questionnaires. 
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7 Methods (Qualitative enquiry) 
7.1 Introduction of chapter 
This chapter outlines the research approach and justification for the inclusion of 
a qualitative analytic component in the study. The data collection method of 
choice was focus group discussions complemented by free text data from 
questionnaires. A description of the patients that took part in this research as well 
as the description of the conduct of the inquiry is provided here. The chapter also 
describes how a health behaviour model is used to interpret dietary and nutritional 
behaviours. A health behaviour change model can in future be incorporated in 
intervention strategies to support adoption and maintenance of healthier 
nutritional intake and lifestyle.  
 
7.2 Research approach and justification 
To provide a comprehensive understanding of the nutritional challenge it was 
important to have a component of the research that sought to understand the 
challenges from the patients’ point of view. The qualitative approach was used to 
address the research objectives of ‘developing an understanding of patients’ 
perspectives of their nutritional challenges, nutritional information and support 
needs and exploring how a health behaviour model, Health Action Process 
approach (HAPA), could be used to improve a potential future intervention 
package’      
 
A qualitative approach is useful in that it situates the research and locates the 
researcher in the world of the research participant to better understand their 
experiences (326). This positioning of the researcher allows for collecting of 
contextual material derived from speech or observation. It also attempts to 
understand the phenomenon of interest in terms of the meanings people bring to 
them (327). Patients' reactions to their disease and treatment are only partially 
related to objective parameters; they are also influenced by expectations 
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surrounding their functional level, and perceptions about themselves and the 
treatment environment (135). It was therefore felt that this component was 
invaluable in facilitating the study of issues in depth. Although qualitative methods 
are often criticised for their subjectivity due to hypotheses generated during data 
collection and analysis, patients’ own perspectives add depth to understanding 
the challenge. 
 
7.3 Focus group discussions 
Focus group discussions were chosen ahead of other qualitative inquiries 
because their primary aim is to describe and understand meanings and 
interpretations of a select group of people to gain an understanding of a specific 
issue (328). This was what the study hoped to achieve with regards to diet and 
nutrition, experiences of nutritional support in the clinical setting as well as ideas 
for an ideal nutrition intervention. Another advantage of focus group discussions 
is that they can provide results quickly. They can generate complex information 
with the minimum amount of time as well as be used with a wide range of people 
and groups in different settings (329). In addition they provide the researchers 
with a great opportunity to appreciate the way people see their own reality and 
hence ‘to get closer to the data’ (330). An additional unique feature of focus group 
discussions is that they explicitly use group interaction as part of the method. 
Group processes assist people to explore and clarify their points of view (331). 
Researchers can obtain more insight of a wide range of views; they also have the 
opportunity to clarify issues or to obtain more views on an aspect they consider 
important. Another important aspect of focus group discussions is that they can 
help researchers understand the meanings people assign to social phenomena 
and to elucidate the mental processes underlying behaviours (5). These 
behaviours are often explained through the study of behavioural change theories. 
The theories attempt to identify and explain the major factors that determine 
behaviour.   
 
The discussions were used to explore women’s’ views on nutrition in their journey 
with ovarian cancer as well as capturing the context, meaning and complexity of 
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managing their situation. Focus group discussions also probed participant health 
behaviours and choices based on some aspects of preliminary results from Study 
A. Some information relating to nutritional support packages was solicited and 
ideas of a future nutritional intervention package explored. The enquiries were 
semi-structured but also followed the naturalistic and emergent design flexibility 
to allow for new concepts to emerge from during the discussion. 
 
7.4 Free text entries (study specific questionnaire) 
Data provided by patients as free text in the study specific questionnaire was 
used as an additional component of the patient perspective study. This ensured 
that diverse women’s perceptions of the nutritional challenges including those 
recruited in study A were captured.  
 
7.5 Topic guide for the focus groups  
Data from baseline and end of acute treatment questionnaires were preliminarily 
evaluated and used alongside the initial objectives to define the direction of the 
inquiry. A draft topic guide for the focus group discussions was developed based 
on review of the literature, the research aims and the researchers’ experience of 
working with women diagnosed with ovarian cancer. The topic guide included 
open-ended prompts about nutrition, areas of diverse beliefs or practices, and 
what participants saw as important for their nutritional support. It covered issues 
such as whether patients were aware of nutrition as being important to their 
treatment and recovery, and what issues they believed should be considered 
when making decisions about their nutrition. A sample is provided in appendix 8. 
 
7.6 Focus group participants 
These are women who had an ovarian cancer diagnoses and were at any stage 
of their cancer journey. Some were undergoing first-line treatment, others were 
in remission and yet others were awaiting treatment for recurrent disease. 
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Patients who have been diagnosed and treated for ovarian have regular follow-
up enabling clinicians to monitor women for side effects, recurrence and overall 
heath. Follow-up of ovarian cancer generally includes a physical examination, 
blood tests to check for tumour markers that may indicate recurrence if raised, 
Computerised Tomography (CT) scans and chest X-Rays are also used to 
monitor patients. Examinations are usually every 2-4 months for the first two 
years after treatment, every six months for the following three years and yearly 
thereafter (180). Women could participate in focus group discussions at any stage 
of their ovarian cancer journey, provided they had had/started treatment for the 
disease. The ideal size of a focus group for most non-commercial topics is 
between five and eight participants. Larger groups can be difficult to control and 
may limit individual’s opportunity to share insights and observations (326). Two 
focus group discussions of 4 people each were conducted.   
 
7.7 Inclusion and exclusion criteria  
7.7.1 Inclusion criteria 
 Women aged 18 years and above who had previously had treatment or 
were on treatment for ovarian malignancy (including fallopian tube and 
primary peritoneal cancer)  
 Women who had not already taken part in study A 
 
7.7.2 Exclusion criteria  
 Women who had not received treatment for their cancer 
 
7.8 Recruitment and patient characteristics 
Eligible patients were identified from the weekly gynaecological oncology clinic at 
the primary research site. Recruitment took place over a 2 month period. For 3 
successive weeks, gynaecology oncology outpatient clinic lists were screened for 
eligible patients. The researcher approached identified women and explained the 
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study to them. Women who expressed interest were given a package containing 
a patient information leaflet, a reply slip confirming their un/willingness to 
participate in the group discussion and a prepaid envelope to send their response 
to the research centre in. Where the researcher could not personally meet with 
the woman, their consultant was asked to pass the information package to them. 
All women who returned the slip were telephoned to acknowledge receipt of their 
response. The telephone call was also used to arrange a suitable date and time 
for the group discussion for those women who wanted to participate. Four 
possible dates and times were suggested and women chose the date that best 
suited them. A total of 62 women were approached in clinic, 27 expressed an 
interest to participate and 16 confirmed their willingness to take part by returning 
their reply slip. Only six women from those recruited in clinic eventually 
participated in the discussions. The majority of women could not attend on any 
suggested dates or other dates that other women could attend in. 
 
7.9 Ovarian cancer charities 
We planned to run the groups with eight participants in each group. However 
while trying to organize a date and time for the first group discussion it became 
apparent that we had insufficient numbers of women. Matching participants to 
dates proved difficult. Moreover women’s treatment plans and health challenges 
made it difficult for them to commit to a date and time. After deliberation it was 
felt that more women should be approached. Since women in the oncology clinic 
had either been approached or declined or were already participating in Study A, 
two gynaecological cancer charities (The Eve Appeal and Ovacome) assisted 
with recruitment. The charities keep registers of women who express a 
willingness to participate in research if opportunity arises. The Eve appeal 
administrator identified 10 women who lived in London (for ease of travel) and 
emailed them the study information package. Women were asked to respond 
directly to the researchers using the reply slip. Ovacome on the other hand, asked 
the researcher to provide a summary of the invitation shown in to post on their 
website. Interested women responded by contacting the researcher directly. 
These women were sent the information package and asked to confirm their 
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willingness to participate through the reply slip. A self-addressed-prepaid 
envelope in which to return the slip was provided.  
 
Eight women from both charities returned the slip confirming their willingness to 
participate. Upon receipt of the reply slip women were telephoned and offered 
possible appointments dates. Three women from Ovacome lived too far to travel 
into London for the discussions including one who lived in Scotland. The available 
dates for the discussion were not suitable for most women. Only two women 
approached via the charities eventually participated in the group discussions. 
Although some others were willing to participate, the dates and times offered 
were unsuitable or they lived too far away (Scotland) to attend the discussions in 
London.  
 
Recruiting patients through the charities could have potentially introduced bias to 
the data through the healthy volunteer effect (332). This is a phenomenon where 
generally healthier individuals offer to participate in research compared to the 
less healthy counterparts. Also, women who are signed up to charities to help 
with research may not be representative of the overall population of ovarian 
cancer patients. They are probably more interested in health and nutrition issues 
than their counterparts who are not. However the small numbers of women 
recruited this way (only two) means the healthy volunteer effect may not have 
had as big an impact than if more women had been recruited in this manner.  The 
characteristics of women who took part in this research are outlined in described 
in Table 36.  
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7.10 Conduct of the focus group discussions 
Participants were involved in a structured and recorded group discussion. The 
recordings were which was later transcribed for analysis. Two discussions with 4 
women each were held a month apart. The discussions took place in a small 
meeting room at a university affiliated with the primary NHS Trust research site. 
One meeting was facilitated by an MSc student, and the other by this researcher.  
Both were observed by the students’ research supervisor who also acted as a 
moderator. Facilitators worked together to recruit participants, set-up dates and 
to review their interview guides. The group discussions were carried out in a 
similar format, albeit with a different emphasis on the endpoints. Everyone sat 
around a table with the audio-recorder placed in the middle. The discussions 
lasted 90 minutes each. Refreshments were provided half way through the 
discussion.  
 
The facilitators opened the discussions by clarifying the purpose of the study and 
highlighting that the opinions of the participants were valued. Although the 
discussions were semi-structured participants were encouraged to express 
themselves and to interact with each other. The discussions were directed using 
a semi structured interview guide prepared beforehand. This helped to ensure 
important issues were discussed. This topic guide included some preliminary 
findings about diet and change in eating habits from study A. The moderator was 
skilled in the interview techniques and strategically asked both steering and 
testing questions during the discussions. 
 
7.11 Data transcription  
Audiotapes from the two focus groups were transcribed verbatim. Participant 
identifiers were removed; women are identified in the text as Respondents one 
to eight. The facilitators are identified as JS and NB and the moderator as AL. 
The Group one audiotape was transcribed using Express Scribe followed by 
double-checking to ensure accuracy. The Group 2 recording was transcribed 
manually to allow the researcher to relive the discussion and to be intimately 
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connected with the data (333). The data from the two groups and used in this 
thesis were wholly analysed by the research as described below.  
 
7.11.1 Data quality assurance 
Multiple coding of the focus group data was used to ensure rigour and counter 
concerns about the address the subjectivity sometimes levelled at the process of 
qualitative data analysis (334). In order to establish consistency of coding for the 
focus group and free text data, the researcher independently coded all the 
transcripts. Discussions of any incongruence took place in supervisory meetings. 
Differences were resolved by discussing the differing interpretations, identifying 
any misunderstandings, and refining code definitions as necessary. The 
researcher would put forward their rational for perceiving a particular meaning 
from the text. The supervisor could probe further or suggest a different 
perspective. A discussion would ensue, until there was consensus or middle 
ground was found. This ensured that a systematic process was followed and 
maintained transparency. Supervisory meetings facilitated reflexivity and 
safeguarded against individual bias by providing opportunities to make 
assumptions explicit and open to challenge (335). These meetings formed a kind 
of auditing that was “built into the research process to repeat and affirm 
(researcher’s) observations” (336).  
 
7.12 Data analysis 
A thematic analysis approach was adopted for evaluating the data. The themes 
were arrived at inductively by using content analysis to generate codes and 
categories (337) and deductively because a set of pre-determined questions 
were posed to the participants to cover important areas.  
 
A systematic and verifiable trail of the analytic process began with reading and 
re-reading of the Group 2 manuscript to discover and understand meaning from 
the data (338). Data was coded to generate an indexed copy of the first transcript. 
The track changes feature in ‘Microsoft Word’ was used to generate the codes. 
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The ‘Add Comment’ command was used to tag each topic (labelling it by meaning) 
throughout the text. This option suited the purpose because Microsoft Word 
automatically and sequentially numbers each additional comment. Equal 
attention was paid to all aspects of the data (339), which is an important aspect 
of the analysis. One hundred and sixty codes (NB1-NB160) and corresponding 
topics were systematically identified. The topics ranged from unclear professional 
advice, reading labels when buying or before eating food, not being ill during 
treatment, putting on weight during or after chemotherapy treatment to being 
obsessive about diet and not wanting to die and many more. The codes and the 
corresponding topics (the index) were copied onto a spread sheet. These were 
then reviewed to ensure that all data had been indexed. Supervision sessions 
were used to have another person cast an eye over segments of data or 
emergent coding frameworks. This was part of quality control of the analytic 
process. 
 
When all data was accounted for, the codes were distilled to generate a revised 
code list. This involved grouping codes recognised as having the same or similar 
meaning. Individual codes and topics were maintained for cross-referencing. The 
next stage from this involved revising the topics and summarising them to be 
more specific and concise for example grouping them by those related to disease 
and symptoms, good food, bad food, and emotions of fear of returning disease 
etc. The initial 160 topics were reduced to 24 and re-coded 1-24, each code 
representing a revised topic. An in-depth review of the codes against topic was 
performed to ensure that text was appropriately located and the meaning not 
overshadowed or lost. The 24 codes and topics were then reviewed against the 
transcript and modified as necessary, to ensure all texts were appropriately 
located. The next step was to group them by contextual similarity into categories. 
Some codes, relating to disease, treatment and group dynamics, were discarded. 
They were deemed to not be relevant for the objectives of this thesis. The relevant 
codes were contextualised and summarised into 9 categories. Each step of the 
analysis was discussed and verified by a second person to maintain integrity of 
data. The 9 categories were felt to represent all data from the group discussions 
that were relevant to the objectives of the research. The 9 categories were 
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therefore used to code the second transcript. In addition, there was an opportunity 
for participants in study A to provide further free text written responses in a 
comments section of the study specific baseline and end of treatment 
questionnaires. These data were also coded using the same 9 categories 
generated from the Group 1 transcript analysis. The final data check and grouping 
revealed five distinct topics or themes that emerged and were relevant for this 
thesis. These are presented with the results in chapter 8.  
 
7.13 Interpreting dietary and nutritional behaviours 
Identifying how women’s behaviour (regarding managing their diet and nutritional 
needs) changed after a cancer diagnosis could provide new opportunities for 
research. Targeted interventions could exploit this understanding of behaviour 
change. The flexible qualitative inquiry in this research allowed for some 
exploration of behaviours around food and diet in the context of known health 
behaviour change models. This thread was interpreted in the context of how 
these findings add to knowledge as well as their potential for incorporation into 
future interventions. The application of behaviour change theories in the areas of 
health has seen increased interest in recent years. The hope is that 
understanding behaviour change can help to improve how services/nutrition and 
intervention are offered. Exploring the issues around diet and nutrition with 
women was therefore also important to explain the underlying processes and 
behaviours women reported to have adopted or discarded following their 
diagnosis with cancer.  
 
The Health Action Process Approach (HAPA) model (340) was found to best 
predict and explain some of the behaviours identified in our study. This behaviour 
change model was not selected a priori; rather it emerged from the evidence. It 
helps to understand and explain the behaviours that were narrated by women 
more objectively. A schematic representation of the model is shown in Figure 33.  
This model proposes that health behaviour change is a process consisting of two 
phases, the motivational and volitional phases (341). Successful behaviour 
change would therefore hinge on the formation of an intention in the pre-
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intentional motivational phase and the translation of that intention into action in 
the post-intentional volitional. An intention is usually to adopt certain health 
behaviour or to change a risky one in favour of another behaviour. Intention 
formation depends on three motivational factors: (1) risk perception – the belief 
that one is at risk, (257) outcome expectancies – the belief that behavioural 
change will reduce a health risk, and (3) perceived self-efficacy – the belief that 
one is sufficiently capable of exercising control over a demanding behaviour (342), 
(343). Individuals will ultimately fall into two groups, pre-intenders and intenders. 
Studies could capitalise on that pre intenders require risk and resource 
communication about the target behaviour while intenders require planning and 
support to translate intension to behaviour (344). An appropriate intervention 
could ensure that both groups are well equipped to move to the next phase.  
 
In the volition phase, individuals initiate action and focus on maintaining the 
changes made despite the obstacles or failures that may occur along the process 
(341). This phase is subdivided into planning, initiation, maintenance, and relapse 
management. Self-efficacy plays an important role in the adoption of target health 
behaviours helping to reorganise intention into an action plan with specific goals 
of when where and how the action should take place. Maintaining the initiated 
action (action control) is on-going; self-regulated and involves focusing attention 
on the task and ignoring distracting stimuli, resisting temptations, and managing 
unpleasant emotions. Self-efficacy moderates the degree to which individuals 
can overcome barriers that arise in the maintenance period. Individuals with high 
coping self-efficacy invest more effort and have a higher probability of developing 
new routines turn them into healthy habits (341). Individuals with a low self-
efficacy could easily relapse unless well supported.  
 
This chapter has outlined the research approach and justification for the 
importance of including patients’ perspectives in trying to understand nutritional 
challenges. The findings from this study and the interpretation of women’s 
behaviours using the HAPA model are presented in chapter 8.  
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Figure 33: The schematic model underlying the Health Action Process Approach (HAPA)        
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8 The patients’ perspectives study results 
(qualitative enquiry)  
8.1 Introduction 
This chapter presents a patient perspective on the nutritional needs of women 
diagnosed with ovarian cancer. While chapters 5 and 6 focused on determining 
the quantitative impact of the disease and its treatment on the physiology, 
‘nutritional status’, here I aim to reveal the human side of the nutritional 
conundrum. By exploring women’s perspectives of the nutritional challenges they 
face, I probe deeper into how women diagnosed and living with an ovarian cancer 
perceive diet and nutrition, and manage their nutritional needs. I also examine 
what women consider would improve self-management of their nutritional needs. 
My aim is to build a patient informed platform on which to make recommendations 
for the future design of nutrition support packages.  
 
Findings are presented in themes. The themes that were identified are 1: the 
perceptions of women of the importance of diet and nutrition from the time of 
diagnosis, 2: the changes that women made to diet and eating habits, 3: the 
availability of nutritional support and advise in clinical settings, 4: the physical and 
emotive impact of disease, symptoms and treatment on diet and nutrition and 5: 
how to meet diet and nutritional needs more efficiently. The themes represented 
common threads and ideas that emerged from the discussions and from the free 
text responses in the study specific questionnaires. They all relate to diet and 
nutrition.  
 
The two focus groups are identified in the text as groups 1 and 2. Participants are 
identified as respondents 1 to 4 in group one and respondents 5 to 8 in group two. 
Individual contributions from the study A participants are identified by the 
participant’s unique study reference number (50xxx). 
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8.2 Participants 
8.2.1 Focus groups 
The characteristics of the participants are outlined in Table 36. Their ages ranged 
from 51 to 74 years. All stages of the disease were represented. Five women had 
advanced disease (stages III and IV), one had stage 2 and two had stage 1. The 
length of time women had lived with the disease, varied from less than six months 
to ten years. Women were at various points on the cancer pathway; some were 
undergoing primary treatment, others were in remission or either undergoing or 
waiting to start treatment for recurrent disease.  
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      Table 36: The characteristics of focus group discussion participants 
          
*Deceased on 31/12/14
Respondent 
 
Group Age Ethnicit
y 
Educatio
n 
Disease 
stage 
Time since 
diagnosis 
Disease state at 
discussion 
Treatment status at 
discussion 
1* 1 65 White 
British 
O-Level IV 6 months Disease progression 
while on treatment 
Neo-adjuvant chemotherapy 
cycle 4 
2 1 51 White 
British 
Degree IIc 12 months Responding to 
treatment 
Surgery then chemotherapy, 
currently on cycle 5 
3 1 62 British-
Indian 
O-Level IIIc 36 months Progressing disease 6 months post 3rd line 
chemotherapy 
4 1 52 Filipino O-Level IV 6 months Responding to 
treatment 
Surgery then chemotherapy. 
On cycle 4 
5* 2 65 White 
German 
Not stated Ic 120 months Recurred 48 months 
ago 
Awaiting 6th line treatment 
with chemotherapy 
6 2 52 White 
British 
Degree III 24 months In remission Completed first line treatment 
of surgery +chemotherapy 18 
months ago  
7 2 74 White 
British 
Diploma III 108 months Recurred 24 months 
ago  
Currently on 3rd line 
treatment with oral Tamoxifen 
8 2 64 White 
British 
Not stated 1a 18 months  In remission Completed 1st line treatment 
with surgery and 
chemotherapy one year ago 
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8.2.2 Women who provided additional free text data 
Participants in study A provided further free text written responses in a comments 
section of the study specific baseline and end of treatment questionnaires. 
Thirteen women entered text at baseline and 23 at the end of treatment. Five 
additional codes were generated which are 1) Information on medicines for 
treatment of comorbidities 2) Impact of non-cancer related pain e.g. related to 
knee replacement or arthritis 3) The impact of the cancer and its treatment on 
social life e.g. not being able to work or exercise 4) Other reasons for avoiding 
certain foods such as allergies and 5) Cancer related pain and/or complications 
such as pain from blood clots; hot sweats post-hysterectomy. Data under these 
codes were excluded from presentation in the thesis, as they did not shed light 
on the research question. Relevant data was included under the existing themes. 
 
8.3 Conduct of the discussions 
The subject of nutrition was of considerable interest to the self-selected group of 
women such that a call for a break was ignored in both groups with women 
preferring to continue the discussion. Although guided, the discussion did expand 
beyond nutrition to other aspects of living with the cancer, which the participants 
were keen to share in the group. These data are only presented here where they 
provide an instructive context for the women’s views on nutrition.  
 
Participants seemed to draw from each other’s experiences. Occasionally there 
was palpable empathy between the women, expressed simply in ‘Ums and Ahs’. 
Suggestions were made of therapies and diet tips that had been helpful. The 
mood, although often light was punctuated by a difficult moment in group1 when 
respondent four was distressed talking about her isolated social circumstance. 
There were occasional strained moments when two speakers held opposing 
views but tensions were easily diffused with a return to amicably discussion.  
 
Participants were generally forthcoming concerning their current health status, 
and the treatments they had undergone. They discussed how they had been first 
diagnosed and the impact living with the disease was having on their diet and 
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lifestyle. Sensitive and personal information was divulged including discussions 
about struggles with alcohol abuse and unfaithful spouses. Humour was used to 
describe or discuss potentially difficult issues, but there was tacit 
acknowledgment of the gravity of their diagnosis which respondent five 
expressed as being ‘Pretty angry at our body’.  
 
8.4 Thematic analysis 
This part of the study explores patient’s perceptions of their nutrition. I felt that 
sustainable long-term benefits could be better achieved if women’s experiences, 
perspectives and opinions informed the development of future nutritional 
intervention packages.  
 
8.4.1 Theme 1:  Perceptions of the importance of diet and 
nutrition from the time of diagnosis  
My primary interest was to find out whether nutrition was perceived to be 
important to participants. If so, when it became important and what behaviours 
and actions women adopted to maintain or improve it. I wanted to explore the 
question in the context of the participants’ views of the role of nutrition in their life. 
I also wanted to find out what women used as indicators of changing nutritional 
status. A preliminary analysis of diet and eating habits data from the study specific 
questionnaire indicated that women altered their diets in response to a suspected 
cancer diagnosis or symptoms.   
 
Three different perspectives on the importance of nutrition were evident. There 
were women (or loved ones) who from the point of diagnosis perceived nutrition 
and diet to be important and set out implementing dietary changes. A second 
group of women said they were too unwell at the beginning to worry about 
aspects of their diet beyond the bare minimum they could tolerate at the time. 
The third group for a variety of reasons did not feel compelled to make changes 
to their diet and continued as they were prior to diagnosis.  
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Respondent six who felt that nutrition was important from the onset and felt 
compelled to change her diet said,  
 
“When I was first diagnosed ….I did wonder if there were things I could do with 
my diet which could help me respond to treatment…”  
 
She seemed to have embraced her situation and then set about acting on her 
needs. She outlined being driven by a desperate desire to be in control of some 
aspect of her life. She felt obligated to find ways to ensure her body was in the 
best state for treatment to work effectively. 
 
The second group of women, because of being unwell due to disease or following 
surgery felt that recovery was their priority. The overwhelming symptoms and/or 
treatment effects preoccupied these women such that they were forthright in 
saying that nutrition information would not have been welcomed at this time. 
Health challenges and the need to recover outweighed nutritional concerns at 
that time for some of these women.  
 
“I was so ill after my operation. ….If you are lying there, and you have tubes down 
there to bits you didn't even know you had, food is the last thing on your mind and 
the thing is when you come home, you think you want to eat something; you know 
to keep your energy levels up; then fine, but actually what you should or shouldn't 
be eating I really didn't have any recollection at all” (Respondent eight) 
 
Respondent two struggled to keep food down post-surgery, and confirmed that 
at this stage “nutritional information would have been sort of overkill”.  
 
Ovarian cancer is often diagnosed late and women can be considerably unwell. 
Tumour spread and symptoms such as ascites, distension and bloating can 
profoundly affect appetite and sometimes cause digestion problems. The priority 
for these women is similar to those with surgical complications; to get better. 
Respondent one articulated sad relief that diagnosis meant that treatment could 
begin and there was hope for symptom relief.  
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“I was relieved that I had been going through such pain and discomfort and then 
I found out what it was and once I knew what it was it was going to be dealt with 
and it was a sheer relief”.  
 
Some of her major symptoms had been that she “couldn’t eat at all”; she “had a 
lot of fluid in her abdomen” and “felt full all the time”. 
The third group of women felt no need to change their dietary habits. These 
women were at different stages of their cancer journey; respondent four had 
recently been diagnosed while respondents three and seven had been living with 
cancer for 3 and 10 years respectively. Their reasons for not changing their diets 
were different and based on good appetite and culture.   
 
“I am eating just like normal, everyday is normal. I have an appetite to eat 
anything (sic).” (Respondent four).  
 
She added that because she had a good appetite, she ate her traditional diet that 
consisted mainly of rice and fish. Respondent seven attributed her lack of diet 
and nutritional concerns to previous unsuccessful dieting experiences:  
 
“I have done that before. I have tried the diet for my arthritis. ..I did it for 18 months 
and in the end I couldn’t stand it”.  
 
She was a retired registered nurse who admitted to being a ‘pernickety eater’ all 
her life preferring fruit and vegetables over meaty or sweet foods.  
 
Respondent three, despite the fact that she had presented with abdominal 
distension and been referred to a dietician seemed unfamiliar with the constant 
worry about food. She confronted respondent two saying;  
 
“Can I just ask you... instead of thinking, can’t you just eat what you feel like 
eating…?” 
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Respondent two interrupted her questioning by clarifying that after her surgery 
she had not felt like eating at all. This conflict demonstrated that nutritional 
challenges and management approaches are unique to each woman.  
 
Though a woman did not change her diet, it was not necessarily the case that 
she considered her nutrition of little importance. Respondent three above referred 
to eating what you feel like eating, suggesting that keeping it simple, familiar and 
about what you want to eat was important and perhaps more sustainable. There 
was also a sense of confidence in some that they were eating healthily and that 
their diet met their needs. 57-year-old volunteer 50014 in her free text response 
implied that there was no need for her to change her diet habits.  
 
“I was always conscious of health issues, studied & practised aromatherapy & 
nutrition”.  
 
The overall sense from the two small groups of women as well free text data was 
that nutrition and diet were important and for some this was a priority right from 
the point of diagnosis. Others battled with symptoms or treatment side effects. 
During this time they ate the little they could tolerate and focused on getting better. 
Women who reported not changing their diet indicated a satisfaction that their 
diet was sufficient. The variety of perspectives and ensuing behaviours around 
diet and nutrition and indeed other aspects of well-being after diagnosis and 
treatment for ovarian cancer are revealed here as highly individualistic. 
Furthermore they are driven by personal goals and modified by both internal and 
external influences (133) unique to the woman as outlined below. 
 
Internal influences impact the emotional and rational aspects while external 
influences are those that one feels they have very limited control over. The 
internal influences were demonstrated in the following comment,   
 
“My framework for it; I think my way of sort of trying to get my head around the 
idea that I had this thing to deal with, what I latched onto was the idea of my 
immune system and that was very powerful for me.  … I started to really look at 
everything as is this good for my immune system or is this bad for my immune 
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system? That was everything from nutrition to stress to emotional reactions to 
things…” (Respondent six) 
 
The above insight suggests underlying machination and a rationalisation process 
that precedes action. This internal process is often riddled with conflict and 
anxiety because of lack of certainty surrounding nutritional advice in cancer. The 
lack of clear nutrition guidelines and the impact of the cancer diagnosis and 
treatment on diet and food intake are further outlined in themes three and four of 
this chapter.     
 
The external influences also play an important role. There was a sense of 
helplessness as women succumbed to the overwhelming symptoms or treatment 
effects. Respondent two conceded that she had altered her diet, commenting;   
 
“Actually it’s the chemo not the cancer. ...it’s the chemo that has changed taste 
also. So there are certain things, like coffee has no taste, or for most of the time 
things taste metallic, which is all chemo, related. So there are certainly foods I 
don’t eat because they don’t taste. It’s like having lots of colours but no pallet” 
  
These challenges often resolve at the end of treatment particularly if it is 
successful. Women’s nutritional needs and diet are constantly changing in the 
context of multiple treatments and over short periods of remission. 
 
The paradigm of mal/nutrition and cancer is therefore not static. As the underlying 
disease and treatment effects resolved, women who had not prioritised nutrition 
did so as they became able to act on their needs. Respondent 2 gave insight into 
this dynamism.  
 
“Somebody said to me you know are you very purist about your food. And I said 
well actually at one stage it was just getting something down”  
This shows that women are able to identify different life stages in their cancer 
journey. Different stages have associated priorities which affect the emphasis 
that might be placed on each outcome of wellness and well-being (133). The 
significance and associated actions shift and change as the journey progresses. 
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Newly diagnosed women battling treatment side effects have different priorities 
and objectives from survivors who have lived with the disease for a while. 
Similarly women whose disease has recurred may have different objectives from 
women who are in remission as pointed out by respondent six who said “..Things 
are all right at the moment. If they were not I suspect I would become obsessive 
about it again”. 
 
Women’s behaviour and actions appeared to be associated with their treatment 
trajectory and the point they had reached on this. Internal and external influences 
determined some of the behaviours around nutrition management.  
 
I was interested to find out what the defining points were for women in terms of 
nutritional status and body composition. What changes if any alarmed them and 
caused them to take action? It emerged that weight was the main index used. 
Weight change was an issue across the different stages of the cancer trajectory. 
Women associated their nutritional well-being with being a particular weight and 
also how they looked with this weight. Fifty-year-old volunteer 50083 said;   
 
“I was putting on extreme weight on the stomach but lost a lot of weight from face, 
arms and breast. I looked gaunt but very fat”   
 
While loss of weight can be stressful because it makes the cancer visible, 
physical change in appearance changes sense of self, which can lead to 
puzzlement and confusion (345), and even challenges identity (346). 
 
Weight falling off during treatment presented its own challenges and distress 
about not being able to complete treatment. Respondent two said about it;  “I did 
actually get worried as I thought unless I can stop the weight going down I’m not 
going to be able to tolerate chemo…” Respondent two. 
 
On the contrary weight gain above a woman’s usual weight particularly during 
remission caused frustration. Respondent five who felt quite well after her 
chemotherapy treatment said,  
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“…I put on a lot of weight. ‘I think it was the steroids, they make you put on a lot 
of weight’...It was absolutely awful. And so I had to go on a diet...”  
 
Nutrition was important to maintain desired weight. Loss of weight was 
immediately associated with complications and poor outcomes. On the other 
hand weight gain beyond that acceptable to a woman, was an ‘awful’ experience 
for some. These views represented two ends of the spectrum in the cancer 
trajectory. Weight loss during treatment was perceived as a cause for alarm. Post 
successful treatment, weight gain beyond a personal healthy weight was also 
cause for alarm because women believed that their best chance to prevent the 
disease from returning or to fight it better if it does return is when their body is at 
its best health and not overweight. 
 
“You think you're doing the right things. …you know; that you are going to avoid 
hopefully it ever returning and if it does at least your body is going to be that much 
fitter. If at any stage it comes back, back you'd like to think your body is that much 
stronger to deal with whatever else is thrown at it”. 
 
The assiduous quest for information and/or guidelines on how to cope with 
disease/treatment and what to/not to eat was another indicator of the importance 
of nutrition.  
 
“… my niece was looking on the website and I meant to bring it today I totally 
forgot, a book on what to eat and what not to eat for cancer patients” (Respondent 
three) 
 
Women sought information to help them make better choices about their diet and 
therefore become healthier as well as to be sure that their diet choices were not 
contraindicated for their cancer and or treatment. Nutrition was a part of the whole 
cancer diagnosis and treatment, rather than a separate piece; for many it was 
affected by disease, symptoms and treatment. A summary of the foods that 
women preferred to or not to eat changes that women made to their diet is 
provided in   Table 37. 
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       Table 37: The reasons given by women for changing their diet after the diagnosis of ovarian cancer 
Respondent Main reasons for 
changing diet 
Preferred food Foods avoided 
1 Distension, ascites Little more frequently Pasta, no longer likes the taste  
2 Treatment effects 
 
Coconut milk, oil or coconut chips, spinach, 
rocket, smoked salmon, fish pie, dark green dark 
red vegetables, beetroot, avocados tomatoes, 
blueberries 
Starchy foods because they do not digest 
well and cause constipation. Raw fish  
To prevent infection Yoghurt, almonds, honey 
3 To prevent infection No change Live bacteria, takeaways (during 
treatment) 
4 None Eating normal. Good appetite to eat anything. Reduced junk food (Kentucky Fried 
Chicken (KFC) and MacDonald’s) 
5 To boost immune system Occasional glass of wine, homeopathic 
supplements, steamed vegetables  
Red meat 
 
6 
Boost Immune system 
 
Organic food only, strong immune supplements, 
grass fed organic meat, olive oil 
Refined sugars, fruits and vegetables 
sprayed with chemicals, processed oils 
or saturated fats 
During treatment to shrink 
tumour 
Budwig protocol i.e. flaxseed oil amalgamated 
with dairy products 
Non organic food 
7 Not clearly stated Fruit and vegetables Fatty food, oil and butter and full-cream 
or milk 
8 Build the body to be strong 
to fight 
Organic food fruits and vegetables, some white 
meat and some fish  
Alcohol, sugar, sweets  
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8.4.2 Theme 2: Dietary and eating habit changes  
The continuum of cancer survivorship includes treatment and recovery; long-term 
disease-free living or living with stable disease; and, for some, living with 
advanced cancer. Each phase has different needs and challenges. Few if any 
studies have evaluated the association between diet and ovarian cancer survival, 
in particular the impact of diet change after diagnosis (347). Thus the role of diet 
in survival from ovarian cancer remains unclear. Despite this lack of scientific 
clarity, diet was one aspect of lifestyle that women they paid concerted attention 
to. In theme 1, women discussed changing or modifying their diet and lifestyle 
following diagnosis. In this theme I look into what practical actions were taken by 
women in an effort to maximize their nutritional wellbeing.  
 
A cancer diagnosis changed everything for participants.  
“You come home and you have to start to learn how to live, lead another life …be 
totally different” (Respondent eight).  
 
This other life encompassed more than diet and nutrition changes and included 
exercise, emotional and psychological wellbeing, sexuality and spirituality as 
mentioned by women during the discussions. Some women acknowledged that 
a total lifestyle change was needed to face up to the cancer illness. With regards 
to dietary changes, refined sugar was one of the food groups that some women 
reduced, or eliminated from their diet because they believed that ‘…cancer cells 
love sugar’ as respondent five voiced. Respondent six, a vegetarian who ate only 
organic food and followed the Budwig protocol adopted a more scientific 
approach to her sugar intake. She elaborated; 
 
“I do actually feel that one of the things I've successfully done is change my diet 
to be much more aware of the glycaemic index of things to relative amounts of 
sugar”  
 
The Glycaemic Index (GI) is a ranking of carbohydrate-containing foods based 
on the overall effect on blood glucose levels. Slowly absorbed foods have a low 
GI rating, while foods that are more quickly absorbed have a higher rating (348). 
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Foods with a low glycaemic index can help even out blood glucose levels and are 
therefore recommended. 
 
Symptoms and effects of treatment also determined what women ate. 
Respondent one who stated that she ate very little but frequently due to her 
ascites commented;   
 
“Well from my point of view it’s the symptoms that cause the nutritional problems 
for me. I've had breast cancer that was over 20 years ago. ..I had a lumpectomy 
and I had radiotherapy and I had no ill effects apart from the effects of the 
radiotherapy and post-surgical effects. So the ovarian cancer is definitely a bigger 
issue”. 
 
On the opposite end of the spectrum respondent eight reported that she had 
increased appetite during treatment that lead her to eat more sweets and 
subsequently she struggled to maintain a healthy weight.  
 
“Minded by the chemotherapy longing for the sweet stuff. I was waking up in the 
middle of the night hungry and munching on biscuits. You know what I mean? 
This real punter of sweet things and taste!”  
 
Weight management was one of the reasons mentioned for changing diet or 
eating habits. This was experienced at both end of the spectrum with some 
women wanting to eat more to curtail weight loss and to continue with treatment, 
“..Just try and eat anything you can.., whereas before it was maybe two, three 
meals a day now it’s just little and often” (respondent one), 
 
While on the other hand some women tried to lose the weight gained during 
chemotherapy,  
 
‘…Well I joined a slimming group and it worked’ (respondent seven). 
The final reason identified for changing diet and eating habits was a desire to be 
healthy. This was in the hope that the body would be strong enough to cope in 
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case the cancer returned. Respondent eight whose diet consisted of some 
organic food, white meat and fish with sweets and alcohol avoidance said; 
 
“You think you're doing the right things. …you know; that you are going to avoid 
hopefully it ever returning and if it does at least your body is going to be that much 
fitter. If at any stage it comes back, you'd like to think your body is that much 
stronger to deal with whatever else is thrown at it”.  
 
Women made dietary changes for therapeutic reasons, due to the impact of 
disease and symptoms, to gain or maintain weight, and also to be healthy. The 
changes tended to follow the cancer journey. Women on first line treatment 
focused on eating to gain or maintain weight or to be able to continue with 
treatment. Women in the post treatment phase focussed more on healthy eating, 
exercise and other lifestyle issues such as mental well-being and involvement 
with social activities. These strategies are important factors in establishing and 
maintaining a sense of well-being and enhancing quality of life(157).  
 
Most women were specific about the foods they preferred to or not to eat. Some 
opted for organic foods, others avoided fatty foods; one participant followed the 
Budwig diet with curative/therapeutic intent. Most eliminated sugar and sweets 
from their diet despite there being no undisputable evidence to support their 
actions. Although there are some dietary constituents and related lifestyle factors 
and characteristics that influence risk and progression of cancer high sugar intake 
has not been shown to increase the risk or progression of cancer (157).  
 
Foods rich in protein were thought of as being good. 
“The CNS said to me, it’s really good you are eating a lot of protein that’s really 
good because it helps prevent muscle wastage”. Respondent two 
 
Changing diet and lifestyle was not without challenges. Women stated that there 
was information overload particularly on the Internet, a lack of clarity and coherent 
guidelines and protocols for nutrition and diet.  
“There so many books, you know. I mean, (names an American author) published 
several books and one of them is a book of 8 survivors of cancer and the title is, 
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‘They Have Done it So Can You’. And they tell you exactly their diet and what 
they were taking and they're all completely different so you think, well what do 
you do? Where do you start or where do you stop?” (Respondent five).  
 
Women chose daily what they believed was best for them and even if they were 
sometimes ambivalent about the efficacy of their dietary strategies they tried to 
adhere to them, and keep motivated to sustain diet and lifestyle changes.  
 
“Yes, it becomes, very, very difficult to make decisions and what goes with what 
and what doesn't go with what and what should you do when you are having 
chemo” (respondent six) 
 
Particular difficulties with eating also had to do with the fear of jeopardising 
treatment if one was not well nourished. Respondent two articulated this while 
highlighting the role her friends and neighbours played by providing her with 
prepared and freezable meals; 
 
“And I do have friends I have very good friends and good neighbours who have 
been fantastic. But I wouldn't be in the state I am as sane and therefore tolerating 
the chemo I suspect if I hadn't had all of that. ……I would have delays and 
reductions in dose, which would have had all sorts of knock on medical 
consequences”. 
 
Women had to eat well to be strong and to continue with treatment, yet making 
sure that they ate nothing that was contra indicated for the treatment. 
“But ready meals do contain additives and things which may not be you know, 
sympathetic to …the to the treatment your receiving” (Respondent three). 
 
In addition, being overly obsessive about what one ate or did not eat could also 
cause stress, which women felt was not conducive to their recovery.   
“I must admit, I buy organic some of it. Some I don't. It's an expensive scenario 
really, and I think if you can't afford organic stuff that you think is going to make 
you feel better then you start to get anxious” . 
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The evidence from our study suggests that most women self-managed their 
nutritional needs, sometimes with help from family and friends. The concept of 
self-management relies on the individual’s ability to manage their symptoms, 
treatment, physical and psychosocial consequences and life style changes 
inherent in living with a chronic condition (349). Some of the practical changes 
and reasons for changing diet are individualistic and based on each woman’s 
needs, and to an extent demonstrating each woman’s perception of the role of 
nutrition in their life after a diagnosis of ovarian cancer. 
 
8.4.3 Theme 3: Availability of diet and nutritional support and 
advice in clinical settings 
Results from study A show that women whose eating habits had changed by the 
time investigations for their cancer begun also had worse nutritional status. 
Furthermore questionnaire results show that more than half of women reported 
not systematically receiving information and support from health care 
professionals during treatment. The information sought from the public domains 
about foods they should eat or avoid was thought to be often contradictory. 
Results from the focus groups elaborate the dietary and nutritional support 
women received. 
 
Two women had been referred to a dietician from the onset. They had first 
presented with advanced disease characterised by distended abdomen and 
severe loss of appetite. One reported that her weight had been ‘falling off’. They 
were counselled and one had nutritional supplements prescribed. Both 
considered the support sufficient for their short term needs. This support had not 
continued beyond the acute phase.  
 
“I did (receive nutritional support), but only because I just was not eating at all. I 
had a lot of fluid in my abdomen and I just could not eat.  I felt full up all the time 
so they got the dietician to come and see me” (Respondent one) 
 
Respondent two had received some nutritional information from her CNS. This 
had come later in her cancer journey when eating was no longer a problem. She 
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said “I found that I could eat, but she (CNS) did ask me about the food, I presume 
actually had she you know been there earlier…”. She was implying that had the 
CNS been involved earlier, she might have been helped when she needed it. 
 
Other women had not received any nutritional support. They recalled that there 
had been nothing asked about their diet. "  
 
“Doctors themselves are no help at all. They just say eat what you like. That's 
what they say to you and if you talk about a special diet like I was on … I'm 
laughed at you know. Not loud but kind of say well, you know but if it makes you 
happy then of course carry on” (Respondent five).  
 
The chasm between patient need and clinical support was further revealed by 
respondent six who thought, “The doctors are slightly cranky about considering 
your nutrition”. The expressed lack of support is particularly disconcerting 
considering that physicians and other health care providers have a unique 
opportunity to guide cancer patients toward optimal lifestyle choices, to optimise 
the survivorship trajectory regardless of the individual's survivorship phase (157). 
 
There was possible breach of moral and ethical codes around the management 
of patient’s nutritional needs where weight was monitored and the patient 
informed that it was dropping each time yet there was no follow-up or a 
management plan for it.   
 
“I remember being weighed and being told the weight had dropped but I don't 
think that was followed up by a question” (Respondent three). 
 
Women emphasised that “diet is important very important in any kind of illness 
and even more so in the cancer patient”. However they also felt let down that 
doctors in particular did not ‘have time’ to discuss these important aspects of their 
lives.   
 
“They told me the plan and I thought yes, that has to be the right road to go. 
Medically they did, but diet wise it wasn't considered” (Respondent one). 
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Nutritional information if/when received was found to be helpful. Respondent 
three although admitting that she was over the worst when she discussed 
nutrition issues with her CNS said of the information given to her regarding eating 
foods high in protein;   
 
“I was spending a lot of time in bed, ...that was a really good point which I didn't 
know before …..that was helpful because obviously ….if you are in bed if there 
are things you can eat which actually might help slow down the muscle wastage 
when you actually are so petit you can’t do a lot of exercise that’s a good thing”.   
 
Most women voiced a lack of coordinated support from clinicians to help them 
manage diet and lifestyle changes they believed would aid their recovery. They 
also expressed that the information they were given in the form of leaflets or that 
which they found in the public domain was often confusing. 
 
“..The booklets that you pick up while you're sitting and waiting to see the doctor, 
you can pick every booklet that's there and obviously with time progressing you 
want to focus on getting better. You know, so then you think I want to do 
something now that's going to get me better. You know, be as positive as you 
can about these things but information that's fed to you, I feel, is contradictory in 
some areas.” (Respondent eight) 
 
Women self-managed their nutritional needs. Most stated that family and friends 
had helped them through some of the difficult times. The next theme explores the 
challenges women faced regarding their food and dietary intake because of the 
cancer. 
 
8.4.4 Theme 4: The physical and emotive impact of disease, 
symptoms and effects of treatment on diet and nutrition 
An ovarian cancer diagnosis can have a strong psychological impact on the 
survivor, due in part to the high mortality and often advanced stage of disease at 
diagnosis (350). Our results in study A show that women identified worry/anxiety 
about a possible/confirmed ovarian cancer diagnosis as one of the reasons they 
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had changed their diet. The emotional and psychological impact of the diagnosis 
and treatment can affect all aspects of a woman’s life including decisions over 
diet and nutrition.  
Women experienced a range of emotions; the pendulum swung from the very 
negative emotions such as frustration, being angry with their bodies, grief, shock, 
sadness, isolation, and anxiety to joy of still being alive. Sixty seven year old 
volunteer 50039 expressed frustrations of the restrictions to lifestyle and dietary 
intake saying;   
 
“The pain on either side of stomach is really bothering me. I am restricted by pain 
and pressure in stomach, getting fed up”.  
 
Feelings of guilt and blame arose from suspicions that one’s previous lifestyle 
may have contributed to causing their cancer,  
 
“I know one of the questions that I ask for sure is why me? What have I 
done? …drinking; been doing that since about 18, I'm now 64. Whoops, could 
that have caused it? Then you look at the things you're eating. Then you think 
you shouldn't have been eating that. Could that have caused it? And you do 
question that. What you've done in your life to induce these things” (Respondent 
eight). 
 
Acceptance and adaption followed the period of questioning and blame. The 
same respondent emphasised that it was a “huge effort” to accept that one was 
“never going to get the same life because it's not the same any more. You can't 
do the same things that you did, you know. And it is different and I think mentally, 
dealing with that, to me, was very hard. I found that really hard”.  
 
She was emphasizing how difficult it was amongst other things, to go to a 
restaurant with her sister and not be able to order her favourite food because she 
believed it to be contraindicated for her diagnosis.  
 
Difficulties were compounded by feelings of isolation on the cancer journey  
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 “You're completely alone with this thing… You know, you're anxious all the time. 
I am about what I am eating or not…” (Respondent five). 
 
Women described their vulnerabilities and uncertainty about implementing 
dietary changes. Respondent two revealed how some of the uncertainties were 
rooted in the fear of derailing treatment;  
 
“….my goodness maybe if I have that one additive you know I'm jeopardising my 
whole recovery. ‘So I found that whole what I call the extreme healthy stuff quite 
terrifying”.  
 
There was perpetual weighing up of whether foods or certain types of nutrients 
were contra-indicated or might interfere with treatment. It was an additional 
anxiety alongside battling treatment effects, fear of disease relapse or living with 
relapsed and untreatable disease.  
 
The difficulties of the burden of the cancer diagnosis and symptom management 
were detailed in the focus group. However, loss of function, hobbies and control 
were sometimes as frustrating especially if they affected the role of the woman 
as a food maker in her home. 82-year-old volunteer 50077 in free text lamented;  
“I've lived a very healthy life. ….diet always lots of fresh fruit & vegetables. Home 
cooked meals. Not too much red meat. …..Large garden and grow my own 
vegetables until this year”. 
 
The stress and lack of motivation to continue making choices that were believed 
to be ideal could be overwhelming even for the more determined woman.  
 
 “..Things that are very difficult to do, I actually think you get to a point where you 
just think it just isn’t working” . 
 
Respondent six was referring here to the difficult choices she had to make trying 
to avoid “fruits and vegetables that are sprayed with chemicals”, and then trying 
to eat organic foods as much as possible, which was “expensive and had 
implications”. She stated that she had relaxed somewhat because ‘things are 
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alright at the moment. If they were not I suspect I would become obsessive about 
it again”. 
Sometimes the challenges were about seemingly simply issues. Respondent five 
found it difficult to adjust to the healthier but “boring” food options. She conceded 
that people who were vegetarian by choice would not necessarily hold the same 
view.  She felt that it was  
 
“Difficult when you are a meat eater and have to become more vegetarian”. 
 
In the midst of the difficult challenges, women adopted some coping strategies 
which included acceptance, taking control, positive thinking and action, and 
reliance on religious beliefs.  
 
Acceptance was important, and it helped to ground participants to their new 
normal. Psychological resilience has been suggested to represent a process of 
adapting well in the face of adversity (351). Patients who employ positive framing 
are thought to be better able to initiate active coping behaviours and tend to 
experience better QOL (352). Respondent two, a lawyer, felt that for her it was 
important that treatment or nutrition intervention programmes made her feel as if 
she was in control and had a choice, 
 
“It was very important that I felt I had a choice I knew I didn't really but yes I 
wanted to be guided but not told...”   
 Positive thinking and spirituality have been said to help discern meaning from a 
cancer experience and to maintain hope (353). Respondent 4 who had reported 
she had no family in the UK, showed how her faith kept her positive and 
demonstrated psychological resilience saying;  
 
 “.. I don’t depress about it. I have my faith about what is happening to me…. I 
have to be strong I cried for that time when they told me…..”(Respondent 4) 
 
The same woman reported that she had not changed her diet, had a good 
appetite and ate her regular food.  
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Women outlined some of the positive actions that helped them. Often it was 
things that in health can be taken for granted, such as walking or gardening. 
Growing one’s vegetables and herbs helped (Respondent two), 
 
“…I’ve been planting herbs.  …therapeutically it has been a fantastic joy… But I 
look at this little Belfast sink with some cut and come again lettuce and I think well 
and that’s my lettuce. I have grown that and I go and pick it so it becomes a 
positive focus in an environment where there are a lot of things you can't do at 
some stage” 
 
The daily dietary concerns of women diagnosed with this disease were clear and 
many. Women tried everything they could to “help their bodies to heal themselves” 
to “shrink whatever was going on” etc. In the process they experienced a range 
of emotional and psychological difficulties following their diagnosis. Their stories 
told of resilience and determination. Individuals prepared to fight, not just for 
quality of life, but also for survival. Fear of death was frequently on the 
background. 
 
‘……Nobody wants to die so that's very important’ (Respondent five) 
 
The emotional and psychological burden of an ovarian cancer diagnosis is 
unavoidable. However effective support systems can help ease some of the 
weight. The next theme explores some of women’s views on how their nutritional 
management could be better managed.  
 
8.4.5 Theme 5: Meeting diet and nutritional needs more 
efficiently 
Study A showed that more than half of recruited patients reported not routinely 
receiving nutritional intervention throughout their treatment. This was despite the 
fact that the majority of women reported that their diet and food intake was 
already affected prior to treatment. The evidence suggested discrepancies 
between nutritional challenges and the endeavours taken to counter them in the 
clinical settings.  
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Women had ideas about what would constitute effective diet and nutritional help. 
It had less to do with actual nutrient supplements, and more about suitable 
guidelines for navigating the difficult journey of eating well in the face a cancer 
diagnosis and its treatment.  
 
“I'm saying if it (leaflet/booklet) gives you a guideline. …Whereas if you've got no 
idea. Myself, I really didn't have a great idea …You know, you're not always 
aware… and I think you need to be made more aware personally” (Respondent 
eight) 
 
For respondent one it was about any intervention being an integral part of the 
treatment process.  
 
“I remember very, very clearly reading the side effects of the treatment of the 
chemo that I was having, Taxol in particular... It could be that there is a paragraph 
making it clear that that it could affect your eating habits...” 
 
Respondent two who suffered from severe constipation, resulting intense 
headaches which she interpreted as possible spread of the cancer to her brain, 
said she would have welcomed information that clearly stated “with the chemo 
you may find digesting these foods difficult because ….it’s affecting your gut”. 
She emphasised that “how it’s phrased” would be important. 
 
Phrasing was repeatedly highlighted as an important aspect of any 
information/advice provided.  Respondent three suggested that a leaflet needed 
to include “clearly marked out reasons why/why not certain foods are good/bad 
for people on chemotherapy. ..Not vague”. Respondent six also thought that a 
leaflet should be “broad, clearly outlining potential challenges and counter 
measures” so that women could apply them if they suited their need. That way 
you would “take what you need when you need it”  
 
Some participants suggested that there should be a consultation with a member 
of the clinical team in the first instance, to discuss and hand out nutrition 
information/leaflet. A clinical nurse specialist (Macmillan nurse) or dietician were 
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suggested as being best placed to provide this support. Respondent two felt that 
it would “in fact probably be useful not to have yet another person” added to the 
long list of specialists that women already see during the initial stages of 
diagnosis and treatment. “Simplicity would be really helpful,” she added.  
 
Respondent eight felt that discussing individual nutritional needs with a health 
care professional, even as a one-off event would be more informative and “better 
than someone saying go away and read this”. Respondent seven concurred and 
eagerly anticipated a time when diet could be a subject between members of the 
clinical team and patients.  
 
“It could be an appointment to see the Macmillan nurse to discuss diet, our 
nutritional intake. …It's lovely to feel that it could be possible”.  
 
Further suggestions were made of the leaflet having a contact number in case 
women needed further clarification,  
 
“..and you could have a contact …if you would like to discuss this further with 
somebody.” Respondent two 
 
The premise that nutritional support should be provided as soon as possible once 
a diagnosis is confirmed to prevent nutritional deterioration and possibly delay or 
offset onset of cachexia is widely accepted. Indeed this work shows that women 
whose diet has been affected by the cancer and its effects before diagnosis had 
worse baseline nutritional status. Women’s views on the timing of 
dietary/nutritional advice are therefore important.  
 
Three participants rejected the idea of nutritional intervention from the onset.  
“I don't think I would have been very receptive (around the time of diagnosis)” 
(Respondent seven)  
 
She had been unwell and presented with large ascites. Respondent eight 
concurred, elaborating that a diagnosis of ovarian cancer comes with many 
psychological challenges that take precedence over issues of nutrition;   
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“When you are diagnosed with it, your brain is concentrating on being diagnosed 
and the thought to think, I've got to worry about food and this and that. That 
wouldn’t have helped me one little bit I'm afraid”. 
 
Respondent 2 who had primary surgery and was opposed to very early 
intervention thought that “to have been able to go and have a chat with somebody 
at the pre-chemotherapy assessment” would have been more “helpful”. This point 
is usually 2-3 weeks after surgery and 1-2 weeks before the start of 
chemotherapy. She felt that at this point the consultation could be best tailored to 
support women who have post-operative complications but also prepare them for 
the possible challenges of chemotherapy treatment.  
 
On the contrary, Respondent six was one of two women who felt that they “would 
have been receptive from day one”. She had proactively sought to eat to boost 
her immune system from the onset. She also strictly followed the Budwig diet 
throughout her treatment in the hope that it would repair her DNA to start 
producing normal cells. These contrasting views suggest that interventions would 
need to be well thought out and take into account the individual needs of women. 
The diverse views support the need for a face-to-face consultation with a health 
care professional during the treatment phase.   
 
Two out of 8 women who forthrightly rejected the idea of early intervention had 
post-surgical complications and would have been more receptive upon recovery 
but prior to the start of their chemotherapy. Three participants who had surgery 
as first treatment but did not have severe symptoms/complications would have 
been more receptive to immediate intervention. Two of three women who 
received chemotherapy as first treatment had also received nutrition intervention 
on the onset. All three women suggested that non-acute intervention would have 
been well received around the start of chemotherapy. This time point coincides 
with that suggested by the two women who had surgery and were opposed to 
earlier intervention. These findings suggest that women who have acute 
nutritional needs when they first present such that their treatment may be 
compromised were identified and provided with professional intervention. Women 
who developed acute nutritional challenges after surgery would not have been 
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receptive to intervention during that time. The women who had no complications 
and tolerated food intake well would have been more receptive from the 
beginning. This apparent paradox may prove challenging for the design and 
delivery of an effective intervention.  
 
Women acknowledged that incorporating a nutrition programme would not be 
easy. It is “quite difficult to generalize about what is good for individual people”, 
Respondent six stated adding that “nutrition in cancer care, it's just so much more 
complicated because ultimately you have to also look at the psychological 
expectations. What feeds your positive bits? What feeds your negativity?” 
 
Developing an effective intervention is beyond the scope of this thesis. However 
women’s views and suggestions provide a basis for making recommendations for 
the development of such an intervention. This qualitative study has demonstrated 
that nutritional needs evolve depending on the impact of the underlying disease 
and symptoms and also women’s own perception of the importance of diet and 
nutrition. 
   
8.5 Summary and discussion of patients’ perspective 
study 
This chapter presented women’s perspectives on the importance of nutrition to a 
woman who is diagnosed with ovarian cancer starting right at the beginning of 
their cancer journey. Most women felt that nutrition was very important to them.  
Although it is possible that the self-selected women participated in focus group 
discussions were more nutritionally aware, evidence suggests that women 
diagnosed with ovarian cancer are motivated more than other cancers, to seek 
information about food choices (157). Many women stated that making daily 
choices of what to or not to eat particularly during treatment was often 
accompanied with anxiety. The anxiety was due to a lack of structured support 
by the clinical team, from conflicting evidence in literature, the fear of 
compromising treatment, and the difficulty of sustaining motivation. Women made 
specific changes to their diet and eating habits based on the effect of the disease 
 
 
241 
 
its symptoms and treatments, perceived physiological need and also the time 
point in their journey with the cancer. The HAPA model suggests that women who 
successfully implement and sustain desired dietary and nutritional changes are 
those who have higher self-efficacy. They believe that they are sufficiently 
capable of exercising control over the difficult behaviour. 
 
The emotional and psychological burden of an ovarian cancer diagnosis was 
worsened by perceived lack of support in an area of care women considered 
central to their well-being. Feelings of being alone, unsupported and sometimes 
patronised by clinicians dedicated to supporting them in their lifestyle choices 
were common. Women had converging views on an ideal support package being 
a leaflet or booklet. It would cover a wide range of nutritional issues but be well 
summarised. This leaflet/booklet would be given following face-to-face 
consultation with a designated member of the clinical team. The context of the 
intervention would be to highlight potential negative side effects of treatment, 
such as constipation but mainly focus on the positive things that women could do 
if they faced difficulties. Women wished for this guidance but not to be told how 
to self-manage their nutritional needs. The suggestion of guidance and not being 
told implies a flexible relationship between the patient and the clinician. This 
flexible relationship would then consider the complex phenomena of where 
people live, what is available, what they can afford, how much time they have to 
dedicate to the process of procuring and preparing food, and even what we is 
allowed in terms of family traditions, societal, religious, and gender norms (110). 
This all add more dimension and possible complications that need to be 
considered when planning intervention.  
 
The nutritional challenges and possible interventions presented here focus on the 
diagnostic and first line treatment phase. This was by design, to reinforce our 
understanding from the women’s perspective of the challenges and possible 
intervention for this very difficult time in a woman’s life. This qualitative study 
complements study A, which assessed nutritional status of women during the 
same period. The presence of women who had been living with the disease for 
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longer in the group discussions served to highlight that nutritional challenges are 
not limited to this specific period, but extend throughout the survivorship phase. 
The challenges and needs are different depending on the life stage of each 
woman. The current American, nutrition and physical activity guidelines for 
cancer survivors (157) acknowledge these differences and suggest that during 
active treatment, some of the overall goals of nutrition intervention should be to 
prevent or resolve nutrient deficiencies, maintain a healthy weight and preserve 
lean body mass. These change to lifelong goals such as weight management, 
healthy diet and an active lifestyle after successful treatment.    
 
The approaches of individual women’s management of their diet and nutritional 
needs were as varied as the women themselves. However the underlying 
processes were often not random. Closer scrutiny of the reasons given for 
wanting to or making dietary changes and navigating the challenges following 
their diagnosis revealed that the behaviours can largely be explained through the 
HAPA health change behaviour model. This self-regulatory framework 
appropriately makes a distinction between setting goals and pursuing them. 
Some women articulated setting and pursuing goals, such as when one 
expressed successfully changing her diet to be more aware of the glycaemic 
index of things relative to the amounts of sugar. In the observational study A, 
women were found to have the intention to act on their diet by eating healthily 
(avoiding sugary and fatty foods while increasing their fruit and vegetable intake). 
However these behaviours were not evident by the end of treatment, suggesting 
that they had either not pursued/engaged or had failed to maintain intended 
behaviours. Part of the reason is that maintaining the chosen actions (dietary 
changes) was outlined as being very difficult, an aspect clearly identified by the 
model. Women expressed that it was difficult to pursue desired eating habits and 
that they often felt like giving up. Risk assessment was also evident in some 
women who articulated being “terrified” of jeopardising their recovery by 
incorporating certain diets or nutritional supplements and rather preferred to take 
instruction from their physicians. It was evident from some women that they 
implemented coping planning, based on their individual circumstances by just 
trying to eat anything they could no matter how small.  
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Not all women reported that they changed their diet in both studies. Some 
perceived that their diet was sufficient for their needs; others would have liked 
support and guidance in making the changes. It is known that nutrition knowledge 
has a profound influence on food choice and nutrient intake (354) and thus 
individuals’ awareness or assumptions about food are key determinant of food 
choices (355). The individual differences between women who reported changing 
their diet and those who did not have not been analysed here, but the two women 
in the focus groups, who were most vocal and reported a methodologically 
approach to managing their diet with specific intentions of cure or maintaining 
muscle mass and treatment were a sociologist and a lawyer. They seem to exhibit 
high levels of self-efficacy, which may have helped them to sustain the changes 
overtime.  
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9 General discussion 
9.1  Nutritional and biochemical statuses 
Our study is the first that we know of, to prospectively assess serial markers of 
nutritional status in a homogenous ovarian cancer population with a control 
group. Our population specific study enables us to make recommendations for 
tailored future interventions. Assessments were carried out prior to the 
commencement of treatment (baseline); during treatment and at the follow-up 
outpatient visit after completion of the acute first-line treatment of surgery and/or 
chemotherapy. This enabled us to identify that weight, BMI and dry lean mass 
and well as biochemical markers; prealbumin, albumin and CRP were already 
impaired in some women by the time they presented to the hospital for 
investigation and treatment for ovarian cancer. Also that some markers did not 
return to normal by the end of treatment.    
 
The self-reported weight change for the 3-month period prior to treatment 
provided valuable information. Three types of weight change were identified; 1) 
weight loss; 2) weight loss then gain; and 3) weight gain (page 130). The 
relevance of these findings is in that significant weight loss (>2%), the threshold 
for identifying the risk of cachexia may already have been reached by the time 
women present at the hospital. Forty three percent of cases reported significant 
weight loss while 17% gained weight in this time. Weight loss at presentation has 
been associated with poor survival, reduced response to treatment, and poorer 
quality of life (QoL) in gastrointestinal and lung cancer patients (173, 356, 357). 
The two main mechanisms of weight loss relate to depletion of body fat, a 
condition that reflects a prolonged, severe, negative energy balance and skeletal 
muscle wasting due to a fall in skeletal muscle protein mass (sarcopenia), a 
situation that reflects the clinical condition of the patient (358). Sarcopenia can 
be fatal as it is characterised by progressive weakness and fatigue and is not 
responsive to nutritional intervention towards the end of life. This reinforces the 
need for early intervention in patients with ovarian cancer which has spread into 
the peritoneum, most of whom have advanced disease (75%) at the time of initial 
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diagnosis (359). Moreover evidence suggests that serous tumours, which are 
rarely detected before they reach an advanced stage and are associated with 
most deaths, would already have progressed to a late stage nearly 1 year prior 
to their discovery (185). Table 3 showed that about 75% of ovarian cancers are 
of a serous type. Weight gain prior to treatment is likely to be due to large tumours 
and accumulation of ascites which is associated with advanced disease. Weight 
gain during treatment can be due to; 1) less activity due to chemotherapy side 
effects; 2) eating more for comfort of due to some medications which may 
increase appetite; 3) fluid retention such as ascites or oedema; and 4) 
chemotherapy treatment e.g. which sometimes contains steroids that can cause 
fat deposits to develop.   
 
Abdominal distension was recorded in 56%, and ascites in 80% of women with 
stage III and IV in our study. These provide a confounding effect for non-
discriminate markers of nutritional status such as weight and BMI. However our 
results also showed that despite the presence of ascites, some women exhibit 
overall weight loss. Therefore weight change remains the simplest way to indicate 
changes nutritional status. Women diagnosed with ovarian cancer viewed gaining 
weight as positively impacting their quality of life (OR = 2.485; p = .06) while 
women in the control group, as might women in the general population, 
associated it with negative well-being (weight: r= -0.52; p < .05) (Table 24). Hess 
et al., (206) also found weight gain during chemotherapy treatment for ovarian 
cancer was associated with improved overall survival. Weight decreases of  >5% 
and 0-5% led to survival of 48.0 and 49.3 months respectively and weight 
increases of  0-5% and >5% resulted in survival of 61.1 and 68.2 months 
respectively.  Like us they found no evidence of an association between change 
in body weight and disease progression. In our study, 55% of cases with stable 
weight and 50% who gained weight by the end of treatment had residual disease 
seen on end of treatment CT scan. The United States National Institute of Health 
includes weight loss as one of the key common Terminology Criteria for Adverse 
Events (CTCAE) in clinical Trials (360).  
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These findings are interesting in relation to contradictory reports in other cancer 
sites. Higher BMI has been associated with recurrence and decreased survival in 
breast (361) and prostate (362) cancers. Hess at al suggest that there may be a 
hormone related explanation for this. Nearly 80% of breast cancers are oestrogen 
receptor (ER) positive (363), and increased or prolonged circulating oestrogen 
promotes the initiation and progression of breast cancer. Excess adipose tissue 
enhances circulating oestrogens, which in turn contributes to the increased risk. 
Ovarian cancer, on the other hand, has not been shown to be hormone-
dependent; with less than 40% of the cancers demonstrating ER positivity (364). 
Weight gain during treatment therefore seems to have a protective effect in 
women diagnosed with ovarian cancer.  
 
A median BMI of 28 (IQR: 23-27) for menopausal cases suggests that women in 
our study were generally overweight or obese despite reports of recent weight 
loss, changes in dietary patterns, depleted biochemical (prealbumin and 
prealbumin (19%) and presence of inflammation (increased CRP (67%)). High 
levels of obesity in menopausal women are in line with population trends that 
indicate a rise in the prevalence of obesity among older adults (365, 366). There 
is concern that existence of excess fat could mask decreased muscle mass 
resulting in ‘sarcopenic obesity’ (367). Sarcopenic obesity occurs with the aging 
process but can be exacerbated by disease and malnutrition or cachexia. 
Increasing obesity trends can render the lower cut off of BMI<20 to identify 
cachexia impractical. This point is highlighted by the participant who lost >40% of 
her baseline body weight by the end of treatment yet her BMI remained within the 
healthy range. A BMI >20 is not indicative of health in ovarian cancer patients as 
it reveals nothing of the underlying body composition, the contribution of excess 
ascetic fluid and inflammatory processes. The association between BMI and 
adverse outcome in ovarian cancer patients is not clear although a meta-analysis 
by Protani et al., 2012 (368) found overall evidence that the risk of survival among 
obese women is 15-20% less than in women with a healthy BMI regardless of 
whether BMI was measured before diagnosis, at diagnosis, or at the 
commencement of chemotherapy. Potential confounders such as ascites that 
may have increased the risk of death were not accounted for. The practice of 
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‘dose capping’ chemotherapy drugs based on body surface area in some centres  
may also account for decreased survival in women with a high BMI (369). A more 
recent study (193) of pre-diagnosis BMI categorized into underweight, (BMI 
<18.5kg/m2), normal (BMI between 18.5 and 25kg/m2), overweight (BMI between 
25 and 30kg/m2) and obese (BM>30 kg/m2) failed to show an association of BMI 
with all-cause or ovarian cancer specific mortality.  
 
We also found, as expected that menopausal cases and controls had the highest 
body fat across all time points (Figure 18); premenopausal cases had the least. 
Premenopausal cases lost more body fat during treatment and had a lower body 
fat % at the end of treatment than at baseline. Menopausal cases gained body 
fat during this period. This was in contrast to lean mass which increased overall 
(baseline to end of treatment) in premenopausal cases (65%, 72% and 68%) 
compared to (59%, 60%, and 58%) in menopausal cases at baseline, during 
treatment and at the end of treatment respectively. We speculate that the 
increase in lean mass during treatment is linked to intravenous infusions during 
surgery or chemotherapy sessions. These findings show that overall younger 
women gain lean mass while older women gain body fat. Lean mass’s importance 
is as a determinant of the pharmacokinetic variability of chemotherapy treatments 
(370-372). Patients with a low lean mass demonstrate a low drug 
metabolism/clearance. They tend to be relatively overdosed and have higher 
rates of chemotherapy-induced toxicity (373). The role of body fat in cancer 
survival has also been examined. Torres et al., (179) investigated the role of pre-
operative body composition measures using CT images to predict outcomes in 
patients with ovarian cancer. In their retrospective study of 82 patients with stage 
IIIC/IV disease, fat composition was the strongest independent predictor of poor 
survival with a greater risk of death at lower levels of subcutaneous and muscular 
fat or total fat. BIA is not able to predict the different types of body fat. Further 
research is required in this area. 
 
Our findings on the lean mass of menopausal women concur with those of Gil et 
al (374) who assessed Body Cellular Mass (BCM), a component of lean mass, 
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and found that women do not re/gain significant BCM during the short term, up to 
12 months from the start of treatment. They also found that changes in body 
composition over the short term are restricted to alterations in body fat. Our 
results contradict these findings for premenopausal cases. We also found that in 
our cases changes to dry lean mass (another component of lean mass) had 
already occurred at baseline assessment. This was evidenced by the significantly 
lower dry lean mass of premenopausal cases compared to premenopausal 
controls (p < .05), (Figure 20). As expected menopausal cases and controls had 
the lowest dry lean mass, which decreases with age. Sub-group analysis by the 
study median age of menopause enabled us to show meaningful differences in 
BMI and body composition of younger versus older women. These findings shed 
light on who might benefit from targeted intervention. For instance menopausal 
women gain body fat, but may be at risk of sarcopenic obesity. If sarcopenia is 
identified those women could benefit from nutritional intervention. Some of our 
subgroup samples sizes were small and the results therefore need to be 
interpreted with caution. 
 
Our study found that at baseline, the biochemical markers prealbumin and 
albumin were depleted in 32% and 19% of cases respectively. More had 
borderline levels hovering 1-3 units above the lower cut-off points. CRP was 
elevated in 67% of the cases. At the end of treatment 9% of cases had low 
prealbumin, 25% had low albumin and 24% had elevated CRP. Prealbumin is the 
preferred nutritional status assessment method for this study. Like albumin, it is 
a negative acute-phase protein, which can be affected by inflammation. However 
its half-life of 2–3 days allows it to be used as a more reliable indicator of acute 
changes in a patient’s nutritional status (375). It correlated well with other 
outcomes in our study including change in diet (shown in appendix 6), change in 
weight and overall health status/quality of life shown in Table 35. Others have 
also suggested that prealbumin is the preferred marker for malnutrition because 
it correlates with patient outcomes in a wide variety of clinical conditions (376). 
Moreover, for cases, it significantly increased (p < .01) between baseline and the 
end of treatment despite the fact that some women had residual disease. Cases 
had significantly lower prealbumin than controls at baseline (p < .01) but not at 
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the end of treatment. Long term protein depletion and inflammation were 
confirmed by low albumin at baseline in 19% of cases with another 14% with 
albumin just 1-3 units above the cut-off level. Albumin has been found to be low 
in women diagnosed with ovarian cancer in other studies (208, 212). Low albumin 
in our study included some women with stable weight and those who gained 
weight, confirming on-going inflammatory processes. That more than 50% of the 
albumin pool is located in the extravascular compartment and only about 5% is 
produced by the liver daily, means that a patient’s day protein consumption has 
little effect on their albumin level (377). That, and its long half-life of up to 20 days 
and potential to be affected by a number of inflammatory conditions, renders it an 
unreliable marker of nutritional status (378). Albumin correlated well with quality 
of life and was associated with the presence of ascites and late stage disease 
These all confirmed that it is a marker of wellness.  
 
Epidemiologic studies suggest that in patients with several types of solid cancers, 
elevated circulating levels of CRP are associated with poor prognosis, whereas 
in apparently healthy individuals from the general population, elevated levels of 
CRP are associated with increased future risk of cancer of any type, lung cancer, 
and possibly colorectal cancer, but not breast or prostate cancer. The association 
between CRP and cancer risk is not well understood but may be due to; 1) 
causality: elevated CRP levels cause cancer; 2) reverse causality: occult cancer 
increases CRP levels; 3) or confounding: where a third factor such as 
inflammation, increases both CRP levels and the risk of cancer. Our findings 
highlight the need for nutritional intervention from early on. We revealed that 
some women lose weight, lean mass, in the case of older women and also have 
depleted serum proteins and inflammation (elevated CRP) at baseline, all 
pointing to ongoing cachectic processes. The presence of residual disease in 
some women, and the high recurrence rate (up to 50% within 18 months of 
diagnosis), indicate an imminent need for second line of treatment at a time when 
the women’s bodies will be weaker to deal with it. For these reasons targeting 
interventions at the earliest point when a confirmed diagnosis of late stage 
ovarian cancer is made, would be the ideal. 
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9.2 Dietary intake  
Sixty-four percent of cases reported making dietary changes in the 3-month 
phase leading to treatment. Dietary changes were associated with advanced 
disease (stage III and IV) (p < .05). Women who reported dietary changes were 
overall less well with low a prealbumin (p < .01) and albumin (p < .05) (Table 29) 
and were more likely to be treated with neo-adjuvant chemotherapy treatment (p 
< .05). Women with early stage disease made fewer changes. There is a school 
of thought that women with early stage disease have biologically less aggressive 
tumours than women with late stages (379, 380). This is supported by the 
evidence that few serous ovarian cancers present at stage I, most present at 
stage III or IV. Changes to diet were largely reactional and/or sometimes 
involuntary in response to symptoms such as loss of appetite, feeling full too 
quickly, fluid in the abdomen and anxiety about cancer or fear of the 
consequences of consuming an unhealthy diet while faced with a diagnosis of 
cancer. The effect of “eating healthy” could not be estimated in this study due to 
the small sample size. Besides, ‘healthy eating’ is a subjective term, it is 
debatable if its adoption when women are facing major surgery and 
chemotherapy treatment can be considered as ‘positive’. Moreover problems  
with digestion, loss of appetite, nausea and vomiting in some patients, makes 
maintaining the necessary caloric intake difficult (359). The symptoms force 
patients to spontaneously reduce their calorie intake. However healthy eating, i.e. 
eating foods that one believes will maintain or improve their health status was an 
important concept, as was revealed in the focus group discussions.  
 
We did not observe any specific dietary patterns or preferences during the 
treatment phase, despite more than half of the women stating that they made 
dietary changes. The single most common reason for changing diet in this phase 
was change in taste. Cravings, increased appetite, and wanting to “eat healthy” 
were also mentioned. Gruenigen et al in 2006 also found that women with ovarian 
cancer did not exhibit large fluctuations in intake of fruit/vegetables and fat 
following surgery and during chemotherapy (381). This affirms that the changes 
we observed prior to treatment were related to signs and symptoms, anxiety or 
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possible ‘intention to please’ or to be seen to eat healthy. Change in diet during 
treatment was associated with weight loss (p < .01) and a decrease in dry lean 
mass (p <.05). Since there is no evidence that residual disease had an impact on 
weight loss during treatment, it seems that how a woman responds physically 
and emotionally to her treatment plays a more significant role in her diet choices. 
  
9.3 Quality of life 
Our analysis of individual EQ-5D dimensions for cases and controls (Figure 27 
and Figure 28) revealed that the prevalence of pain/discomfort and 
anxiety/depression was higher in premenopausal cases than their menopausal 
counterparts across all time points. These findings are consistent with a recent 
literature review by Astrup at al., (2016) (382) showing that among oncology 
patients, younger patients significantly reported more symptoms that older 
patients. Their review found no evidence that this was due to younger patients 
receiving more aggressive treatments. In this study, it was expected that controls 
would report similar levels of problems to cases at baseline because pelvic pain 
has been found to be the reason women present to general gynaecological 
departments for investigations (94% of the time) (383). However the relatively 
high symptom burden at the end of treatment in controls is baffling. It is possible 
that controls had chronic problems or had not fully recovered from surgery. We 
found the frequency of anxiety and depression in our study to be higher than 
previously reported for ovarian cancer patients. In a meta-analysis by Watts et 
al., (2015) (384), depression was found to be highest prior to treatment (25.3%), 
decreasing to (23%) during treatment with a further decrease at the end of 
treatment (12.7%). They reported anxiety separately. It was lowest prior to 
treatment (19.1%) then rising and plateauing ‘during’ and at the end of treatment 
(26.2% and 27.1%, respectively). The differences between these results and our 
own may be partly explained by the differences in the instruments used to collect 
data. The Euroqol EQ-5D records ‘some problem’, which women might complete 
as ‘no problem’ if they were asked a ‘yes’ or ‘no’ question as was the case with 
the study specific questionnaire. It is also possible that the NHS Trust where 
recruitment took place saw more complex cases that would have been the case 
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prior to the setup of referral centres. Watts et al., also suggest that the onset and 
progression of psychological distress in patients with cancer is likely to be 
chronic, with peaks and troughs of severity that occur during key stages of the 
cancer journey. In the general population, depression disproportionately affects 
women, with a lifetime prevalence of 21% (385). 
 
We found no association between all nutritional status outcomes (weight, BMI, 
body fat, dry lean mass and lean mass) and problems with all 5 dimensions at 
baseline, during treatment and at the end of treatment for cases and for controls. 
There was significant association found using the Kruskal Wallis test between 
pain/discomfort and extracellular water, p < .05 and a borderline association (p = 
.06) between pain/discomfort and total body water at baseline. These 
associations were found when using pain data from Euroqol EQ-5D and not 
medical records or the study specific questionnaire (affirming the issue of different 
data sources sometimes yielding different results). Since BIA analysis is meant 
to account for fluid changes, we expected to find some association between 
ascites and extracellular water. These associations provide a possible link 
between ascites and total and extracellular water in that ascites causes 
distension which in turn is associated with pain/discomfort. Prealbumin was the 
only outcome to be significantly associated with difficulties with usual activity, p < 
.05 at baseline for cases. This suggests a link between nutritional status and 
women’s abilities to carry out their daily activities. While Devlin et al., (2017) (386) 
analysed the contribution of each dimension of the EQ-5D to quality of life in 
prostate cancer patients, we found no evidence of such analysis in the nutritional 
status of ovarian cancer or gynaecological patients.  
 
On the VAS scale where 0 was the ‘worst’ health and 100 the ‘best’ health, cases 
were shown to have lowest scores at baseline 50 (range: 10-100), 57 (range: 0-
100) during treatment and 70 (range: 20-100) at the end of treatment. The related 
sample Wilcoxon signed rank test showed that the difference between ‘during 
treatment’ and end of treatment was, (p <.05). The Kruskal Wallis showed a 
significant association between health status and the presence of ascites at 
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baseline, p < .05 and between health status and type of first treatment, p < .01. 
We know that women who are treated with chemotherapy first have more 
advanced disease and or comorbidities. It is therefore logical that this would be 
reflected in their perception of their overall health. We only observed significant 
differences by the age of menopause, during treatment where younger women 
had higher health status scores. This could be explained by the fact that younger 
women tend to have early stage disease and therefore are likely to have 
successful surgery. Alternatively, in other mainly older women it may have been 
too early in the treatment process for the benefits of chemotherapy to be felt. 
Controls had lower overall health status throughout. Median scores increased 
from 45 (range: 3-95) at baseline to 66 (range 8-93) at the end of treatment. Our 
findings contradict others who have found cancer patients to have lower quality 
of life than other groups (384). Personal experience of the researcher with women 
newly diagnosed with ovarian cancer revealed a sense of determination by 
women to ‘beat’ the cancer. Perhaps there was a conscience effort to be ‘positive’ 
about treatment and the future which may have translated into higher health 
scores.   
 
Spearman’s correlation, (Table 26), showed that out of all nutritional, body 
composition and biochemical markers, prealbumin, (r = .478, p < .01) and albumin 
(r = .42, p < .05) were the only ones to positively and significantly correlate with 
quality of life at baseline. These findings confirm albumin as a marker of well-
being. Significantly, they also show a strong relationship between nutritional 
status nutritional status (assessed by prealbumin) and quality of life. In their meta-
analysis Lis et al., (387) found that studies that looked at nutrition and quality of 
life focused on weight and BMI. We have not found evidence of studies that used 
prealbumin in gynaecological patients. However, similar findings to ours were 
observed by Rambod et al., (2017) (388) in haemodialysis patients. They found 
that prealbumin correlated with both markers of nutritional status and 
inflammation without any statically significant interaction between dietary protein 
intake and inflammatory cytokine. Our study showed in Table 29 that low 
prealbumin was associated with changes to diet at baseline. Rambod et al., 
concluded that the clinical associations of prealbumin with quality of life and 
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survival (which they found) indicates that it is a useful marker to stratify risk even 
when patients have normal albumin. Prealbumin had a borderline significant 
correlation with quality of life in controls, (r = .494, p = .07) at baseline. Albumin 
was not assessed in these patients. Better nutritional status was found to be 
positively associated with better QoL in gynaecological patients (389).  
 
Our study has shown that prior to treatment for ovarian cancer or benign 
conditions, women report problems with most dimensions of quality of life 
assessed using the Euroqol EQ-5D.  Most of the problems persist particularly in 
younger controls. We also showed that quality of life is worst among controls, 
which was unexpected. Importantly we have shown a link between quality of life 
and prealbumin for cases and controls at baseline. Quality of life assessment 
could therefore be useful in identifying vulnerable patients such as younger 
women or those whose find it difficult to carry out their usual activities. 
Appropriate symptom management strategies would then be employed.  
 
9.4 Women’s perceptions of current nutritional 
support 
Women in both our studies did not perceive that they are provided adequate 
nutritional support. Other researchers also confirm that patients and family 
caregivers express a lack of acknowledgement from healthcare professionals 
regarding cancer cachexia (390) and that they perceive physicians to focus on 
disease and treatment outcomes and not patient’s individual experiences (391, 
392). Nutritional intervention was associated with increased albumin (p < .05) in 
our observational study. This increase is likely due to helpful nutritional 
support/advice that improved patients eating habits and therefore wellbeing. The 
advice may also have helped women to eat well and continue with treatment, 
which improved their underlying health status. Nutritional intake (protein 
consumption in particular) and illness are the two most influential factors 
regulating hepatic albumin synthesis (393). It could also have been coincidental 
since albumin detects underlying illness (394), women with low albumin could 
 
 
255 
 
have been less well and therefore more likely to request help or be identified as 
needing help/support even though we found no evidence that low albumin was a 
selection criteria for intervention.  
 
The intervention in our study was based on current practice and was ad hoc at 
best. We could not establish referral criteria (that is, on what basis women 
received intervention). The intervention itself ranged from patients being handed 
a Macmillan nutrition and cancer leaflet to counselling and prescription of 
nutritional supplements. Different members of the clinical team including a nurse, 
clinical nurse specialist, pharmacist, doctor or dietician delivered it. The goals for 
the intervention given were not always clear. They could have been to maintain 
food intake, counter certain symptoms such as pain, nausea etc., to increase 
nutrient intake to counter weight loss, or any combination of these. For these 
reasons, we cannot firmly conclude that the non-effect on other markers of 
nutritional status was due to the ineffectiveness of intervention. Halfdanarson et 
al., (244) in their systematic review and meta-analysis of the effect of diet 
counselling on quality of life in cancer patients found a borderline statistically 
significant effect (p < .05) suggesting that dietary counselling may provide 
positive impact on QoL. More evidence is required and another promising 
randomised controlled trial, Eating as Treatment (EAT) a health behaviour 
change intervention provided by dieticians to improve nutrition in patients with 
head and neck cancer undergoing radiotherapy has recently started recruiting in 
Australia (395). The results are awaited with much anticipation as their findings 
may be relevant to or need to be replicated/adapted in other cancers.   
 
Although the role of diet and specific dietary constituents in survival from ovarian 
cancer is not clearly understood, women identified it as an important aspect of 
their recovery from disease and for their new life, living with a cancer diagnosis. 
Women changed their diet as early as 3 or more months prior to a confirmed 
diagnosis. The relationship between symptoms, advanced disease and change 
in diet is substantiated by the consistency of our findings with those of Goff et al 
(396) who showed that women experienced symptoms for a median of 2–3 
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months before consulting a health care provider and that women with advanced 
stage disease were significantly more likely to have symptoms than women with 
early stage disease. Unfortunately, lack of consensus among health care 
providers (159) on how to manage diet following a diagnosis of ovarian cancer 
means that women are inadequately supported. This lack of clarity permeates 
down to other mediums of communication and instruction such as books, the 
Internet and leaflets etc.). As a result women reported women are frustrated and 
feel alone in their quest for constructive information. Their diet management 
efforts often hampered by the difficulty in sustaining motivation, the negative side 
effects of chemotherapy and the need to satisfy cravings and increased appetite 
due to steroids and chemotherapy. Women made changes sometimes based on 
unfounded self-determined or Internet researched ideologies or myths such as 
consuming only organic foods, or the theory that “sugar feeds cancer”. There is 
no evidence that high sugar intake increases the risk or progression of cancer, 
however, sweets and beverages are rich in calories and thus can promote weight 
gain, which may be undesirable. In addition most foods that are high in added 
sugar contribute little other nutrients to the diet and often substitute more 
nutritious food choices (157). There is no evidence either that organically grown 
vegetables and fruits are have more potential cancer-preventive constituents 
(157), although respondent six’s perspective that chemicals used in production 
and preservation of non-organic food are her main concern cannot be dismissed 
without evidence. Recently diagnosed women talked more about immediate 
concerns relating to symptoms and surgery complications while women who had 
been living with cancer longer talked more about a healthy lifestyle. Diet and 
nutritional needs are therefore constantly changing and women have to adapt at 
each stage of their journey. 
 
Women told of diet being one of the few areas they felt they had control over. 
This is common in cancer patients (397, 398). Focusing on the subjective 
experience of individuals through qualitative research provides insight into an 
additional layer of the complexity of this syndrome and the potential opportunity 
to incorporate psychosocial support for improving its management (399). Thus, 
understanding dietary change in the context of a behaviour change model may 
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help to develop effective ways to influence and positively alter behaviour. Diet 
and eating habits are a complex behavioural phenomenon that results from an 
interaction of many social, economic, religious, gender, health and practical 
factors (110). A sustainable change in eating habits therefore entails behaviour 
modification which is often difficult to achieve as it encompasses social, emotional 
and cognitive factors (275). Whether by design, because of symptoms or due to 
perceived lack of support by clinicians, women demonstrated varying degrees of 
self-efficacy in how they managed their dietary needs. Self-efficacy is the 
individual's belief in his or her capacity to execute behaviours necessary to 
produce specific performance attainments and reflects confidence in the ability to 
exert control over one's own motivation, behaviour, and social environment (281). 
The behaviours that were discussed closely related to some health behavioural 
change models in particular the ‘Health Action Process Approach’ (HAPA) (275). 
This is an open framework of various motivational and volitional constructs that 
are assumed to explain and predict individual changes in health behaviours. We 
observed the 2 implicit phases of the model; the intention to act (women stating 
that they were eating more fruit and vegetables or wanting to be healthy) and the 
post intentional volition or actual behaviour (mixed behaviours due to choice, side 
effects of treatment or stage of survival-relaxing rules when in remission). The 
model acknowledges that intention (to consume a healthy diet) is not a proxy for 
action (intake) (321). The verbalised concepts of a ‘new life’, ‘helping one’s body 
to cope better’, anxiety from consuming unhealthy food and not wanting to die 
are in line with risk perceptions and outcome expectancies of this model. 
Moreover the emphasis on self-efficacy at each action, coping and maintenance 
strategy were well exhibited or desired by women. Support and provision of 
accurate information by health care providers would empower women to deal 
more effectively with barriers that arise in their journeys. This model explains how 
women responded to the intrinsic and extrinsic factors that determine their 
reaction to a diagnosis of ovarian cancer with regards to their dietary habits. 
Some immediately wanting to use their diet to promote healing, others wanting to 
change their diet but being restricted by health limitations etc. This understanding 
can assist future interventions/practice by incorporating techniques which 
promote healthy eating self-efficacy by using behavioural education such as 
confidence building, shaping positive attitudes towards health behaviours, 
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overcoming automatic negative thoughts (275) as part of the intervention. Some 
women stated that they wanted reassurance that they were eating appropriately 
while some admitted that they wanted support to make the right choices. These 
women could potentially benefit from interventions that also include confidence 
building and shaping positive attitudes. Our research confirmed that nutrition and 
diet are important for women and they expect clinicians to engage with this aspect 
of their care. Furthermore evidence suggests that interaction with health care 
professionals is more efficient in helping to modify behaviour (400) than 
information or awareness alone. It is important that clinicians are empowered 
through evidence to effectively carry out their role.   
 
9.5 Women’s needs and how they could be better met  
Women conveyed that a one to one consultation with a designated member of 
the clinical team reinforced by a well-constructed leaflet for further reference 
would be an ideal form of intervention. Designing a diet-based intervention was 
not an aim of this research, however this information provides understanding of 
what might be an effective intervention approach in future studies. Emphasis is 
on a diet based intervention. The British Dietetic Association recommends that 
intake via ordinary foods and beverages is the first step in the process of 
providing nutritional support and that nutritional supplements are a second step 
which may be used for some people (401). Some authors have demonstrated the 
impact of contact with clinicians in affecting health behaviours and improving 
some nutritional outcomes. Bourdel-Marchasson et al (402) found that individual 
dietary counselling in older patients at risk for malnutrition during their 
chemotherapy treatment for cancer was associated with an increase in dietary 
intake although not  with change in weight or decrease in mortality. Similarly 
Baldwin et al (403) found that dietary advice with or without oral nutritional 
supplements may improve weight, body composition and grip strength, sadly they 
found no evidence of benefit on survival. A large randomised control trial looking 
at the effect of individualized nutritional counselling on muscle mass and 
treatment outcome in patients with metastatic colorectal cancer undergoing 
chemotherapy is yet to report (404). The Enhanced Recovery After Surgery 
 
 
259 
 
(ERAS) (238), a perioperative treatment protocol introduced just over a decade 
ago which included early introduction of oral diet and fluids after surgery showed 
improved individual recovery that resulted in patients leaving the hospital earlier 
(405). It must be noted that early introduction of diet is only one component of 
this program whose underlying goals are to decrease variability in practice, 
reduce morbidity, enhance rate of recovery, and shorten postoperative length of 
stay (406). Other regular diet based forms of intervention have been through 
telephone interviews. Telephone interviews have been shown to successfully 
improve dietary intake (407) in a healthy population. None of the trials so far have 
been specific to ovarian cancer patients or have demonstrated improvement in 
survival in cancer patients. The impetus is to now evaluate the association 
between post diagnosis diet and ovarian cancer survival.   
 
Preferred timing of the intervention was controversial; women who preferred it to 
commence as soon as possible around the time of surgery were likely to view 
nutrition as potentially therapeutic. They were prone to follow strict protocols of 
chosen diets such as consuming fruit and vegetables only, follow the Budwig 
protocol or consume only organic foods. The ideal time for the majority of women 
was suggested to be around the start of chemotherapy. This time seems more 
suitable for intervention for the following reasons; 1) a number of women are 
diagnosed and staged during surgery, 2) women who undergo neoadjuvant 
chemotherapy treatment undergo rigorous clinical work-up procedures to confirm 
diagnosis, and extent of the spread 3) ascites is likely to be well documented or 
drained at this stage and 4) nutritional issues arising from surgery can be 
addressed while also focussing on possible side effects from chemotherapy.  
 
Malnutrition can negatively affect the clinical decision to resect tumour, which is 
the main and potentially curative step in the management of cancer or it can also 
necessitate a reduction in the dose of cytotoxic agents and/or modify the radiation 
timing between temporary or definite cessation of treatment (408). Stopping or 
delaying treatment can reduce time of remission and overall survival (409). Yet 
there are no internationally accepted protocols for nutritional intervention in the 
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management of disease related malnutrition (214). Furthermore cancer survivors 
receive inconsistent and non-evidence based advice from many sources about 
foods they should eat or avoid (157) which can be confusing. Our mixed method, 
multiple assessment technique research prospectively investigated changes in 
the markers of nutritional status in women undergoing first line treatment for 
ovarian cancer. We also solicited women’s views on the importance of nutrition 
and dietary intake. This places our study in a unique position to confirm that 
current practice could be improved. Patient involvement and perspectives on 
what would constitute a suitable nutritional intervention should be considered.   
 
We demonstrated that weight loss may not be the ‘cardinal diagnostic criterion’ 
(410) of cachexia in this particular population. In fact an additional category of 
‘weight gain’ is necessary for ovarian cancer patients where ascites is prevalent 
particularly prior to treatment. Baracos et al., (2011) also showed that 61% of 
male and 31% of the female patients with non-small-cell lung cancer (NSCLC) 
were sarcopenic despite the fact that 50% of all the patients were overweight or 
obese. This confirms that malnutrition and or cachexia are not just in the severely 
underweight patient (411). The high prevalence of obesity in the general 
population means that patients may have normal weight even if they have lost 
significant muscle (412). In addition the concept of paradoxical weight gain due 
to ascites and oedema in some cancer patients is acknowledged in research (88), 
yet there is no evidence of translation of this knowledge into clinical practice when 
assessing patient nutritional status. These can mask true nutritional deterioration 
as well as be signs that the patient is progressing towards refractory cachexia 
(88). The opportunity for intervention could therefore be missed or be identified 
late in the disease trajectory, when patients are in the refractory stage of cachexia 
with little opportunity to reverse their malnutrition. Emphasis on cachexia being 
characterised by severe weight contributes to the notion that nothing can be 
done, when in fact earlier intervention can potentially make a difference.  
 
Women demonstrated concerted efforts in seeking nutritional information on their 
own or with the help of family in keeping with evidence that cancer survivors seek 
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information about food choices, physical activity, and dietary supplements to 
improve their treatment outcomes, quality of life, and overall survival (157). 
Women with ovarian cancer in particular have been shown to express a stronger 
need for information and participate in their health care than patients with either 
breast cancer or prostate cancer (352) which has been ascribed to demonstrate 
a need to control and cope with a diagnosis of a disease with very poor prognosis 
(352). Seeking information is empowering and helps women to make informed 
lifestyle choices (157). This understanding presents an opportunity to capitalise 
on the possible ‘teachable moment’ (159) to provide nutritional support to meet 
short and long term needs. Since a cancer diagnosis is an event or opportunity 
when individuals might be more motivated to make changes that may reduce their 
health risks (413-415), intervention opportunities including modifying health 
behaviours must be maximised on.  
 
The phases of cancer survivorship are marked 1) active treatment and recovery; 
2) living after recovery, including survivors who are disease free or who have 
stable disease; and 3) advanced cancer and end of life (157). Our research 
focused on identifying and understanding nutritional challenges in first phase, our 
suggested “ideal teachable moment”. The hope is that latter phases can be 
positively impacted by intervention that starts in this phase. Ovarian cancer 
survivors live with a disease that has a 20% and 6% 5 year survival if diagnosed 
with stage 3 and 4 respectively (290); a 40-50% rate of recurrence of cancer 
within 3 years in women who achieve a remission after first-line chemotherapy, 
and an average duration of survival of 12 to 18 months after recurrence (289). 
This means that the patient-clinician contact is likely to be more frequent than in 
other chronic diseases. Therefore a model of care that involves both clinicians 
and patients taking control of meeting or supporting the meeting of nutritional 
needs is urgently required.  
 
People who are identified as malnourished in hospital and in the community may 
be considered for referral to a dietician. In routine clinical practice the poor 
nutritional status of many patients is not recognised and many do not receive any 
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advice (416, 417). Evidence from our study supports this. Women are generally 
investigated for ovarian cancer as outpatients. The Clinical Nurse Specialists 
(CNSs) or other clinicians use their judgement as to who receives support 
(source: CNS). The emphasis on From Home To Operation (FHTO) (418) versus 
conventional admission the day before surgery protocols now apply to most 
women undergoing surgery. This scenario limits opportunities for nutritional 
screening and/or assessment to be carried out prior to surgery. European, 
American, and Australian guidelines on the nutritional management of 
malnourished patients with cancer emphasis that it should be a priority. These 
guidelines recommend that nutrition receives prompt attention and interventions 
are commenced in malnourished patients or those in whom difficulties with eating 
are anticipated (246, 419, 420). The NHS guidance on ‘Holistic assessment of 
the supportive and palliative care needs of people with cancer’, published in 2007 
(421) states that ‘holistic needs assessment’ should be part of every cancer 
patient’s care. It further says that this assessment can make a huge difference to 
a patient’s overall experience and has the potential to improve outcomes by 
identifying and resolving issues quickly and can enable patients to more fully 
engage in their care and facilitates choice. NICE guidelines state that all hospital 
inpatients should be nutritionally screened on admission and all outpatients at 
their first clinic appointment and that screening should be repeated weekly for 
inpatients and for outpatients if there is clinical concern (422). Furthermore the 
‘Malnutrition Universal Screening Tool’ (MUST) (423) designed to help identify 
adults who are at risk of malnutrition including cancer patients is the tool of choice 
in many NHS Trusts. Despite this, malnutrition/cachexia remains rarely identified 
or managed. Most nutritional activities are conducted on an opportunistic basis in 
the hospital (424). There are issues of time constraints, lack of training and 
resources, but there is also evidence to suggest that lack of knowledge about 
clinical nutrition in the oncology field and a lack of an adequate evidence base for 
therapy are largely responsible (425). Coa et al., (159) showed that health care 
providers prioritised the strength of evidence and were less likely to discuss diet 
with their patients if they perceived the evidence base as weak.  
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9.6 Recommendations for the future 
9.6.1 Randomised Control Trial (RCT) 
Our primary recommendation is the implementation of a well-designed 
prospective, multicentre, randomised control trial assessing the effectiveness of 
individual dietary counselling (aiming to optimise energy and protein intake) 
versus regular diet. Our earlier work found no evidence of such a trial in patients 
diagnosed with ovarian cancer (5). More recent reviews have concluded the 
same, Billson et al. (2013) (237) and Obermair et al., (2017) (426). We feel that 
there is a sufficient theoretical basis for conducting such a trial. None has been 
done in this patient group, others have found such intervention to help maintain 
weight in other cancer sites (427) and there is evidence from this thesis that 
women are open to it. We have identified our study population as women newly 
diagnosed with ovarian, fallopian tube cancer or primary peritoneal cancer 
because they have the same treatment pathway. Some of the outcomes over and 
above targeted standard nutrition markers could be endpoints that are key for 
other disciplines and specialties such as toxicity, frailty and quality of life. 
 
The Medical Research Council, MRC (318) published guidelines on developing 
and evaluating complex interventions. We would be guided by them and frame 
our trial along the four main principles of feasibility, development, implementation 
and evaluation. In the feasibility stage we would aim to ‘define our intervention’. 
We suggest counselling based on a regular diet because it is cost effective can 
work in everyday practice. Others have combined counselling with leaflets and/or 
nutritional supplements. A practical and sustainable intervention would be 
preferred. We also suggest that a health behaviour model in particular the HAPA 
model be used to improve compliancy and self-efficacy. The next stage would be 
to ‘pilot the study. This is a key step do determine feasibility. At this point we 
would want to evaluate what is possible to do, in terms of the amount of time 
patients are willing/or forced by poor health to commit to the study. We would 
also be interested to identify the best tools of assessment. Recruitment rates will 
be established in order to estimate the duration of the main trial. Data collected 
at this stage will help to determine the minimum number of patients to be enrolled 
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in order to achieve the required statistical power and effect size (the point at which 
the differences in outcomes between the two groups become apparent). The pilot 
study will also help to determine the amount of resources required (Cost) i.e. 
human resources (clinicians, nurses, dietician etc.), materials, laboratory 
facilities, travel costs etc., and supplements if required. Findings from the pilot 
study will be used to develop an appropriate study protocol and documents as 
well as to seek funding. They will also help to guide the type of trial required. 
Ethical considerations about providing intervention to only the treatment arm will 
be made. Timing of the intervention will be established. We showed in our study 
that some women would prefer intervention from the onset, while others preferred 
the period following surgery but before chemotherapy. Implementation of the 
larger trial will follow, due analysis and evaluation of the pilot study.     
 
9.6.2 Other recommendations 
We recommend that a more objective method of nutritional status/body 
composition assessment such as CT scans and BIA be adopted for regular use 
in clinical practice. It could be used alongside the standard body weight which we 
have been demonstrated to not be able to characterise weight change where 
ascites is present. CT scans could also be creatively used to accurately assess 
body composition and its changes over time since virtually all women diagnosed 
with cancer will be imaged prior to treatment as well as for their follow-up. There 
would be initial cost in training personnel and acquiring required software, but 
method would be cost effective long term. BIA is relatively cheap, easy to use, 
non-invasive and validated for use in cancer patients and can be used where 
more frequent assessments are required than can be done by CT scanning. 
These methods could be used with or independently of weight and BMI and would 
be helpful in clarifying the source of change in body composition or function at 
little additional cost. 
 
We also recommend that clinicians consider that cancer cachexia is not always 
indicated by severe weight loss and a low BMI. Ascites and oedema can lead to 
paradoxical weight gain (88), ascites is common occurring in up to 77% prior to 
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treatment and 31% in women with relapse (190). Moreover it has been 
demonstrated that even though some patients may regain weight this weight is 
from an increase in adipose tissue and not muscle mass which impacts most 
upon morbidity and mortality (22, 94). It is therefore important that patients’ 
nutritional status is objectively assessed for dose calculation as well as meeting 
nutritional needs.  
 
9.7 The limitations and strengths of the study 
9.7.1 Limitations 
The limitations of our observational study include that the study population is 
generally very ill. The high symptom burden and treatment effects affected the 
number of patients that were willing to participant, be subsequently followed up 
and return questionnaires. Our sample size was relatively small, as such our 
subgroup analysis where used needs to be interpreted with caution. Firm 
conclusions on some of our findings cannot be inferred. We have assumed that 
changes had a negative impact on food intake. Furthermore our end of treatment 
time point ranged from 3-6 months from the completion of chemotherapy, 
depending on the logistics of identifying and assessing patients when they 
returned for follow-up. This could have had consequences on body composition. 
We hope that any effect of this is lessened by that there was no systematic bias 
to who was assessed at three or six months. The limitations also include that our 
control group was not matched for age, race or menopausal status. This could 
have had an impact on age affected nutritional status markers such as dry lean 
mass and body fat. The controls sample size is so small that subgroup analysis 
was not always possible. Although all identified potential participants were 
approached for the observational study, selection bias was possible in our focus 
group discussions since less ill patients and more nutritionally aware women may 
have volunteered to participate. Not all collected data has been included in the 
analysis. Our EORTC quality of life data remains largely unused partly because 
this instrument is not validated for our non-cancer control group. These data will 
be analysed and published in peer review journals beyond this thesis. 
Nonetheless we feel that the weaknesses in our work highlight the need for 
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further research as highlighted in our recommendations for future work. There 
were strengths to the study too as highlighted in the next session.  
 
9.7.2 Strengths  
This is the first study to use a mixed method approach including a health 
behaviour perspective to objectively identify the problem of malnutrition and also 
to gain insight of the problem and possible intervention from patients’ 
perspectives. Assessing nutritional status at multiple time points enabled us to 
show changes over time. A future intervention incorporating patients’ suggestions 
is likely to be more acceptable to them and may yield more informative results. 
Use of multiple methods for the assessment of nutritional status allowed for 
identification of those markers that are more effective in capturing malnutrition in 
a population where weight and BMI are not very informative at individual level. 
Our study collected pre-diagnosis diet and weight change data which confirmed 
that nutritional and diet changes are already occurring in this time, information 
that may be lost if history was not included. In addition the study of controls in our 
observational study enabled us to identify that dry lean mass, which had been 
previously reported as unchanged in other studies, had in fact already changed 
at baseline assessment. We used all our observational study data in the analysis 
because there was no systematic bias to who or when women were assessed. 
The group discussions involved women at different stages of survival, from 
recently diagnosed to 10 year survivors. This allowed for different perspectives 
that are related to the cancer trajectory to be captured. The insight gained 
warrants an intervention that incorporates some of women’s views and 
suggestions. Our quality of life findings showed that nearly all 
dimensions/domains are affected in cases and controls and that younger women 
report more problems.  
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9.8 Conclusion 
Conclusive evidence is essential for raising attention to clinical problems, 
associated with malnutrition/cachexia. Well-designed, targeted, randomised 
controlled trials with specific interventions incorporating health behaviour 
approaches aimed at preventing rather than treating nutritional complications, 
may improve both nutritional status outcomes such as lean body mass and 
oncology outcomes such as longer disease free intervals and improved survival. 
The potential for benefit of interventions remains at the early stage rather than 
later when the patient has become likely refractory to anti cachexia treatment. 
Ovarian cancer is aggressive and highly lethal which warrants nutritional 
interventions that target a woman’s entire life. Such interventions will require a 
partnership between clinicians and patients, since most of oncologic care occurs 
in outpatient settings. 
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Author 
Type of 
study  
Type of 
patients 
No of 
patients 
Objective Relevant findings Conclusions 
Pearl et al., 
1998 (428) 
A 
randomized 
controlled 
trial  
All 
gynaecological 
oncology 
patients 
200 To evaluate the safety and 
efficacy of early oral feeding 
after intra-abdominal 
surgery in gynecologic 
oncology patients. 
Time to development of bowel 
sounds, time to initiation of clear liquid 
and regular diets, and hospital stay 
significantly longer in the traditional 
group 
Early postoperative 
feeding in gynecologic 
oncology patients 
undergoing intra-
abdominal surgery is safe 
and well tolerated. 
Steed et al., 
2002 (429) 
A 
randomized 
controlled 
trial  
Gynaecological 
oncology/ 
107 To compare early oral 
intake and the traditional 
timing of feeding after major 
gynecologic surgery and the 
effects on the length of 
hospital stay. 
Significant reduction in the LOS* for 
those patients on the early feeding 
regimen. Median length of stay for 
was 4.0 days (P =0.001) compared to 
6.0 days for traditional group. There 
was no difference in the incidence of 
emesis 
Early postoperative 
dietary advancement 
resulted in a decreased 
LOS* and appears to be 
safe, with no increased 
adverse effects 
Schilder et., 
al., 1997 
(258) 
A 
prospective 
controlled 
trial  
Mixed 
Gynecology  
96 To determine whether, 
when compared with 
traditional dietary 
advancement, early oral 
intake following major 
gynecologic surgery leads 
to a reduction in the length 
of hospitalization 
No statistical difference in the number 
of subjects who required 
postoperative antiemetics or biscodyl 
suppository. Statistically significant 
reduction in the LOS* for those 
patients on the early feeding regimen, 
(4.02 days +/- 0.30 versus 3.12 days 
+/- 0.16 (P = 0.008)) 
Early postoperative oral 
intake results in a 
decreased LOS* and is 
well tolerated when 
compared with traditional 
dietary management 
Cutillo et al., 
1999 (430)  
A 
randomised 
controlled 
study 
Gynaecological 
oncology 
61 To evaluate the feasibility, 
safety, and tolerance of 
early feeding in patients 
undergoing surgery for 
gynecologic malignancies 
Early oral feeding was associated with 
a significantly faster resolution of 
postoperative ileus (P < .01), with a 
more rapid return to a regular diet (P 
< .01), with an earlier first passage of 
stool (P < .01), and with a shorter 
postoperative stay (P < .05) than 
patients in arm B 
Early feeding is feasible 
and well tolerated and is 
associated with reduced 
postoperative discomfort 
and a more rapid recovery 
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Author 
Type of 
study  
Type of 
patients 
No of 
patients 
Objective Relevant findings Conclusions 
Pearl et al., 
2002 (431) 
A 
randomized 
controlled 
trial  
Gynaecological 
Oncology 
254 To prospectively evaluate 
the safety and efficacy of a 
regular diet as the first meal 
after intra-abdominal 
surgery in gynecologic 
oncology patients 
The time to development of bowel 
sounds, passage of flatus, and 
hospital stay were comparable for 
both groups. Febrile morbidity, 
pneumonia, wound complications, 
and atelectasis occurred equally in 
both groups  
A regular diet as the first 
meal after intra-abdominal 
surgery in gynecologic 
oncology patients is safe 
and efficacious 
Minig el al., 
2009 (432) 
A 
randomized 
controlled 
trial  
Gynaecological 
oncology  
51 To assess the outcome of 
early oral postoperative 
feeding (263) compared 
with traditional oral feeding 
(309) in gynecologic 
oncology patients 
undergoing laparotomy with 
associated intestinal 
resection. 
Hospital stay in patients who received 
EOF was 6.9 days versus 9.1 days in 
the TOF group (P = 0.022). Use of 
analgesic and antiemetic drugs, 
intensity of pain, intestinal function 
recovery, mean levels of 
postoperative satisfaction, 
postoperative complications, and 
quality-of-life scores did not differ  
Early resumption of oral 
intake is feasible and safe 
and significant reduction in 
LOS* was demonstrated. 
Gerardi et al., 
2008 (257)  
A Clinical 
Pathway  
Ovarian and 
primary 
peritoneal  
64 To evaluate the safety, 
feasibility, and economic 
impact of a clinical pathway, 
including rapid diet 
advancement, for patients 
undergoing recto sigmoid 
colectomy as part of 
cytoreductive surgery for 
advanced ovarian and 
primary peritoneal cancers. 
 
 
Patients who had rapid diet 
advancement had a significantly 
shorter median LOS* (7 days vs. 10 
days, p=0.014) and lower median 30-
day post-operative hospital cost 
($19,700 vs. $25,110, p=0.028) 
A critical pathway 
incorporating rapid diet 
advancement is feasible, 
safe, and associated with 
a significant reduction in 
LOS* and hospital-related 
costs 
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*LOS Length of hospital stay/hospitalization 
 
Author 
Type of 
study  
Type of 
patients 
No of 
patients 
Objective Relevant findings Conclusions 
Gupta et al., 
(256) 
Retrospecti
ve chart 
review 
Ovarian Cancer 98 The impact of improvement 
in nutritional status on 
ovarian cancer survival 
Patients with an improved nutritional 
status at three months had 
significantly better survival than those 
with deteriorated nutritional status 
independent of age, stage at 
diagnosis, prior treatment history, and 
tumour response. 
Improvement in nutritional 
status is associated with 
better survival.  
Note: Study treats 
patients who had and had 
not received treatment at 
baseline similarly. Also 
some patients received 
parenteral nutritional 
support. 
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Appendix 3: Questionnaires 
 
Appendix 3.1 Baseline questionnaire including quality of life questionnaires 
 
 
 
 
Nutritional Status of Women Referred to a Gynaecological Oncology Centre for 
Treatment of a Pelvic Mass 
 
Patient questionnaire I 
We are interested in collecting some information about you, your health and your nutrition. Please answer all 
the following questions, even if you are not sure about exact details/dates.  If you wish, you can give additional 
information on the sheet provided at the end of the questionnaire. We understand that some questions may 
appear to be negative, please be assured that we do not want to upset you, and we make no prior assumptions 
about your experiences. We would like you to answer the questions as honestly as you can as this will help us 
understand your current situation before we can make any suggestions for the future interventions. We 
appreciate your help and support with this study.  
 
Section 1: PERSONAL INFORMATION 
  
1.1  Today’s Date     /      / 
 
1.2   Study Ref.       
 
1.3   Surname 
 
1.4   Name   
    
1.5  Date of Birth     /      /  
 
1.8  Contact Tel  
 
 
1.9 ETHNIC GROUP 
What is your ethnic group? Choose one section from A to E, then select the appropriate option to 
indicate your ethnic group  
A. White 
1. British 
2. Irish 
3. Any Other White background, please write in   _____________________________ 
 
B. Mixed 
4. White and Black Caribbean 
5. White and Black African 
6. White and Asian 
7. Any Other Mixed background, please write in    _____________________________ 
 
C. Asian or Asian British 
8. Indian 
9. Pakistani 
10. Bangladeshi 
11. Any Other Asian background, please write in   _____________________________ 
Nutritional status of women referred to a gynaecological cancer centre: Q1-Baseline v2 Dec 2010                                   
1 / 1 
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Nutritional status of women referred to a gynaecological cancer centre: Q1-Baseline v2 Dec 
2/13/2010                               
D. Black or British Black 
12. Caribbean 
13. African 
14. Any Other African background, please write in _____________________________ 
 
E. Chinese or other ethnic group 
15. Chinese 
16. Any Other, please write in _____________________________ 
 
 
1.10 What is your marital status? (please tick) 
 
Single  never married           Cohabiting/Married         Widowed       Separated/divorced  
Other (please specify) 
 
1.11 What qualification do you have from school, college or the equivalent? (please tick) 
 
  “O” level or equivalent  
  “A” level or equivalent 
  Clerical or commercial qualification (e.g. secretarial) 
  Nursing or teaching  
  College/University degree 
  None of the above 
 
Section 2: HEALTH and LIFESTYLE INFORMATION 
 
This section focuses on your health, diet and eating habits. It is to help gather information that we currently do 
not know about in women referred with a pelvic mass. There are no right or wrong answers. Please complete all 
the questions. If you wish to include extra relevant information, please use the additional sheet provided at the 
end of the questionnaire.  
  
2.1 Has your weight changed in the last 3 months? 
        Yes           No   I don’t know 
 
If you have gained or lost weight please indicate which and by how much  
        Gained weight          Lost weight  (please tick) 
 
    .        kg or                  st         lbs 
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Nutritional status of women referred to a gynaecological cancer centre: Q1-Baseline v2 Dec 
3/13/2010 
 
2.2 Have your eating habits changed in the last 3 months? Please tick    
               Yes        No (if no go to 2.6) 
 
 
2.3 If yes please tell us what brought about this change  
 
 
2.4 What are you eating now that you were not eating more than 3 months ago (list).   
 
 
 
2.5  What are you avoiding now, that you were eating more than 3 months ago? (list) 
 
 
 
2.6 Have you noticed any change in the smell of certain foods in the last 3 months? 
               Yes        No (if no go to 2.8) 
 
2.7 If yes, please tell us how this change affects what you eat 
 
 
 
 
2.8 Have you noticed any change in taste in some foods in the last 3 months? 
               Yes        No (if no go to 2.10) 
 
2.9 If yes please tell us how this change in taste affects what you eat. 
 
 
 
 
2.10 Have you ever been a regular smoker?      Yes         No (If no go to 2.15) 
 
2.11 If yes, how many cigarettes per day do you currently smoke?  
 
2.12 How many cigarettes per day did you smoke 3 months ago? 
 
2.13 If you have given up, when did you give up smoking (month and year)              / 
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2.14 On average how many cigarettes did you smoke per day before you gave up? 
 
2.15 Do you drink alcohol?           Yes                                         No (if no go to Section 3) 
 
2.16 If yes; how many of the following do you drink per week? 
 
 
 
 
 
 
 
2.17 How much alcohol did you drink 3 months ago? 
 
 
 
 
 
 
 
Section 3:MENSTRUAL AND MEDICAL HISTORY 
In this section we ask about information relating to your menstrual history and any other medical 
conditions you may have. Please complete all the questions in the following section. Feel free to provide 
additional information on the extra sheet provided 
3.1 Have your periods stopped completely? (have you gone at least 6 months without having a 
period and you are not pregnant or on the contraceptive pill) 
Yes 
                        No 
                         Don’t know as I started to take HRT before my periods had stopped 
(If ‘no’ or ‘don’t know’, go to 3.4) 
3.2 If yes, how old were you when your periods stopped completely? Years 
  
Nutritional status of women referred to a gynaecological cancer centre: Q1-Baseline v2 Dec 4/13/2010  
Wine (glass) 
Beer, Lager or cider (half pint) 
Alcohol and amounts 
Spirits, e.g. brandy, whisky, vodka 
) 
Port, sherry, vermouth, liqueurs (glass) 
Drinks per week? 
Wine (glass) 
Beer, Lager or cider (half pint) 
Alcohol and amounts 
Spirits, e.g. brandy, whisky, vodka 
Port, sherry, vermouth, liqueurs (glass) 
Drinks per week 3 months 
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3.3 What was the reason your periods stopped? 
Natural menopause  
Surgery (e.g. hysterectomy/removal of ovaries) 
Chemotherapy, radiation or other treatment 
Don’t know 
Other (please specify) 
 
3.4 Do you currently have abdominal pain or discomfort  
                   Yes                    No (if no go to 3.5) 
 
 If yes please indicate which  
                   Pain                   Discomfort 
 Has the pain/discomfort been      continuous              or   intermittent?        
 
Please tell us for how long this has been going on  
 
3.5 Have you been diagnosed with any other medical condition in the past?  
       Yes                         No (if no go to 3.7) 
 
3.6 If yes please list all the conditions and the year of diagnosis 
 
 
 
 
 
 
 
 
 
 
Nutritional status of women referred to a gynaecological cancer centre: Q1-Baseline v2 Dec 
5/13/2010                                   
 
 
Medical Condition 
 
 
Year of diagnosis 
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Nutritional status of women referred to a gynaecological cancer centre: Q1-Baseline v2 Dec 
6/13/2010                 
3.7 Do you currently take regular (that is every day or almost every day) medication including 
hormones e.g. HRT or supplements e.g. vitamin C?  
 
       Yes        No  (if no go to Section 4) 
 
If yes, please give the name of the medication and how long you have been using it. 
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Extra Information 
Please feel free to add extra relevant information on this page 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for helping us with our research 
Additional Information from Section 1 of Questionnaire 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional Information from Section 2 of Questionnaire 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional Information from Section 3 of Questionnaire 
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Nutritional status of women referred to a gynaecological cancer centre: Q1-Baseline v2 Dec 
2010  
 
Section 4: QUALITY OF LIFE  
In this section we ask you to evaluate your diet and general well-being using 3 questionnaires that have been used 
in other studies in the past and shown to provide useful information. The questions are about how you perceive 
your health or some aspects of your health to be in the specified time period. The first questionnaire, the functional 
assessment of anorexia/cachexia therapy asks you about your appetite and food intake while the last two are about 
your general well being. 
 
4.1 The Functional Assessment of Anorexia/Cachexia Therapy (FAACT) (A/CS-12) 
4.2 EORTC QLQ-C30 (version 3) 
4.3 EuroQol EQ-5D 
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The Functional Assessment of Anorexia/Cachexia Therapy (FAACT) 
(A/CS-12) questionnaire 
 
 
 
 
 
 
 
 
 
Please answer all of the questions yourself by circling the number that best applies to you. 
During the past 7 days; 
 Not at all 
A little 
bit 
Somewhat 
Quite a 
bit 
Very 
much 
I have a good appetite 0 1 2 3 4 
The amount I eat is sufficient to 
meet my needs 
0 1 2 3 4 
I am worried about my weight 0 1 2 3 4 
Most food tastes unpleasant to me 0 1 2 3 4 
I am concerned about how thin I 
look 
0 1 2 3 4 
My interest in food drops as soon 
as I try to eat 
0 1 2 3 4 
I have difficulty eating rich or 
“heavy” foods 
0 1 2 3 4 
My family or friends are 
pressuring me to eat 
0 1 2 3 4 
I have been vomiting 0 1 2 3 4 
When I eat, I seem to get fully 
quickly 
0 1 2 3 4 
I have pain in my stomach area 0 1 2 3 4 
My general health is improving 0 1 2 3 4 
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EuroQol EQ-5D Quality of life questionnaire 
 322 
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Appendix 3.2: During treatment questionnaire including quality of life 
questionnaires 
 
 
 
Nutritional Status of Women Referred to a Gynaecological Cancer 
Centre for Treatment of a Pelvic Mass 
 
Patient Questionnaire II (During treatment) 
 
We are interested in collecting some information about your health and your nutrition during 
your treatment so far. Please answer all the following questions, even if you are not sure about 
exact details/dates. If you wish, you can give additional information on the sheet provided at 
the end of the questionnaire. We understand that some questions may appear to be negative, 
please be assured that we do not want to upset you, and we make no prior assumptions about 
what your experiences are. We would like you to answer the questions as honestly as you can 
as this will help us understand your current situation before we can make any suggestions for 
the future interventions. We appreciate your help and support with this study.  
 
Section 1: PERSONAL INFORMATION 
 
1.1 Today’s Date   /     / 
 
1.2 Study Ref.    
 
1.3 Surname 
 
1.5 Date of Birth 
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Section 2: HEALTH and LIFESTYLE INFORMATION 
This section focuses on your health, diet and eating habits. There are no right or wrong 
answers. Please complete all the questions. Please complete all the following questions. If 
you wish to include extra relevant information, please use the additional sheet provided at the 
end of the questionnaire. 
2.0  Do you currently live (please tick all relevant) 
 
 Alone        Partner/Spouse         Parents        Relative/s        Child/ren       friend                                                                                                 
Other (please specify) 
 
2.2 Have your eating habits changed since you had surgery or started chemotherapy? Please 
tick            
  Yes                No  (if no go to 2.6) 
 
2.3  If yes please tell us what brought about this change  
 
 
 
2.4 What are you eating now that you were not eating at surgery/start of chemotherapy? 
(please list).   
 
 
 
 
2.5  What are you avoiding now, that you were eating at surgery/start of chemotherapy? 
(please list) 
 
 
 
2.6  Have you noticed any change in the smell of certain foods since surgery or start of 
chemotherapy? 
            Yes                                                   No (if no go to 2.8) 
 
2.6.1 If yes please describes this change  
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2.7 Please tell us how this change affects what you eat 
 
 
 
2.8 Have you noticed any change in how some foods taste since surgery/start of 
chemotherapy? 
          Yes                              No (if no go to 2.10) 
 
2.8.1 If yes please describe the change 
 
 
 
2.9 Please tell us how this change in taste affects what you eat 
 
 
 
 
2.10 Do you smoke?          Yes                           No (if no go to question 2.15) 
 
2.11 If yes, how many cigarettes per day do you smoke?  
 
2.15 Do you drink Alcohol?             Yes                     No (if no go to Section 3) 
 
2.16 If yes; how many of the following do you drink per week? 
 
 
 
 
 
 
 
 
 
 
 
 
Wine (glass) 
Beer, Lager or cider (half pint) 
Alcohol and amounts 
Spirits, e.g. brandy, whisky, vodka 
(single) 
Port, sherry, vermouth, liqueurs 
(glass) 
Drinks per week? 
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Section 3: MEDICAL HISTORY 
In this section we ask about information relating pain and other medical conditions you may 
have. Please complete all the questions in the following section. Feel free to provide additional 
information on the extra sheet provided 
3.4 Do you currently have abdominal pain or discomfort (please indicate which one) 
         Yes                     No (if no go to 3.7) 
 
 If yes please indicate which                   Pain                      Discomfort 
 
Has the pain/discomfort been?             Continuous     or           Intermittent        
 
Please tell us for how long this has been going on  
 
3.7 Do you take regular medication (that is every day or almost every day) including 
hormones e.g. HRT or supplements such as vitamin C?  
           Yes               No (if no go to Section 4) 
 
If yes, please give the name of the medicine and how long you have been using  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name of Medication 
 
No of years/months 
using 
 
 
 
 
 
 
 
  
 
 
328 
 
Section 4: QUALITY OF LIFE  
The quality of life questionnaires were the same as those administered at 
baseline questionnaire 1  
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Appendix 3.3: End of treatment questionnaire including quality of life 
questionnaires 
 
 
 
Nutritional Status of Women Referred to a Gynaecological Cancer 
Centre for Treatment of a Pelvic Mass 
 
Patient Questionnaire III (End of treatment) 
We are interested in finding out about your health and nutrition throughout your treatment 
journey which just ended. Please answer all the following questions, even if you are not sure 
about exact details/dates. If you wish, you can give additional information on the sheet 
provided at the end of the questionnaire. We understand that some questions may appear to 
be negative, please be assured that we do not want to upset you, and we make no prior 
assumptions about what your experiences are. We would like you to answer the questions as 
honestly as you can as this will help us understand your current situation before we can make 
any suggestions for the future interventions. We appreciate your help and support with this 
study.  
 
Section 1: PERSONAL INFORMATION 
 
1.1 Today’s Date   /     / 
 
1.4 Study Ref.    
 
1.5 Surname 
 
1.5 Date of Birth 
 
Section 2: HEALTH and LIFESTYLE INFORMATION 
This section focuses on your health, diet and eating habits. There are no right or wrong 
answers. Please complete all the questions. Please complete all the following questions. If 
you wish to include extra relevant information, please use the additional sheet provided at the 
end of the questionnaire. 
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2.0 Do you currently live with (please tick all relevant) 
Alone        Partner/Spouse         Parents         Relative/s       Child/ren        friend  
Other (please specify) 
 
2.2 Did your eating habits change during the treatment period? Please tick    
         Yes                No (if no go to 2.6) 
 
2.3 If yes please tell us what brought about this change?  
 
 
2.4 Please list all foods that you are eating now, that you did not normally eat before 
your diagnosis?    
 
 
2.12 Please list all foods that you ate before your diagnosis but are now avoiding? 
 
 
2.13 Did you notice any change in the smell of certain foods during treatment? 
         Yes                  No (if no go to question 2.8) 
2.13.1  If yes please describe this change 
 
 
2.14 Please tell us how this change affected what you ate during treatment 
 
 
 
2.15 Did you notice any change in the taste of certain foods during treatment? 
           Yes          No (if no go to 2.10) 
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2.15.1 If yes please describe the change 
 
 
 
2.16 Please tell us how this change affected what you ate during treatment 
 
 
 
2.17 Do you smoke?           Yes                No  (if no go to 2.15) 
 
2.18 If yes, how many cigarettes per day do you currently smoke?  
 
2.15 Do you drink Alcohol?         Yes         No (if no go to 2.17) 
 
2.16 If yes; how many of the following do you drink per week? 
 
 
 
 
 
 
2.17 Did you receive any nutrition information, advice, counselling or support from 
hospital staff (for example nurses, doctors, dieticians etc.) as part of your care?  
 
  Yes                Yes but not enough             No (If no go to 2. 21)     
 
2.18 If yes please tell us from whom you received the information, advice, 
counselling or support 
 
 
 
    
Wine (glass) 
Beer, Lager or cider (half pint) 
Alcohol and amounts 
Spirits, e.g. brandy, whisky, vodka 
(single) 
Port, sherry, vermouth, liqueurs 
(glass) 
Drinks per week? 
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2.19 Was this information helpful to you at the time? 
         Yes                           No  
2.20 If yes please tell us how it was helpful  
                                                                     
            
 
2.21 Please tell us what kind of nutrition information, advice, counselling or support 
you think might have been helpful to you during your treatment? 
                      
 
 
 
2.22 On your own initiative, since diagnosis, have you sought out information on 
diet and nutrition from other sources such as the internet, leaflets, friends, GP 
etc.? 
            Yes                   No (If no go to 2.24) 
 
2.23 If yes can you please tell us where you sought this information 
 
 
 
2.24 Please tell us why you sought/or did not seek this information 
 
 
 
2.25 Do you feel that you know enough about what to eat to give your body the best 
nutritional support for recovery? 
             Yes                  No  
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2.26 Can you tell us what your health care team could do to support you more with 
your nutrition and diet? 
 
 
 
 
Section 3:MEDICAL HISTORY 
In this section we ask about information relating pain and other medical conditions you 
may have. Please complete all the questions in the following section. Feel free to 
provide additional information on the extra sheet provided 
3.4 Do you currently have abdominal pain or discomfort (please indicate which one) 
         Yes                  No (if no go to 3.5) 
 If yes please indicate which 
                   Pain                 Discomfort 
Has the pain/discomfort been?             Continuous      or          Intermittent        
Please tell us for how long this has been going on  
 
3.7 Do you take regular medication (that is every day or almost every day) including 
hormones (e.g. HRT, Thyroxine or supplements such as Vitamin C?  
Yes                  No (if no go to Section 4) 
 
If yes, please give the name of the product, how long you have been using it and 
whether you are currently using it. 
 
 
 
 
 
 
 
Name of Medication 
 
No of years/months 
using 
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Extra Information 
Please feel free to add extra relevant information on this page 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional Information from Section 1 of Questionnaire 
 
 
 
 
 
 
 
 
 
 
Additional Information from Section 2 of Questionnaire 
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Section 4: QUALITY OF LIFE  
The quality of life questionnaires were the same as those administered at 
baseline and during treatment in questionnaires I and II. 
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Appendix 4: Patient information leaflets  
Appendix 4.1 Cases 
 
Nutritional Status of Women Referred to a Gynaecological Cancer 
Centre for Treatment of a Pelvic Mass 
 
Patient Information leaflet  
We invite you to take part in a research study looking at the nutritional status of women 
who are referred to the centre with a pelvic mass. Please read this leaflet which tells 
you about the study and what it involves and ask the researcher if there is anything that 
is not clear. Take time to decide whether or not you wish to take part.    
 
What is the purpose of the study? 
The purpose of the study is to gather detailed nutritional information from women 
diagnosed with either a non-cancerous (benign) or cancerous pelvic mass. We know 
that nutrition is important for patients who are having surgery and/or other treatments 
in hospital. Good nutritional status increases patients’ ability to undergo treatments, 
and improves quality of life. What we do not know is whether malnutrition is a 
problem at the very beginning of the treatment pathway of women referred with a 
pelvic mass or how it changes over time. We also do not have solid research evidence 
about when and what to provide as nutritional intervention to improve short and long 
term patient health outcomes. This study is the first step to investigating this.  
 
In the study we gather information about factors that underlie a person’s nutrition and 
how these may change during investigations and treatment of a pelvic mass. We want 
to thoroughly investigate these factors in the period before treatment, through surgery 
and during any additional treatment. Gathering accurate information about how 
nutritional status may change during this period will help to decide the best timing and 
future design of tailored nutritional intervention to improve the existing nutrition 
support in gynaecological oncology treatment here at UCLH and also in other NHS 
centres.  
 
Why have I been chosen? 
You have been invited to take part in the study because you are undergoing 
investigations and treatment of a pelvic mass at the gynaecological oncology centre. 
Your doctor will have discussed your diagnosis with you or mentioned that at this time 
we do not know what your final diagnosis will be. You are eligible to participate 
whether investigations show you have a non-cancerous (benign) mass or if 
unfortunately the mass you have is shown to be a cancer. We understand and recognize 
that this is often a difficult time for women. This study will not interfere with your 
regular care in any way. You are being asked to take part in the study at this time 
because it is important to find out in detail the status of your nutrition and how it may 
change leading up to your surgery or treatment. This information may be important in 
any future effort to improve women’s nutrition to enable them not only to tolerate 
treatment better, but to also modify their diet and lifestyle for long term benefit. We 
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want to gather information that will allow us to make comparisons between women 
who may have different nutritional needs. These comparisons will be made at the end 
of the study and will be important in designing future nutrition interventions specific 
to the needs of each group.  
 
What does the study involve?  
The researcher, Nyala Balogun, will explain the study to you, give you a copy of this 
information sheet and answer any questions you may have. You are free to take the leaflet 
away to consider whether or not you are willing to take part. If you are willing to take part you 
will be asked to sign a consent form and will be given a signed copy to keep, and a copy will 
also be placed in your hospital records. You will still be free to withdraw from the study at 
any time without giving a reason.  
 
Taking part in this study involves 3 or 4 assessments depending on your diagnosis. Each 
assessment will last approximately 45 minutes and will include weight, height and 
measurement of body composition (the proportion of fat and fat-free mass in the body). You 
will also be required to complete a questionnaire and donate a blood sample. Assessments will 
be carried out on entry to the study, immediately before surgery, 2-3 weeks after surgery and 
in the case of further treatment at completion of this. 
 
Measurement of body composition will be done while you are lying down. This test is done 
using a small portable machine called a Quadscan. Small stickers called electrodes are attached 
to your wrists and ankles and connected via wires to the Quadscan machine. The machine works 
by passing a small electrical current through the body. The current passes freely through the 
fluids contained in muscle tissue, but encounters some resistance when it passes through fat 
tissue in your body. The resistance of the fat tissue to the electrical current is the 'bioelectrical 
impedance' measurement. When considered alongside a person's height, gender and weight, the 
measurements can then calculate figures for body fat, and fat-free (lean) mass. This method of 
measuring body composition is called Bioelectrical Impedance Analysis (BIA). It is safe and 
painless and will take no more than 5 minutes. This will be carried out in clinic but where it is 
more convenient to you the nurse researcher will arrange to visit you at home.  
 
You will also be asked to donate 4 tubes of blood in total (2 for serum and 2 for plasma) 
throughout the study. Each tube holds about half a tablespoon of blood (10ml). You will be asked 
to donate two samples at your first or second assessment and 2 more samples at your final 
assessment. The blood samples will be used for this study to analyse indicators of nutritional 
status such as serum albumin. Results from the samples taken pre-operatively will be compared 
with those taken at the end of treatment. We will also compare group results from samples taken 
from women with benign ovarian tumours to those from women with cancer. Any remaining 
samples after these analyses will be stored at University College London. Use of these samples 
in future related studies would need the approval of an independent Ethics Committee.  
 
You will also be asked to complete a questionnaire. The questions ask you about your nutrition 
and your recent and current health. For example we ask if you have noticed any weight change 
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in the last 3 months. You can complete the questionnaire at the time of your body composition 
assessment or you can complete it at a later date and post it back to the research team in a 
prepaid envelope provided. The questionnaire will take about 20 minutes to complete.   
 
The assessments are designed to coincide with your hospital appointments and treatment 
where possible. The initial and second assessments are similar for all women who participate, 
carried out at entry to the study, and immediately before treatment. Afterwards the assessment 
schedule will depend on your treatment pathway. If you are diagnosed with a benign mass and 
only require surgery as treatment, your 3rd and final assessment will be conducted when you 
attend outpatient clinic for your post operation follow-up, usually 2-3 weeks after the surgery. 
If you have a cancer diagnosis and require further treatment, the 3rd  
 
assessment will be at your post operation follow up clinic (2-3 weeks after surgery). You will 
also have a 4th and final assessment at the end of your additional treatment which may be 4-5 
months after your surgery.  
 
If there are no further planned hospital visits before treatment commences, the researcher will 
ask if you are willing to telephone her on the number or for her to telephone you after a 
minimum of 24 hours to ask if you are willing to participate. In this case you have an option 
of a visit at home by the researcher, where this is convenient and acceptable to you to take 
informed consent and perform the assessments. Where no other acceptable options are 
available, we will take informed consent when you attend for treatment on the ward or 
outpatients clinic. 
 
The researcher will telephone you following each assessment to reassure you about your 
participation in the study and to address any concerns that may have arisen following your 
assessment. Your participation in the study will not jeopardise your care in any way. Your care 
team will already be monitoring your progress throughout this time, but if we have a concern 
about any result that we find we will seek your permission to inform your consultant so that you 
are supported appropriately.  
 
Some information we collect during the study such as the questionnaire quality of life 
information and Bio electrical impedance information is for the purposes of the research only 
and will not be analysed until the end of the study. However tests such as your weight which are 
used in clinical practice can be fed back to you throughout the study.   
 
The researcher will also collect information about your condition and hospital investigations and 
treatment from your medical records. Only members of the research team involved in the project 
may look at your hospital notes. 
 
Your nutrition will be monitored by your care team including a dietician as part of your regular 
care through out this period. At the end of the study we will provide you with your individual 
full results summary showing your nutrition ‘foot print’ throughout the study. We will seek 
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guidance from the dietician and clinical team on how best to provide self-management 
information and counselling where it is appropriate based on your results. 
 
Do I have to take part? 
You do not have to take part. It is entirely up to you to decide whether or not to take part in 
the study and you can withdraw at any time, without giving a reason. A decision not to take 
part or a decision to withdraw from the study will not affect the care or treatment you receive 
in any way.  
 
What tests will be carried out on the samples I give for this study? 
Your blood samples will be analysed for markers of nutritional status before treatment and at 
the end of treatment using known proteins such as serum albumin. Any remaining samples 
after analysis will be frozen and stored for future studies.   
 
What are the possible disadvantages and risks of taking part? 
The assessments and questionnaires involve your time and there is the possibility of local 
bruising when blood is taken from a vein in your arm. We will try as far as possible to arrange 
for the blood to be taken  
 
during your other routine tests, to avoid an additional needle stick. Where this is not possible 
a nurse- researcher trained as a phlebotomist will take the sample.  
 
We understand that facing the possibility of a cancer diagnosis can be a difficult time for some 
women.  We assure you that if there were any issues raised by the study that are upsetting to 
you or which you feel you need support with, the researcher would ensure your consultant was 
aware of your concerns so that appropriate care could be arranged.  
 
What are the possible benefits of the study? 
You may find participation in the study benefits you personally because you can discuss your 
dietary and food habits with the researcher. Information obtained will help us design an effective 
and acceptable nutritional support package for women in the future.  
 
At the end of the study when the results have been analysed we will provide each woman with 
the results of their nutritional status throughout the time that they were in the study. You may 
find this information useful to you for making decisions about your diet for the future. 
 
How will the blood samples and questionnaires be used in the future? 
If any blood samples remain after the study, they will be coded, frozen and stored for future 
use. The samples and information collected during the assessment including quality of life 
questionnaire information will be stored indefinitely at the Women’s Cancer Research 
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Department, under the custodianship of University College London. If in future there are 
circumstances where further studies are designed for the benefit of women then the researchers 
will approach the ethical committee for approval to use the samples from this study. All 
samples and data will be anonymised for storage and will not be traceable back to you. 
 
Will what I contribute to the study be confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled 
in confidence. Assessment measures and completion of questionnaires will take place in 
private, and the information will not contain your name or any personal information, only a 
study identification number. Questionnaires will be held together with information from your 
medical records in a lockable draw or password protected computer in the Department of 
Gynaecological Oncology, at University College, London. Only those members of the research 
team who are directly involved in analyzing the information will have access to the files on 
the computer. All the samples you give will be coded and Dr. Anne Lanceley the Chief 
Investigator for this project has the overall responsibility for confidentiality and data security. 
Identities of participants will not be revealed in any publication or report relating to this research. 
 
Involvement of your doctor 
The health professional in charge of your care here at UCLH and your GP will be informed in 
writing of your participation in this study. A copy of your signed consent form will be kept in 
your hospital notes. 
 
What will happen to the results of the research study? 
The results of the study will be written up as part of a PhD thesis. We will publish peer 
reviewed papers & articles for the media which cater to clinical academics & to practitioners 
and users in health care settings. No personal identifiers will be used in reports and 
publications. The full results of the study will be available in 2013, two years after the 
beginning of recruitment when we will send a full summary of the findings to every 
participant. We will also provide you with your individual full results summary showing your 
nutrition ‘foot print’ throughout the study. We will seek guidance from the dietician and 
clinical team on how best to provide self-management information and counselling where it is 
appropriate based on the results. You may find this information helpful in the period following 
your treatment. The results of the study will also be made available to relevant gynaecological 
charities, including The Eve Appeal and Ovacome. In addition, we will collaborate with the 
UCLH / UCL Patient and Public Involvement (PPI) in Research Coordinator and with the 
UCLH/UCL press offices to develop contacts with local and national media and to contribute 
material for the UCL/UCLH websites (including to the dedicated pages on the Research 
Patients Support Network and PPI in Research).  
 
Who is organising and funding the research? 
Dr. Anne Lanceley is the Chief Investigator and Professors Martin Widschwendter & Alastair 
Forbes are co-supervisors of the study. The study is run from the Women’s Cancer Research 
Department; Institute for Women’s Health, University College London and is funded by the 
Comprehensive Biomedical Research Centre (CBRC) at University College London Hospital 
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(UCLH)/University College London (UCL). No payments are made to the researchers 
conducting this study.  
 
Who has reviewed this study? 
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect your interests. This study has been reviewed and given a 
favourable opinion by North London Research Ethics Committee 3. 
 
What do I do if I wish to make a complaint about the research? 
If you wish to complain about any aspect of the research, you should contact the nurse-
researcher or the Chief Investigator, Dr. Anne Lanceley on 0207 7679 6807 or by email at 
(a.lanceley@ucl.ac.uk). If you feel you do not receive a satisfactory response and wish to take 
the matter further you should contact patient Advice and Liaison Service (PALS), either on 
line at www.pals.nhs.uk or your local PALS office giving the project title and the Chief 
Investigator’s contact details.  
 
Contact details 
If you are interested in participating or you would like to ask questions about any aspect of the 
study please contact the researcher Nyala Balogun:    
 
By telephone:  
By email:  Nyaladzi.Balogun@ucl.ac.uk 
By post:  Women’s Cancer Research Department  
Institute for Women’s Health University College London  
1st Floor, Maple House 
149 Tottenham Court Road  
London, W1T 7DN.  
 
Thank you very much for taking time to read this information about the study.  
 
 
 
 
 
Appendix 4.2 Controls 
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Nutritional Status of Women Referred to a Gynaecological Cancer 
Centre for Treatment of a Pelvic Mass 
 
Patient Information leaflet  
We invite you to take part in a research study looking at the nutritional status of women 
who are referred to UCLH with a pelvic mass or for a gynaecological condition that 
requires surgery. Please read this leaflet which tells you about the study and what it 
involves and ask the researcher if there is anything that is not clear. Take time to decide 
whether or not you wish to take part.    
 
What is the purpose of the study? 
The purpose of the study is to gather detailed nutritional information from women 
diagnosed with a benign (non- cancerous) gynaecological condition that requires 
surgery to remove the womb and/or ovaries or a cancerous pelvic mass. We know that 
nutrition is important for patients who are having surgery and/or other treatments in 
hospital. Good nutritional status increases patients’ ability to undergo treatments, and 
improves quality of life. What we do not know is whether malnutrition is a problem 
from the very beginning of the treatment pathway for women and how it changes over 
time. We also do not have solid research evidence about when and what to provide as 
nutritional intervention to improve short and long term patient health outcomes. This 
study is the first step to investigating this.  
 
In the study we gather information about factors that underlie a person’s nutrition and 
how these may change during investigations and treatment of a gynaecological 
condition. We want to thoroughly investigate these factors in the period before 
treatment, and through surgery. Gathering accurate information about how nutritional 
status may change during this period will help to decide the best timing and future 
design of tailored nutritional intervention to improve the existing nutrition support in 
our gynaecological departments here at UCLH and also in other NHS Trusts.  
 
Why have I been chosen? 
You have been invited to take part in the study because you are undergoing 
investigations and treatment of a gynaecological condition (involves your womb or 
ovaries and fallopian tubes). Your doctor will have discussed your condition with you 
and told you that you will have an operation to remove the mass, womb and/or the 
tubes and ovaries. We understand and recognize that this is often a difficult time for 
women. This study will not interfere with your regular care in any way. You are being 
asked to take part in the study at this time because it is important to find out in detail 
the status of your nutrition and how it may change leading up to your surgery and after. 
This information may be important in any future effort to improve women’s nutrition 
to enable them not only to tolerate treatment better, but to also modify their diet and 
lifestyle for long term benefit. We want to gather information that will allow us to make 
comparisons between women who may have different nutritional needs. These 
comparisons will be made at the end of the study and will be important in designing 
future nutrition interventions specific to the needs of each group.  
What does the study involve?  
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The researcher, Nyala Balogun, will explain the study to you, give you a copy of this 
information sheet and answer any questions you may have. You are free to take the 
leaflet away to consider whether or not you are willing to take part. If you are willing 
to take part you will be asked to sign a consent form and will be given a signed copy 
to keep, and a copy will also be placed in your hospital records. You will still be free 
to withdraw from the study at any time without giving a reason.  
 
Taking part in this study involves 2 or 3 assessments depending on the length of time 
from when we first assess you and your treatment. If this period is more than two weeks 
then we will conduct another assessment before your surgery. Each assessment will 
last approximately 45 (25min if you chose to take and complete the questionnaire at 
home) minutes and will include weight, height and measurement of body composition 
(the proportion of fat and fat-free mass in the body). You will also be required to 
complete a questionnaire and donate a blood sample. Assessments will be carried out 
on entry to the study, immediately before surgery, 2-3 weeks after surgery when you 
attend for your follow-up.  
 
Measurement of body composition will be done while you are lying down. This test is 
done using a small portable machine called a Quadscan. Small stickers called electrodes 
are attached to your wrists and ankles and connected via wires to the Quadscan machine. 
The machine works by passing a small electrical current through the body. The current 
passes freely through the fluids contained in muscle tissue, but encounters some 
resistance when it passes through fat tissue in your body. The resistance of the fat tissue 
to the electrical current is the 'bioelectrical impedance' measurement. When considered 
alongside a person's height, gender and weight, the measurements can then calculate 
figures for body fat, and fat-free (lean) mass. This method of measuring body 
composition is called Bioelectrical Impedance Analysis (BIA). It is safe and painless and 
will take no more than 5 minutes. This will be carried out in clinic but where it is more 
convenient to you the nurse researcher will arrange to visit you at home.  
 
You will also be asked to donate 4 tubes of blood in total (2 for serum and 2 for plasma) 
throughout the study. Each tube holds about half a tablespoon of blood (10ml). You will 
be asked to donate two samples at your first or second assessment and 2 more samples 
at your final assessment. The blood samples will be used for this study to analyse 
indicators of nutritional status such as serum albumin. Results from the samples taken 
pre-operatively will be compared with those taken at the end of treatment. We will also 
compare group results to those of samples taken from women who are diagnosed with 
cancer of the ovary. Any remaining samples after these analyses will be stored at 
University College London. Use of these samples in future related studies would need 
the approval of an independent Ethics Committee.  
 
You will also be asked to complete a questionnaire. The questions ask you about your 
nutrition and your recent and current health. For example we ask if you have noticed any 
weight change in the last 3 months. You can complete the questionnaire at the time of 
your body composition assessment or you can complete it at a later date and post it 
back to the research team in a prepaid envelope provided. The questionnaire will take 
about 20 minutes to complete. The assessments are designed to coincide with your 
hospital appointments and treatment where possible. The initial and second 
assessments are carried out at entry to the study and immediately before surgery and 
the final assessment at 2-3 weeks after the surgery, when you attend for your follow.    
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The researcher will telephone you following each assessment to reassure you about 
your participation in the study and to address any concerns that may have arisen 
following your assessment. Your participation in the study will not jeopardise your 
care in any way. Your care team will already be monitoring your progress throughout 
this time, but if we have a concern about any result that we find we will seek your 
permission to inform your consultant so that you are supported appropriately.  
 
Some information we collect during the study such as the questionnaire quality of life 
information and Bio electrical impedance information is for the purposes of the 
research only and will not be analysed until the end of the study. However tests such 
as your weight which are used in clinical practice can be fed back to you throughout 
the study.   
 
The researcher will also collect information about your condition and hospital 
investigations and treatment from your medical records. Only members of the research 
team involved in the project may look at your hospital notes. 
 
Your nutrition will be monitored by your care team including a dietician as part of your 
regular care through out this period. At the end of the study we will provide you with 
your individual full results summary showing your nutrition ‘foot print’ throughout the 
study.  
 
Do I have to take part? 
You do not have to take part. It is entirely up to you to decide whether or not to take 
part in the study and you can withdraw at any time, without giving a reason. A decision 
not to take part or to withdraw from the study will not affect the care or treatment you 
receive in any way.  
 
What tests will be carried out on the samples I give for this study? 
Your blood samples will be analysed for markers of nutritional status before treatment 
and at the end of treatment using known proteins such as serum albumin. Any 
remaining samples after analysis will be frozen and stored for future studies.   
 
What are the possible disadvantages and risks of taking part? 
The assessments and questionnaires involve your time and there is the possibility of 
local bruising when blood is taken from a vein in your arm. We will try as far as 
possible to arrange for the blood to be taken  
during your other routine tests, to avoid an additional needle stick. Where this is not 
possible a nurse- researcher trained as a phlebotomist will take the sample.  
 
We understand that facing major surgery can be a difficult time for some women.  We 
assure you that if there were any issues raised by the study that are upsetting to you or 
which you feel you need support with, the researcher would ensure your consultant 
was aware of your concerns so that appropriate care could be arranged.  
What are the possible benefits of the study? 
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You may find participation in the study benefits you personally because you can discuss 
your dietary and food habits with the researcher. Information obtained will help us 
design an effective and acceptable nutritional support package for women in the future. 
At the end of the study when the results have been analysed we will provide each 
woman with the results of their nutritional status throughout the time that they were in 
the study.  
 
How will the blood samples and questionnaires be used in the future? 
If any blood samples remain after the study, they will be coded, frozen and stored for 
future use. The samples and information collected during the assessment including 
quality of life questionnaire information will be stored indefinitely at the Women’s 
Cancer Research Department, under the custodianship of University College London. 
If in future there are circumstances where further studies are designed for the benefit 
of women then the researchers will approach the ethical committee for approval to use 
the samples from this study. All samples and data will be anonymised for storage and 
will not be traceable back to you. 
 
Will what I contribute to the study be confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. Assessment measures and completion of questionnaires will 
take place in private, and the information will not contain your name or any personal 
information, only a study identification number. Questionnaires will be held together 
with information from your medical records in a lockable draw or password protected 
computer in the Department of Gynaecological Oncology, at University College, 
London. Only those members of the research team who are directly involved in 
analyzing the information will have access to the files on the computer. All the samples 
you give will be coded and Dr. Anne Lanceley the Chief Investigator for this project 
has the overall responsibility for confidentiality and data security. Identities of 
participants will not be revealed in any publication or report relating to this research. 
 
Involvement of your doctor 
The health professional in charge of your care here at UCLH and your GP will be 
informed in writing of your participation in this study. A copy of your signed consent 
form will be kept in your hospital notes. 
 
What will happen to the results of the research study? 
The results of the study will be written up as part of a PhD thesis. We will publish peer 
reviewed papers & articles for the media which cater to clinical academics & to 
practitioners and users in health care settings. No personal identifiers will be used in 
reports and publications. The full results of the study will be available in 2013, two 
years after the beginning of recruitment when we will send a full summary of the 
findings to every participant. We will also provide you with your individual full results 
summary showing your nutrition ‘foot print’ when you were in the study. The results 
of the study will also be made available to relevant gynaecological charities, including 
The Eve Appeal and Ovacome. In addition, we will collaborate with the UCLH / UCL 
Patient and Public Involvement (PPI) in Research Coordinator and with the 
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UCLH/UCL press offices to develop contacts with local and national media and to 
contribute material for the UCL/UCLH websites (including to the dedicated pages on 
the Research Patients Support Network and PPI in Research).  
 
Who is organising and funding the research? 
Dr. Anne Lanceley is the Chief Investigator and Professors Martin Widschwendter & 
Alastair Forbes are co-supervisors of the study. The study is run from the Women’s 
Cancer Research Department; Institute for Women’s Health, University College 
London and is funded by the Comprehensive Biomedical Research Centre (CBRC) at 
University College London Hospital (UCLH)/University College London (UCL). No 
payments are made to the researchers conducting this study.  
 
Who has reviewed this study? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been reviewed 
and given a favourable opinion by North London Research Ethics Committee 3. 
 
What do I do if I wish to make a complaint about the research? 
If you wish to complain about any aspect of the research, you should contact the nurse-
researcher or the Chief Investigator, Dr. Anne Lanceley on 0207 7679 6807 or by email 
at (a.lanceley@ucl.ac.uk). If you feel you do not receive a satisfactory response and 
wish to take the matter further you should contact patient Advice and Liaison Service 
(PALS), either on line at www.pals.nhs.uk or your local PALS office giving the project 
title and the Chief Investigator’s contact details.  
 
Contact details 
If you are interested in participating or you would like to ask questions about any 
aspect of the study please contact the researcher Nyala Balogun:    
 
By telephone: 020 3447 2119 
By email:  Nyaladzi.Balogun@ucl.ac.uk 
By post:  Women’s Cancer Department  
Institute for Women’s Health University College London  
1st Floor, Maple House 
149 Tottenham Court Road  
London, W1T 7DN.  
 
Thank you very much for taking time to read this information about the study.  
 
 
 
 
Appendix 5: Consent forms 
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Appendix 5.1 Consent Form 1: Study A 
 
Thank you for reading the information about our research project. If you would like to take 
part, please read and sign this form. 
 
Title of Project: Nutritional Status of Women Referred to a Gynaecological 
Cancer Centre for Treatment of a Pelvic Mass 
 
Name of local researcher: Ms Nyala Balogun             Initial 
I confirm that I have read the attached information sheet dated…………….. 
(Version ………) for the above study and have been given a copy to keep  
 
I have been able to ask questions about the study and I understand why the 
research is being done 
 
I agree to give samples of blood to be used for this research study and understand 
that giving a sample for this research is voluntary  
 
I understand that these tests will be solely for research purposes  
 
 
I give permission for the storage of serum and plasma from the blood samples 
for future research  
 
I understand that some of the samples may be used for testing for genetic 
influences on nutritional status in future   
 
I understand that any future research on my samples will only be carried out with 
approval from an independent ethics committee and that my confidentiality will 
be protected at all times 
 
I agree to complete the questionnaires required for the study 
 
I give permission to the research team or regulatory authorities to look at my 
medical notes or pathology slides for research purposes 
 
I understand that any accessed information will be kept confidential 
 
I understand that I am free to withdraw my approval for use of the samples at any 
time, without giving any reason and without my medical care or legal rights being 
affected 
 
I agree that the samples I have given and the information gathered can be stored 
by the custodians, University College London, for use in the current study and 
for possible use in future studies as described in the information sheet   
 
I know how to contact the research team if I need to and how to get information 
about the results of the research 
 
 
 
 
_________________________ _________________ ____________________ 
Name of volunteer Date  Signature 
 
 
_________________________ _________________ ____________________ 
Name of person taking consent Date  Signature 
Study Number: 
Appendix 5.2 Consent Form 2:  Patient Discussion Group  
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Thank you for reading the information about our research project. If you would like to take 
part, please read and sign this form. 
 
Title of Project: Nutritional Status of Women Referred to a Gynaecological 
Cancer Centre for Treatment of a Pelvic Mass 
 
Name of local researcher: Ms Nyala Balogun 
        Initial 
I confirm that I have read the attached information sheet 
dated……………….….. (Version …) for the above study and have been given 
a copy to keep  
 
I have been able to ask questions about the study and I understand why the 
research is being done 
 
 
I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason and without my medical care or legal 
rights being affected 
 
I understand that sections of my medical notes may be looked at by responsible 
individuals from the research team or regulatory authorities where it is relevant. 
I give permission for these individuals to have access to my records 
 
I confirm that the interview has been explained to me and I am willing to take 
part in a tape recorded interview with the researcher for the above study   
 
I give permission for information from this study to be transcribed, held 
anonymously in a computer and used for this research   
 
I give permission for my stored information to be used for future research   
I understand that any future research on my information will only be carried 
out with approval from an independent ethics committee and that my 
confidentiality will be protected at all times 
 
I know how to contact the research team if I need to and how to get information 
about the results of the research 
 
 
 
 
___________________ _________________ ___________________________ 
Name of volunteer Date  Signature 
 
 
__________________ _________________ ___________________________ 
Name of person taking consent Date  Signature 
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Appendix 6: Pearson’s Correlations of changes in variables for cases 
Variable Correlation Pain 
Swellin
g 
Ascites Weight BMI %Fat 
Dry lean 
mass 
Prealbu
min 
Albumin 
Health 
state 
End of T 
eating 
habit 
Baselin
e eating 
habit1 
Prior 
wt. loss 
Pain 
Pearson 
Correlation 
1 .025 -.025 .054 .129 -.278 .164 .117 .211 .174 .305 -.142 -.040 
Sig. (2-tailed)  .851 .852 .716 .387 .106 .354 .508 .164 .405 .079 .345 .800 
N 58 58 58 48 47 35 34 34 45 25 34 46 43 
Swelling 
Pearson 
Correlation 
.025 1 .234 .025 -.011 .216 .105 .342* .325* .268 .123 .202 -.244 
Sig. (2-tailed) .851  .077 .866 .939 .213 .555 .048 .029 .195 .488 .179 .115 
N 58 58 58 48 47 35 34 34 45 25 34 46 43 
Ascites 
Pearson 
Correlation 
-.025 .234 1 -.256 -.215 -.043 -.251 .497** .353* .237 .147 .406** -.192 
 Sig. (2-tailed) .852 .077  .079 .146 .804 .151 .003 .017 .254 .407 .005 .219 
Pearson 
Correlation 
58 58 58 48 47 35 34 34 45 25 34 46 43 
Weight 
Pearson 
Correlation 
.054 .025 -.256 1 .829** .540** .664** -.127 .020 .007 -.359* -.285 .072 
Sig. (2-tailed) .716 .866 .079  .000 .001 .000 .475 .904 .974 .037 .068 .659 
N 48 48 48 48 47 35 34 34 40 25 34 42 40 
BMI 
Pearson 
Correlation 
.129 -.011 -.215 .829** 1 .606** .724** -.092 -.035 -.093 -.330 -.265 -.231 
Sig. (2-tailed) .387 .939 .146 .000  .000 .000 .611 .833 .658 .060 .093 .157 
N 47 47 47 47 47 35 34 33 39 25 33 41 
39 
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Variable Correlation Pain 
Swellin
g 
Ascites Weight BMI %Fat 
Dry lean 
mass 
Prealbu
min 
Albumin 
Health 
state 
End of T 
eating 
habit 
Baselin
e eating 
habit1 
Prior 
wt. loss 
%Fat 
Pearson 
Correlation 
-.278 .216 -.043 540** .606** 1 .259 -.170 -.062 .215 -.267 .090 -.253 
Sig. (2-tailed) .106 .213 .804 .001 .000  .139 .426 .750 .391 .197 .631 .186 
N 35 35 35 35 35 35 34 24 29 18 25 31 29 
Dry lean 
Pearson 
Correlation 
.164 .105 -.251 .664** .724** .259 1 .103 .047 -.298 -.345 -.120 -.246 
Sig. (2-tailed) .354 .555 .151 .000 .000 .139  .630 .809 .230 .091 .528 .207 
N 34 34 34 34 34 34 34 24 29 18 25 30 28 
Prealbu
min 
Pearson 
Correlation 
.117 .342* .497** -.127 -.092 -.170 .103 1 .161 .081 .072 .380* -.340 
Sig. (2-tailed) .508 .048 .003 .475 .611 .426 .630  .403 .765 .745 .042 .071 
N 34 34 34 34 33 24 24 34 29 16 23 29 29 
Albumin 
Pearson 
Correlation 
.211 .325* .353* .020 -.035 -.062 .047 .161 1 .839** .236 .319 -.100 
Sig. (2-tailed) .164 .029 .017 .904 .833 .750 .809 .403  .000 .200 .054 .562 
N 45 45 45 40 39 29 29 29 45 23 31 37 36 
Health 
state 
Pearson 
Correlation 
.174 .268 .237 .007 -.093 .215 -.298 .081 .839** 1 .140 .200 .083 
Sig. (2-tailed) .405 .195 .254 .974 .658 .391 .230 .765 .000  .504 .338 .702 
N 25 25 25 25 25 18 18 16 23 25 25 25 24 
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*.      
Correlation is significant at the 0.05 level (2-tailed);   **. Correlation is significant at the 0.01 level (2-tailed). 
X: Significant;          X: Close to being significant 
 
 
Variable Correlation Pain 
Swellin
g 
Ascites Weight BMI %Fat 
Dry lean 
mass 
Prealbu
min 
Albumin 
Health 
state 
End of T 
eating 
habit 
Baselin
e eating 
habit1 
Prior 
wt. loss 
During 
T’tment 
diet 
change 
Pearson 
Correlation 
.305 .123 .147 -.359* -.330 -.267 -.345 .072 .236 .140 1 .155 -.316 
Sig. (2-tailed) .079 .488 .407 .037 .060 .197 .091 .745 .200 .504  .406 .089 
N 34 34 34 34 33 25 25 23 31 25 34 31 30 
Baseline 
diet 
change 
Pearson 
Correlation 
-.142 .202 .406** -.285 -.265 .090 -.120 .380* .319 .200 .155 1 -.251 
Sig. (2-tailed) .345 .179 .005 .068 .093 .631 .528 .042 .054 .338 .406  .104 
N 46 46 46 42 41 31 30 29 37 25 31 46 43 
Prior wt. 
loss 
Pearson 
Correlation 
-.040 -.244 -.192 .072 -.231 -.253 -.246 -.340 -.100 .083 -.316 -.251 1 
Sig. (2-tailed) .800 .115 .219 .659 .157 .186 .207 .071 .562 .702 .089 .104  
N 43 43 43 40 39 29 28 29 36 24 30 43 43 
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Appendix 7: The percentage of women reporting levels 1 to 3 of EQ-3D  
Appendix 7.1: Cases reporting levels 1 to 3 by dimension and menopausal status 
EQ-5D dimension*  
  
  
Baseline During treatment End of treatment 
Pre-
menopausal 
Menopausal 
Pre-
menopausal 
Menopausal 
Pre-
menopausal 
Menopausal 
Mobility Missing 11% 0% 14% 6% 20% 10% 
  level 1 45% 53% 43% 37% 60% 53% 
  level 2 44% 42% 43% 57% 20% 37% 
  level 3 0% 5% 0% 0% 0% 0% 
Self-Care 
Missing 0% 0% 14% 6% 20% 10% 
level 1 89% 89% 71% 77% 80% 33% 
level 2 11% 11% 14% 17% 0% 10% 
level 3 0% 0% 0% 0% 0% 0% 
Usual Activity 
Missing 0% 0% 14% 6% 20% 10% 
level 1 89% 42% 29% 14% 60% 43% 
level 2 11% 39% 43% 60% 20% 47% 
level 3 0% 18% 14% 20% 0% 0% 
Pain/ 
Discomfort 
Missing 0% 0% 14% 6% 20% 10% 
level 1 11% 29% 14% 6% 20% 40% 
level 2 68% 68% 43% 66% 60% 50% 
level 3 11% 3% 29% 3% 0% 0% 
Anxiety/ 
Depression 
Missing 0% 0% 14% 6% 20% 10% 
level 1 11% 32% 29% 40% 0% 60% 
level 2 88% 47% 43% 46% 80% 27% 
level 3 11% 21% 14% 9% 0% 3%% 
Total (n)  9 38 7 35 5 30 
         *Level 1 = no problem; level 2 = some/moderate problem; level 3 = extreme problem
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Appendix 7.2: Controls reporting levels 1 to 3 by dimension  
EQ-5D Dimension Baseline End of treatment 
Mobility Missing 0% 10% 
level 1 65% 50% 
level 2 35% 40% 
Level3 0% 0% 
Self-Care Missing 0% 10% 
level 1 100% 80% 
level 2 0% 10% 
level 3 0% 0% 
Usual Activity Missing 0% 0% 
level 1 47% 40% 
level 2 53% 60% 
level 3 0% 0% 
Pain/Discomfort Missing 0% 0% 
level 1 29% 50% 
level 2 65% 40% 
level 3 6% 10% 
Anxiety/Depression Missing 0% 0% 
level 1 29% 50% 
level 2 65% 50% 
level 3 6% 0% 
Total (n)   17 10 
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Appendix 8: Focus group topic guide 
 
Focus Group Discussion 22/Aug 2012 
Introduction 
In the last 16 months we have been assessing nutritional status of women 
referred for investigations and treatment of ovarian masses in two 
gynaecological cancer centres London. The assessments start from before 
treatment and we followed women up throughout their treatment 
surgery/chemotherapy.  We looked at weight changes, body composition 
changes, diet changes and we are analysing blood samples for nutritional 
protein changes. It is important for us do carry this study out so that we can 
characterise some of these changes and relate their effects to patient well-being 
and quality of life. But also help to strategize how and when effective nutrition 
intervention may be possible. The analysis of some of the results is ongoing, but 
we do have some preliminary findings, some of which we’d like to explore with 
you today.  But before we do that I would like to open the discussion by asking 
for your perspectives on   
 
1. Patient’s perspective  
 The issue of nutrition, is it a problem in patients diagnosed with ovarian 
cancer while they are undergoing investigations and initial treatment of 
surgery and or chemotherapy?  
 If not when is it an issue?  
 When do you start to think it is an issue/problem? E.g. weight loss, 
treatment stoppage, tiredness etc. 
 
 
2. Self/systematic/clinical management 
 Some of the findings from our study have shown that women loose or 
indeed gain weight prior to presenting to their GP or A& E for the first time. 
What were your experiences?  
 Did you lose or gain weight at a different time? 
 At what point did you think ok, this is a problem; I will have to deal with it? 
Or this is a big problem my clinicians need to deal with it. 
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 Were/are you comfortable talking to friends/family/clinician about issues 
of nutrition.  
 
3.  Women told us that they changed their diets somewhere along their 
journey, avoiding rough food e.g. vegetables, bread, sweets and biscuits, 
full fat cheeses, alcohol, red meat, acidy food etc. 
 
They ate soup, green tea, more fruit and veg, raw vegetables, vegan diet, 
muesli, more omega 3, just greens, more fish etc., 
 
 I am interested in exploring this further, what are/were your experiences 
with this. 
  
What triggers the change? Symptoms, fear, etc. 
Where did you go for the information? 
Who helped you? 
For those out of treatment is this sustainable? 
 
 
4. The clinical pathway 
 Were you satisfied with the nutritional support you received before and 
during your   treatment  
 Was it adequate? Did you need help that you feel you did not receive. 
Could anything have been handled better? 
 Did you have easy access to help, a dietician etc. 
 What could have been different and of benefit to you? 
 
5. If an additional element of nutrition (assessments/intervention) was 
added to your care pathway, where would you fit it in and who of the 
clinical team would you like to deliver this service for you? 
 
Additional if there is time 
 How would you describe the impact of your nutrition on your overall health, 
in view of the disease and treatments? 
 If you were in our main group and we have to feedback your nutrition 
results, how would you have preferred that to be, post, face to face etc.? 
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Appendix 9: Ethics committee favourable opinion letter 
 
 
North London REC 3 
Level 7 Maternity, Room 019 
Northwick Park Hospital 
Watford Road 
Harrow 
HA1 3UJ 
 
 Telephone: 020 8869 3928  
Facsimile: 020 8869 5222 
03 March 2011 
 
Dr Anne Lanceley 
Senior Lecturer 
University College London 
1a, 1st Floor Maple House 
149 Tottenham Court Road 
London 
W1T 7NF 
 
 
Dear Dr Lanceley 
 
Study Title: Nutritional Status of Women Referred to a 
Gynaecological Cancer Centre for Treatment of a Pelvic 
Mass 
REC reference number: 11/LO/0001 
 
Thank you for your letter of 25th February 2011 responding to the Committee’s request for 
further information on the above research and submitting revised documentation. 
 
The further information was considered in correspondence by a sub-committee of the REC 
on 3rd March 2011.  A list of the sub-committee members is attached.   
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised, subject to the conditions specified below. 
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 
the study (see “Conditions of the favourable opinion” below). 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
Management permission or approval must be obtained from each host organisation prior to 
the start of the study at the site concerned. 
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For NHS research sites only, management permission for research (“R&D approval”) should 
be obtained from the relevant care organisation(s) in accordance with NHS research 
governance arrangements.  Guidance on applying for NHS permission for research is 
available in the Integrated Research Application System or at http://www.rdforum.nhs.uk. 
 
Where the only involvement of the NHS organisation is as a Participant Identification Centre 
(PIC), management permission for research is not required but the R&D office should be 
notified of the study and agree to the organisation’s involvement. Guidance on procedures 
for PICs is available in IRAS. Further advice should be sought from the R&D office where 
necessary. 
 
Sponsors are not required to notify the Committee of approvals from host organisations. 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied 
with before the start of the study or its initiation at a particular site (as applicable). 
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
  
Document    Version    Date    
Protocol  3, February 2011     
GP/Consultant Information Sheets       
Participant Information Sheet: main study   3, February 2011     
REC application  2  24 February 2011  
Questionnaire: Patient Questionnaire 1  2, December 2010     
Questionnaire: Patient Questionnaire 2  2, December 2010     
Questionnaire: Patient Questionnaire 3  2, December 2010     
Patient Questionnaire IV  2, December 2010     
CV M. Widschwendter       
Participant Information Sheet: patient group  2, February 2011     
Evidence of insurance or indemnity       
Investigator CV       
Participant Consent Form: form 1  2, December 2010     
Participant Consent Form: form 2 patient discussion 
group  
2, December 2010     
Covering Letter    25 February 2011  
Letter from Sponsor    15 October 2010  
Consultant Letter  1, December 2010     
CV N. Balogun (Student)       
CV A. Forbes       
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
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After ethical review 
 
Now that you have completed the application process please visit the National Research 
Ethics Service website > After Review 
 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views 
known please use the feedback form available on the website. 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Progress and safety reports 
 Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
We would also like to inform you that we consult regularly with stakeholders to improve our 
service. If you would like to join our Reference Group please email 
referencegroup@nres.npsa.nhs.uk.  
 
11/LO/0001 Please quote this number on all correspondence 
 
With the Committee’s best wishes for the success of this project 
 
Yours sincerely 
 
 
 
 
Dr Jan Downer 
Chair 
 
Email: alison.okane@nwlh.nhs.uk 
 
Enclosures: List of names and professions of members who were present at the 
meeting and those who submitted written comments  
 “After ethical review – guidance for researchers”  
 
Copy to: Clara Kalu, UCL/UCLH/RFH Joint Biomedical Research Unit 
[R&D office for NHS care organisation at lead site] 
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North London REC 3 
 
Sub-Committee of the REC in correspondence 3rd March 2011 
 
 
Dr. J. Downer (Chair)  Consultant Anaesthetist 
Mrs. D. West (Vice-Chair)  Lay Member 
Ms. F. Nathoo   Lay Member 
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Appendix 10: Ethics Committee favourable opinion of substantial 
amendment  
 
 
                                                              NRES Committee London - Harrow 
                                                 Level 7 Maternity, Room 019 
                                         Northwick Park Hospital 
                         Watford Road 
              Harrow 
                 HA1 3UJ 
 
                                 Tel: 020 8869 3928 
                                  Fax: 020 8869 5222 
 
03 November 2011 
 
Dr Anne Lanceley 
Senior Lecturer 
University College London 
1a, 1st Floor Maple House 
149 Tottenham Court Road 
London 
W1T 7NF 
 
 
Dear Dr Lanceley 
 
Study title: Nutritional Status of Women Referred to a 
Gynaecological Cancer Centre for Treatment of a Pelvic 
Mass 
REC reference: 11/LO/0001 
Amendment number:  
Amendment date: 12 October 2011 
 
The above amendment was reviewed by the Sub-Committee in correspondence recently. 
 
Ethical opinion 
 
The members of the Committee taking part in the review gave a favourable ethical opinion of 
the amendment on the basis described in the notice of amendment form and supporting 
documentation. 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
 
 Document  Version  Date  
Participant Information Sheet  1, 
September 
2011  
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R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
 
11/LO/0001:     Please quote this number on all correspondence 
 
Yours sincerely 
 
pp Dr. J. Downer 
Committee Chair 
 
E-mail: alison.okane@nwlh.nhs.uk 
 
 
Enclosures: List of names and professions of members who took part in the review 
 
Copy to: Clara Kalu, UCL/UCLH/RFH Joint Biomedical Research Unit 
Mr Philip Diamond, University College London Hospitals NHS Foundation 
Trust 
NRES Committee London - Harrow 
 
Sub-Committee in correspondence November 2011 
 
 
Dr. J. Downer (Chair)  Consultant Anaesthetist 
Ms. M. Otter   Clinical Pharmacist 
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 Appendix 11: GP letter 
 
 
 
 
GP Name 
GP Address 
 
Date 
 
Dear Dr. (GP Name) 
 
Re: Nutritional Status of Women Referred to a Gynaecological Cancer Center for Treatment of 
a Pelvic Mass 
 
I am writing to let you know that your patient ___________ is a participant in the above mentioned study looking 
at changes in nutritional status in women referred to University College London Hospitals (UCLH) for treatment 
of a pelvic mass. The study will assess and compare the nutritional status of women with a diagnosis of ovarian 
cancer with those who are diagnosed with benign ovarian disease from the time of referral and through treatment.  
 
Malnutrition is highly prevalent in this patient population because early diagnosis is not always possible and late 
diagnosis, when the cancer has spread to the abdomen or further is associated with worsening nutritional and 
performance outcomes. Furthermore nutrition still lacks consideration as part of the core treatment pathway in 
gynaecological cancer.    
 
The study uses a Quadscan 4000 (Bioelectrical Impedance) to assess body composition and evaluates it against other 
parameters such as serum albumin, diet patterns and quality of life scores (EORTC – C30 and EuroQol Group EQ-
5D). Patients will be assessed at 3 time points during the course of the study, at baseline (before the start of any 
treatment), during treatment (after surgery or first cycle of chemotherapy) and at the end of treatment (end of 
neo/adjuvant chemotherapy). The outcome measures will include the level of nourishment (nutritional status) and 
quality of life of participants.    
 
The study is in fulfilment of a PhD thesis and we hope to recruit 100 women over a period of 12-15months. If 
your patient is found to be severely malnourished and requires further primary care support, with her permission, 
we will inform her dietician and or consultant who may contact you about her follow up.   
 
If you have any questions regarding the study or you require further information, do not hesitate to contact Ms 
Nyala Balogun at the Gynaecological Cancer Research Centre on 0207 3806919 or via Email: Nyaladzi 
Balogun@ucl.ac.uk 
 
 
 
Yours sincerely, 
 
 
 
Dr Anne Lanceley (Senior Lecturer), Lead Investigator 
Dept Gynaecological Oncology  
Institute for Women’s Health    
University College London 
1st Floor Maple House 
149 Tottenham Court Road 
London  
W1T 7DN 
 
Tel 02076796807   
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 Appendix 12: Ovacome online invitation letter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
You are invited to take part in a research study being conducted at University College London 
(UCL), looking at the nutritional issues faced by women who are diagnosed with ovarian cancer 
and how they could be supported better. It consists of two stages. The first stage of this study 
recruited patients receiving care for a pelvic mass at the University College Hospital and 
assessed how their nutritional status/well-being changed through diagnosis and during the 
course of their treatment. You are being invited to take part in the second stage of this study 
where you are asked to be involved in a discussion group that will address issues surrounding 
nutritional challenges, support and the acceptability of future nutritional interventions 
packages. The discussion groups will take place on the 22nd of August at 2 PM. You will be 
compensated for your travel and refreshments will be provided. Please respond directly to the 
research team on 07933079428/0203 447 2119 or via email Nyaladzi.Balogun@ucl.ac.uk.  
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Appendix 13: Challenges encountered during treatment 
 
Reason  Challenge 
Patient Patients too unwell to participate 
 Patients prioritising care, such as attending for a blood test, ECG or scan 
 Family not wanting patients to participate as they perceive them to be too 
unwell 
 Patients not wanting a home visit by researcher 
 Patients becoming too unwell for subsequent assessments 
 Patients preferring to have treatment first before considering research 
Clinician Gatekeeping (clinician suggesting patients is too unwell or timing is 
inappropriate) 
 Clinicians dismissing patients after consultation (while researcher attends 
to other patients) 
Researcher Multiple patient appointments 
 Other commitments (meetings, conferences etc.)  
Holidays/sickness 
Logistical Appointments or surgery dates being changed  
 Patients not having further hospital appointments prior to treatment 
 Patients being admitted on the morning of surgery and not willing to 
consider research at this stage 
 Lack of dedicated space for patient assessment 
Patients waiting long to be seen by clinical team and not willing to wait any 
long for research purposes 
Specific to 
controls 
Improved screening algorithms for identifying benign disease and therefore 
less number of patients being referred to a cancer centre  
 Younger population with work commitments and therefore less additional 
time available for research during clinic visits 
 Less clinic visits (opportunity to recruit) prior to surgery 
 Clinics randomly spread during the week, coinciding with other researcher 
commitments 
 Frequent changes in clinic appointments 
 Patients waiting long hours in preadmission area prior to surgery adding 
anxiety and change of heart by those who had previously agreed to 
participate  
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Appendix 14: Publications  
 
Balogun N, Forbes A, Widschwendter M, Lanceley A. Noninvasive nutritional 
management of ovarian cancer patients: beyond intestinal obstruction. Int 
J Gynecol Cancer. Jul 2012 (25): 1089-95. 
 
Abstract	
Objective:	Malnutrition,	suffered	by	more	than	50%	of	patients	with	ovarian	cancer	during	the	course	
of	their	disease,	significantly	compromises	the	effectiveness	of	treatment,	causes	distress,	and	
increases	morbidity	and	mortality.	This	review	outlines	the	nutritional	challenges	faced	by	women	
with	ovarian	cancer	and	evaluates	the	evidence	base	for	current	practice	and	possible	opportunities	
for	intervention	in	clinical	settings.	
Methods:	PubMed	and	MetaLib	databases	were	searched	for	literature	on	nutrition	and	
cancer/ovarian	cancer	using	terms	and	truncations	covering	cancer,	cachexia,	mouse	models,	
malnutrition,	and	nutrition	intervention.	MEDLINE	and	Cochrane	databases	were	separately	searched	
for	interventional	studies	and	clinical	and	randomized	controlled	trials	published	in	English	(UK/United	
States)	that	involved	oral	nutrition	and/or	supplementation/intervention	in	ovarian	cancer	patients.		
Results:	Malnutrition	continues	to	be	a	significant	challenge	in	ovarian	cancer	management	despite	
significant	improvement	in	treatment	pathways	and	understanding	of	metabolic	pathways	and	the	
role	of	inflammation.	There	is	little	evidence	of	studies	designed	to	evaluate	the	impact	of	additional	
oral	nutrients	in	this	population.	Seven	studies	found	compared	"early"	versus	"traditional"	
postoperative	oral	feeding	after	major	gynecological/oncological	surgery,	and	1	study	evaluated	the	
impact	of	nutritional	status	on	survival.	The	7	studies	found	evidence	of	safety,	tolerability,	reduction	
in	length	of	hospitalization,	and	rapid	recovery	after	early	feeding.	There	is	no	evidence	of	benefit	of	
additional	oral	nutrients	in	this	population.		
Conclusions:	
Current	guidelines	and	protocols	of	nutritional	management	of	ovarian	cancer	seem	to	be	based	on	
expert	opinion.	There	is	need	for	extensive	collaborative	evidence	for	nutritional	management	
decisions	made	in	the	treatment	of	patients.	Prospective	cohort	studies	could	help	evaluate	the	
impact	of	changes	in	nutritional	status	on	health/nutritional	outcomes,	disease	recurrence,	quality	of	
life,	and	survival.	These	would	form	a	basis	for	well-designed,	targeted,	randomized	controlled	trials	
with	specific	and	controlled	nutrients/counseling	aimed	at	preventing	rather	than	treating	nutritional	
complications.	
	
Key	Words:	
Malnutrition,	Ovarian	cancer,	Nutritional	status,	Cachexia,	Nutrition	intervention	
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Tumor	growth	and	progression	are	characterized	by	specific	alterations	of	energy	and	nutrient	
intake	and	metabolism,	which	result	in	the	cancer	cachexia	syndrome.1	This	syndrome	is	complex	
and	is	characterized	by	anorexia,	early	satiety,	severe	weight	loss,	weakness,	immunodepression,	
anemia,	edema,	and	depression.2-4	It	can	result	in	death.	Tumor	growth	and	the	host	immune-
specific	activation	are	responsible	for	these	processes.5	Chemotherapy	treatment	often	compounds	
the	problem.	Current	guidelines	for	protocols	of	nutritional	management	of	ovarian	and	other	
cancer	patients	are	often	lacking	in	evidence	and	are	based	on	expert	opinion.6	Although	intestinal	
obstruction,	which	affects	up	to	30%	of	ovarian	cancer	patients,	is	a	significant	complication,	it	has	
been	well	described	elsewhere.7-9	This	review	focuses	on	the	nutritional	challenges	faced	by	
patients	with	ovarian	cancer	and	the	limited	evidence	for	noninvasive	nutritional	intervention.	We	
refer	to	current	practice	in	the	United	Kingdom	and	suggest	possible	future	research	in	oral	
nutrition	intervention	in	this	patient	population.	
The	Problem	of	Malnutrition	in	Ovarian	Cancer	
The	location	of	the	ovarian	tumor	deep	in	the	abdomen	limits	the	possibility	of	a	precise	early	
diagnosis.	Late	diagnosis	is	associated	with	advanced	disease,	which	in	turn	is	associated	with	
worsening	nutritional	and	performance	outcomes.	These	are	caused	by	(1)	reduced	ability	to	eat	
(feeling	too	full	too	quickly,	nausea	and	vomiting),	(2)	bowel	obstruction,	and	sometimes	(3)	
diarrhea,	the	consequences	of	which	may	cause	patients	to	stop	eating.	The	psychological	impact	of	
a	disease	arising	in	a	reproductive	organ	consequently	reduces	appetite	and	nutritional	intake.10	As	
with	other	cancers,	derived	systemic	and	metabolic	disturbances,	which	lead	to	specific	humoral	
and	inflammatory	responses,3	result	in	detrimental	metabolic	alterations.	In	addition,	cancer	
treatments,	particularly	chemotherapy,	often	cause	complications	that	compound	the	nutritional	
problem.	Pathways	that	result	in	cancer	cachexia	are	well	documented	3	and	involve	inadequate	
food	intake,	metabolic	alterations,	and	specific	humoral	and	inflammatory	responses.	These	
pathways	and	those	involving	some	hormones	such	as	ghrelin,	insulin,	and	leptin;	neuropeptides;	
and	neurotransmitters	that	play	a	role	in	the	metabolism	of	nutrients	and	maintenance	of	
homeostatic	functions	have	since	become	better	understood.	Manipulation	of	these	may	be	
significant	in	the	management	of	cancer	malnutrition.	The	dynamics	of	individual	contributors	
evolve	during	the	course	of	the	disease,	such	that	malnutrition	should	be	viewed	as	a	continuum	
that	requires	regular	reassessment.3	Factors	that	lead	to	cancer	cachexia	in	ovarian	cancer	are	
summarized	in	Figure	1.	Malnutrition	compromises	both	treatment	and	recovery,	resulting	in	worse	
overall	outcomes	and	increased	resource	utilization.	One	of	the	challenges	so	far	has	been	to	
provide	evidence	for	the	place	of	nutritional	care	in	the	treatment	pathway.	The	negligible	response	
of	cachexia	to	available	pharmacological	and	nutritional	interventions	has	led	a	general	view	that	
nothing	can	be	done,	and	palliation	of	the	worst	effects	of	this	complex	metabolic	picture	is	all	that	
can	be	achieved.11	Further	challenges	have	been	caused	by	lack	of	criterion-standard	methods	of	
determining	nutritional	status,	universally	accepted	clinical	definitions	of	key	terms	such	as		
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malnutrition	and	cachexia,	and	assessment	parameters	being	affected	by	illness	and	injury	leading	to	
inability	to	isolate	the	effect	of	malnutrition	from	the	influence	of	disease.12,13.	Progress	is	being	
made,	and	international	groups	are	working	together	to	provide	universally	acceptable	and	clinically	
relevant	definitions	of	key	terms	and	consensus	statements.11,14	Disease-related	malnutrition	has	
recently	been	defined	as	the	point	at	which	the	severity	or	persistence	of	inflammation	results	in	a	
decrease	in	lean	body	mass	associated	with	functional	impairment	and	at	least	partially	attributable	
to	a	decrease	in	nutrient	intake,	but	also	tightly	linked	to	the	effect	of	the	inflammatory	state	on	
intermediary	metabolism.14	There	is	emerging	evidence	indicating	that	those	mechanisms	ultimately	
leading	to	the	severe	wasting	of	cachexia	are	operating	early	during	the	natural	history	of	disease	11	
and	increased	muscle	proteolysis	suggestive	of	cachexia	being	detectable	in	cancer	patients	even	in	
the	absence	of	weight	loss.15	This	and	the	fact	that	anorexia	is	one	of	the	most	common	symptoms	
prompting	women	to	see	their	general	practitioner	highlight	the	need	for	effective	early	intervention	
in	cancers	where	malnutrition	and	cachexia	are	highly	prevalent.	
	Nutrient	Intake/Availability	
The	detrimental	effects	of	reduced	intake	due	to	disease	effect	or	treatment	are	unquestionable.	
Currently,	there	are	marked	variations	in	clinical	practice.16	Literature	and	advice	on	nutritional	
management	of	patients	undergoing	treatment	for	ovarian	cancer	are	not	clear,	and	
recommendations	made	by	advisory	bodies	in	Europe,	United	States,	and	Australia	for	cancer	
patients	lack	evidence	and	are	largely	based	on	expert	opinion.6	In	bowel	obstruction,	for	instance,	it	
has	not	been	clearly	identified	which	patients	should	be	treated	aggressively	and	what	mode	of	
therapy	should	be	pursued.7	The	lack	of	clarity	is	also	reflected	in	often	contradictory	information	
given	to	patients.	Patients	themselves	tend	to	seek	out	information	and	have	been	shown	to	reduce	
consumption	of	some	types	of	food	such	as	fat,	sugar,	and	red	meat	and	increase	consumption	of	
fruit	and	vegetables	with	the	hope	of	aiding	cure	of	their	disease.17	Patients	may	see	the	tumor	as	a	
reason	to	eat	"healthy	food"	and	may	thus	compromise	themselves	at	a	time	when	they	need	high	
energy-dense	intakes.	There	is	also	some	evidence	that	suggests	that	restricted	calorific	intake	
increases	longevity	in	multiple	species	and	slows	several	age-related	biological	functions,	including	
decreased	immune	function	and	tumorigenesis.18-20	The	biological	mechanisms	of	this	process	are	
neither	clearly	understood	nor	have	been	demonstrated	unequivocally.	However,	suggesting	that	
deprivation	rather	than	supplementation	may	be	part	of	the	answer	to	malnutrition	and	tumor	
progression	seems	counterintuitive.	There	is	a	need	for	further	research	with	key	carcinogenesis	
and/or	energy	balance	pathways	to	provide	important	understanding	of	the	calorie-cancer	
relationship.21	
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Even	though	nutritional	intake	has	been	shown	to	be	substantially	reduced	in	patients	with	cancer	
experiencing	weight	loss,22	it	is	not	always	diminished.	Once	a	critical	point	is	reached,	the	complex	
interplay	between	underlying	disease,	metabolic	alterations,	and	reduced	availability	of	nutrients	will	
eventually	and	inevitably	cause	death.11	Adequate	intake	often	fails	to	reverse	the	cachectic	process	
where	inflammation	is	present.		
Metabolic	and	Inflammatory	Pathways	
The	metabolic	and	immune	changes	in	cancer	are	well	documented	and	are	not	necessarily	cancer-
specific.	They	are	thought	to	be	mediated	by	the	pathophysiological	process,	that	is,	tumor,	or	host-
derived	chemical	factors,	for	example,	peptides,	neurotransmitters,	cytokines,	and	lipid-mobilizing	
factors,	and	are	associated	with	hypertriacylglycerolemia,	lipolysis,	and	acceleration	of	protein	
turnover.23	Host	and	tumor-derived	factors	seem	to	interact	with	intracellular	signaling	mechanisms	
to	disrupt	skeletal	muscle	protein	balance.24	Tumor	cells	increase	nutrient	uptake	and	angiogenesis	
to	support	the	up-regulation	of	metabolism	necessary	for	unrestricted	growth,	and	they	have	a	high	
degree	of	anaerobic	glycolysis	and	produce	large	amounts	of	lactate	and	a	net	uptake	of	amino	
acids.23	Significant	research	has	been	carried	out	on	metabolic	pathways	and	the	role	of	the	
inflammation	on	malnutrition	and	cachexia.	These	include	efforts	to	understand	the	role	of	cytokines	
as	inflammatory	mediators	that	can	influence	a	change	in	the	cognitive	and	autonomic	processing	
that	governs	the	initiation	and	cessation	of	ingestion,25	strategies	with	molecules	able	to	block	
cytokine	production	by	either	destabilizing	their	mRNA	or	inhibiting	their	synthesis	or	to	interfere	
with	cytokine-receptor	interaction,26	and	exploration	of	anticytokine	strategies	combined	with	oral	
supplements	and	treatments	aiming	to	modulate	inflammatory	processes	associated	with	cachexia.6	
There	has	also	been	work	on	analysis	and	understanding	of	DNA	sequences,	RNA	transcripts,	and	
metabolism,	which	may	in	the	future	allow	for	the	identification	of	specific	genotypes	and	
phenotypes	that	may	help	with	metabolic	profiling	and	lead	to	individualized	dietary	therapies,27	
although	this	needs	further	exploration.	In	the	last	decade,	there	was	a	surge	in	interest	in	hormones	
that	influence	metabolic	homeostasis	including	insulin,	leptin,	and	ghrelin	and	neuropeptides.	They	
are	involved	in	the	metabolism	of	nutrients	and	maintenance	of	homeostatic	functions.28-36	It	is	
thought	that	there	are	relatively	normal	insulin	secretion	in	cancer	and	reduced	insulin	sensitivity	
(peripheral	insulin	resistance),	resulting	in	inefficient	metabolism	and	availability	of	carbohydrates	to	
the	body.	The	other	hormones	and	neuropeptides	are	implicated	in	energy	control,	feeding	behavior,	
and	accretion	of	fat.	Understanding	their	roles	presents	research	opportunities,	where	manipulating	
them	to	stimulate	food	intake	or	prevent	breakdown	of	body	reserves	potentially	improving	patient	
outcomes	seems	a	real	potential.	
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Importance	of	Adequate	Nourishment	in	the	Face	of	Disease	and	Treatment	
Up	to	40%	of	all	cancer	patients	die	of	the	effects	of	malnutrition	rather	than	of	the	malignancy	
itself.37	It	has	been	said	that	the	chance	of	surviving	ovarian	cancer	mainly	depends	on	(1)	patient	
characteristics,	(2)	tumor	biology,	and	(3)	the	quality	of	treatment.38,39	Whereas	the	first	2	are	
nonmodifiable,	the	latter	can	be.	Nutrition	is	an	important	aspect	of	quality	of	treatment	that	could	
potentially	impact	on	patient	outcomes38;	hence,	strategies	that	support	and	ensure	maintenance	
of	adequate	nutrient	intake	and	utilization	in	the	presence	of	symptoms	and	through	treatment	
need	to	be	found.		
Treatment	
Malnutrition	alters	cellular	physiology	and	organ	function,	affecting	surgical	outcome	and	
postoperative	morbidity	and	mortality.40-42	The	feasibility	of	complete	cytoreduction	is	related	to	
tumor	volume	and	location,	it	is	also	related	to	a	patient's	ability	to	withstand	a	long	operation	(age,	
performance	status,	nutritional	status).43	Malnourished	patients	undergoing	surgery	are	more	likely	
to	have	complications	such	as	increased	blood	loss,	poor	wound	healing,	infections,	and	admissions	
to	intensive	care	units,44,45	while	those	undergoing	adjuvant	chemotherapy	show	a	decreased	
response	to	the	treatment,	increased	risk	of	chemotherapy-induced	toxicity,	and	increased	risk	of	
complications	and	death	during	the	course	of	treatment.46	Failure	to	complete	intended	
chemotherapy	regimen	is	also	common.	Comorbidities	such	as	chest	infections	due	to	decreased	
immunity	and	electrolyte	imbalance	with	implications	for	lung	function	and	cardiac	complications	
are	also	common.		
Quality	of	Life	
A	diagnosis	of	ovarian	cancer,	pain,	anxiety,	anger,	fear,	and	difficult	treatments	affect	all	aspects	of	
a	woman's	life	including	her	sexuality,47,48	resulting	in	reduced	quality	of	life.	Low	quality	of	life	in	
turn	contributes	to	psychological	distress,	which	feeds	into	the	vicious	cycle	of	aggravated	
nutritional	intake	and	weight	loss,	further	plunging	quality	of	life.	This	cycle	is	exacerbated	by	
relapse	or	disease	progression,	which	occurs	in	the	majority	of	patients	within	18	months	of	
diagnosis.		
Evidence	Base	for	Current	Clinical	Practice	
We	sought	to	determine	what	clinical	trials	or	other	studies	of	noninvasive	nutrition	intervention	in	
ovarian	cancer	patients	had	been	carried	out	by	searching	MEDLINE	and	the	Cochrane	databases.	
The	findings	were	unexpected;	no	randomized	controlled	trials	were	identified	that	evaluated	the	
impact	of	additional	oral	nutrients	or	other	interventions	such	as	diet	counseling.	Gupta	et	al39	
evaluated	the	impact	of	nutrition	on	survival	in	a	cohort	of	women	diagnosed	with	ovarian.	
Interpretation	of	their	results	is	complicated	by	the	fact	that	their	baseline	assessment	includes	
patients	who	had	received	treatment	and	those	who	had	not.	The	other	7	studies	identified	(Table	
1)	evaluated	the	efficacy	and	safety	of	early	postoperative	feeding	compared	with	delayed	feeding.	
Even	so,	only	1	study55	focused	on	only	ovarian	and	peritoneal	cancer	patients,	the	rest	(6	studies)	
included	all	gynecological	cancers	with	one	(Schilder	et	al	[1997]51)	including	noncancer	patients.		
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Health	outcomes	related	to	surgical	protocols	were	the	primary	outcome	for	all	the	studies.	They	
showed	that	the	former	was	safe	and	well	tolerated	by	patients	and	also	that	there	was	reduction	in	
postoperative	complications	such	as	infection	and	length	of	stay.	This	evidence	supports	the	
postoperative	Enhanced	Recovery	Programme	(oral	intake	as	soon	as	possible	after	surgery)56-58	
currently	practiced	in	many	surgical	settings	in	the	UK	National	Health	Service.	Gupta	et	al39	
followed	up	patients	in	the	medium	term.	Although	they	found	that	patients	who	were	well	
nourished	at	baseline	or	whose	nutritional	status	improved	at	3	months	had	significantly	better	
survival	than	those	whose	nutritional	status	deteriorated,	the	challenge	remained	in	that	the	baseline	
was	not	clearly	defined.		
	
The	majority	of	patients	treated	for	ovarian	cancer	in	the	United	Kingdom	do	not	receive	a	nutritional	
management	package	at	the	onset.	There	are	exceptions	where	nutritional	problems	interfere	with	
planned	treatment	and	patients	are	referred	to	a	dietitian	for	intervention.	Patients'	weight	and	
height	are	assessed	at	first	contact	and	before	treatment.	Comprehensive	nutritional	screening	is	
often	carried	out	only	at	the	time	of	admission	to	a	ward.	Even	so,	there	are	questions	of	how	well	
applied	the	assessment	outcomes	are	to	daily	patient	care.	Nutritional	support	tends	to	be	more	
robust	where	there	are	complications	or	in	end	stages	where	enteral	and	parenteral	routes	are	
preferred	and	usually	as	part	of	the	palliation.	There	is	no	clear	evidence	of	what	type	of	nutrients	
could	be	used	effectively	to	slow	down	or	reverse	cachexia	and	what	doses	and	conditions	would	
enable	this	to	happen.	Moreover,	researchers	often	focus	on	very	specific	and	usually	short	periods	
(around	treatment)	for	assessment	and	intervention,	whereas	we	know	that	the	processes	that	lead	
to	cachexia	precede	any	signs	or	symptoms.			
	
SUMMARY	
It	is	possible	that	the	limited	number	and	scope	of	nutrition	intervention	research	highlight	the	
challenges	of	working	with	patients	diagnosed	with	this	low-incidence	but	deadly	disease.	There	
needs	to	be	clear	evidence	of	the	categorical	changes	in	nutritional	status	of	patients	in	relation	to	
survival	or	death.	The	understanding	of	these	changes	and	how	they	relate	to	tumor	characteristics	
(histopathology,	stage,	grade,	etc)	and	patient	characteristics	(age,	weight,	activity	level,	etc)	can	
move	forward	attempts	to	provide	targeted	and	individually	tailored	nutritional	intervention.	
Prospective	cohorts	assessing	nutritional	status	over	a	number	of	years	could	be	a	good	starting	
point.	Evidence	from	such	cohorts	can	be	used	to	design	randomized	controlled	trials	to	establish	
whether	nutrition	intervention	at	any	stage	in	the	disease	trajectory	will	achieve	improvement	
beyond	short-term	indices	such	as	quality	of	life,	recurrence,	prognosis,	and	survival.	So	far,	only	
short-term	benefits	such	as	length	of	hospital	stay,	early	return	to	oral	diet,	and	a	reduction	in	
complications	and	infection	rates	have	been	demonstrated.	Also,	questions	need	to	be	answered	
about	which	particular	nutrients	linked	to	the	causation	of	cachexia	can	be	used	effectively	to	slow	
down	or	reverse	this	condition	and	what	doses	and	conditions	would	enable	this	to	happen.	
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CONCLUSIONS	
Guidelines	for	nutritional	management	of	ovarian	cancer	patients	are	largely	based	on	expert	
opinion.	There	is	a	need	for	a	clear,	objective,	comprehensive,	and	long-term	assessment	of	
nutritional	status	of	patients	with	ovarian	cancer,	how	this	changes	at	different	stages	of	the	cancer	
trajectory,	and	how	the	changes	impact	health	and	nutritional	outcomes,	disease	recurrence,	quality	
of	life,	and	survival.	This	would	provide	a	basis	for	well-designed	randomized	controlled	trials	with	
specific	and	controlled	nutrients/counseling	targeted	at	identified	specific	needs
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